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1.0 SUMMARY
The aim of this study was to establish human macrophage hybridoma cell lines which 
would be used to investigate the replication of the human immunodeficiency virus type-1  
(HIV-1). Polyethylene glycol (PEG) was selected to mediate fusion between human 
macrophages and monocytic cell lines. Rapid methods to detect conditions favouring 
fusion were developed. However, despite the optimization of protocols, no 
macrophage hybridomas were successfully isolated. The results suggest that 
macrophages can exert a negative regulation on the replication capacity of hybridomas.
In the absence of macrophage hybridomas, established immature monocytic cell lines 
were used to investigate the role of the cell cycle in the replication of HIV-1. A  range 
of chemicals were titrated and compounds that could inhibit in G1/G0, S and G2/M of 
the cell cycle were selected. The phenotype of treated cells was compared to that of 
exponentially replicating controls in an attempt to identify any differences that could 
potentially affect viral replication. Ultrastructural examination of cells treated with 
compounds to block replication in G1/G0 or in G2/M showed that cytoplasm of treated 
cells contained abundant paired cisternae. Further studies indicated an apparent 
correlation between the presence of paired cisternae and intracellular accumulation of 
HIV-1 virions.
Infection studies showed that U937 TIC" cells were more permissive for a lymphotropic 
strain of H IV -1 than for a monocytotropic isolate. Intracytoplasmic p24 antigen levels 
were significantly higher in U937 TIC" cells that had been treated with 300 jiM 
mimosine. This result was thought to be due to induction of cellular differentiation, 
rather than to a cell cycle related phenomenon.. However, accumulation of cells in 
G2/M following treatment with 1 x 10-8M colchicine, (and to a lesser extent 75 JiM 
GR39457A), caused a significant enhancement of viral replication which was not 
dependent on significant changes in the host cell phenotype.
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5.0 INTRODUCTION
5.1 GENERAL INTRODUCTION
In the early 1980s increasing numbers of patients (particularily young American males) 
were reported to be presenting with unusual opportunistic infections, including 
pneumocystis pneumonia and mycobacterial infections, and with previously rare cancers 
such as Kaposi's Sarcoma (Gottlieb et al., 1981). The frequency of these opportunistic 
infections indicated that the patients were immunocompromized. The condition became 
known as the Acquired Immunodeficiency Syndrome (AIDS) and was first formerly 
described in 1981 (Siegal et al.). The causative agent of AIDS, now known as the 
human immunodeficiency virus (HIV), was first isolated in 1983 by Barre-Sinoussi et 
al, from a patient with lymphadenopathy. Subsequently, HIV was confirmed by Gallo 
et al. (1984) to be the aetiological agent of AIDS. Two years later a second strain of 
the virus (HIV-2) was isolated in West Africa (Clavel et al., 1986). The identification 
of HTV as the causitive agent of AIDS prompted a massive research effort to establish a 
method of preventing or controlling the spread of infection. A  detailed knowledge of 
the pathogenesis of HIV and of the host immune response to the infection was required 
before rational attempts at drug or vaccine design could be initiated.
Despite extensive research over the last decade, HIV infection is still being transmitted 
and cannot be cured. Current estimates suggest that over 10 million people .are now 
infected with HIV. By September 1993, in the United States of America alone there 
were at least 339, 250 patients with AIDS (Centres for Disease Control and Prevention 
Statistics).
A  progressive depletion of CD4+ T-lymphocytes observed in blood isolated from AIDS 
patients prompted speculation that T-lymphocytes may be infected with HIV in vivo. 
Indeed, the virus was first isolated from T-lymphocytes obtained from a patient with 
lymphadenopathy (Barre-Sinoussi et al ; 1983). The association of HIV with Class II- 
restricted T-lymphocytes suggested that CD4 may function as the cellular receptor for 
HIV (Klatzman et al, 1984a; Popovic et al, 1984a). Preincubation of CD4+ T- 
lymphocytes with monoclonal anti-CD4 antibodies was shown to specifically block 
infection by HIV (Dalgleish e/ al, 1984; Klatzman et al., 1984b). Formal confirmation 
that CD4 was the receptor for HIV-1 was provided by Maddon et al. (1986) whilst 
Evans et al. (1988) showed that the same molecule was utilized as the receptor for HIV- 
2. The CD4 glycoprotein is mainly expressed on T-lymphocytes (that are MHC class
II-restricted in their functions) and by cells of the mononuclear phagocytic lineage 
(Sattentau and Weiss, 1988). Peripheral blood monocytes express CD4 at much lower 
levels than T-lymphocytes (Filion et al., 1990). Susceptibility to HIV infection has been 
correlated with the level of CD4 expression on host cells (Asjo et al., 1987).
In the haematopoietic system, CD4+ T-lymphocytes are the major targets for HTV 
infection. The CD4+ T-cell count declines dram atically during the course of infection 
and is used to monitor disease progression (Barre-Sinoussi et al., 1983; Klatzman et al., 
1984a; Seligmann et al., 1987). Early reports indicated that isolation of HIV was most 
efficient using mitogen-stimulated T-lymphocytes (Gallo et al., 1983) or actively 
replicating T-cell lines (Zagury et al., 1986). The in vitro replication of HIV in T- 
lymphocytes is characterized by the formation of multinucleated giant cells or syncytia 
and subsequent cell death (Lifson etal, 1986; Yoffe et al., 1987). Significant titres of 
progeny virus are released by budding from the host cells during this lytic infection 
cycle.
Mononuclear phagocytes infected by HIV have been identified in vivo (Levy et al.,
1985; Murray et al., 1985). In contrast to the characteristic depletion of T-cells in 
AIDS patients, changes in blood monocyte number and phenotype are minimal even in 
the late stages of disease (Gendelman et al., 1989). Increasing evidence suggests that 
cells of the mononuclear phagocytic lineage may be involved in the transmission of the 
virus (e.g. Pearce-Pratt and Phillips, 1993), and may be amongst the first cells infected in 
new hosts. Macrophages, which divide infrequently in vivo, have been reported to be 
the predominant HIV-1 infected cells in tissues (Ho et al, 1986; Pemo et a l ,1993). 
The exception to this is probably in the lymph nodes where the main infected cell type is 
thought to be the follicular dendritic cells, which have been associated with high levels 
of virus production in vitro (Pantaleo et al, 1993). Evidence suggests that the 
infection cycle in myeloid cells differs from the lytic cycle that is characteristic of HIV  
replication in T-lymphocytes. Infection of human monocytes with HIV in vitro gives 
rise to a persistent low level infection characterized by restricted virus production 
(Bernstein et al, 1991). In such cultures, minimal cytopathology is associated with low 
levels of reverse transcriptase activity released into the culture supernatant (Gendelman 
et al, 1988). The restricted release of HIV from myeloid cells is associated with 
sequestration of the virus into intracellular vacuoles (Orenstein et al., 1988).
Productive infection of T-lymphocytes by HIV is restricted to cells which have been 
activated and are proliferating (Stevenson et al, 1990a). This has been associated with 
expression of the nuclear factor-KB (NF-kB). This factor is a pleiotropic regulator of a
variety of genes implicated in cellular response to injury. Binding of NF-kB to distinct 
sequences in gene promoters can upregulate transcription of these genes. In a similar 
manner, sequences in the viral LTR can bind NF-kB, and this has been associated with 
enhanced replication of H IV -1 in T-lymphocytes (Nabel and Baltimore, 1987; Duh et 
al, 1989). The virus can infect quiescent T-cells, but reverse transcription is limited 
and proviral intermediates cannot integrate into the host chromosomes (Zack et al, 
1990).
By contrast, it is less clear whether or not cells of the mononuclear phagocyte lineage 
must be proliferating in order to support the replication of the virus. Some reports have 
suggested that, similar to T-lymphocytes, HIV requires monocytes to be proliferating in 
order for infection to be established (e.g. Schuitemaker et al., 1990), but there is 
increasing evidence that HIV-1 can replicate successfully in quiescent and y-irradiated 
human monocytes (Bernstein etal, 1991; Weinberg etal., 1991) and dendritic cells 
(Langhoff et al., 1991). In vitro differentiation of human monocytes into macrophages 
has also been associated with enhanced susceptibility to productive infection 
(Schuitemaker et al., 1990). Unlike T-lymphocytes, the replication of HIV-1 is not 
dependent on the expression of NF-kB. This was demonstrated by studies reported by 
Griffin et al. (1989) where the promonocytic cell line U937 was shown to support 
replication of HIV-1. These cells do not express NF-kB until differentiation has been 
induced. However, although NF-kB is not required for replication, it has been 
associated with enhanced virus production in myeloid cells. Studies have indicated that 
exogenous addition of glutathione, (an abundant thiol that functions to protect myeloid 
cells from reactive oxygen intermediates), can both inhibit NF-kB and suppress HIV  
replication in human monocyte-derived-macrophages (Lioy et al, 1993).
The differences in the replication cycle of HIV in T-lymphocytes and monocytes 
presumably reflect biochemical differences between the cell types. In order to design 
effective therapies or vaccines it will be essential to understand the factors controlling 
viral replication in both cell lineages. This has been highlighted by experiments 
investigating the mode of action associated with the antiviral drug 3'-azido-3'- 
deoxythymidine (zidouvidine, AZT). The thymidine analogue AZT is the principal drug 
in clinical use against HIV. When phosphorylated this compound selectively inhibits the 
viral reverse transcriptase enzyme (Furman et al., 1986). In vitro studies demonstrate 
that AZT is significantly more effective controlling acute as opposed to established 
infections (Crowe et al, 1989). Treatment with AZT is associated with clinical 
remission, although a small proportion of T-lymphocytes and monocytes remain latently 
infected and can act as a reservoir of virus during therapy (McElrath et al, 1991).
The compound has significantly less anti-HIV activity in monocytes compared to T- 
lymphocytes (Richman et al, 1987). It was initially thought that the differences in 
activity reflected more efficient phosphorylation of AZT in T-lymphocytes (Pemo et al,
1988). However, it has subsequently been shown that there are two thymidine kinase 
enzymes active in eukaryotic cells. Cytosolic TK1 is expressed strictly during S phase 
and is responsible for phosphoiylation of AZT in T-lymphocytes, and TK2 which is 
constitutively expressed as a mitochondrial enzyme is associated with phosphorylation of 
AZT in myeloid cells (Amer et al, 1992). A  further aspect of treatment with AZT was 
highlighted by the studies reported by Weiss et al (1990). These authors showed that 
interleukin-1 (IL-1) was released normally from AZT treated human monocytes but its 
extracellular activity was inhibited. Interuption of intracellular communication 
pathways by altering the activity of cytokines has significant implications for correct 
functioning of the host immune system.
Further studies are required to provide information on the factors controlling the 
replication of H IV -1 in cells of the mononuclear phagocytic lineage. Results may 
provide ideas to assist in the design of more effective therapeutic strategies. However, 
in vitro experiments are limited by the availability of suitable cell lines or homogenous 
isolated cells. Macrophages represent terminally differentiated cells and cloned 
macrophage cell lines are unavailable. It is difficult to obtain human macrophages from 
tissues and maintain them in culture in sufficient quantities to facilitate functional 
studies. Most experiments have therefore utilized monocytes isolated from blood that 
have been matured into macrophages either in culture dishes or in Teflon bags (Sutton 
and Weiss, 1966; van derMeer etal, 1985; Eales et al, 1987). Such cells are quite 
heterogeneous in both function and surface antigen expression, and this limits their 
usefulness. There are some cloned monocytic cell lines available, but these tend to be 
immature and do not display all the characteristics associated with macrophages. The 
work presented here was designed to establish a novel myeloid cell line, with a more 
mature phenotype than those of the available cell lines. The replication of H IV-1 could 
then be studied in the new cell line and the importance of host cell proliferation on viral 
replication could be determined.
PART T; THE M ONONUCLEAR  PHAGOCYTE SYSTEM
5.2. THE MONONUCLEAR PHAGOCYTE SYSTEM
Phagocytic cells play an important role in innate immunity, particularity with respect to 
the limitation of microbial growth. The cells are collectively termed the mononuclear 
phagocyte system (van Furth et al., 1972; previously referred to as the 
reticuloendothelial system). Cells of the mononuclear phagocyte system can initiate and 
amplify immune responses, with individual cells capable of synthesizing over 100 
products. The cells can process and present antigens directly to others, and can 
communicate by the secretion of cytokines. The many biological functions that are 
attributed to cells of the mononuclear phagocyte system all depend on the successful 
completion of the differentiation pathway from immature precursor cells to mature 
macrophages. All mononuclear phagocytes are thought to originate from granulocyte- 
macrophage colony forming units, which are stem cells present in the bone marrow 
(Metcalf, 1971). The most immature cell identified as a member of the mononuclear 
phagocyte system is the monoblast. These cells express IgG Fc receptors and display 
limited in vitro phagocytic capacity for antibody-opsonized erythrocytes, although 
antibody-opsonized bacteria are only rarely ingested (van Furth et al, 1979). The 
monoblast has relatively low levels of non-specific esterase and lysosomal enzymes 
which are characteristic of mononuclear phagocytes. Each monoblast can divide to 
produce two promonocytes. These cells have a greater capacity to phagocytose 
antibody-opsonized microorganisms, but although they express C3b receptors, there is 
no ingestion of complement-opsonized bacteria (van Furth and Diesselhoff-den Dulk, 
1970). It is believed that each promonocyte can divide to produce two monocytes, 
which remain in the bone marrow for less than 24 hours before entering the peripheral 
blood. Monocytes express a range of surface antigens, exhibit the capacity to 
phagocytose antibody- and complement-opsonized bacteria and contain increased levels 
of lysosyme and non-specific esterase enzymes. The half-life of monocytes in the 
circulation has been estimated to be 72 hours (Whitelaw, 1966).
During an acute inflammatory reaction circulating monocytes can be recruited as 
immune effector cells to sites of inflammation, injury, allograft or tumour rejection. 
Cytokines can stimulate enhanced production and release of monocytes from the bone 
marrow, leading to an overall increase in the number of circulating monocytes.
However, the time spent in the peripheral blood is shorter than under normal conditions, 
due to an efflux of monocytes from the circulation into inflammatory exudates (van
Furth et al., 1973). Monocytes become adherent to the vascular endothelium and 
migrate between the endothelial cells and subendothelial structures, a process termed 
diapedesis. The adherence process is thought to involve integrin molecules.
Intracellular adhesion molecule-1 (ICAM-1, CD54) expressed constitutively on the 
endothelial cells can bind to lymphocyte function associated molecule-1 (LFA-1 ,
GDI 1 a/CD 18) expressed on the monocyte cell surface (Rothlein et al., 1986). Certain 
cytokines such as interleukin-1 (IL-1) and interferon-* (IFN-y), that may be produced 
during inflammation, can upregulate the expression of ICAM-1 by endothelial cells and 
facilitate monocyte margination and migration to appropriate sites (Dustin et al, 1986).
Once in the tissues, environmental factors induce the monocytes to mature into 
macrophages. These differentiated cells express IgG Fc and C3b receptors which 
function during phagocytosis of antibody- or complement-opsonized bacteria. Cells 
which have left the blood remain in the tissues for several months. Evidence suggests 
that tissue macrophages may undergo limited replication within the tissues (van Furth,
1989). Macrophages generally show little evidence of mitotic activity, but, it is possible 
that certain tissue macrophages including alveolar macrophages and Kupffer cells (in the 
liver) proliferate when stimulated (Lasser, 1983). Macrophages present in certain 
tissues tend to display certain phenotypes and can be distinguished histologically. The 
terms assigned to macrophages isolated from specific tissues are outlined in Table 5.1.
5.2.1 Phenotypic characteristics of monocytes and macrophages
The cells which constitute the mononuclear phagocyte system are a phenotypically and 
functionally diverse group. This great heterogeneity makes it difficult to examine the 
effects of external agents on monocyte/macrophage characteristics. Thus, it is often 
useful to use monocytic cell lines which provide a homogeneous group of cells. 
However, this approach has obvious drawbacks, particularly since the lines are generally 
immature. The following sections will describe the functional and phenotypic 
characterisitics of monocytes and macrophages and compare these with those of the 
lines which have been used in this thesis.
5.2.2 Cellular morphology
Monocyte to macrophage differentiation can be studied in vitro where it can be induced 
by the presence of as yet undefined serum components (Johnson et al, 1977). If serum 
is absent from the culture medium, monocytes will survive if adhered to plastic, but will 
rapidly die if maintained in a suspension culture (Musson, 1983). Human monocytes
Table 5.1 Distribution o f mononuclear phagocytes
Tissue/Organ Mononuclear
phagocytes
Specific functions
Bone marrow Monoblasts
Promonocytes
Monocytes
Macrophages
Immature precursor cells 
Immature precursor cells
Support haematopoietic differentiation
Peripheral blood Monocytes
Bone Osteoclasts
Central nervous 
system
Microglia Cells express CD4
Connective tissue Histiocytes
Endocrine organs
Gastrointestinal tract
Genitourinary tract Phagocytose foreign antigens
Liver KupfFer cells Clearance of particulate and soluble 
Ag
Lung Alveolar macrophages Local defence from airboume 
pathogens
Lymph nodes Initiation of immune responses when 
presented with antigen e.g. by 
Langerhans' cells
Mucosa associated 
lymphoid tissue
First line of defence against pathogens 
entering via the mucosa
Skin Histiocytes/Langerhans'
cells
Cells effect presentation of foreign 
antigens to lymph nodes
Spleen Red pulp macrophages Phagocytosis/degradatation of red 
blood cells in red pulp 
Trapping/processing of foreign 
antigens in white pulp
Synovium Type A  cells
Thymus Involved in removal of apoptotic T- 
cells
Serous cavities Pleural macrophages 
Peritoneal macrophages
Inflammatory tissues Epithelioid cells 
Exudate macrophages 
Multinucleate giant 
cells
are small (10 - 12|xM) uniformly rounded cells. In the presence of serum, freshly 
isolated monocytes adhere, flatten and spread. After 6 - 8  days in vitro they have a 
heterogeneous appearance with a large variation in cellular shapes (Zuclcerman et al., 
1979). The increase in cell size is accompanied by a corresponding increase In the 
cytoplasm to nuclear ratio and the numbers of cytoplasmic granules and lipid inclusions. 
The extent and rate of these morphological changes can be enhanced by addition of IFN- 
y or reactive vitamin D3 derivatives to the culture medium (Andreesen et al., 1990).
5.2.3 Surface antigen expression
Significant alterations in surface antigen expression occur during the in vitro 
differentiation of monocytes into macrophages. Virtually all monocytes express CD 14, 
a receptor for complexes of lipopolysaccharide (lps) and lps-binding protein (Wright et 
al., 1990), and CD 18, the p-chain of the CD11 integrin complex. The expression of 
CD 14 was decreased in monocytes maintained in the absence of serum, but the 
expression was retained in the presence of serum (Andreesen et al, 1990). Irrespective 
of the stage of differentiation, Valentin etal ( 1991) report that 80 - 95% of the human 
monocytes that they isolated reacted with antibodies to the integrin molecules CD1 la 
and CD 1 lb as well as CD32 (Fey receptor II).
The molecules primarily responsible for the distinction between self and non-self in 
mammalian cells are a group of surface glycoproteins coded for by the genes of the 
major histocompatiblility complex (MHC). Two classes of MHC molecules exist,
(Class I and Class II), which primarily function during antigen presentation. MHC 
molecules are expressed by antigen presenting cells, such as cells of the mononuclear 
phagocyte system. Expression of Class II molecules on isolated human monocytes 
increased significantly during the first 24 hours of culture in vitro. This rapid increase 
was independent of the presence of serum in the culture medium (Andreesen et al,
1990). Presentation of antigens to T-lymphocytes is stabilized by direct interaction of 
surface CD4 with MHC Class II molecules (Gay et al., 1987). The CD4 molecule has 
been sequenced and the molecule is thought to have four regions of homology with 
immunoglobulin (Maddon et al, 1985). When CD4 is expressed on T-cells it is non- 
covalently associated with p56lck and may therefore be involved in signal transduction 
(Veillette et al., 1988). By contrast, in myeloid cells the CD4 molecule is not 
associated with this tyrosine kinase (Sorio et al, 1993). Isolated monocytes show a 
wide variation in expression of CD4, CD54 (ICAM-1) and CD64 (Fey receptor I). 
However, after 15 days in vitro maturation, the antigenic profile was more uniform
(Valentin et al., 1991). The level of CD4 expression had decreased to below the 
sensitivity of the test. No monocytes had expressed CD 16 (Fey receptor III) but the 
matured monocyte-derived macrophages all expressed this antigen. CD54 (ICAM-1) 
and CD51 (the a-chain of the vitronectin receptor) were shown to increase with time in 
culture. The expression of CD35, like CD4, was markedly decreased.
Cell surface receptors for the Fc portion of immunoglobulin have been shown to play an 
important role in the immune response. Mononuclear phagocytes express several 
receptors for the Fc portion of antibody molecules. FcyRI (CD64) is expressed by 
monocytes and macrophages and binds monomeric IgG with high affinity (Ravetch and 
Kinet, 1991). Expression of this receptor is greatest on tissue macrophages where it is 
protected from high concentrations of irrelevant IgG. FcyRI expression can be induced 
by exposure of myeloid cells to IFN-y. The receptor is active in vitro in antibody 
dependent cellular cytotoxicity (ADCC) and can activate respiratory burst activity when 
cross-linked (Anderson et al., 1986). The receptor also plays an important role in the 
clearance of immune complexes (Unkeless etal., 1989).
FcyRII (CD32) is a low affinity receptor for immune complexes and opsonized bacteria. 
Binding of an appropriate ligand to CD32 expressed on the surface of a monocyte can 
result in phagocytosis followed by an oxidative burst. Some variability exists within the 
FcR classes, with the greatest variability in the CD32 (FcyRII) receptor class. The 
CD32 cell surface receptor is encoded by three homologous genes, all of which are 
expressed by monocytes. The genes code for proteins with almost identical 
extracellular and transmembrane domains, but distinctive cytoplasmic tails.
Transfection of the individual CD32 genes into cells has shown that the isomers can all 
bind the same panel of anti-CD32 monoclonal antibodies (Stuart et al., 1989). Further 
studies have shown that CD32A mRNA can be regulated in U937 cells and in blood 
monocytes at both the transcriptional level and the post-transcriptional level (Alevy et 
al., 1992). Treatment of U937 cells with PMA and IFN-y results in an enhanced 
expression of CD32C transcripts. Such studies have indicated that CD32A and CD32C 
isomers are differentially regulated and this implies that the molecules may have different 
functions (Alevy et al., 1993).
FcyRIII (CD 16) is a low affinity receptor for monomeric IgG, but can also bind immune 
complexes and mediate phagocytosis (Ravetch and Kinet, 1991). A  transmembrane 
form of CD 16 is expressed on natural killer cells and macrophages. The immune 
system has the capacity to eliminate potential pathogens by opsonizing them with 
specific IgG which enhances the binding to Fcy-receptors expressed on the surface of
myeloid cells (Unkeless et al, 1988). The efficiency of this phagocytosis can be 
enhanced as complement can act synergistically with immunoglobulin.
M ol or Mac-1 (CD1 lb/CD 18) is CR3 (the receptor for the complement component 
iC3b). Mac-1 and p i50,95 (CD11 c/CD 18) have a more restricted expression than 
LFA-1. Both antigens are normally expressed on monocytes, macrophages, PMN and 
natural killer cells (Amaout, 1990). Mac-1 and p i50,95 are stored in intracellular pools 
in circulating monocytes and granulocytes. Binding of chemoattractants to specific 
receptors results in translocation of Mac-1 and pi 50,95 to the cell surface. This 
increases the adhesiveness of these cells and mediates binding to endothelial cells, 
allowing the cells localize in the vicinity of an immune reaction (Springer et al, 1987).
5.2.4 Cellular adherence and integrins
Cell migration and immune functions often require contact between specific cells. A  
family of structurally related heterodimers, termed the integrins, are now widely 
regarded as the molecules that mediate specific cellular adhesion (Springer et al, 1987). 
The identification of a heritable condition (leucocyte adhesion deficiency, LAD) in which 
expression of integrin molecules is restricted or absent has facilitated research into this 
area (Anderson et al, 1985). Immune cells isolated from LAD patients have been 
shown to be deficient in surface of expression of three glycoproteins: lymphocyte 
function-associated antigen 1 (LFA-1 or CDlla),  Mac-1 (CDl lb )  and pl50, 95 
(CD1 lc). ICishimoto et al (1987) showed that leucocyte adhesion deficiency was 
caused by a defect in the gene coding for the common p subunit, (now termed CD 18), 
of these molecules. The ligand for LFA-1 is known as intercellular adhesion molecule-1 
(ICAM-1; CD54) (Marlin and Springer, 1987). ICAM-1 is widely distributed and the 
expression of this molecule can be upregulated by inflammatory cytokines.
Adhesion of monocytes to vascular endothelial cells (EC) and the subsequent stretching 
and migration of monocytes over the luminal surface of EC are essential steps in the 
emigration of monocytes from the circulation into tissue at sites of inflammation. 
Beekhuizen et al (1992) investigated the molecules involved in the stretching of 
monocytes on cultured human venous endothelial cells stimulated with the cytokines 
rIL-4 and rIL-la. Their results suggested that ICAM-1, but not VCAM-1, present on 
cytokine-stimulated EC was essential for the stretching of EC-bound monocytes.
Adherence acts as an important regulatory signal for human peripheral blood monocytes 
and can stimulate the cells to differentiate into macrophages (Haskill et al, 1988).
Isolated human monocytes, stimulated to differentiate by adherence to plastic, express 
CD lib  and CD 11c. The expression of CD lib  and CD 11c was significantly higher in 
adherent cells but over 60% of cells expressed these antigens (Bennett et al, 1992).
The expression and function of the major surface antigens expressed by mononuclear 
phagocytes is summarized in Table 5.2.
5.2.5 Enzyme activty characteristic of mononuclear phagocytes 
Cellular esterase activity is ubiquitous but under defined reaction conditions, the activity 
of particular enzymes can be used to identify certain cell types (Yam et al, 1971). a- 
Naphthyl acetate esterase (a-NAE) and a-naphthyl butyrate esterase are primarily found 
in mononuclear phagocytes and may be used to distinguish them from other 
mononuclear cells (which contain negligible leves of the enzymes). a-NAE activity is 
usually demonstrated by a cytochemical test which depends on the hydrolysis of specific 
ester linkages resulting in the liberation of naphthol compounds. When the latter are 
released in the presence of freshly formed diazonium salts, highly coloured, insoluble 
complexes are deposited at the site of enzyme activity. The non specific esterase 
activity of human mononuclear phagocytes can be inhibited by sodium fluoride. An 
extensive study of human monocytes stained for a-NAE activity indicated that some 
monocytes may show more enzyme activity than others, probably reflecting the number 
and composition of lysosomes (Kaplow, 1975). Further studies have indicated that two 
distinct populations of monocytes can be isolated from peripheral blood, but both large 
and small cells are associated with high levels of a-NAE activity (Wang et al, 1992).
An adaptation of the standard cytochemical staining method was used to quantify the a- 
NAE activity of monocytic cell lines (Cook and Eales, 1994). The results indicated that 
different cell lines were associated with different levels of non-specific esterase activity.
In humans, approximately 90% of blood monocytes have peroxidase activity in their 
primary lysosomes. The remaining 10% of monocytes are not associated with activity 
of this enzyme. It has been shown that by maturing monocytes in vitro, the 
characteristic of peroxidase activity in the monocyte lysosomes is lost, but that the 
enzyme activity later reappears in association with the nuclear envelope and rough 
endoplasmic reticulum. The latter pattern of peroxidase activity is thought to be 
associated with mature resident tissue macrophages Bos et al (1988).
Monocytes cultured in vitro have been shown to undergo a decrease in lysosomal 
myeloperoxidase activity (Locksley etal., 1987; Rosmarin et al, 1989). 
Myeloperoxidase accounts for approximately 5% of the total cellular protein of a
Table 5.2 Expression and function of myeloid surface antigens
Antigen Function Expression Reference
CD4 HIV receptor Expression decreases 
during differentiation
Maddon etal., 1985 
Kazazi etal, 1989
CDlla Integrin a-chain Mentzer et ai, 1986 
Rothlein etal., 1986
CD lib Integrin a-chain, 
CR3
Monocytes Beller etal, 1982 
Ross et al., 1985
CDllc Integrin a-chain, 
CR4
Monocytes, 
macrophages 
Enhanced expression 
during differentiation
Myonesefa/., 1988 
Valentin et al, 1991
CD13 ? ! Monocytes, 
some macrophages
Bordessoule et al, 1993
CD14 Lps/lbp complex 
receptor
Monocytes Wright etal, 1990 
Esfahani etal., 1993
CD16 FcyRIII Cultured monocytes, 
macrophages
Unkeless et al, 1988 
Wong et al, 1991
CD18 Integrin p-chain Monocytes,
macrophages
Beller et al, 1982
CD23 FceRII Macrophages Unkeless et al., 1987
CD25 EL-2 receptor Macrophages O'Laughlin et al., 1992
CD32 FcyRII Monocytes,
macrophages
Hogg, 1988 
Wong et al, 1991
CD35 CR1 Monocytes Horwitz, 1982
CD36 Thrombospondin
receptor
Monocytes Barnwell ef al, 1985
CD40 Member of TNF 
receptor family
Inducible with GM-CSF, 
EL-3 or IFN-y
Alderson etal., 1993
CD44 Adhesion Macrophages Kansas et al., 1990 ’
CD54 Ligand for LFA - 1  
(ICAM-1)
Cultured monocytes Valentin etal., 1991
CD64 FcyRI Monocytes,
macrophages
Unkeless et al, 1988 
Wong etal., 1991
CD71 Transferrin
receptor
Macrophages Andreesen et al, 1990
HLA-DR MHC Class II Inducible with EFN-y 
Cultured monocytes
Littman etal., 1989 
Valentin etal., 1990a
HLA-DP MHC Class II Inducible with IFN-y Gonwaefar/., 1986
HLA-DQ MHC Class II Inducible with EFN-y Gonwa et al., 1986
Lectins Carbohydrate
binding
Monocytes,
macrophages
Mokoena and Gordon, 
1985
monocyte. The enzyme can catalyse the oxidation, by hydrogen peroxide, of chloride 
ions to free chloride and hypochlorous acid (Edwards and Swan, 1986). These 
products are strong oxidising and halogenating agents which are toxic to 
microorganisms. Although myeloperoxidase can catalyse the production of potent 
microbicidal agents it is not thought that this activity is essential, as hereditary lack of 
this enzyme is usually symptomless. It is probable that one of the major roles of 
myeloperoxidase is to degrade hydrogen peroxide to water with the formation of free 
halogen and hypohalous acid being very limited. A  further microbicidal activity 
associated with myeloperoxidase is due to the positive charge that this protein has at a 
neutral pH. Bacteria have to maintain a net negative charge, but this can be destroyed 
by interaction with the cationic myeloperoxidase enzyme.
Myeloperoxidase plays an important role in the metabolism of leucotrienes. Freshly 
isolated monocytes can degrade leucotriene C4 (LTC4) but as the cells are matured in 
vitro and the myeloperoxidase activity decreases, theability of the cells to degrade LTC4 
is lost. Experimental data reported by Neill et al (1985) showed that addition of 
myeloperoxidase to monocyte-derived macrophages partially restored the capacity to 
degrade LTC4. This leucotriene (LTC4) is degraded in appropriately stimulated 
monocytes by an oxygen-dependent pathway. The major products of this reaction are 
all of the isomers of leucotriene B4 (LTB4), a biologically active compound with potent 
effects on granulocyte chemotaxis, chemokinesis and activation. Appropriately 
stimulated monocytes from myeloperoxidase-deficient patients do not produce LTB4 
unless the enzyme is added. It is possible that the decrease in leucotriene derivatives 
secreted by maturing monocytes would regulate the production of these potent 
inflammatory mediators in vivo.
5.3 FUNCTIONAL CHARACTERISTICS OF MONOCYTES AND 
MACROPHAGES
5.3.1 Chemotaxis and chemokinesis
Monocytes express a variety of surface receptors which are used constantly to sample 
the environment. The cells exhibit a capacity to bias their movements along 
concentration gradients, a process termed chemotaxis. The rate of movement can also 
be enhanced by exposure to certain chemicals a process called chemokinesis. Human 
monocytes express between 20 000 - 80 000 receptors/cell for TV-formyl-methionyl- 
leucyl-phenyl-alanine (FMLP) (Snyderman et al, 1986). This peptide is required for 
initiation of prokaryotic replication, but is then cleaved off and released. Monocytes
can respond to the presence of bacteria by biasing their movement towards higher 
concentrations of FMLP (Schiffinan etal., 1975; Pike et al., 1980). Other receptors 
associated with chemotaxis include those that can bind the inflammatory mediators 
leucotriene B4, platelet activating factor, IFN-y and complement fragment C5a 
(Snyderman et al, 1971). The molecules are thought to remain attached to the cell for 
a maximum of 5 minutes, after which they are either digested or fall off. A  model to 
explain the mechanisms underlying monocyte locomotion has been proposed (Stossel et 
al, 1985; Yin, 1987). A  protein, termed gelsolin, is associated with the cytoskeleton 
and is thought to control the state of actin. Actin filaments can exist either as a gel 
(where actin filaments are contracted and cross-linked by an actin-binding protein) or a 
sol (where the fibres are in a relaxed state). In the presence of ATP and myosin, actin 
filaments can contract and enter the gel form. Calcium ion concentrations in excess of 2 
x 10_7M  activate gelsolin to relax actin into the sol form. The binding of chemotactic 
peptides to surface receptors has several effects including a rapid increase in cytosolic 
calcium concentration. Thus, repeated stimulation of surface receptors would result in 
calcium fluxes, which would cause repeated contraction and relaxation of actin filaments 
and result in movement biased towards increasing concentrations of the 
chemoattractants.
5.3.2 Phagocytosis of microorganisms
In addition to initiating locomotion, binding of FMLP to specific receptors has been 
linked with respiratory burst activation, lysosomal enzyme degranulation (Snyderman 
and Pike, 1984) and the activation of the protein kinase C (PKC) pathway (Nishizuka, 
1984). The signal transduction pathways that operate during chemotaxis ensure that 
monocytes arriving at sites of infection are activated. If mononuclear phagocytes 
recognise an antigen as foreign they can respond by ingesting the particle. The process 
of phagocytosis is acquired during the maturation of myeloid cells; and is rapid taking 
only 15-20 seconds. Electron microscopical studies have demonstrated that 
pseudopodia extend from the phagocyte to surround the particle (Aggeler and Werb, 
1982). The mechanism by which phagocytosis occurs has been explained by the "zipper 
hypothesis", which suggests that each time a receptor contacts a ligand an intracellular 
signal causes the pseudopodia to move around the particle (Griffin et al, 1975). The 
ingested material enters the cell inside a vacuole or phagosome. Lysosomal enzymes 
involved in the degradation of phagocytosed material are synthesized in the endoplamsic 
reticulum and packaged by the Golgi apparatus into stuctures called primary lysosomes. 
The fusion of lysosomes and phagosomes, releases the granular contents of the former 
into the resulting phagolysosomes (Nichols et al, 1971). Phagocytosis requires
constant ligand/receptor contact, and involves calcium fluxes acting on actin and 
myosin, in a similar manner to that which results in movement of the whole cell during 
chemotaxis. Many in vitro studies have utilized erythrocytes to demonstrate 
phagocytosis. Such experiments have shown that binding of erythrocytes alone may be 
insufficient to initiate phagocytosis, and that an additional stimulus, such as a phorbol 
ester, is required for ingestion (Wright and Silverstein, 1982).
Monocyte-derived macrophages (MDM) (cultured adherent to glass in vitro for 5 days) 
express complement receptors CR1 (CD35), CR3 (CD1 lb/CD 18) and CR4 
(CD 11 c/CD 18). Antibodies specific for these receptors were shown to inhibit 
phagocytosis of Mycobacterium leprae in fresh non-immune serum (Schlesinger and 
Horwitz, 1991). MDM activated by IFN-y exhibit markedly reduced adherence and 
ingestion of M. leprae. This correlated with decreased surface expression of CR1, but 
not CR3 or CR4.
5.3.3 Opsonization enhances phagocytosis
Phagocytosis of bacteria is a complex process dependent upon the physical and chemical 
characteristics of the bacterial surface and the complementary macrophage receptors. 
Mononuclear phagocytes express several surface antigens that function to mediate 
phagocytosis. The expression of such receptors can be regulated by cytokines. 
Microorganisms frequently become coated with factors present in serum and body fluids 
which can enhance phagocytosis, termed opsonins. Complement and antibody can both 
opsonize particles and enhance their subsequent phagocytosis. A  receptor involved in 
complement-mediated phagocytosis is CR1 (CD35), the ligand for complement 
component C3b/C4b. CR1 is expressed at a level of approximately 3000 receptors per 
unstimulated myeloid cell. Macrophages can directly bind complement opsonized 
antigens via CR1, but require activation before ingesting them. The second signal can 
be provided by interaction of mononuclear phagocyte fibronectin or laminin receptors 
with ligand (Horwitz, 1982). A  second type of complement receptor, CR3 
(CD 1 lb/CD 18), also mediates phagocytosis of particles and subsequent respiratory 
burst activity in mononuclear phagocytes (Beller et al, 1982).
5.3 4 Respiratory burst activity
Macrophages are metabolically active cells deriving energy from aerobic glycolysis 
(Oren et al, 1963). However, the basal metabolism of these cells can be significantly 
affected by receptor-ligand interactions or phagocytosis (Adams and Hamilton, 1984).
A  series of events can be triggered that result in a significant increase of oxygen uptake,
known as the 'respiratory burst1, during which large quantities of glucose are 
metabolized by the hexose monophosphate shunt. This is accompanied by production 
of large amounts of superoxide (0 2") and hydrogen peroxide ( H ^ ) .  The respiratory 
burst is essential for the effective killing of certain common pathogenic bacteria and 
fungi. An alteration in activity of membrane-bound oxidase complexes reduces 
molecular oxygen to form superoxide anions (0 2~) (Baboir, 1984). Superoxide 
dismutase (SOD), a cellular enzyme, converts the 0 2" ions to hydrogen peroxide 
(H20 2). H20 2 itself has weak microbicidal activity, but the compound acts as a 
precursor for reactions whose products are significantly more toxic. A  further reaction, 
catalysed by myeloperoxidase (MPO), between H20 2 and chloride ions produces 
hypochlorite ions. can also react with 0 2" ions to produce the oxidizing radicals
singlet oxygen and hydroxide anions. These free radicals contain an unpaired electron 
and are therefore unstable, reactive, and highly effective microbicidal agents. The 
intracellular production of toxic oxygen metabolites is carefully regulated to prevent 
toxicity to the host cells. Experiments using azide indicated that MPO, rather than 
catalase, was the predominant enzyme involved in controlling levels of the potentiality 
toxic HjOj in isolated monocytes (Nakagawara et al, 1981). The survival of any 
microorganisms within myeloid cells may lead to replication within phagocytes and 
result in persistent infection, as the pathogens may be protected from immune 
surveillance mechanisms.
Monocytes are very active in generating reactive oxygen intermediates (ROI). This 
capacity increases during the first 3 days in vitro, but then decreases and is virtually 
absent after 6 days. The changes in ROI production correlate with decreases of 
myeloperoxidase (MPO) activity to neglibible levels following 6 days of culture 
(Locksley et al, 1987).
Cytochrome b_245 is the putative terminal component of the oxidase system of 
phagocytes. The in vitro maturation of human monocytes is accompanied by a dramatic 
synthesis of this cytochrome (Garcia et al, 1986). A subcellular fractionation 
experiment showed that the cytochrome was distributed within the plasma membrane. 
The maturation-induced increase in the concentration of cytochrome b_245 showed a 
close correlation with the capacity of the cells to produce superoxide. The process of 
phagocytosis is followed by the respiratory burst in which reactive oxygen metabolites 
are produced. Nitro Blue Tetrazolium (NBT) is a yellow dye which acts as an 
hydrogen acceptor. When NBT is reduced it forms insoluble blue formazan crystals 
and this is frequently used as a histological technique for the microscopical 
demonstration of the respiratory burst activity of phagocytic cells. However, the
Several other methods have been described that investigate different stages of the 
respiratory burst. Experimental data reported by Rothe and Valet (1990) indicated that 
hydroethidine (HE) was oxidised at an early stage of the reactive oxygen metabolism of 
phagocytic cells, and that 2',7'-dichlorofluorescein (DCFH) was oxidized at a later stage. 
HE is the non-fluorescent sodium borohydride-reduced derivative of ethidium bromide 
(EB) and was reported to be predominantly oxidized by superoxide anions (O2*) . HE, 
in contrast to EB, can permeate the membrane of viable cells and be directly oxidized to 
red fluorescent EB, which becomes trapped in the nucleus by intercalation into DNA. 
The later reactive oxygen intermediates can be detected using 2 ',7'-dichlorofluorescein 
diacetate (DCFH-DA). DCFH-DA can penetrate viable cells and be disacetylated to 
2',7'-dichlorofluorescein (DCFH) by cytosolic enzymes. Once trapped, intracellular 
non-fluorescent DCFH can be oxidized to fluorescent 2',7'-dicholofluorescin (DCF) by 
oxygen metabolites generated during the respiratory burst. It has been reported (Rothe 
and Valet, 1990) that DCFH is partly oxidized by hydrogen peroxidase (H20 2) and 
phagosomal peroxidases.
5.3.5 Microbial killing
Several reports have indicated that oxygen-independent mechanisms can control the 
replication of several pathogens. Human alveolar and peritoneal macrophages take up 
and kill Toxoplasma gondii without any oxidative burst, and this killing was not affected 
by scavengers of superoxide, peroxide, singlet oxygen or hydroxyl radicals (Catterall et 
al, 1987). The killing of Leishmania major and Toxoplasma gondii was markedly 
reduced in monocytes cultured in vitro for 3 days. This indicated that oxygen- 
dependent mechanisms were unlikely to be involved in the control of these organisms, as 
the production of ROI is at a maximum at this time (Rook, 1989). The study of 
oxygen-independent microbicidal activity has been facilitated by the isolation of cells 
from chronic granulomatous disease (CGD) patients, in which the oxidase system is 
defective. CGD patients are particularily susceptible to certain common pathogenic 
bacteria and fungi (Gallin and Fauci, 1983). In vitro experiments have demonstrated 
that these cells, which are incapable of generating toxic oxygen metabolites, can kill a 
wide range of organisms including viruses, protozoa, fungi and bacteria. ,
A variety of granule-associated proteins in macrophages have antimicrobial activity. 
These include collagenases, deoxyribonucleases, sulphatases, lipases, elastase,
intracellular deposition o f insoluble formazan particles leads to an increase in granularity
and reports have shown that this can be detected as an increase o f 90° light scatter by
flow cytometry (Blair et al, 1985, 1986).
phosphatases, polysaccharidases and sulphatases. Primary lysosomes fuse with 
phagocytic vacuoles (phagosomes) containing ingested materials, to form secondary 
lysosomes or phagolysosomes (Nichols et al., 1971). The mechanisms by which fusion 
occurs are not understood, but the formation of the secondary lysosomes are thought to 
be necessary for the degradation of the ingested material.
Bacteriostasis within mononuclear phagocytes may result from deprivation of essential 
nutrients. Iron is essential for the replication of most microorganisms, but the 
availability of iron within macrophages remains unknown. Normal monocytes can 
support the growth of tryptophan-requiring auxotrophic mutants of Legionella 
pneumophila, which indicates that tryptophan is available within monocytes (Mintz et 
al., 1988). However, exposure to IFN-y causes degradation of tryptophan in 
monocytes, and depletion of this amino acid was implicated in the subsequent inhibition 
of replication of Toxoplasma gondii (Ozaki et al., 1987).
There are differences in the mechanisms by which blood monocytes and tissue 
macrophages kill some microorganisms. Human monocytes readily kill Candida 
albicans, whereas macrophages do not (Lehrer, 1975). Macrophages will, however, 
kill Candida pseudotropicalis as this organism does not require peroxidase activity in 
order to be destroyed (Lehrer and Cline, 1969).
In vitro studies have shown that human monocytes stimulated with either PMA or 
opsonized zymosan are virucidal to HIV-1 (Chase and Klebanoff, 1992). This virucidal 
activity could be inhibited by azide and by catalase, indicating that the killing process 
was mediated by myeloperoxidase. Further studies demonstrated that the anti-HIV 
activity of human monocytes stimulated to differentiate by adherence progressively 
declined between 3 and 9 days in in vitro culture. This decline in virucidal activity 
correlated with decreasing myeloperoxidase activity.
Cytosolic free Ca2+ is essential for IgG-stimulated killing of Staphylococcus aureus by 
human monocytes (Zheng et al, 1992). Earlier reports had shown that killing of S. 
aureus by human monocytes requires continuous stimulation by serum factors e.g. IgG.
5.3.6 Secretory activity of monocytes/macrophages
Activation of human monocytes/macrophages by a variety of stimuli results in the 
oxidative metabolism of arachidonic acid and the generation of prostaglandins, 
leucotrienes and HETE. The activation of human monocytes by lps is regulated
through the synthesis of cyclooxygenase and results in the production of prostaglandin 
(Fu et al., 1990). Isolated human peritoneal macrophages under resting conditions 
synthesize and release significant quantities of the cyclooxygenase products PGE2 and 
thromboxane B2. These products increased linearly with time and were dependent on 
de novo protein synthesis. The addition of a calcium ionophore resulted in a decrease in 
the generation of immunoreactive cyclooxygenase products. The results of studies 
reported by Mackenzie et al (1992) show that the inhibitory effects of the calcium 
ionophore were due to a down-regulation of the cyclooxygenase enzyme. The 
generation of cyclooxygenase products is dependent on the continual synthesis of the 
cyclooxygenase enzyme and the synthesis of this enzyme forms a crucial rate limiting 
step in the enzymatic chain.
EFN-y is implicated in the function of the immune system. Exposure of monocytic cells 
to EFN-y results in several changes including stimulation of the expression of an 
hydroxylase enzyme that enables the monocytes to convert the inactive form of vitamin 
D 3 (25(OH)D3) into the biologically active form (l,25(OH)2)D3. The active form of 
vitamin D3 has been associated with the induction of differentiation and alterations of the 
antibacterial capacity of monocytic cells. During the maturation process, the 
modulation of surface antigen expression is accompanied by acquistion of the capacity 
to produce cytokines. IL-1, IJL-6 and TNF-a are among the cytokines produced by 
macrophages and these compounds are all known to play an important role in host 
defence, immune and inflammatory responses.
Mononuclear phagocytes are an important source of IL-1 because they can infiltrate 
many different tissues and synthesize large amounts of the cytokine. The production of 
IL-1 by monocytes is induced by a variety of endogenous and exogenous factors 
including endotoxin (lipopolysaccharide, lps). Experiments have shown that monocytes 
stimulated with lps rapidly and transiently increase transcription of IL-1 message by 200 
to 300-fold, followed by a decrease to low but constant levels within 6 hours (Fenton et 
al., 1987). IL-1 has a poor signal peptide and is not found in the endoplasmic reticulum 
of stimulated monocytes (Bakouche et al., 1987). These observations suggest that the 
protein is not secreted by conventional mechanisms. EL-1 has been detected in 
lysosomal fractions which suggests that precursor molecules may be cleaved in 
lysosomes before being transported to the plasma membrane in endosomal vesicles. In 
vitro observations suggest that there are two forms of EL-1. EL-1 a  is thought to 
function predominantly while associated with the plasma membrane, while EL-lp is 
believed to be the secreted form (Bakouche et al, 1987). The biological activities 
associated with EL-1 are both diverse and profound, and common symptoms such as
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Tumour necrosis factor-a was initially identified as a product of macrophages (Carswell 
et al., 1975). This cytokine is actively involved in regulation of the immune system and 
is a major effector molecule in macrophage-mediated tumour cell cytotoxicity (Urban et 
al, 1986). Production of TNF-a is induced in response to infection by bacteria 
(Carswell et al, 1975), viruses (Aderka et al, 1986; Eifel etal, 1979; Wong and 
Goeddel, 1986), and parasites (Scuderi et al, 1987), suggesting a role for TNF-a in 
infection. The cytokine has been shown to have intrinsic antiviral activity on some cell 
types and act synergistically with the antiviral activity of EFN-yon a variety of cell types 
against RNA, DNA  and retrovirus infections, including HIV (Wong et al., 1988). In 
addition, TNF-a selectively kills virus-infected cells (Aderka et al., 1985; Wong and 
Goeddel, 1986) and this action is likewise enhanced by IFN-y. A  combination of TNF- 
oc and IFN-y kills 20% of HIV-infected HUT-78 cells and selectively inhibits the 
production of full-length viral mRNA in some chronically infected cells (Wong et al,
1988). Human monocyte-derived macrophages infected with certain strains of HIV-1 
release TNF-a and IL -6 into culture medium at 16-21 days after infection, coincident 
with peak viral replication and reverse transcriptase activity (Le Nauor et al, 1994).
A  study of cytokines produced by human peripheral blood monocytes that had been 
isolated by adherence to plastic and cultured in vitro in serum-ffee medium showed that 
the cells constitutively produced large amounts of macrophage colony-stimulating factor 
(M-CSF). The cells were also found to secrete high levels of tumour necrosis factor-a 
(TNF-a) and interleukin-6 (EL-6) during the first week and granulocyte macrophage 
colony-stimulating factor (GM-CSF) during the third week (Bennett et al, 1992). All 
cultures of human peripheral blood monocytes that were older than 3 weeks had 
detectable levels of CSF-1 present (Sechler et al, 1989). The cytokines released by 
mononuclear phagocytes are summarized in Table 5.3.
muscle and joint aches may be due to IL-1 induced PGE2 production. The best known
property o f EL-1 is its ability to cause fever by acting on the hypothalamus (Dinarello et
al., 1988).
5.3.7 Antigen presentation
One of the major functions of the macrophage is to assist in initiating and facilitating 
cell-mediated immune responses against pathogens. Antigens taken into mononuclear 
phagocytes either non-specifically or via specific receptors are subjected to degradation, 
probably within phagolysosomes or other specialized organelles. In the case of protein 
antigens, peptides are generated and recycled to the cell surface in association with
Table 5.3 Summary o f major cytokines produced by mononuclear phagocytes
Cytokine Source Target Main actions Reference
Interleukin-1 
(IL -l)
Monocytes, 
Macrophages, 
Dendritic cells
T-lymphocytes
B-lymphocytes
Liver
Endometrium
Hypothalamus
Lymphocyte
activation
Fever
Inflammatory
mediator
Auron etal, 1984 
Fenton et al, 1987
Interleukin-6
(EL-6)
Mononuclear
phagocytes
B-lymphocytes
T-lymphocytes
Liver
Proliferation 
Acute phase 
proteins
Gauldie et al, 1987 
Tosato etal, 1988
Interleukin-8
(IL-8)
Mononuclear
phagocytes
Neutrophils
Eosinophils
T-lymphocytes
Chemotactic
factor
Friedland et al, 1993
Tumour
necrosis
factor-a
(TNF-a)
Activated 
monocytes and 
macrophages
Tumour cells Cytotoxicity Carswell etal, 1975 
Feinman et al, 1987
Transforming 
growth 
factor-p 
(TGF-p)
Activated
macrophages
Assoian etal, 1987
Colony
stimulating
factors
(CSF)
Mononuclear
phagocytes
Progenitor cells Induction of 
growth and 
maturation
Haskill etal, 1988 
Epling-Bumette et al, 
1993
MHC Class II molecules. Intracellular antigen processing may also result in peptides 
associating with MHC Class I molecules. Peptides presented in association with MHC 
can be recognized by the appropriate MHC Class II- or Class I-restricted antigen 
specific T-cells (CD4+ and CD8+, respectively). The primary requirement for 
presentation in the context of Class I molecules is cytoplasmic localization of the 
antigen. Processed cytoplasmic antigens are thought to associated with Class I 
molecules before release from the endoplasmic reticulum (Nuchtem et al., 1989; 
Yewdell and Bennik, 1989). Antigens endocytosed and degraded in endosomes can 
only be presented in the context of Class II molecules (Moore et al., 1988). T-cell 
interaction with the Class II/peptide conformation is required, but is not sufficient alone 
for T-cell activation to occur. T-cell activation requires a second signal such as IL-1 
which stimulates T-cell growth and differentiation, by inducing receptors for IL-2 and 
stimulating EL-2 production. This may require other macrophage/T-cell interactions 
which may be mediated by cell surface adhesion molecules.
5.3.8 Tumoricidal activity
Monocytes and macrophages frequently infiltrate tumours and lysis of neoplastic cells is 
thought contribute to control of tumour growth. Cultured human monocytes have been 
reported to kill tumour cells when activated with cytokines and endotoxin. Certain 
products secreted by macrophages including prostaglandins, EL-1 and tumour necrosis 
factor-oc (TNF-a) are believed to prevent tumour cells from dividing. TNF-a is an 
important cytotoxic mediator produced by human monocytes. Also, IFN-y plays a role 
in cytotoxicity increasing the sensitivity of target cells to TNF-a (Feinman et al., 1987). 
Macrophages can also selectively destroy tumour cells by an unknown mechanism that 
requires contact between macrophages and the neoplastic cells to be mainatined for 
periods of 1 - 3 days. A  further process, termed antibody dependent cellular 
cytotoxicity (ADCC), can result in the lysis of antibody-coated tumour cells (Adams and 
Hamilton, 1984).
5.4 HUMAN MONOCYTIC CELL LINES
Macrophages represent a terminally differentiated cell type and cloned macrophage cell 
lines are unavailable. It is difficult to obtain human macrophages from tissues and 
maintain them in culture in sufficient quantities to facilitate functional studies. Most 
investigations of human macrophage function have therefore utilized monocytes isolated 
from peripheral blood that have been matured into macrophages either in culture dishes
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(Sutton and Weiss, 1966) or in Teflon bags (Andreesen et al, 1983). The usefulness of 
such cells is limited by the heterogeneity of their functional capabilities and phenotypes. 
Certain cloned cell lines with monocytic characteristics are available and these can 
provide large quantities of homogeneous cells for in vitro experiments. The functional 
and phenotypic characteristics associated with these cell lines is more restricted than that 
displayed by macrophages. However, maturation of these cell lines into cells with 
macrophage-like characteristics can be induced by exposure to certain chemicals. Such 
cell lines have elicited much interest both as a model of cell proliferation and of cellular 
differentiation.
5.4.1 Establishment and characterization of the HL-60 cell line 
The HL-60 cell line was originated from the peripheral blood lymphocytes of an adult 
female with an acute promyelocytic leukaemia (Collins et al, 1977). Examination of 
appropriately stained nuclei indicates that cells contain an average of 44 chromosomes 
(43 - 47 in metaphase nuclei). HL-60 cells replicate in vitro with a population doubling 
time of 36 - 48 hours (Collins, 1987). In vitro culture of these cells requires that the 
concentration is maintained between 1 x 105 and 1 x 106/ml. The density dependence of 
these cells results from constitutive production of a vital growth factor (Perkins et al,
1984). The myeloid character of HL-60 cells is confirmed by cytochemical 
demonstration of myeloperoxidase, ASD chloracetate esterase and lysozyme enzyme 
activity, although the cells lack non-specific esterase activity (Gallagher et al, 1979). 
Unstimulated HL-60 cells express low levels of CD64 (FcyRl), complement component 
C3b and FMLP (chemotactic peptide) receptors (Miyaura et al, 1981). Despite the 
presence of appropriate receptors, the cells are not competent for phagocytosis (Harris 
and Ralph, 1985). Receptors for EL-6, the multifunctional cytokine that regulates the 
growth and differentiation of various tissues, are expressed by EEL-60 cells, suggesting 
that the cells could respond to this cytokine (Yamasaki et al, 1988). The transferrin 
receptor (CD71) is essential for iron transport into proliferating cells. This antigen is 
not expressed by monocytes, but is critical for the replication of HL-60 cells (Omary et 
al, 1980; Judd etal, 1980). CD4 is expressed on the surface of HL-60 cells, but in 
contrast to expression on T-lymphocytes, the molecule is constitutively endocytosed and 
recycled. Immunogold labelling and electron microscopy demonstrated that CD4 is 
excluded from coated pits on T-cells, but utilizes this mechanism to enter HL-60 cells 
(Pelchen-Matthews etal, 1991).
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5.4.2 Induction of granulocytic maturation of HL-60 cells
Chemicals including dimethylsulphoxide (DMSO) and retinoic acid have been reported 
to induce HL-60 cells to differentiate into mature cells with granulocytic characteristics 
(Brietman et al, 1980; Collins et al, 1978). Significant changes in intracellular calcium 
concentrations were not associated with chemical induced granulocytic maturation of 
HL-60 cells (Tasaka et al, 1991). Undifferentiated HL-60 cells have a limited capacity 
for the respiratory burst and their ability to kill microorganisms is therefore poor 
(Collins, 1987). Mature granulocytes can undergo a stimulus-induced respiratory burst 
and HL-60 cells exposed to DMSO or retinoic acid develop this function (Blair et al.,
1985). Exposure of HL-60 cells to DMSO resulted in an accumulation of cells in the 
G1/G0 phase of the cell cycle and subsequent acquistion of phagocytic capacity (Blair et 
al., 1986). Treatment of HL-60 cells with 6-thioguanine has also been reported to 
induce cellular differentiation (Schwartz et al, 1984). However, 6-thioguanine 
associated growth arrest occurred in a variety of cell cycle phases, suggesting that the 
effect was a result of cytotoxicity, rather than a specific inhibition of replication.
5.4.3 Induction of myeloid differentiation of HL-60 cells 
Treatment of HL-60 cells with phorbol esters or biologically active 1,25- 
dihydroxyvitamin D 3 (calcitriol) induces growth arrest and maturation into cells with 
macrophage-like phenotype (Rovera, et al, 1979; Rossi etal, 1987). HL-60 cells 
induced to differentiate along the monocytic pathway by TPA revert to the 
undifferentiated phenotype after 3 -4  weeks (Hass, 1992a). In contrast to the 
chemicals used to initiate granulocytic maturation, agents used to stimulate myeloid 
differenitation induce a PKC-mediated influx of calcium ions (Tasaka etal, 1991). The 
in vitro maturation of human monocytes into macrophages has been associated in a 
reduction of myeloperoxidase activity. Likewise, induction of myeloid differentiation of 
HL-60 cells by exposure to Vitamin D 3 resulted in >95% reduction of mRNA coding for 
myeloperoxidase (Tobler et al, 1988). This indicates that expression of the enyzme is 
controlled at the genetic level during maturation into myeloid cells.
Differentiation of monocytes is associated with extensive changes in surface antigen 
expression. Alterations in the expression of certain surface antigens have been recorded 
during PKC induced maturation of HL-60 cells. Myeloid differentiation was 
accompanied by enhanced production of mRNA coding for specific integrin molecules. 
Surface expression ofCDllb/CD18 (CR3, Mac-1) and of CDllc/CD18 (pl50, 95) 
temporarily and quantitatively reflected the enhanced expression of mRNA coding for 
these antigens, (Rosmarin et al, 1989; Bellon etal., 1994). Interestingly, results
suggest that CD 18 is regulated at the transcriptional level, whereas CD1 lb is regulated 
post-transcriptionally (Hickstein et al, 1989). Expression of the vitronectin receptor 
(CD49d/CD29; VLA-4) is down-regulated during monocytic maturation. TP A  
induced maturation of HL-60 cells is also associated with an increase in the number of 
receptors for the chemotactic peptide FMLP, and an increased actin content (Sham et 
al, 1991).
Tests for antibody dependent cytotoxicity (ADCC) and phagocytosis confirmed the 
presence of functionally active receptors for IgG on Vitamin D3 but not TP A, treated 
HL-60 cells (Rossi et al, 1987). Treatment with Vitamin D3 induced the expression of 
Leu M3 in about 30 - 50% of HL-60 cells, and an increase (up to 20%) in the 
expression of HLA-DR, but not HLA-DQ (MHC class II antigens). Expression of 
these antigens was also enhanced following exposure to TP A. Treatment of HL-60 
cells with rEFN-y has been shown to induce monocytoid differentiation (Ball et al,
1984) and to reduce CD4 expression (Faltynek et al, 1989).
5.4.4 Establishment and characterization of the THP-1 cell line
The THP-1 cell line was first established by culturing cells isolated from the blood of a
1 -year-old boy suffering from acute monocytic leukaemia (Tsuchiya et al, 1980). 
Morphologically, the cultured cells retained the appearance of leukaemic cells, growing 
in loose clumps in suspension. The myeloid character of the cells was confirmed by the 
demonstration of lysozyme production and the presence of a-naphthyl butyrate esterase 
activity that could be inhibited by sodium fluoride. Approximately 6% of the cells could 
spontaneously phagocytose latex particles or IgG-sensitized sheep erythrocytes. The 
cells were shown to express the myeloid-associated antigens FcyRI (CD64), FcyRII 
(CD32) and C3b receptors, as well as the MHC antigens HLA-A2, -A9, -B5, -DrWl, - 
DrW2, but lacked surface and cytoplasmic immunoglobulins. A  karyotype analysis of 
THP-1 cells after 8 months in culture revealed that almost all of the cells had a diploid 
(46 + X,Y) number of chromosomes (Tsuchiya et al, 1980). Subsequent experiments 
using a specific fluorochrome marker for DNA that shows a dose-dependent increase of 
fluorescence emission over a broad range of D N A  concentrations estimated that the 
average DNA  content of THP-1 cells was 7.5 pg per cell (Shapira et al, 1993).
5.4.5 Surface antigen expression of THP-1 cells
THP-1 cells have a range of monocytic surface antigens. Expression of these antigens 
can be modified by treatment of the cells with cytokines or phorbol esters. A  summary
5.4.6 Induction of myeloid differentiation in THP-1 cells
Early reports demonstrated that treatment of THP-1 cells with phorbol esters would 
induce maturation into cells with phenotypic and functional characteristics associated 
with macrophages (Tsuchiya et al., 1982). Cells treated with PMA became adherent 
and proliferation ceased. This was accompanied by an increase in the percentage of the 
cells that could phagocytose latex beads or IgG-sensititzed sheep erythrocytes to 60 - 
70% of the population (Auxerx et al., 1992). Such differentiation into cells with 
macrophage-like phenotype, induced by exposure of THP-1 cells to phorbol esters may 
not be permanent. Three to four weeks after treatment, cells have been shown to revert 
back to the undifferentiated phenotype (Hass et al., 1993). A  combination of metabolic 
changes to restore the original cell phenotype and down-regulation of markers 
associated with the monocytic differentiation accompany upregulation of cell cycle 
genes, as the cells regain proliferative capacity (Hass et al, 1992a).
Changes in surface antigen expression occur concommitant with chemical-induced 
differentiation of THP-1 cells (see table 5.4). Regulation of antigen expression may be 
controlled at both pre- and post-transcriptional levels. For example, treatment of THP-1 
cells with PMA decreases both gene and membrane expression of CD64 (FcyRI), but 
reduces only membrane expression of CD32 (FcyRII) suggesting that different 
regulatory mechanisms are operating (Auxwerx et al, 1992).
5.4.7 Secretion of inflammatory mediators by THP-1 cells
During the differentiation and maturation of myeloid lineage cells there is an alteration in 
the surface antigens expressed by the cells. Concomitant with these changes in antigen 
expression, the capacity to produce cytokines is acquired. Mononuclear phagocytes 
can secrete a variety of inflammatory mediators which play an important role in host 
defence, immune and inflammatory responses. Experiments have shown that when 
THP-1 cells are exposed to conditions or physiological concentrations of chemicals that 
would induce the release of cytokines from myeloid cells, the cell line can respond in a 
similar manner. THP-1 cells do not constitutively produce any detectable amounts of 
protein or mRNA coding for TNF-a or IL-1 p (Molina et al., 1989). However, 
stimulation of the cells with lipopolysaccharide (lps), in the presence or absence of IFN- 
y, resulted in secretion of both TNF-a and EL-lp into the culture medium. THP-1 cells
o f the surface antigens reported to be expressed by THP-1 cells their moderation by
exposure to cytokines is shown in Table 5.4.
Table 5.4 Surface antigen expression of THP-1 cells and moderation by cytokines
Antigen Function Effect of cytokines Reference
CD4 MHC Class II 
receptor
Constitutively expressed 
Expression decreased by IFN-y and 
PMA
Faltynek et al, 1989 
Auxerxetal, 1992
CD 11b Integrin, part of 
CR3
Constitutively expressed 
Up-regulated by Vitamin D3
Vey etal, 1992 
Thieblemont et al, 
1993
CD 14 Lps/lbp complex 
receptor
Exposure to biologically active 
vitamin D, induces expression
Vey etal, 1992 j 
Kitchens etal, 1993
CD 16 FcyRHI Neither expressed or inducible Auxerxetal, 1992
CD18 Integrin, part of 
CR3
Constitutively expressed Thieblemont et al, \ 
1993
CD23 FceRU,
low affinity IgE r
Expression enhanced by TNF-a, 
IFN-y, IL-4, EL-6  and EL-8.
Willheim etal, 1991 
Gessl etal, 1993
CD32 FcyRII Constitutively expressed 
IFN-y up-regulates expression 
PMA down-regulates expression
Tsuchiya etal, 1980 
Gaffney et al, 1988 
Auxerxetal, 1992
CD35 Complement 
receptor (CR1)
Constitutively expressed Thieblemont et al, 
1993
CD54 ICAM-1, 
ligand for LFA-1
Constitutively expressed 
Expression down-regulated by 
PMA
Expression up-regulated by EFN-y 
Expression induced by IFN-y
Gaffney etal, 1988 
Auxerxetal, 1992 
Vey etal, 1992 
Perez etal, 1993
CD64 FcyRI IFN-y induces expression Gaffney etal, 1988
HLA-DR MHC Class II Constitutively expressed 
Vitamin D3 up-regulates 
expression
IFN-y up-regulates expression
Chantry -el al , -1990 
Rossi et al, 1987 
Vey etal, 1992
Mo-5 Receptor ? Constitutively expressed Goldstein et al, 1993
can also secrete TNF-a and IL-1 in response to treatment with GM-CSF (Chantry et al.,
1990). Studies reported by Scanned et al (1993) showed that THP- 1  cells remained 
viable when exposed to 1% oxygen for 24 hours, and similar to macrophages, the cells 
released TNF-a following 30 minutes hypoxia.
The cytokines TNF, EL-6 and EL-8 are important in the recruitment and activation of T- 
lymphocytes to sites of infection. Phagocytosis of latex beads, or of Toxoplasma 
gondii, by THP-1 cells resulted in a minimal level of gene expression and secretion of 
the three cytokines. By contrast, phagocytosis of Mycobacterium tuberculosis resulted 
in increased gene expression and secretion of the cytokines, particularity IL~8 (Friedland 
etal., 1993). These observations may partially explain the frequency of non­
inflammatory responses to T. gondii in immunocompentent individuals. Similar 
disparity in the induction of cytokines was recorded in THP-1 cells induced to 
differentiate by exposure to IFN-y or vitamin D3 (Vey et al, 1992). IFN-y was 
observed to induce the cell surface expression of HLA-DR and CD54, in conjunction 
with production of IL-1 p, TNF-a and EL-6. By contrast, l,25(OH)2D3 increased cell 
surface expression of CD1 lb and CD 14, but failed to stimulate cytokine production.
Lps can also induce production of IL-1 P, TNF-a and IL6 by THP-1 cells. Treatment of 
lps-stimulated THP-1 cells with flurbiprofen (a non-steroidal anti-inflammatory drug) 
completely abolished IL -6 and substantially reduced EL-lp and TNF-a production 
(Lozanski etal, 1992).
Monocytes stimulated by a variety of agents express a tissue factor (a membrane-bound 
glycoprotein) that plays a critical role in blood coagulation, as a cellular receptor and 
cofactor for factor Vila. Treatment of THP-1 cells with prostacyclin resulted in 
elevated levels of cyclic AMP and a corresponding decrease in tissue factor expression 
(Crutchley et al., 1992).
5.4.8 Establishment and characterization of the U937 cell line 
The human cell line, U937, was originally derived from a patient with histiocytic 
lymphoma (Sundstrom and Nilsson, 1976). The initial report indicated that U937 cells 
were round or somewhat polygonal with a mean diameter of 12.5 pM. The population 
doubling time was estimated to be 95 hours. Recent passages of the line grow more 
quickly with doubling times between 20 and 48 hours (Hass et al.t 1992b). Compared 
to normal monocytes, U937 cells express few receptors for antibody, complement or 
chemotactic peptides. The cells express receptors for histamine and insulin. Only a 
small percentage of U937 cells are spontaneously phagocytic and production of toxic
oxygen products is weak (Harris and Ralph, 1985). They can phagocytose latex beads 
and formalin-fixed Staphylococcus aureus but not zymosan. Fischer et al (1980) 
reported that U937 cells are not chemotactic under normal conditions. Monocytes and 
macrophages characteristically produce large amounts of the enzyme lysozyme, a 
property also exhibited by U937 cells (Ralph et al, 1976).
5.4.9 Surface antigen expression of U937 cells
A  range of monocytic surface antigens are expressed by U937 cells. The demonstration 
of the CD4 antigen on the surface of U937 cells was the first indication that cells other 
than T-lymphocytes could express this antigen (Wood et al, 1983). However, in 
contrast to T-cells, CD4 is not linked to p 5 6 ^  in myeloid cells, and activation is not 
associated with kinase activity (Sorio et al, 1993). Incubation of U937 cells in the 
presence of the monosialoganglioside GM1 induced internalization and subsequent 
degradation of CD4. Phorbol esters activate phosphokinase C (PKC) and induce the 
endocytosis and subsequent lysosomal degradation of membrane CD4 in U937 cells. 
Although synthesis and transport of the molecule to the cell surface are unaffected by 
activation, the increased rate of endocytosis is observed as a net down-regulation of 
CD4 expression (Petersen etal, 1992).
The expression of CD32 (FcyRII) on U937 cells was shown to be highly regulated by 
agents including PMA, IFN-y and GM-CSF (Alevy et al, 1992). Two isomers of 
CD32 exist, which differ in their cytoplasmic tail. Results indicate that expression of 
CD32a and CD32c by U937 cells is differentially regulated, which may imply that the 
molecules have different functions (Alevy et al, 1993). Detection of surface antigens 
using monoclonal antibodies indicates that expression can be modified by treatment of 
the cells with cytokines or phorbol esters. A  summary of the surface antigens reported 
to be expressed by U937 cells and their moderation by exposure to cytokines is shown in 
Table 5.5.
5.4.10 Induction of U937 cells to differentiate into macrophage-like cells 
Unstimulated U937 cells have monoblastic and immature monocytic characteristics. 
Further differentiation of U937 into cells resembling monocytes and macrophages can be 
induced by exposure to certain immunological mediators or PKC activators including 
phorbol esters. Exposure to PMA induces U937 cells become adherent and express the 
phenotypic properties of macrophages, including up-regulated expression of Fey and 
CR3 receptors (Minta and Pambrun, 1985). Incubation of U937 cells in the presence of
Table 5.5 Surface antigen expression of U937 cells and moderation by cytokines
Antigen Function Effect of cytokines Reference
CD4 MHC Class II 1 
receptor
Constitutively expressed at 
relatively high levels 
Down-regulated by IFN-y 
Up-regulated by Vitamin D,
Moscicki et al., 1983 
Stewart etal, 1986 
Faltynek etal., 1989 
Hewison et al., 1992
C D lla Integrin
CD lib Integrin Up-regulated by Vitamin D3, 
GM-CSF and IFN-y
Tsukamoto etal, 1992a
CDllc/
CD18
Integrin/CR3 Induced by PMA Bellon etal, 1994
CD13 Aminopeptidase Induced by PMA Hewison etal., 1992
CD14 Lps/lbp complex 
receptor
Up-regulated by Vitamin D 3 Kelsey etal, 1990
CD18 Integrin [3-chain Constitutively expressed Valentin et al, 1990b
CD23 FceRII Expression enhanced by TNF-a, 
IFN-y and IL-4.
Willheim et al, 1991 
Gessl etal, 1993
CD32A FcyRIIA Up-regulated by PMA Alevy et al, 1992 
McKenzie et al, 1992
CD32C FcyRIIC Up-regulated by PMA and 
IFN-y
Alevy etal, 1993
CD49d/
CD29
VLA-4, integrin Down-regulated by PMA Bellon etal, 1994
CD59 Variable expression Van den Berg et al, 1994
CD64 FcyRI Induced by IFN-y 
Low density lipoprotein (LDL) 
optimizes expression 
Binds C-reactive protein
Perez et al 1993 
Bigler et al, 1990
Crowell et al, 1991
CD71 Transferrin
receptor
Constitutively expressed 
Down-regulated by PMA
Ju Metal, 1980 
Hewison et al, 1992
HLA-DR MHC Class II Not expressed
Inducible with IFN-y, not IL-4
Mosciki etal, 1983 
Littman et al, 1989
Factor H ? C3b receptor Expressed by >95% U937 cells Malholta and Sim, 1985
Cl-INH Complement factor Expressed by 16% of cells Randazzo etal, 1985
EL-6r Receptor for IL -6 Constitutively expressed 
Down-regulated by PMA
Yamasaki e tal, 1988 
Oberg and Nilsson, 1992
IFN-y r IFN-y receptor GM-CSF up-regulates expression 
on Vitamin D, pre-treated cell
Zuckerman and 
Schrieber, 1988
FMLP r Chemotactic 
peptide r
Induced by Vitamin D3 Poliak al, 1989
Mo-5 Receptor ? Goldstein et al, 1993
lymphokine-rich supernatants from PHA-stimulated mononuclear cells stimulates their 
differentiation into functionally responsive cells that express high affinity binding sites 
for chemotactic factors including FMLP (Fischer et al, 1980). Vitamin D3 also induces 
expression of FMLP receptors on U937 cells. Subsequent binding of FMLP induced a 
rapid and reversible rise in the intracellular cytosolic free calcium ion concentration.
This could be blocked by pertussis toxin, indicating the involvement of inositol (1,4,5)- 
trisphosphate generation. However, although treatment of U937 cells with Vitamin D 3 
induces a functional NADPH oxidase, that is linked to phorbol ester and opzonized 
zymosan stimulated respiratory burst activity, the enzyme was not activated by binding 
of FMLP alone (Polla et al, 1989). The expression of FMLP receptors by U937 cells 
was accompanied by increased lysosomal enzyme secretion and chemotaxis (Pike et al, 
1980). Phenotypic and functional aspects of Vitamin D3 induced maturation of U937 
cells can be augmented by IFN-y (Kelsey et al, 1990). IFN-y had little effect alone but 
increased butyrate esterase staining and expression of CD 14 and CD32 (FcyRII) by the 
Vitamin D3 treated cells. This correlated with enhanced phagocytosis of antibody- 
opsonized bacteria and subsequent respiratory burst activity.
5.4.11 Synthesis of complement components by U937 cells
In common with human monocytes and macrophages, U937 cells have been shown to 
synthesize a number of proteins of the complement system. The complement proteins 
synthesized by U937 cells include: Cl inhibitor (Randazzo et al, 1985), protein D 
(Bamum and Volanakis, 1985) and complement factors B (Minta and Pabrum, 1985) 
and H. The expression of Factor H by U937 cells is restricted to the surface of the 
cells, with no secretion of the factor detected (Malholta and Sim 1985). Complement 
proteins C2 (Littman et al., 1989), C3 (Bengio etal., 1986; Tsukamoto etal, 1992a) 
and C4 (Tsukamoto et al., 1992b) can also be synthesized by U937 cells. Such 
biosynthesis and expression tends to be modulated by cytokines or differentiation 
inducing agents such as PMA. IFN-y and EL-4 can induce up-regulation of C2 synthesis 
in human monocytes. However, only the former cytokine was associated with 
augmented C2 synthesis in U937 cells (Littman et al, 1989). Unstimulated U937 cells 
produced a small amount of C3, but no measurable C4. Treatment with either PMA or 
IFN-y enhanced C3 synthesis, but only IFN-y induced C4 synthesis (Tsukamoto et al, 
1992b). These results indicate that production of C3 and C4 is independently 
regulated. The relationship between cell differentiation and complement synthesis by 
U937 cells was further investigated using combinations of GM-CSF (lOOOU/ml), 
Vitamin D 3 (10*7M ) and IFN-y (lOOOU/ml) (Tsukamoto et al, 1992a). Similar to EFN- 
y, Vitamin D 3 and GM-CSF enhanced C3 production by U937 cells in a dose-dependent
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manner, but unlike IFN-y did not stimulate C4 synthesis. A  synergistic enhancement of 
C3 production was observed when U937 cells were incubated with combinations of 
either Vitamin D 3 and IFN-y, or with GM-CSF and IFN-y. This synergy can be 
explained by the up-regulation of specific IFN-y receptors in response to Vitamin D3 and 
GM-CSF which had previously been recorded by Zuckerman and Schreiber (1988). A  
maximal enhancement of C3 production was observed when U937 cells were incubated 
with all three agents. C3 synthesis was observed to parallel the expression of its 
specific receptor CR3 (CD1 lb/CD 18, C3bi receptor) (Tsukamoto et al, 1992a). As 
the synthesis of C3 by U937 cells is thought to be closely related to cell maturation, 
expression of CR3 could be used to indicate the differentiation status of the cells.
5.4.12 Secretion of inflammatory mediators by U937 cells
During the PMA-stimulated differentiaion of U937 cells, IL -6  mRNA expression was 
transiently up-regulated and IL -6  protein was detected in the medium (Oberg et al, 
1992). By contrast, maturation induced by Vitamin D3 did not lead to an-increase in 
IL -6  expression.
Colony stimulating factors (CSFs) are a heterogeneous group of glycoproteins that are 
required for the proliferation and differentiation of haematopoietic cells in vitro. 
Granulocyte-macrophage colony stimulating factor (GM-CSF) can enhance the effector 
functions of mature cells of the myeloid lineage, as well as enhancing the growth of early 
progenitor cells. GM-CSF has been shown to inhibit neutrophil migration, stimulate 
neutrophil phagocytosis and enhance macrophage tumoricidal activity in vitro.
Cannistra et al (1987) report a study of the mechanisms of action of GM-CSF on the 
proliferation and differentiation of the U937 monocytic cell line. GM-CSF is inhibitory 
to the proliferation of U937 cells and this inhibition was reported to be associated with 
the secretion of biologically active tumour necrosis factor (TNF). rGM-CSF was 
shown to induce expression of the TNF gene in both peripheral blood monocytes and 
U937 cells. The data suggests that some of the biological effects of GM-CSF may be 
amplified through the release of monokines such as TNF. The phagocytosis o f IgG- 
opsonized zymosan has also been reported to induce U937 cells to secrete TNF-a (Jiang 
etal, 1992).
5.5 MYELOID HYBRIDOMAS
Characterization of the molecular basis of human macrophage function has been 
hampered by the limited replication capacity associated with the terminally differentiated
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nature of these cells and the lack of immortalized cell lines. The few cell lines that are 
available tend to express the characteristics associated with immature monocytes. The 
characteristics of these cell lines have been observed to change during prolonged in vitro 
culture, and the same cells may display different phenotypes or functions in different 
laboratories. Early reports describing the in vitro culture of human macrophages state 
that the cells divide (Lewis, 1925; Chang, 1976). However, more recent work 
suggests that mononuclear phagocytes do not divide outside the bone marrow 
(Zuckerman et al., 1979; van Furth et al., 1979) or describe the division rate as 
negligible (Treves, 1986). The notable exception to these observations is the data on 
pulmonary macrophages presented by Bitterman etal. (1984) which shows that alveolar 
macrophages can divide in vitro. Results reported by Sechler et al. (1989) indicate that 
human blood monocyte-derived macrophages can divide in culture. These authors 
suggest that without transformation human monocyte-derived macrophages could be 
passaged from primary cultures and replicate. However, the finite nature of such cell 
lines would limit their usefulness.
Several groups have attempted to immortalize human macrophages by a variety of 
techniques, in the hope that cell lines with phenotypic and functional capacities 
associated with mature mononuclear phagocytes could be isolated. The successful 
fusion of human monocytes, (activated in vitro by exposure to interferon-y for 24 - 48 
hours), with HGPRT- U937 cells was first reported by Shaked and Mayer (1986). The 
fusion protocol used a ratio of 5 : 1 monocytes to U937 HGPRT" cells. After washing 
the cells with medium, the cells were exposed to 35% PEG 1500 (pH 8.2) for a total of 
7 minutes. The PEG was carefully removed by dilution and the cells were incubated in 
selective medium containing 1 (ig/ml azaserine. Growth of hybridomas was first 
observed microscopically at 6 - 9 weeks after fusion (Shaked et al., 1991). The true 
hybrid nature of the fusion products was confirmed by demonstration that the cells had 
acquired donor HLA-DR and monocyte-specific antigens not usually expressed by U937 
cells. A  karyotype analysis confirmed that the hybridomas contained a higher 
chromosome number (50 - > 100) than the parental cells (44 - 47). Ten of the 
hybridoma clones were tested for functional characteristics associated with 
macrophages. Unlike the parental U937 cells, four of the clones were shown to secrete 
high levels of IL-1 when stimulated with lipopolysaccharide. Certain clones were 
observed to phagocytose IgG-coated ox erythrocytes. Surface antigen expression by 
the monocyte hybrids was reported to be stable (Shaked et al., 1991). Indeed, the 
hybridoma lines were used to study the expression of MHC Class II antigens in 
association with the antigen presentation capacites of interferon-y activated clones 
(Shaked et al., 1992). However, human-human hybrids are generally unstable, losing
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chromosomes during periods of prolonged culture (Mayer et al., 1982), and these 
isolated human hybridomas were no exception. Significant chromosomal loss and some 
loss of function were recorded during continuous culture over a 3 - 6 month period 
(Shaked etal, 1991).
The isolation of a stable human macrophage hybridoma was reported by Shimoda et al 
(1988). This hybridoma was established by somatic cell fusion between human 
peripheral blood monocytes, (that had been matured in vitro adherent to plastic for 8 
days), and an 8-azaguanine resistant clone of U937 cells. The fusion protocol utilized 
exposure to 45% PEG 4000, and growth of the hybrid was detected after 2  weeks 
culture in selective medium. The cell line exhibited typical macrophage-like 
morphology and was stongly adherent. Both the hybridoma and U937 cells were 
associated with intracellular nonspecific esterase activity. In contrast to the parental 
cells, hybridoma cells could phagocytose latex particles. The hybrid nature of the novel 
cell line was confirmed by a karyotype analysis. Hybrid cells contained 88.6 +/- 9.4 (64 
-110) chromosomes compared to 57 +/- 6.1 (40 - 70) in the parental U937 cells. 
Lipopolysaccharide stimulated hybridoma cells were demonstrated to secrete a novel 
cytotoxic factor, distinct from tumour necrosis factor (TNF), lymphotoxin (LT) or 
interleukin-1 (IL-1).
Hybridoma cell lines, that were relatively stable in continuous in vitro culture for at least 
six months, were isolated following fusion of non-activated human monocytes (matured 
in Teflon bags for 8 days) with HGPRT” U937 cells (Sperber et al, 1990a). Fusion 
was achieved by exposing a 10 : 1 ratio (macrophages to U937 cells) to 35% PEG 1500 
(pH 8.2 ) for 8 minutes. Growth was first observed after 8 weeks culture in selective 
medium and the overall fusion efficiency was determined to be 0.0006%. The fusion 
products were documented as true hybrids by the acquisition of donor class IM HC  
molecules, as well as donor derived macrophage surface antigens. Two of the 
hybridoma clones had distinctive morphology being larger than the parental cells with 
dendritic processes and an adherent growth pattern. The macrophage hybridoma clones 
were demonstrated to be infected by HIV-1IIIB either by CD4-dependent or CD-4 
independent routes (Sperber et al, 1990b). A  range of cloned hybridomas with 
characteristics representing a range of cells with monocyte to macrophage functions 
were selected. These cells were used as a model system to investigate the effect of a 
chronic infection with HIV-1IIIB on the phenotype and functionality of these clones 
(Sperber et al, 1993). The chronically infected hybridomas failed to express Class II 
MHC antigens or produce IL - 1  and did not process or present antigens to appropriate
T-cells. The model demonstrated that multiple defects in monocyte function may 
contribute to the early impairment of immune function observed in AIDS.
5.5.1 Immortalization of myeloid cells
The problems associated with obtaining sufficient human monocytes, and the 
heterogeneity of the isolated cell populations, limits the usefulness of these cells.
Several human myeloid cell lines are available but none provides an ideal system. 
Experiments were therefore carried out in an attempt to produce a novel myeloid cell 
line. There are several well described methods for immortalizing cells. However, as 
the aim was to utilize any new cell line to investigate the replication of HTV, techniques 
resulting in the introduction of viral genes into the target cells were not considered.
The simplest method of immortalizing cells is to fuse the cells with partners which have 
an immortal phenotype. Such fusion products (termed hybridomas) may retain the 
phenotype of immortality, along with some of the characteristics of the cell of interest.
Viruses can mediate the fusion of cells, and before more defined techniques were 
available, inactivated Sendai virus was frequently used to mediate the fusion of cells 
(Harris and Watkins, 1965). The use of viruses to mediate fusion was not considered, 
as it was possible that any virus products may interfere with subsequent studies of the 
replication of HIV, which can itself mediate the fusion of CD4+ cells.
Fusion of cells has also been induced by electric fields. The electrofusion technique 
comprises two main processes. Close contact between cells is established by 
dielectrophoresis and this is followed by electrical breakdown of the membrane which 
gives rise to small pores and allows the fusion of the apposed membranes (Zimmerman 
et al., 1984). The techique has the advantage that a low cell number is required, and 
the cells are not exposed to chemicals or viruses (Vienken et al, 1983). Optimization 
of the technique to generate antibody-producing human hybridomas was reported by 
Ohnishi et al (1987). The efficiency of electrofusion is not, however, always as high as 
for chemical mediated fusion (Ah-Sing et al, 1988). However, human monocytes do 
not survive well at low cell density, and this technique was not therefore attempted.
Cellular fusion can also be induced by exposure to certain chemicals. The use of 
polyethylene glycol (PEG, H0(CH2CH20 )nCH2CH20H) as a chemical fusogen has been 
well described in respect of the formation of lymphocyte heterohybridomas during the 
production of monoclonal antibodies. The successful PEG-induced fusion of human 
monocyte-derived macrophages with the promonocytic cell line U937 has been reported
(Shimoda et al., 1988; Woo et al., 1988; Sperber et al., 1990a). The protocol utilized 
by the former two groups was to aliquot 4 x 106 mononuclear cells into each well o f a 
24-well tissue culture plate. The non-adherent ceils were removed by washing and the 
cells were allowed to differentiate for a period of 7 to 8 days. The macrophages were 
mixed in a ratio of 10:1 with HGPRT" U937 cells and the cells were fused by exposure 
to 50% w/v PEG 4000 for 1 minute. The latter authors purified human monocytes by 
adherence and cultured them in Teflon bags for 8 days. The fusion was carried out by 
exposure of the cells to 35% w/v PEG 1500 for 8 minutes. Fusion protocols generally 
adopt either a short exposure (of 1 - 2  minutes) to a relatively high concentration of 
PEG (40 - 50% w/v) or a longer exposure (o f several minutes) to a lower concentration 
(30 - 40% w/v PEG) of the polymer. PEG has been associated with cytotoxicity if 
these times are exceeded. When high concentrations of the polymer are used, damage 
to cells can be minimized by ensuring that the PEG is diluted slowly.
5.5.2 Mechanism of PEG-inducedfusion
PEG is a highly water soluble polymer of ethylene oxide (Bailey and Koleske, 1967) 
which has freqently been used as a chemical cell fusogen for a wide variety of cell types. 
The chemical has the advantages that it is cheap, readily available and is associated with 
a high fusion efficiency and a low degree of cytotoxicity (Boni and Hui, 1987). The 
precise mechanism of PEG-induced fusion is yet to be elucidated. However, the results 
obtained from several different types of technique suggest a hypothesis that is consistent 
with several observations concerning the fusion process. It is currently thought that 
successful fusion is essentially a two-step process. Firstly, PEG must facilitate contact 
between the lipid bilayers. Once in contact, a transient destabilization of the membrane 
would allow fusion to occur. The second stage of the process occurs when the PEG is 
removed by dilution and the area of contact established between the cells expands, 
allowing fusion to be observed.
In order to explain the mechanism of PEG-induced fusion, it is necessary to first 
understand some of the properties associated with the polymer. The interaction 
between PEG and water was investigated by Baran et al (1972) by using high-resolution 
proton nuclear magnetic resonance (NMR) to study the mobility of water molecules at 
various concentrations of PEG. The results showed that each PEG monomer could 
bind 3 -4  water molecules, while structuring up to 16. This corresponds to all of the 
water being structured at a 13% w/v concentration of the polymer, and all water 
molecules being bound when the PEG concentration is increased to 38 - 45% w/v. This 
is observed as the viscosity seen in most PEG solutions. Differential scanning
colorimetry (DSC) studies have shown that the number of water molecules bound per 
polymer unit increased from 1.8 for PEG 200 to 2.7 for PEG 6000 (Tilcock and Fisher,
1982). The increased potential for binding water observed with higher molecular 
weight PEG was attributed to the random coiling of the polymer in aqueous solution, 
which provides additional sites for water entrapment. This orientation of water 
molecules in the presence of PEG results in a decrease of polarity, which would tend to 
destabilize biological membranes. It is imperative that cells are in close proximity for 
fusion to occur. This may occur as a result of the cells being brought together by 
exclusion from the PEG-water network. It is probable that the stabilizing hydration 
layer surrounding the lipid surface of biological membranes represents a major barrier to 
membrane fusion (Melver, 1979). The ability of PEG to bind water, may allow the 
removal of the hydration shell surrounding the lipid molecules of the cell surface and 
lead to the exclusion of a second molecular species. Dehydration alone is not sufficient 
to induce fusion as is demonstrated by the inability of dextrans or other dehydrating 
agents to mediate fusion (MacDonald, 1985). PEG differs from other dehydrating 
agents by its abilities to structure water, bind to phospholipids, form salt complexes and 
aggregate membrane proteins.
It is known that there are differences between manufacturers and between batches with 
respect to the heterogeneity of polymerization and purity of PEG. Impurities, such as 
catalysts or terminators of polymerization, antioxidants and oxidative decomposition 
products may exert effects on cell fusion or viability (Smith et al., 1982). Fusion 
between erythrocyte ghosts and cultured cells was only observed using unpurified PEG 
(Wojcieszyn etal, 1983).
Even if the local dehydration effects are sufficient to result in the removal of the 
hydration shell surrounding the cells, direct contact can still be prevented by the 
presence of proteins protruding from the cellular membranes. Electron micrographs of 
PEG-treated membranes have demonstrated that the membrane proteins tend to 
aggregate into clusters, which leaves bare patches of high lipid content (Maroudas, 
1975). It is thought that this clustering of proteins allows the lipid bilayers to contact 
and fuse. Freeze-fracture electron microscopy of cell cultures treated with PEG have 
revealed that at concentrations below the critical level for fusion, (approximately 30% 
w/v), no aggregation of the intramembrane proteins (IMP) occurs (Roos et al, 1983). 
The decrease in polarity (associated with the PEG-water network) also results in a 
decrease of the electrostatic repulsion between the bilayers which would facilitate the 
fusion process. Cytoplasmic streaming may also increase the probability of contact
The final stage of the fusion process is to remove PEG by dilution. This is required to 
"seal” the bilayer defects at the contact points and to allow for the expansion of these 
areas when the cell swells. Although lipid exchange may take place during PEG 
treatment, the actual fusion of biological membranes is only observed after the removal 
of the polymer. Studies reported by Wojcieszyn et al. (1983) suggest that the 
cytoskeleton may be the structural force that impedes the completion of the fusion 
process in the presence of PEG. In order for membranes to fuse in the presence of 
PEG, the cells must come into contact, and the membrane must then destabilize. 
Freeze-ffacture electron microscopy of cells that had been treated with PEG 6000 
showed what appeared to be protein-free lipid droplets blebbing off. Other experiments 
have demonstrated that cells exposed to PEG increase their permeability (Blow et al, 
1978). Exposure of cells to PEG results in a transient bilayer instability and an increase 
in membrane permeability.
5.5.3 Selection of hybridomas
If successful fusion occurs then any fusion product(s) would have to be isolated from the 
unfused monocytes/macrophages, and from the parental cell line. The usual method 
relies on the fact that monocytes/macrophages will naturally die after a few weeks in 
culture. The differentiation of any fusion products from the parental cell line however, 
requires that the parental cell line has a biochemical marker that can be used to prevent 
further replication of these cells. The methods for the selection of fusion products have 
been well described in the context of monoclonal antibody technology. The most 
frequently used biochemical markers are defect in the genes coding for the enzymes 
thymidine kinase (TK) and hypoxanthine guanine phosphofuranosyl transferase 
(HGPRT). Both of these enzymes are required for the 'scavanger pathway' of DNA  
synthesis. Certain chemicals are known to be inhibitory to the TK and HGPRTase 
enzymes and by culturing cells in the presence of increasing concentrations of these 
chemicals mutant cell lines can be produced. Cell lines with defects in either of these 
enzymes can replicate normally using the 'de novo' pathway of DNA synthesis.
However, the incorporation of aminopterin in the medium inhibits the 'de novo' pathway 
and prevents the replication of DNA  in the parental cells (see Figure 5.1). As fusion 
products can synthesize DNA, (using the 'scavenger' pathway), they can replicate in the 
presence of aminopterin and can therefore be selected.
junctions forming between membranes, but it could also limit the time for which they
exist (Lucy, 1970).
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Figure 5.1
DNA  synthesis and the mechanism of HAT selective medium. Most cells can make 
DNA either de novo or via the 'scavenger pathway1, using either an endogenous or an 
exogenous source of pre-formed bases. Growth of cells in increasing concentrations of 
the lethal purine analogue 6-thioguanine can select for an HGPRT" phenotype. These 
drug-marked cells can only synthesize DNA  de novo , and cannot therefore replicate in 
HAT medium which contains aminopterin specifically to block this pathway.
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5.6 CLINICAL FEATURES OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION
5.6.1 General clinical features of AIDS
The Aquired Immune Deficiency Sydrome (AIDS) was first recognised following the 
occurrence of a unusual range of pathogens and previously rare tumours in a group of 
young homosexual males (Gottlieb et al., 1981; Siegal et al., 1981). The most 
common AIDS-related opportunistic infection in the United States is pneumonia caused 
by the protozoa Pneumocystis carinii (Kaplan et al., 1987). Other pathogens 
associated with the opportunistic infections characteristic of the late stages of AIDS 
typically include Candida albicans, Cryptococcus, Salmonella typhimurium, 
Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Herpes Simplex 
virus (HSV) and Cytomegalovirus (CMV). Mycobacterium avium is an intracellular 
pathogen that predominantly parasitizes mononuclear phagocytes. In America, this 
pathogen is observed as the most frequent cause of disseminated infection in patients 
with the later stages of the infection (Horsburgh, 1991). In vitro studies have recently 
demonstrated that pretreatment of human monocytes with HIV-1 gp l20 inhibits 
phagocytosis and enhances intracellular growth of M. avium suggesting that HIV-1 
products may contribute to the pathogenesis of opportunistic infections (Shiratsuchi et 
al., 1994).
Kaposi's sarcoma (KS) was a rare cancer in the United States before 1981, particularly 
in young healthy adults. Occurrence of the tumour had been restricted to elderly and 
immunosuppressed patients, until it was recognized in a population of young 
homosexual males (Hymes etal., 1981). The association of this tumour with human 
immunodeficiency virus (HIV) infection appears to be restricted to the homosexual 
population, but the reasons for this remain unclear (Guinan et al, 1985; Haverkos and 
Drotman 1985).
The type of opportunist infections and occurrence of rare tumours indicated that HIV  
infection caused a defect in immune function. The dysfunction of cell-mediated 
immunity is particularily apparent and has been shown to result from infection of the 
cells involved (Metroka et al., 1983).
Some individuals suffer from a range of neurological symptoms including AIDS-related 
dementia. Neurological dysfunction has been shown to result from replication of HIV  
in brain cells (Sharer 1992; Achim et al., 1993).
5.6.2 Epidemiology of HIV infection
The results of epidemiological studies have indicated that ADDS is an infectious disease 
transmitted by close sexual contact, and by blood or blood products (Ammann et al, 
1983). Several populations at increased risk of contracting AIDS were quickly 
identified (Masur et al, 1982; Jaffe et al, 1983). These included homosexuals, 
intravenous drug abusers and blood product recipients, especially haemophiliacs 
(Stonebumer et al, 1990). Heterosexual contact has been identified as a major route of 
HIV transmission in adults, and is now believed to account for a high proportion of 
HIV-1 infections, particularity in Africa and Asia (W.H.O. report, 1993). The rate with 
which HIV is transmitted may be influenced by several factors including the frequency o f 
sexual contact and the amount of infectious material transmitted. A  person engaging in 
frequent, unprotected, sexual intercourse with a range of infected partners is at much 
greater risk of infection than an individual who engages in occasional contacts with a 
single partner (Fischl et al, 1987; Mastro et al, 1994).
Heterosexual transmission of H IV -1 is likely to involve transmission of virus present in 
seminal fluid to inflammatory cells, particularly macrophages, present in the 
endometrium and peritoneal cavity. In vitro studies have shown that peritoneal 
macrophages are easier to infect than monocytes in healthy women (Olaffson et al,
1991). The survival of HIV in the female genital tract and thus the likelihood of 
transmission may also be influenced by the presence of Lactobacillus acidophilus.
These bacteria are commonly present in the vagina and can generate hydrogen peroxide 
at concentrations that kill HIV (Klebanoff etal, 1991).
Parenteral infection following inoculation of blood by transfusion (Ammann et al,
1983), use of infected blood products, needle sharing among intravenous drug users, 
needle-stick injury and exposure to open wounds or mucous membranes have also been 
documented as routes of viral transmission. The rate of infection following transfusion 
has been dramatically reduced following the introduction of screening programmes. 
Maternal transmission of H IV -1 has also been reported, with about 15 - 35% of infants 
bom to seropositive mothers becoming infected with the vims (Ryder et al, 1989; 
European Collaborative Study, 1991). The factors influencing maternal transmission of
Two strains of the human immunodeficiency virus have now been identified and both 
can cause AIDS and related illnesses. Infection with HIV-2 is particularily prevalent in 
West Africa, but persons infected with this strain of virus are now being identified more 
frequently in other parts of the world. HIV-2 is more closely related to the simian 
immunodeficiency virus (SIV) than to HIV-1, and appears to be less virulent.
Regulation of replication at the genetic level also differs between the two strains.
HIV has been shown to be present in all body fluids that contain white blood cells. It is 
thought that the transmission of HIV most frequently occurs via infected cells, and not 
free virus. This observation has important implications for prevention, treatment and 
vaccine designs.
5.6.3 Clinical features of HIV infection
Infection with HIV can result in a spectrum of clinical features ranging from 
asymptomatic, to a rapid disease progression with mortality resulting from a 
complicating infection or malignancy. The period following infection is usually 
asymptomatic. However, early reports indicated a higher than expected incidence of 
AIDS risk group patients presenting with clinical symptoms indictative of immune 
deficiency, several years before developing full-blown AIDS. Typically, such 
individuals were reported to have a persistent generalized lymphadenopathy (PGL) with 
lymph nodes remaining enlarged for periods of at least three months (Metroka et al,
1983). Some individuals are reported to develop the clinical features of an acute 
infection. This usually appears within 2 -6  weeks of exposure to the virus. Symptoms 
have been reported to include fever, myalgia, arthralgia, lethargy, lymphadenopathy, 
pharyngitis, nausea, headaches, photophobia and rashes. Clincal signs of the acute 
phase of infection normally resolve after a period of 1 -2  weeks. HIVJnfected 
individuals then enter a clinically latent phase that may last from a few years to more 
than a decade. The factors that influence the length of this asymptomatic phase have 
not been elucidated and it remains to be determined whether all HIV infected persons 
will eventually develop AIDS. The onset of the AIDS syndrome is usually indicated by 
opportunistic infections for example Pneumocystis carinii pneumonia. AIDS-related 
dementia has also been described, and this has been associated with viral replication 
within the central nervous system. Progression of the disease is associated with a shift 
from predominantly monocytotropic strains of HIV to T-cell tropic Variants
HIV are still unclear, but it is probable that both intrauterine and perinatal infections can
occur (Consensus workshop, 1992).
5.6.4 HIV: the aetiological agent of AIDS
The aetiological agent of AIDS, HIV, was first isolated from the lymph node of a man 
with persistant lymphadenopathy in 1983 (Barre-Sinoussi et al). The virus was 
confirmed to be the aetiological agent of AIDS by Gallo et al (1984). Two years later, 
a second strain of the virus (HTV-2) was isolated in West Africa (Clavel etal, 1986). 
HIV has been characterized as a retrovirus belonging to the lentivirus family. The virus 
is typical of this family, which has been associated with a long period of latency between 
infection and the onset of clinical symptoms. Electron microscopical studies have 
shown that the virus has a cone-shaped core, the viral capsid, which is thought to 
provide protection for the viral nucleic acid and enzymes required for the early steps of 
replication (Gelderblom et al., 1987). Similar to many other viruses, the HIV capsid is 
composed of identical subunits arranged with an icosahedral symmetry. Such utilization 
of repeating subunits is a stategy adopted by many viruses to minimize the genetic 
information required to code for the capsid. Immunoelectron microscopy studies have 
demonstrated that the HIV capsid is composed of a 25 kD protein (p25) (Gelderblom et 
al., 1987). The capsid is surrounded by a myristolyated 17 kD protein (p i7) that 
provides the matrix for the viral structure and is vital for the integrity of the virions 
(Gelderblom et al, 1989). Recent results suggest that the pl7 matrix is required for 
incorporation of the envelope glycoproteins into mature virions (Yu et al , 1992). 
Further experiments have shown that the association of H IV -1 capsid and envelope 
glycoproteins is very sensitive to minor alterations in the matrix protein (Dorfman et al., 
1994). Thin-section electron microscopy has demonstrated that the viral surface 
characteristically has 72 knobs containing trimers or tetramers of glycoproteins 
projecting through the envelope (Ozel etal, 1988; Pinter et al, 1989; Earl etal,
1990). These knobs are derived from a precursor glycoprotein of 160 000 molecular 
weight (gpl60). Post-translational modifications result in the cleavage of gpl60 to 
produce the external (gpl20) and transmembrane (gp41) parts of the knobs, which 
project through the lipid bilayer or envelope (McCune et al, 1988). CD4 
transmembrane endoplasmic reticulum retention signal mutants have been used to study 
cleavage of gpl60. The results from these studies indicated that gpl60 can itself bind 
to gp l20 and that cleavage to produce gpl20 and gp41 probably occurs in the 
endoplasmic reticulum (Raja et al., 1993). Recent studies utilized CD4+ clones 
expressing either gpl60 or gpl20 of H IV -1 under the transcriptional control of an 
inducible promoter (Koga et al, 1994). Expression of gpl60 was associated with
(Schuitemaker et al., 1992b). Once full-blown AIDS has been clinically identified the
prognosis is poor with an expected survival period o f 1 -2 years.
intracellular accumulation of CD4/gpl60 complexes and a complete disappearance of 
surface CD4, which preceded single cell death. It is possible that this mechanism could 
contribute to the cytopathology and CD4+ T-cell depletion observed in HIV 
seropositive individuals. By contrast, clones expressing gpl20 neither exhibited any 
depletion of surface CD4 nor showed any apparent cytopathic effect (Koga et al.,
1994). The surface projections play an important role in the life cycle of the virus as 
they are involved with binding to specific receptors and subsequent entry into cells 
(Dalgleish et al., 1984; Olshersky et al., 1990). The envelope is derived from the host 
cell membrane during the final stage of maturation as the HTV particles bud from the 
infected cells. The structure of HIV is shown in Figure 5.2.
The virus genome is protected by the viral capsid and consists of around 9.8 kb on two 
identical strands of ribonucleic acid (RNA). This nucleic acid encodes three genes 
(Gag, Pol and Env) that, respectively, encode the capsid proteins, the enzymes required 
for replication, and the envelope proteins. The capsid proteins are made as a single 
polypeptide chain (p55) that is cleaved late in the virus relication cycle into p25, p i7, p7 
and p9 by a viral protease. In order to replicate, the virus must convert its RNA into a 
DNA copy and this requires the activity of an RNA-dependent DNA  polymerase 
(reverse transcriptase, RT). The Pol precursor is cleaved to produce reverse 
trancriptase, protease and integrase enzymes. The virus genome also encodes several 
regulatory proteins (Haseltine, 1991; Cullen, 1991). Interestingly, recent results 
indicate that one such gene, vif, can encode a product that plays a role during the final 
stages of packing the viral nucleoprotein core and can influence infectivity o f progeny 
virions (Hoglund et al., 1994). Another regulatory gene, vpr, has been identified as 
essential for replication of H3V-2 in human macrophages (Hattori et al., 1990). A  
diagram representing the genomic organization of HIV is shown in Figure 5.3.
5.7 REPLICA TION CYCLE OF H IV
5.7.1 Binding of HIV to CD 4
The replication of HIV is initiated when the gpl20 knobs projecting from the virions 
interact with specific molecules expressed on the surface of host cells. The major 
receptor for HIV has been identified as the CD4 molecule (Klatzman et al., 1984b) 
which is expressed on a subset of T-lymphocytes and mononuclear phagocytes 
(Sattentau and Weiss, 1988). Reports indicate that discrete populations of CD4+ 
monocytes are associated with either bright or dim fluorescence when stained for CD4. 
The number of CD4+ monocytes in peripheral blood have been shown to decline at a
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Figure 5.2
Schematic diagram of the structure of the human immunodeficiency virus (HIV), using 
the nomenclature adopted by Leis et al. (1988). The viral RNA (in association with 
nucleocapsid, NC, p7), and viral reverse transcriptase (RT) and integrase (IN) enzymes 
are present inside the viral capsid (CA). (The capsid, consisting of repeating subunits of 
p25, is responsible for the characteristic cone-shaped core of virions examined by 
transmission electron microscopy.) A protein matrix (MA, p i7) surrounds the capsid, 
which in turn is covered with a lipid bilayer (derived from the host cells during budding). 
Spikes of the transmembrane glycoprotein (TM, gp41) and surface glycoprotein (SU, 
gpl20) project through the lipid envelope. These surface spikes initiate the viral 
infection cycle by binding to specific receptors on the surface of host cells.
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Figure 5.3
Schematic structure of the genomes of HIV-1 and HIV-2, two strains of human 
immunodeficiency virus, which is the causitive agent of AIDS. The standard retroviral 
genes (green) - gag, pol and env - are present along with several other genes coding for 
regulatory productis (red). The long terminal repeat (LTR) elements, which are 
characteristic of retroviral proviruses, and crucial to regulated expression of the virus are 
shown in blue. (The diagram is adapted from that of Gallo et al., 1988).
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similar rate to T-cells during disease progression (Lucey et al., 1991). The decline in 
CD4+ monocytes is most apparent in the population associated with the higher density 
of CD4 (Schnizlein-Bick et al, 1992). The results suggest that the monocytes with low 
CD4 surface antigen expression are more likely to contain monocytotropic HIV variants, 
than the cells expressing a higher density of the CD4 antigen.
Molecular studies have indicated that for virus binding, the V I region of the CD4 
molecule interacts with a region in the fourth conserved portion of gp l20 (amino acids 
413 - 447) near the C terminal end (Arthos et al, 1989; Cordonnier, et al, 1989). 
However, further studies have shown that the conformation of gpl20 is important for 
CD4 binding, thus indicating that other noncontiguous regions of the molecule may be 
involved (McDougal et al, 1986). Viruses expressing mutant gpl20 have been 
associated with varing cell tropism and sensitivity to sCD4 neutralization (Koito et al, 
1994). These differences were attributed to alterations in the conformation of gpl20.
In one study substitution of a single amino acid, tryptophan at position 432, could 
abrogate CD4 binding and render the virus non-infectious, whilst substitution of 
isoleucine at position 425 resulted in a virus that could infect T-cell lines but not myeloid 
U937 cells (Cordonnier, et al, 1989). It is thought that the interaction of gpl20 with 
CD4 changes the conformation of the molecules resulting in exposure of a fusion 
domain in gp41. The exposure of such a domain would constitute an important step in 
the entry of HIV (Sattentau and Moore, 1991). It has been proposed, that in addition 
to CD4, permissive cells would express a specific receptor for gp41 (Quershi et al,
1990; Wilde/ al, 1992). Evidence for this receptor comes from studies that have 
demonstrated the formation of syncytia between CD4+ and CD4' cells (Perez et al, 
1992). However, evidence that gp41 can support the cell fusion and subsequent entry 
of HIV, in the absence of gp!20, is currently lacking (Marcon and Sodroski, 1994). 
Other studies have indicated that treatment of cells with the phorbol ester PMA inhibits 
CD4-gpl20-gp41 mediated fusion by modulating an accessory component in the target 
CD4-expressing cells (Golding et al., 1994). It is not thought that gpl20 has to be 
completely shed, in order for gp41 to be sufficiently exposed (Dimitrov et al., 1992), 
although there is some evidence that protease activity may enhance the exposure of the 
molecule resulting in higher infectivity (Clements et al, 1991; Kido et al, 1991). 
Surface expression of CD4 is down-modulated following infection with HIV (Hoxie et 
al, 1986; Poulin et al., 1991). However, CD4 does not internalize with the virus and 
CD4-related signal transduction events are not thought to be required for virus entry 
(Orloff et al, 1991). I
5.7 2 Formation of syncytia
The formation of multinucleated giant cells, (or syncytia), is a characteristic of HIV  
replication in T-lymphocytes in vitro (Lifson et al., 1986) Syncytia have also been 
recorded to form in cultures of human monocytes two weeks after infection with HIV-1 
(Gendelman et al., 1988). However, only certain clinical isolates have the capacity to 
induce syncytia formation in vitro (Schwartz et al., 1989). Monocytotropic isolates 
tend to be associated with slow in vitro growth characteristics and cannot induce 
formation of these multinucleated giant cells (Schuitemaker et al., 1991). It was 
initially thought that syncytia formed as a result of HIV-infected cells (expressing viral 
antigens on their surface) binding to uninfected CD4+ cells, resulting in subseqent fusion 
and cytolysis (Yoffe et al., 1987). Formation of syncytia can be blocked by monoclonal 
anti-CD4 antibodies, indicating that the fusion is mediated by binding of viral gpl20 to 
CD4 (Somasundaran and Robinson, 1987).
However, there is mounting evidence that interaction of gpl20 with CD4 is not the only 
factor required for efficient syncytial formation. Chesbro et al. (1990) expressed CD4 
on U87MG (astroglioma) and SCL1 (squamous cell carcinoma) cell lines. Binding of 
HIV-1 gpl20 to these cell lines occurred but was not associated with syncytial 
formation. Further evidence that syncytial formation requires more than just binding of 
HIV-1 gpl20 to CD4 was provided by studies reported by Skinner et al. (1988) and 
Page et al. (1992). These authors showed that monoclonal antibodies with specificity 
for the V3 (CD4-binding) region of gpl20 could block syncytia formation and neutralize 
virus infectivity, without affecting binding to CD4. Studies using a range of gp l20 
molecules with mutations in the V3 region confirmed that syncytia formation could be 
prevented without affecting CD4 binding (Freed and Risser,1991). Other evidence that 
binding of CD4 and subsequent cell fusion are separate processes has been provided by 
Allaway et al. (1993). These authors tested a range of compounds and showed that 
molecules that inhibited HIV attachment acted synergistically with those that inhibited 
HIV-1 fusion. It is believed that the interaction of CD4 with gpl20 induces a 
conformational change in the latter molecule which exposes the viral gp41 glycoprotein. 
gp41 is thought to mediate fusion of the viral envelope with the host cell membrane 
(Freed et al., 1992), but it could also be envisaged that this molecule plays a role in the 
fusion of infected and uninfected cells. This has been investigated by Perez et al.
(1992) who demonstrated that gp41 could mediate syncytial formation between CD4+ 
and CD4" cells, in the absenceof gpl20. However, the CD4 molecule may itself play an 
active role in the fusion process. Evidence supporting this comes from studies that have 
investigated the infection of CD4+ cells isolated from chimpanzees. These cells were 
shown to bind HIV and support viral replication, but failed to fuse with uninfected cells.
5.7.3 CD4-independent routes of entry
Transfection experiments have demonstrated that the expression of CD4 is insufficient 
to render cells permissive for infection with HTV (Clapham et al, 1991) and certain 
CD4" cell lines can be infected by the virus (e.g. Patterson and Knight, 1987). The 
extent of virus replication in CD4“ cell lines is generally low. The limited extent of 
virus production in such CD4‘ cells is probably due to inefficient viral entry as fewer 
than 1% of the cells become infected (Mellert et al., 1990; Brack-Wemer et al, 1992). 
In certain cases, receptors other than CD4 have been identified that can mediate HIV 
infection. A  mannose-binding lectin, present on certain CD4“ cells has been shown to 
be capable of binding gpl20 (Curtis et al, 1992) and may function as the HIV receptor 
on these cells. Galactosyl ceramide (Gal-C) has also been identified as a potential 
receptor that mediates entry of HIV into neural cells (Harouse etal, 1991) and into 
colon epithelial cells (Yani et al, 1992). Recent studies have demonstrated that gpl20 
binds to Gal-C at a site that is conformationally close to the V3 loop of CD4 (Cook et 
al, 1994).
5.7.4 Cell-to-cell transmission of HIV
In vitro studies have confirmed that HIV can pass directly from cell-to-cell, but infection 
still requires interaction of gpl20 with CD4 and reverse transcriptase activity (Sato et 
al, 1992). The importance of gpl20 in cell-to-cell transmission was demonstrated 
using a clone of HIV defective in the precursor molecule gpl60. Cell-to-cell 
transmission of this virus failed to occur (St Luce et al, 1993). Cellular adhesion may 
contribute to the transmission of virus between cells. HIV can move from monocytes 
or lymphocytes to epithelial cells during such close cell contact that neutralizing 
antibodies do not block the transfer (Gupta et al, 1989; Phillips and Bourbinaiar,
1992). Such cell to cell transfer of HIV may be facilitated by integrin molecules 
stabilizing close contact of cells (Hildreth and Orentas, 1989). Experiments have 
indicated that the integrin molecule CD 18, or the protein complex CD1 la-c/CD18, in 
addition to CD4, participate in infection and cytopathic effect of H IV -1 in vitro 
(Valentin et al, 1990b). Results from an in vitro model of HIV cell-to-cell 
transmission demonstrated that infection of new cells was not prevented by the presence
As human and chimpanzee CD4 differs by only 5 amino acids these results provide
further evidence that a domain required for HIV-mediated syncytium formation lies
outside the virus binding site (Camerine and Seed, 1990).
5.7.5 Entry and uncoating of HIV
The initial interaction of a virus glycoprotein with specific cellular receptors is the first 
stage of infection. This is followed by entry and uncoating of the virus. Enveloped 
viruses enter cells following fusion with the cell membrane. Many enveloped viruses, 
including influenza virus, are known to enter cells by receptor-mediated endocytosis. 
Virions bound to susceptible host cells via specific receptors are endocytosed into 
intracellular vesicles. The acidic environment of these vesicles encourages the viral 
envelope to fuse with that of the endosome and thus release the viral nucleic acid into 
the cells. In vitro studies using chemicals to raise the intracellular pH have shown that 
this can block this route of entry. An early study using ammonium chloride to raise the 
pH of medium containing Jurkat cells showed an inhibitory effect on HIV infection 
(Maddon et al, 1986). However, infection was not prevented, but delayed, suggesting 
that the compound was having an alternative affect on the cells metabolic pathways, or 
on viral assembly and processing. In keeping with this is the observation that virions 
produced in the presence of ammonium chloride show a low degree of infectivity 
(McClure et al., 1988). Subsequent experiments have demonstrated that entry of HIV  
into T-lymphocytes is unaffected by pH (Stein et al, 1987; McClure et al, 1988).
Viral entry by a pH-independent mechanism indicates that the viral envelope can fuse 
directly with the plasma membrane. Other evidence that HIV is able to fuse, enter, and 
infect cells directly at the surface is provided by the studies reported by Maddon et al 
(1987). These authors transfected CD4 molecules lacking cytoplasmic tails, and 
therefore signal transduction capacity, into HeLa cells. The CD4 mutants were unable 
to undergo cytosis in the host HeLa cells, yet HIV infection could be detected as readily 
as wild-type CD4-expressing HeLa cells. Similar results were reported by Bedinger et 
al (1988) who used truncated and chimeric CD4 molecules that were resistant to 
internalization by phorbol ester, yet were permissive for HIV entry and replication. The 
entry of HIV into CD4" cells also occurs in a pH-independent manner (Tateno et al.,
1989). Electron microscopy studies have confirmed that direct fusion of the viral 
envelope with the cell membrane, and also receptor-mediated endocytosis via clathrin- 
coated pits can mediate entry of HIV into lymphocytes and macrophages (Grewe etal.,
1990). The exact mechanism for this process in HIV infection has not been elucidated.
Infection of myeloid cells by HIV can be mediated by antiviral antibodies and specific Fc 
receptors expressed on the cell surface. This triggers a series of events that may result
o f the antiviral compound AZT or by neutralizing antibodies (Gupta et al, 1989). This
observation has important implications for the in vivo control o f viral replication.
in the phagocytosis of the virus. Since HIV can replicate within these cells, it is 
possible that this represents a method of viral entry that is specific for this cell type 
(Robinson et al., 1991; Haubrich et al., 1992). In a similar manner to that described for 
antibody, the binding of complement-coated virions may be mediated by receptors for 
the iC3b component of complement (CR3, CD 1 lb/CD 18) which are expressed by 
myeloid cells (e.g. Reisinger et al, 1990). The CD1 lb/CD 18 molecule is part of the 
integrin superfamily and can mediate cellular adhesion as well as functioning as a 
complement receptor.
5.7.6 Reverse transcription and integration of viral nucleic acids 
Once the virus has entered a cell, several intracellular events occur that lead to 
integration of a provirus into the host chromosomes. Viral RNA, present in the 
cytoplasm in association with core proteins, is reverse transcribed. This process results 
in the conversion of the single-stranded, positive sense RNA into double-stranded linear 
D NA  (cDNA) proviral intermediates. Reverse transcription also generates the long 
terminal repeat (LTR) elements, which are characteristic of retroviral proviruses and 
crucial to regulated expression of the virus. Reverse transcriptase is not a normal host 
cell enzyme, and the enzyme is therefore present in the virus particle. Recent data 
indicates that the migration of viral nucleoprotein preintegration complexes into the 
nucleus is an active process that requires the continued association of linear DNA  
proviral intermediates with virion gag proteins (Bukrinsky et al, 1992). Proviurses 
integrate into the host chromosome, as circular but non-covalently bound molecules.
The process requires a single viral 32 kDa protein termed integrase (Famet and 
Haseltine, 1991) which is present in preintegration complexes. The integration of viral 
DNA seems to be essentially random in respect of the host sequences, although studies 
have shown that adenosine is preferred next to the target site (Hong et al, 1993). 
Integration of the viral cDNA into the host nucleic acid is essential for productive 
infection. In permissive, activated, T-cells, HIV undergoes integration and replication 
within 24 hours (Kim et al, 1990) but the process takes around 48 hours in 
macrophages (Munis et al, 1992). Reverse transcription is inefficient and viral DNA  
cannot integrate in resting T-lymphocytes (Stevenson et al, 1990b) but replication 
competent unintegrated forms can persist prior to activation of the host cells (Miller et 
al, 1990). As the T-cells start to replicate, they become permissive for HIV and the 
virus DNA  integrates (Bukrinsky et al, 1991). In myeloid cells, HIV can integrate into 
non-replicating D NA  (Weinberg et al, 1991). The process of reverse transcription is 
responsible for generating much genomic variability. It has been estimated that 
approximately 1 error occurs during every replication cycle. All retroviruses, including
5.7.7 Late stages of the viral replication cycle
The earliest mRNA species produced in infected cells appear to be the regulatory 
elements (reviewed by Greene, 1990, 1991). Retroviral proteins are translated as 
polypeptides that are post-translationally cleaved by a viral protease. Many viral 
proteins also undergo glycosylation, phosphorylation or myristolation by host enzymes. 
Both the precursor and mature cleavage products of the envelope gpl60 are heavily 
glycosylated (Mizouchi et al, 1988). The function of the N-glycans are not known, 
although deglycosylation of env gene products leads to reduced infectivity and capacity 
to form syncytia (Kozarsky et al, 1989). The final stage of the virus replication cycle is 
the maturation of the virions as they bud from the host cell membrane. The virus 
envelope is derived from the host cell membrane during the budding process, but ail host 
glycoproteins are excluded from the membrane during the process. HIV-1 specific Vpu 
is involved with enhancement of viral detachment from the cell membrane and 
degradation of CD4 in the endoplasmic reticulum. These processes have been shown to 
be regulated by phosphorylation (Schubert and Strebel, 1994). The replication cycle of 
HIV is outlined in Figure 5.4.
In vitro, studies have shown a wide variety of human cells are susceptible to infection by 
HIV, but the extent of infection varies and can depend on the strain of virus. These cell 
culture studies indicate that successful replication is determined both by viral entry into 
the cells and by later events in the virus replication cycle. Sucessful entry of HIV into a 
cell may be followed by a latent phase, which may occur because of the failure of viral 
nucleic acids to integrate into the host chromosome, or because the transcription of the 
viral proteins does not occur. Viral cDNA may remain integrated but in a latent state 
for long periods, which are determined by factors that have not been elucidated. In the 
haematopoietic system, CD4+ helper T-lymphocytes are major targets for HIV infection. 
These cells are only permissive for HIV infection in vitro when they have been activated 
and are replicating (Zack et al, 1990). In most solid tissues, the cells of the 
mononuclear phagocyte system form the major reservoir of virus. The exception to this 
is probably in the lymph nodes where the predominantly infected cell type is thought to 
be the follicular dendritic cells; which have been associated with high levels of virus 
production in vitro (Pantaleo et al, 1993). Evidence suggests that the infection cycle in 
myeloid cells may differ from the budding of mature virus particles from the host cell
HIV, package two complete copies o f their genome into every virion. It is possible that
recombination between the strands may occur, and provide a further source o f variation.
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Figure 5.4
Overview of the main stages in the replication cycle of H IV-1 in permissive cells. The 
viral replication cycle is initiated when the viral glycoprotein spikes bind to a specific 
receptor on the host cell surface. CD4 is the main receptor, and binding of gpl20 to 
CD4 is thought to cause a conformational change that exposes gp41. The mechanisms 
by which the virus enters the cell and uncoats are still unclear, but probably involve fusion 
of the viral and host cell membranes. Once inside the cell the virus forms pre-integration 
complexes and reverse transcribes its RNA genome. The DNA copies of the viral 
genome move to the nucleus where they integrate randomly into the host chromosomes. 
When the cell is activated viral proteins are transcribed and progeny virions are produced. 
Virions mature by budding either through the host cell membrane, or in myeloid cells into 
intracellular vesicles.
membrane of T-lymphocytes. In myeloid cells, HIV can be found sequestered in 
intracellular vacuoles, and release of virus from these cells is often restricted.
Isolates of HIV obtained early in the course of infection, from asymptomatic individuals, 
usually display slow replication kinetics, are non syncytium-inducing and are tropic for 
primary cells but not for transformed T-cell lines (Popovic and Gartner, 1987; 
Schuitemaker et al., 1991). Isolates from later stages of disease show more diverse 
phenotypes and are characterized by having a higher rate of replication and the capacity 
to induce syncytia (Fenyo et al, 1988). It has been proposed that the highly virulent 
strains of HIV may be present in early stages of acute infection but are suppresssed by 
the competent anti-HIV response mounted by the host, while macrophage-tropic slow 
growing isolates escape immune surveillance and establish a persistent infection 
throughout the asymptomatic period of disease.
5.7.8 Assays available to detect replication of the virus
Replication of HIV in vitro can be monitored by microscopical observation of cytopathic 
effects (CPE), assays to determine cell death (e.g. use of MTT), detection of virus 
specific enzyme activity (e.g. reverse transcriptase, RT) or the immunological detection 
of specific viral antigens (e.g. p24). The formation of multinucleated giant cells or 
syncytia and subsequent cell death is a characteristic of HIV infection of T-lymphocytes 
in vitro (Lifson et al, 1986; Yoffe et al, 1987). The fusion of infected cells expressing 
viral antigens on their surface and uninfected CD4+ cells is thought to be mediated by 
interaction of gpl20 and CD4. Close contact of cells initiated by CD4/gpl20 binding 
may be enhanced or stablized by interaction of cellular adhesion molecules.
Monoclonal antibodies to the integrin LFA-1 (CD11 a/CD 18) have been shown to block 
cell aggregation and syncytium formation, but not virus infection (Hildreth and Orentas, 
1989, Pantaleo et al, 1991). Cell-to-cell fusion may be an early sign of HIV infection 
in vitro, but it is unclear whether it contributes to the CD4+ cell depletion in the infected 
host. There is no evidence of multinucleated giant cells occurring in vivo, except in the 
brain (Sharer et al, 1982). Cytopathology and cell death occurring during acute HIV  
infection in vitro have been linked to accumulation of viral cDNA in the cytoplasm of 
cells (Shaw etal., 1984; Laurent-Crawford and Hovanessian, 1993).
The previous sections have briefly described the aetiological agent of the Acquired 
Immunodeficiency Syndrome, and the mechanisms by which it replicates. The response 
of the host to the replication of HIV, which occurs primarily in cells of the immune 
system is discussed in the following section.
5.8 IM M U N O L O G Y  O F  H I V  IN F E C T IO N
5.8.1 Host responses during HIV infection
Early observations of the frequency and type of opportunistic infections observed in 
AIDS patients indicated that the indivuals were suffering from a severe defect in their 
cell-mediated immune function. The most conspicuous immunological defect 
associated with HIV infection was the quantitative depletion of the CD4+ T-lymphocyte 
population. Studies on the blood of AIDS patients showed that the ratio of CD4+ 
helper/inducer T-lymphocytes to CD8+ suppressor/cytotoxic T-cells was reversed (Lane 
et al, 1983). This observation suggested that the CD4+ T-cell may be infected with the 
aetiological agent of the disease, now known to be HIV. The virus was indeed first 
isolated from CD4+ T-lymphocytes obtained from a patient at risk of AIDS (Barre- 
Sinoussi et al, 1983) and in vitro studies subseqently showed that CD4+ cells were 
major targets for the virus. In situ hybridization studies have used HIV probes to 
investigate the number of CD4+ lymphocytes present in peripheral blood of infected 
individuals. Examination of peripheral blood at any given time reveals the presence of 
only around 1:106 cells expressing viral proteins (Harper et al, 1986). However, a 
number of defects have been recorded in the function of lymphocytes isolated from HIV 
seropositive individuals that had normal numbers of lymphocytes (Fauci, 1987;
Pinching, 1990). Studies have indicated that production of cytokines, including EL-2 
and IFN-y are down-regulated (Maggi etal., 1987) and signal transduction is abnormal 
in lymphocytes isolated from HTV infected patients (Nye et al, 1992). These defects 
contribute to the significant defects in immunity characteristic of HIV infection.
5.8.2 Humoral immune responses
Although the characteristic of the late stages of AIDS is a severe immunosuppression, 
studies showed that in the early stages of infection the immune system is activated and 
can respond to the pathogen. The activity of the humoral immune system can be 
demonstrated by the production of specific antibodies against the virus (Samgadharan et 
al, 1984). The first antibodies to appear (2 - 12 weeks after infection) are IgM anti-p24 
(core) and anti-gp41 (transmembrane), whilst antibodies against pool gene products 
appear later. The timing of antibody appearance may correlate with clinical symptoms 
suggestive of an acute infection. Although the presence of neutralizing antibodies has 
been associated with a healthy carrier state, the humoral immune response never 
completely controls the infection, and the virus persists (Arendrup et al, 1993). 
Neutralizing antibodies are directed against the viral surface antigens, particularly the 
envelope antigen gp!20. A high mutation rate during the transcription of this antigen
results in virus that can escape from antibody neutralization. This has been 
demonstrated by culturing HIV in vitro in the presence of antibodies. The 
neutralization capacity associated with these antibodies decreased with time (McKeating 
etal, 1989).
5.8.3 Cell mediated immunity
HIV specific cell mediated immunity has been demonstrated and the development of 
cytotoxic T-cells against infected cells expressing viral antigens has been documented 
(Walker et al., 1987). The antiviral response of CD8+ T-cells could be a major 
mechanism for the control of HIV replication in PBMC of the host. Antiviral CD8+ 
cells are found at highest levels in asymptomatic individuals, and can suppress virus 
replication in cultured CD4+ lymphocytes and macrophages without killing the infected 
cells. The CD8+ antiviral activity is not MHC-restricted and can suppress the 
replication of all strains of H IV -1, HIV-2 and SIV in a non-cytolytic manner. The 
effect appears to be mediated by activated CD8+ cells expressing CD28.
Many of the organisms that cause widespread infection in AIDS patients, such as 
Mycobacterium avium - Mycobacterium intracellulare (M. avium complex), 
Cryptococcus neoformans and Candida albicans are normally contained by cells of the 
mononuclear phagocyte lineage. In healthy individuals, these pathogens would 
normally activate the complement system and the opsonized organisms would bind to 
specific C3 receptors which are present primarily on Kupffer cells. If patients are 
injected with C3-coated erythrocytes there would be a rapid initial clearance from the 
blood as the erythrocytes attach to the C3 receptors. The attached cells would either be 
phagocytosed by the Kupffer cells or be released back into the circulating blood 
following cleavage of the complement components. The clearance of C3-coated 
erythrocytes was studied in AIDS patients. The release of cells was significantly higher 
in AIDS patients than in control homosexual males (Bender et al., 1987) suggesting that 
phagocytosis was decreased. In a similar manner, circulating IgG-sensitized 
erythrocytes can attach to splenic macrophage Fc receptors, which triggers phagocytosis 
and removes the erythrocytes from the circulation. Patients with AIDS had significantly 
higher clearance times than healthy controls indicating a phagocytic defect. An assay 
developed to investigate phagolysosomal fusion following phagocytosis of yeast was 
used to study monocytes isolated from healthy volunteers and from HIV infected 
individuals (Pittis et al., 1993). These authors showed that defects in phagolysosomal 
fusion correlated with low CD4 counts. The basis of the defect was not investigated, 
although recombinant gp l20 was shown to inhibit normal phagolysosomal fusion.
Severely immunologically compromised (SCID) mice can be repopulated with human 
peripheral blood mononuclear cells. These animals have been used as an in vivo model 
of HIV infection (Martino et al., 1993). In tissue culture macrophage-tropic strains of 
HIV tend to be relatively non-cytopathic. However, in the SCID model, the 
macrophage-tropic HIV strains were associated with a faster depletion of CD4+ cells, 
than infection with highly cytopathic strains (Mosier et al, 1993). The results suggest 
that the relatively non-cytopathic strains, perhaps secondary to replication in 
macrophages, compromise the function of CD4+ T-lymphocytes and produce the 
gradual but persistent loss of these cells by means other than direct cell killing. It is 
possible that changes in the pattern of cytokines released by HIV-infected macrophages 
could occur and reduce the level of CD4+ cells via apoptosis (programmed cell death). 
Cytokines released from infected macrophages, such as TNF-a are known to induce 
apoptosis.
5.9 REPLICATION OF H IV  IN  HUMAN MONOCYTES AND MONOCYTIC 
CELL LINES
HIV-1 replication in mononuclear phagocytes is reported to be dependent on their stage 
of maturation and differentiation (Gazzolo and Mace 1990). The limited availability 
and heterogeneity of isolated human mononuclear phagocytes has restricted the use of 
these cells in investigations of viral replication. The monocytic cell lines, THP-1 and 
U937, have frequently been used as a model for studying the replication of H IV -1. 
Monocytotropic isolates of H IV -1 do not usually productively infect immature myeloid 
cell lines in vitro. However, a small proportion of non-differentiated THP-1 cells can 
be infected with the monocytotropic HIV-1BA_L isolate (Kitano et al, 1990).
Biologically active vitamin D3, and related analogues, induce differentiation of both 
monocytic cell lines and human peripheral blood monocytes. Use of these chemicals 
has been associated with enhanced replication of both monocytotropic and lymphotropic 
variants of H IV -1 (Skolnik et al., 1991). The release of mature virions from THP-1 
cells was restricted, unless the cells were treated with maturation-inducing chemicals 
including DMSO, dibutyryl cAMP, Vitamin D 3 and TP A (Kitano et al, 1990). The 
increase of permissiveness for the monocytotropic H IV -lBa_L isolate in a proportion of 
phorbol ester treated THP-1 cells correlated with a decrease in permissiveness for the 
lymphotropic isolate HIV-1LAI (Meylan et al, 1993). Interestingly, no difference in the 
binding of H IV -1 to permissive or non-permissive cells could be detected, and 
attachment could not be blocked by anti-CD4 antibodies, providing evidence for a CD4- 
independant route of virus entry into THP-1 cells.
Two major patterns of H IV -1 replication in human mononuclear phagocytes have been 
recorded. HIV-1 infection of human monocytes, cultured in vitro for at least 2 days, 
results in efficient virus production, as measured by reverse transcriptase (RT) activity in 
culture supernatants, whereas HIV-1 infection of fully differentiated macrophages yields 
a low but sustained extracellular virus release, only demonstrable by the more sensitive 
p24 assay (Valentin et al, 1991). This suggests that multiple levels of regulation 
control the replication of HIV in human monocyte-derived-macrophages. THP-1 cells 
have been used to model HIV-1 infection of human myeloid cells, and results have 
confirmed that following successful receptor/virus interaction the course of infection 
may vary (Mikovits et al, 1990). The virus may enter a latent state with no viral 
antigens detectable on the infected cells. This would be particularly important in vivo 
as virus-infected cells could be disseminated into various tissues; with the absence of 
viral antigen expression ensuring that the cells are not detected by the normal immune 
surveillance mechanisms. Alternatively, the cells may become chronically infected, with 
low levels of virus released. The most productive form of infection has been associated 
with accumulation of mature virions within intracytoplasmic vesicles, or with enhanced 
budding of the virus from the cell surface. In cells with restricted HTV expression, 
nuclear factor(s) were found that blocked the formation of /^-associated DNA binding 
complexes, suggesting that initiation of transcription was negatively regulated (Mikovits 
et al, 1990). However, the factors controlling the viral replication cycle in myeloid 
cells have not yet been elucidated.
CD4 is an important accessory molecule in the activation of MHC Class II-restricted T- 
cells and has been identified as the receptor for HIV (Dalgleish et al, 1984; Klatzman et 
al, 1984b). In vitro experiments have demonstrated a correlation between the number 
of human monocytes expressing CD4 and the proportion which can be infected with 
HIV-1 (Potts et al, 1990). One of the first indications that cells other than T- 
lymphocytes expressed CD4 was the demonstration of the molecule on the surface of 
U937 cells (Wood et al, 1983). Detailed studies of the virus/receptor interaction have 
indicated that binding of viral gpl20 to host CD4 molecules results in a conformational 
change of gpl20 which exposes gp41. It has been suggested that interaction of gp41 
with a host cell protein is involved with the entry and subsequent fusion of the virus and 
cell membranes. This observation prompted speculation that permissive cells may 
express a specific receptor for gp41. The first evidence for such a receptor is the recent 
identification of surface proteins that can directly bind HIV-1 gp41 on U937 cells (Chen 
etal, 1993).
Cells of the mononuclear phagocytic lineage are permissive for infection with HIV (e.g. 
Rich et al, 1992). Freshly isolated human peripheral blood monocytes are not as 
susceptible to in vitro infection with the virus as those which have been allowed to 
differentiate into cells with characteristics of macrophages (Schuitemaker et al, 1992a). 
This observation is surprising in view of the progressive decrease of CD4 expression 
recorded during in vitro maturation of human monocytes (Valentin et al, 1990a). 
However, evidence for a CD4-independent route of entry for cells of the mononuclear 
phagocyte system has come from several studies. Bone marrow myeloid precursors 
devoid of CD4 are readily infected with HIV (Folks et al, 1988) and it has been shown 
that HIV can enter myeloid U937 cells in the presence of saturating concentrations of 
anti-CD4 antibodies (Pauza and Price, 1988). A  series of monocyte hybridomas 
expressing different levels of CD4 were shown to be readily infectable with HIV. The 
level of CD4 expression did not appear to be a factor in determining susceptibility to 
infection and alternative methods of viral entry including non-specific phagocytosis were 
postulated (Sperber et al, 1990b).
Treatment of human peripheral blood monocytes, U937 cells, and to a lesser extent 
THP-1 cells, with rIFN-y resulted in a dose-dependent decrease of surface CD4 
expression (Faltynek et al, 1989). Addition of the phorbol ester, PMA, to THP-1 cells 
also induced a dose-dependent decrease of CD4 expression (Auxerx et al, 1992). 
Down-modulation of CD4 and suppression of viral replication were linked to the 
expression of the viral nef gene in U937 and THP-1 transfectants (Tsenetsugu-Yokota 
et al, 1992). The CD4 antigen becomes undetectable on monocytic cell lines, including 
U937 cells, infected by HIV-1. Studies have revealed that steady-state levels of CD4 
mRNA were unaffected by infection with the virus, with the generation of intracellular 
complexes between gpl60 and CD4 responsible for the disappearance of cell surface 
CD4 in H IV -1-infected U937 cells (Bour et al, 1991). Further in vitro studies revealed 
that the presence or synthesis of viral gpl60 led to a failure to efficiently generate CD4 
protein (Wainberg et al, 1993).
The range of surface antigens expressed by these cells changes markedly during 
differentiation. Myeloid cells can express receptors for the constant portion (Fc) of IgG 
antibody molecules (FcyRI, CD64; FcyRII, CD32; and FcyRTQ, CD64). These 
receptors can mediate the binding of antibody-coated virions, which subseqently enter 
the cells by endocytosis (Homsy et al, 1988). The expression of Fc receptors has 
important implications for attempts to control infection using conventional vaccine 
technology. The in vitro replication of HIV in human peripheral blood mononuclear 
cells was enhanced by addition of sub-neutralizing concentrations of antibody (Gras et
al, 1988). Serum obtained from seropositive individuals was shown to mediate 
antibody enhancement of viral infection in a manner that was blocked by anti-CD64, but 
not anti-CD4 monoclonal antibodies (Homsy et al, 1989). However, other reports 
suggest that CD4 may play a role in antibody enhancement of HIV infection (Jouault et 
al, 1989; Takeda and Ennis, 1990). Clinically, infection of HTV seropositive 
individuals with other unrelated viruses has been associated with the progression of the 
disease. Herpes viruses, for example, may play a role as cofactors in HIV infection. A  
mechanism that may account for this has been elucided in studies reported by 
McICeating et al (1990). These authors showed that infection of CD4" fibroblasts with 
cytomegalovirus (CM V) induced the cells to express Fc receptors on their surface.
This rendered the cells susceptible to infection with HIV through antibody-virus 
complexes.
The complement receptors CR1 (CD35) and CR3 (CD1 lb/CD 18) have been implicated 
in mediating CD4-independent entry of HIV into myeloid cells. HIV-1 can activate the 
complement system via the Classical pathway. Low concentrations of H IV-1 were able 
to infect U937 cells more easily in the presence of complement (Reisinger et al., 1990). 
Similarity, when sub-optimal amounts of complement-opsonized HIV-1 and HIV -2  were 
used to infect THP-1 cells, higher and earlier productive infection of the cells was 
observed (Thieblemont et al., 1993). The infection could be blocked using anti-CRl 
and anti-CR3 antibodies, but not by anti-CD4 or anti-LFA-1 (CD 11 a/CD 18) antibodies. 
These observations indicate that complement can mediate productive infection of 
monocytic cell lines independently of CD4.
Monoclonal antibodies to the integrin p-chain CD 18 efficiently inhibit syncytium 
formation induced by the interaction of H IV -1 infected monocytoid cells and CD4+ T 
cells. The antibodies also interfere with the cell-free HIV-1 infection of U937 cells 
(Valentin et al., 1990b). These authors reported that anti-CD 18 monoclonal antibodies 
do not inhibit binding of the viral envelope glycoprotein gpl20 to the cell surface 
receptor CD4. This indicates that CD 18, or the protein complex CD1 la-c/CD18, in 
addition to CD4, participate in the infection and cytopathic effect associated with HIV- 
1. This suggests that intracellular adhesion may contribute to virus transmission from 
cell to cell, which may be an important mechanism in the spread of virus.
The growth rate of U937 and THP-1 cells was not affected by chronic infection with 
HIV-1 (Ushijima et al., 1993). However, chronically infected U937 cells were reported 
to be more differentiated than uninfected U937 cells (Gazzolo and Mace, 1990). This 
suggests that the viral gene expression can trigger the maturation process. Endogenous
Infection with HTV-1 has been associated with modulation of surface antigen expression. 
CD4 expression was down-regulated on infected THP-1 and U937 cells, whilst the 
expression of CD 15 (a granulocytic marker) was up-regulated (Ushijima etal., 1991). 
The density of MHC Class II antigens (HLA-DR and HLA-DQ) and of CD1 lc was 
enhanced on the HTV-1 infected THP-1 cells. CD 14 (the receptor for lps complexed to 
a binding protein) and CD20 (a B-cell resticted antigen) expression was low on both cell 
lines and did not alter significantly on the infected cells (Ushijima et al., 1993).
THP-1 cells do not constitutively produce any detectable amounts of protein or mRNA 
for the cytokines TNF-a or EL-(3. However, when stimulated with lps, or lps and IFN- 
Y, TNF-a and IL-1 [3 were detected in supernatants of both uninfected and chronically 
H IV -1-infected THP- 1  cells. However, lps stimulation of acutely HTV-1-infected THP- 
1 cells resulted in phenotypic changes associated with maturation and increased IL-1 (3, 
TNF-a and virus production were recorded (Molina et al, 1989). Treatment of human 
macrophages with IFN-a, IFN-p and IFN-y or lps prevented the establishment of 
productive HIV infection (Kombluth etal, 1989).
The effects of phagocytosis on the transcription of HIV were modelled by Shattock et 
al (1993 a). These authors showed that phagocytosis ol Mycobacterium tuberculosis 
by THP-1 cells affected HIV replication by up-regulating viral transcription and down- 
regulating viral release. Increased viral trancription and decreased viral release was 
likewise observed when THP-1 cells were induced to become adherent by exposure to 
lps (Shattock et al, 1993b).
IFN-a was shown to restrict the replication o f HIV in U937 cells probably by acting on
proviral transcription and by interfering with transcriptional factors involved with
transactivation o f the LTR (Gazzolo and Mace, 1990)
PARTJHe JNFLHENCE o f  t h e  c e l l  c y c l e  q n  r e p l i c a t i q n  OF H IV
5.10 THE CELL CYCLE
5.10.1 Cell cycle of eukaryotic cells
The replication of eukaryotic cells has been extensively studied and it has been shown 
that once a cell becomes committed to divide it passes through a discrete series of four 
events. The cell cycle is initiated when a cell enters G1 (the first gap). The synthesis 
of DNA  is restricted to a certain period which is defined as the synthesis (or S phase) of 
the cell cycle. At the end of the S phase, cells enter the second gap (G2) and then 
undergo division by mitosis (M). The cells can then re-enter G1 or enter a quiescent 
state (termed GO). Propidium iodide can be used to stain DNA in the nuclei of cells. 
When excited with light from an argon ion laser (488 nm) propidium iodide emits red 
light (625nm). The fluorescence intensity provides a useful measure of the DNA  
content of a cell (Crissman and Steinkamp, 1973; Fried et al., 1976). When an 
exponentially replicating population of cells is stained with propidium iodide and the red 
fluorescence is analysed by flow cytometry, it would be expected that there would be 
two peaks of fluorescence - one representing cells in G1/G0 and one with double the 
intensity of the G1/G0 peak representing cells in G2/M. The remaining cells (which 
would be in S phase) would have an intermediate intensity of fluorescence. A diagram 
showing the relationship of propidium iodide staining intensity to replication of DNA  
during the cell cycle is shown in Figure 5.5.
5.10.2 Cell cycle inhibitors
Several compounds have been identified that can be used to interupt normal progression 
of eukaryotic cells through their replication cycle. Details of some of these chemicals, 
and their reported mechanisms of action are described below.
Aphidicolin (C20H34O4) is a tetracyclic diterpene tetraol that is isolated from 
Cephalosporium aphidicola and certain other fungi (Huberman, 1981). The compound 
is reported to be a specific inhibitor of mammalian polymerase a  and blocks cells at the 
Gl/S boundary (Tobey et al, 1988).
Colchicine is a plant alkaloid, which can block replication during metaphase without 
affecting chromosome condensation. In the presence of colchicine, no spindle forms, 
and there is no movement of the chromosomes towards the poles of the cell. Every a(3
Fluorescence 2 (FL2 )
Figure 5.5
Cell cycle and propidium iodide analysis. The diagram shows the replication cycle of 
eukaryotic cells. The cell cycle is initiated when a cell enters G1. DNA synthesis is 
restricted to S phase, and when complete cells enter G2, before dividing by mitosis (M). 
Following mitosis cells may either enter a quiescent state (GO) or return to Gl. Cells in 
G2/M have double the DNA content of G1/G0 cells, and S phase cells have an 
intermediate DNA content. Propidium iodide stainedcellsfluoresce red with an intensity 
proportional to the DNA content of the cell. The diagram shows where markers would 
be set for analysis.
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dimer of tubulin contains one high-affinity binding site for the compound. Tubulin with 
a bound colchicine molecule can add to the end of a microtubule, but the presence of 
one or two colchicine-bearing tubulins prevents further addition of any other tubulins 
whether or not they contain bound colchine (Osborn and Weber, 1975).
5-fluoro-2?-deoxyuridme prepared at a concentration of 10*8M  was shown to inhibit 
the conversion of formate into DNA  thymine and block DNA synthesis (Bosch et al., 
1958). This compound was also reported to block DNA synthesis in eukaryotic cells by 
Ruechert and Mueller (1960). These authors reported that concentrations of 10"6 M  
completely inhibited the growth of HeLa cells. 5~fluoro-2'-deoxyuridine was shown to 
act by inhibiting the enzyme thymidylate synthase (Jackson, 1978) and thus to prevent 
D NA  synthesis from occurring.
Hydroxyurea (CH4N 20 2), can inhibit DNA synthesis by decreasing 
deoxyribonucleotide pools (Skoog and Nordenskjold, 1971). This was shown to result 
from the inhibition of ribonucleotide reductase (Reichard and Ehrenberg, 1983). 
Hydroxyurea treatment results in little or no reduction in protein synthesis and therefore 
cells with low DNA but high protein content accumulate (Adams and Lindsay 1967). 
Exposure of cultured human fibroblasts to a concentration of lfr3 M  hydroxyurea for a 
period of 24 hours was reported to synchronize the cells (Tobey et al, 1988). The 
yield of chromosome aberrations can be enhanced by exposure of cells in the G2 phase 
of the cell cycle to hydroxyurea. It is thought that this effect occurs because the 
compound can interfere with the normal repair mechanisms (Antoccia et al, 1992). 
Hydroxyurea has been used clinically for the treatment of certain carcinomas.
However, therapeutic concentrations of hydroxyurea are associated with cellular 
toxicity. The mechanism of this toxicity was investigated by Skog et al (1992). These 
authors showed that rapid replication of cells following release from hydroxyurea 
contributed to the elevation of cell death. Prothymosin a is a nuclear protein related to 
cell proliferation. When cellular replication was interupted using hydroxyrea the 
expression of the protein was not altered in HL-60 cells (Dosil et al, 1993).
Mimosine reversibly blocks cells (e.g. HL-60 cells) in late Gl, 1 - 2 hours before the 
Gl/S border (Hoffman etal, 1991). A  stock solution prepared in PBS at 10 mM and a 
300 p.M concentration is used to reversibly block the cell cycle. It is thought that 
mechanism by which mimosine blocks cells from replicating involves the chelation of 
iron (Boehme and Lenardo, 1993).
Thymidine (C 10H 14N 2O5) (l-[2-Deoxy-p-D-ribofuranosyl]-5-methyluracil) (M. wt. 
242.2) was first reported to inhibit DNA  synthesis in mammalian cells by Xeros (1962). 
The mechanism by which thymidine blocks DNA synthesis appears to be through a 
feedback inhibition resulting from an increase in the thymidine triphosphate pool 
affecting the deoxycytidine triphosphate pathway (Gentry et al., 1965). Exposure to 
2mM thymidine for 12 - 16 hours is an effective method of inducing cell synchronization 
(Puck, 1964). Treatment of cells with thymidine prevents progression through S-phase 
but does not interfere with progression through other stages of the cycle. This results 
in an accumulation of cells at the Gl/S border with the remainder arrested in S-phase.
If the thymidine is washed off and the cells cultured for 9 hours, all cells should have left 
S phase and reached the Gl/S boundary, or be in G2/M. Further exposure to 2mM 
thymidine for 12  - 16 hours results in synchronization of the cell growth.
5.10.3 Effect of cell cycle on retrovirus replication
There is general agreement that the host cell cycle plays a central role in controlling 
early stages of retrovirus replication, including reverse transcription, nuclear entry and 
integration. However, the mechanisms by which this control is mediated are poorly 
understood. There is evidence that cell proliferation is necessary for productive 
infection of the related oncoviruses (Varmus and Swanstrom, 1984, 1985). However, 
the stage at which replication is prevented remains unclear. Avian Sarcoma Virus,
Rous Sarcoma Virus and Moloney murine leukaemia (MoMLV) viruses do not undergo 
a complete reverse transcription step when they infect quiescent fibroblasts (Varmus et 
al, 1977; Fritsch and Temin, 1977; Harele/a7., 1981). In GO-arrested cells, viral 
D NA  is synthesized at only 10% of the level obtained in proliferating cells, with a lower 
extent of plus strand DNA relative to minus strand DNA. However, a complete form 
of viral DNA  has been reported in cells blocked at the Gl/S-border using aphidicolin 
(Chinsky and Soeiro, 1982; Hsu and Taylor, 1982) and in mutant cells that are 
temperature-sensitive for S phase (Richter et al., 1984). In both of these cases, the 
infection cycle was blocked after reverse transcription and prior to circularization and 
integration. Further studies compared the replication of MoMLV in fibroblasts arrested 
at G1/G0 by serum deprivation, in G l by hydroxyurea and at the Gl/S border by 
aphidicolin (Goulaouic et al, 1994). Reverse transcription of MoMLV in the G1/G0 
arrested cells was completed in a dose-dependent manner in the presence of increasing 
nucleoside concentrations, without reinitiating the cell cycle. However, subsequent 
integration of the DNA  was not observed. MoMLV reverse transcription was inhibited 
in the presence of the ribonucleotide reductase inhibitor hydroxyurea, but was not 
affected by the DNA polymerase a inhibitor aphidicolin. These results indicate that for
oncoretroviruses cellular nucleotide availability, rather than the arrest point in the host 
cell cycle, is a major factor controlling the reverse transcription step. The subseqent 
integration of the proviral DNA  appears to require host cells to progress through their 
replication cycle.
HIV-1 has recently been shown to persist in a latent form in quiescent lymphocytes as an 
incompletely reverse transcribed viral DNA form (Zack et al, 1990, 1992) or as an 
entire extrachromosomal viral DNA (Stevenson et al, 1990b). The virus has also been 
shown to replicate in lymphocytes blocked at the Gl/S border (Li et al, 1993a). 
However, the establishment of productive infection required activation of the 
lymphocytes and induction of cell proliferation. By contrast, the prerequisite for 
replication of HTV in cells of the mononuclear phagocyte lineage is not so clear. Some 
reports have suggested that similar to T-cells, HIV required monocytes to be 
proliferating in order for infection to be established. However, there is increasing 
evidence that the virus can productively infect non-dividing myeloid cells (Schuitemaker 
et al, 1992a), monocytes (Weinberg et al, 1991) and dendritic cells (Langhoff et al,
1991). This suggests that either HIV is fundamentally different from the 
oncoretroviruses and can produce proteins that allow integration into non-dividing 
genomes or that the host cells can provide a specific factor. Lewis et al (1992) 
demonstrated that CD4+ HeLa cells blocked in the cell cycle at G2 could be infected 
with HIV-1. The virus could infect, integrate and produce viral proteins in these non­
proliferating cells, that were not of the macrophage lineage, indicating that the infection 
was determined by a property of the virus. The pre-integration complexes of HIV are 
significantly larger than those of the murine and avian retrovirues suggesting that the 
difference in size is related to the capacity to enter the nucleus in non-dividing cells. 
Blood monocytes, which have a limited potential for cell division, are rarely productively 
infected with HIV in vivo. By contrast, macrophages, which divide infrequently, have 
been reported to be the predominant HIV-1 infected cells in human tissues (Pemo et al,
1993). This suggests that a cells state of differentiation (rather than replication) may 
determine its susceptibility to HIV-1 infection. It is possible that the factors controlling 
HIV replication differ in proliferating and non-proliferating cells, and this may contribute 
to the more restricted virus production characteristic of mononuclear phagocytes 
(Bernstein et al, 1991). The anti-cancer drug adriamycin is known to affect DNA  
metabolism. Treatment of cells with this compound prevented HIV replication in 
macrophages, but not in T-lymphocytes (Bergamini et al, 1992). It is thought that 
adriamycin , and may have interfered with an interaction between HIV and the host 
nucleic acid.
Successful infection of human peripheral blood monocytes was only established after the 
cells had been cultured in vitro for 2  days, during which time, probably as a consequence 
of plastic adherence, differentiation had been induced (Schuitemaker et al, 1992a). 
Terminal differentiation induced by treatment with IL-1 or biologically active vitamin D3 
resulted in complete resistance to HIV-1 infection probably as a result of a 
pretranscriptional block. This implies that susceptibility to HIV-1 infection is limited to 
a discrete phase during differentiation. The importance of differentiation status was 
likewise demonstrated when in vitro treatment of promonocytic cell lines with the 
differentiation-inducing agent, biologically active vitamin D3, resulted in enhanced 
susceptibility for HIV-1 infection (Skolnik et al, 1991). Terminally differentiated cells 
of the human macrophage lineage do not normally divide in culture, but can be infected 
in vitro by HIV (Valentin et al, 1990c). Gamma irradiation, an accepted inhibitor of 
cell proliferation, does not abolish the ability of these cells to be infected by HTV in 
vitro, (Langhoff et al, 1991). Indeed, HIV nucleic acid was shown to integrate into the 
chromosomal DNA of non-proliferating, (y-irradiated), human monocytes in vitro 
(Weinberg et al, 1991). Low levels of in vitro proliferation of monocytes can be 
enhanced by addition of IL-3 or GM-CSF. These compounds may also induce changes 
to the differentiation status of the monocytes. Treatment of cultured human peripheral 
blood monocyte-derived macrophages with GM-CSF resulted in enhanced HIV infection 
(Pemo etal, 1989).
5.11 AIMS OF PROJECT
Aims of the project were to develop a macrophage hybridoma which would have more 
mature characteristics than the immature cell lines available for use. This would then be 
used to investigate the role of cell cycle in the growth of HIV in macrophages, a 
problem with natural cells since they rarely undergo cycling. If cycling is required, this 
might be due to stage related expression of certain cell markers,stage related membrane 
fluidity or may indicate that HIV infects newly recruited inflammatory macrophages 
rather than resident tissue macrophages.
6.0 MATERIALS
The following chemicals and reagents were used in the experiments described in this
thesis:-
Absolute alcohol 100 , (C2H5OH) (ethyl alcohol), Hayman Limited.
Absolute methanol, Sigma: 17-5.
Acetic acid, glacial, (CH3COOH), Analytical grade, Fisons: A/0400/PB17; M. wt. 
60.05.
Acetone, (CH3COCH3), Analytical grade, Fisons: A/0600/17; M. wt. 58.08.
Acridine orange, Taab: A020; M. wt. 301.82.
2-Amino-6-mercaptopurine (C5H5N 5S), (6-thioguanine; 2-AG), Sigma: A-4882; M. 
wt. 167.2.
Aminopterin (x 50), Sigma: A5159; lyophilized and y-irradiated, when reconstituted to 
10ml contains 2 x 10-5M  aminopterin; M. wt. 440.4.
Anti-Bromodeoxyuridine (BrdU) FITC conjugate, Becton Dickinson: 7583, 
containing gelatin and 0 .1% azide.
Anti-human CR3 (Leu-15) (G D Ilb ) phycoerythrin conjugate, Becton Dickinson: 
7557, containing gelatin and 0.1% azide.
Anti-human FcyRl FITC conjugate (CD64), Medarex: 021 401.
Anti-human H LA-DR phycoerythrin conjugate, Becton Dickinson: 7367, containing 
gelatin and 0.1% azide.
Anti-human Leu-3a (CD4) FITC conjugate, Becton Dickinson: 7323, containing 
gelatin and 0.1 % azide.
Anti-human Leu-11c (CD16) phycoerythrin conjugate, Becton Dickinson: 7617, 
containing gelatin and 0.1% azide.
Anti-human Leu-M3 (CD14) FITC conjugate, Becton Dickinson: 7493, containing 
gelatin and 0 .1% azide.
Anti-human LFA -la  (C D lla ) FITC conjugate, Becton Dickinson: 7983, containing 
gelatin and 0.1% azide.
Anti-human T8-FITC/S6F1-RB1, Coulter: 6603831.
Anti-human transferrin receptor (CD71) FITC conjugate, Becton Dickinson: 7513, 
containing gelatin and 0.1% azide.
Anti-KC57, Coulterlmmunology: PN 6604665, for detection of intracellular p24 
antigen.
Anti-sheep red blood cells, Serotec: MCA 84S; supernatant from clone SP1/HL, IgM  
class monoclonal antibody raised in mice.
Aphidicolin (C20H34O4), Sigma: A0781; approximately 95% isolated from Nigrospora 
sphaerica, M. wt. 388.5.
5-Azacytidine (C8H 12N 40 5),(4-amino- 1 -(3-D-ribofuranosyI-s-triazin- 2[lH]one), Sigma: 
A1287; lyophilized and y-irradiated, M. wt 244.2.
5-Bromo-2'-deoxyuridine (C9H nBrN20 5), (5-BU, BrdU), Sigma: B-5002; M. wt. 
307.1.
Butylated hydroxy toluene (C 15H240), (BHT; 2,[6]-Di-tert-Butyl-r-cresol), Sigma: 
B1378;M. wt. 220.4.
Centrifuge tubes, 15ml polypropylene tubes, Nunc Intermed.
Centrifuge tubes, 50ml Blue Max polypropylene tubes, Becton Dickinson, Falcon: 
2070.
Ciclopirox olamine (C 12H 17N 0 2.C2H7N0), (6-cyclohexyl- 1 -hydrox-4- methyl-2[lH]- 
pydidone ethanolamine salt), Sigma: C0415; approximately 97%, M. wt. 268.4.
Colchicine (C22H25N 0 6), Sigma: C9754, M. wt. 399.4.
Demecolcine (C2IH25N 0 5), Sigma: D7385; (N-Deacetyl-N-methyl-colchicine), M. wt.
371.4.
2,7-Diaminofluorene (C 13H 12N 2), Sigma: D9251; Crystalline, M. wt. 196.3.
2’,7’-Dichlorofluorescin diacetafe (C24H 16C120 7), Kodak Eastman Ltd: 134 8820; M. 
wt. 487.29.
2,4,6-tri(dimethylaminomethyl) phenol, (DMP-30), Taab: D032, M. wt. 265.40.
N,N-Dimethyl-formamide (C3H7NO), Sigma: S8564; M. wt. 73.09.
Anti-human LFA-lb  (CD18) FFTC conjugate, Becton Dickinson: 7953, containing
gelatin and 0.1% azide.
Dimethyl sulphoxide (DMSO), Sigma: D-5879; M. wt. 78.13.
5,5-DiphenyIhydantoin (C^Hj lN 20 2Na), (5,5-Diphenyl-2,4-imidazolidinedione, 
phenytoin), sodium salt, Sigma: D 4505; approximately 99%, sodium salt, M. wt.
274.3.
DodecenyS succinic anhydride (DDSA), Taab: D027; M. wt. 266.38.
Epon/Taab 812 resin, Taab: T026; M. wt. 306.
Ethanol 96 (C2H5OH + H20), (ethyl alcohol), Hayman Limited.
Ethylenediamine tetraacetic acid (EDTA) (dipotassium salt), Sigma: ED2P; M. wt.
368.4.
FACScan tubes, polystyrene,round-bottomed (12 x 75 mm) tubes, Beclcton Dickinson, 
Falcon: 2052.
Fluorescein diacetate (C24H 160 7), Sigma: F7378; M. wt. 416.4.
Foetal bovine serum, ICN Flow: 29-101-54, endotoxin tested, sterile filtered.
Foetal bovine serum, Sigma: F4010; Hybrimax, endotoxin tested, sterile filtered.
Formaldehyde solution (40% w/v), (H.CHO), analytical grade, BDH: 10113, M. wt.
30.03.
Giemsa stain, Taab: G042.
L-Glutamine, 200 mM solution, Sigma: G7513; sterile filtered and endotoxin tested.
Glutaraldehyde, (Pentane-l,-dial) Grade 1: 25% aqueous solution, Sigma: G5882.
Glycerol (C^OH.CHOH.CHjOH), Fisons: G/0650/17; M.wt 92.10.
Granulocyte macrophage colony stimulating factor (rHuGM-CSF), Boehringer 
Mannheim: 1087 762.
HAT media supplement (50 X), Sigma: H0262; lyophilized and y-irradiated, when 
reconstituted to 10ml contains 5 x 10'3M  hypoxanthine, 2 x 10*5M  aminopterin and 8 x 
lO^M thymidine.
Heparin, sodium salt, Grade 1 -a from porcine intestinal mucosa, Sigma: H3149.
High Growth Enhancement Medium, ICN Flow: 12-337-54, 500 ml.
HT media supplement (50 X), Sigma: HO 13 7; lyophilized and y- irradiated, when 
reconstituted to 10ml contains 5 x 10'5M hypoxanthine and 8 x lO^M thymidine.
Hydrochloric acid (HC1), 1.18 specific gravity, reagent grade, Fisons: H/1150/PB17;
M. wt. 36.46.
Hydroethidine (C21H21N 3), Kodak Eastman Ltd.: 199 8756; M. wt. 315.42.
Hydrogen peroxide (H20 2), Fisons: H/1860; 200 volume, (60% w/v).
Hydroxyurea (CH4N 20 2), Sigma: H8627; M. wt. 76.05.
Kanamycin solution, Sigma: K0254; 50mg kanamycin/ml in 0.9% NaCl, sterile filtered.
Lauryl sulphate (C 12H250 4SNA), Sigma: L5750; sodium dodecyl sulphate (SDS), M. 
wt. 288.4.
Leibovitz L-15 medium (Modified), ICN Flow: 12-510-54, 500 ml.
Lymphoprep, Nycomed; (Bouyant density 1.077 +/- 0.001 g/ml (20oC); Osmolarity 
280 +/- 15 mOsm).
L-a-LysophosphatidyScholine, (Type 1: approx. 99% from egg yolk, lysolecitihin), 
Sigma: L4129.
Methyl nadic anhydride (M NA), Taab: M012; M. wt. 178.19.
Microtitre plates, (96-well, flat-bottomed), Nunc Intermed: 1-67008-F96.
Mimosine, Aldrich Chemical Co Ltd: M8716-4; approximately 98%, M. wt. 198.18.
Mouse IgG1? kappa (MOPC-21), mouse isotype control FITC conjugate, Sigma: 
F6397.
M TT (C l8H 16N 5SBr) (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), 
Sigma: M-2128, M.wt. 414.3.
a-Naphthyl acetate (non-specific esterase) cytochemical kit, Sigma: 91-A containing 
a-naphthyl acetate solution (91-6), Fast Blue BB base solution (91-7), Trizmal 7.6 
concentrate solution (91-8), sodium nitrite solution (91-4) and citrate solution (91-5).
Nitro Blue Tetrazolium (C40H30Ci2N 10O6) (NBT), Sigma: N6876; (2,2'-Di-p- 
nitrophenyl-5,5'-diphenyl-3,3'-[3,3'-dimethoxy-4,4'-diphenylene]-ditetrazolium 
chloridej-ditrazolium chloride), methanol content 5%, M. wt. 817.6.
Nonidet P-40, Sigma: N6507; (nonionic detergent).
Osmium tetraoxide (Os04, Osmic acid), Sigma: 05500; M. wt.:254.2.
Paraformaldehyde (CH20 )3, Sigma: P6148; (Trioxymethylene), M. wt. 90.09.
Phorbol 12-myristate 13-acetate (C36H560 8) (PMA), Sigma: P8139;
(4b,9a, 12b, 13a,20-Pentahydroxytiglia-1,6-dien-3-one 12b-myristate 13-acetate), M. 
wt. 616.8.
Phosphate buffered saline (Dulbecco 'A') tablets, Oxoid: Brl4a, pH7.3.
Photographic paper, Ilford: MGX.1M; RC deluxe, multigrade III, glossy.
Polyethylene glycol (PEG), Sigma: P3640; Average molecular weight 3350.
Polyethylene glycol (PEG), Sigma: P5402; Average molecular weight 1450.
Polyoxyethylene sorbitan monolaurate (Tween 20), Sigma: P-1379.
Potassium chloride (KC1), Fisons: P/4280/53; Analytical grade, M. wt. 74.56.
Propan-2-ol ((CH3)2CHOH), (/so-propyl alcohol), analytical grade, BDH: 10224, M. 
wt.: 60.10.
Propidium iodide (C27H34N 4I2), Sigma: P4170; M. wt. 668.4.
Pyruvic acid (C3H40 3), (a-ketopropionic acid), Sigma: P-1656; M. wt. 88.06.
Retro-tek HTV-1 p24 antigen E.LXS.A. kit, Cellular Products Inc.
RNase, DNase-free, Boehringer Mannheim: 1119 915; from bovine pancreas, 500jig/ml.
R P M I1640 medium, Sigma: R0883; with sodium bicarbonate and without L- 
glutamine, sterile filtered, endotoxin tested.
RPM I 1640 medium, phenol red-free, ICN Flow: 73-128-54; with sodium bicarbonate 
and without L-glutamine, sterile filtered, endotoxin tested.
Sheep red blood cells (in Alsever's), Serotec: C14AA.
Sigmacote, Sigma: SL-2 .
Sodium chloride (NaCl), Fisons: S/3160/53; Analytical grade, M. wt.58.44.
Sodium hydroxide, pellets, (NaOH), Fisons: S/4920/53; M. wt. 40.00.
Sodium hypochlorite solution (14% available chlorine), BDH: 30169.
Sodium tetraborate (N a^O ^ lO H jO ), Sigma: B9876; (Borax), M. wt. 381.4.
Peroxidase (myeloperoxidase), leucocyte cytochemical kit, Sigma:390-A; containing
peroxidase indicator reagent (390-1) and Trizma 6.3 buffer concentrate (90-3C).
Tannic acid, Taab: T046, M. wt. 1701.22.
Thymidine (C 10H 14N 2O5), (1 -[2-Deoxy~p-D-ribofuranosyI]-5- methyluracil), Sigma: 
T9250; crystalline, approximately 99 - 100%, M. wt. 242.2.
Tissue culture flasks, 25cm3, vented, Beckton Dickinson, Falcon: 3109.
Tissue culture plates, (24-well plates), Nunc Intermed: 1-43982.
Tris(dimethylamiiiomethyI)-phenoI (DMP-30), Taab.
Triton X-100, (t-octylphenoxypolyethoxyethanol), Sigma: X-100.
Trizma hydrochloride (C4H nN 0 3.HCl), (Tris[hydroxymethyl]aminomethane 
hydrochloride), Sigma: T3253; (Tris-HCl), M. wt. 157.6.
Triton X-100 (t-Octylphenoxypolyethoxyethanol), Sigma: X-100.
Trypan Blue (C34H24N 60 14S4Na4), Sigma: T8154; 0.4% solution prepared in 0.81% 
sodium chloride + 0.06% potassium phosphate dibasic, M. wt. 960.8.
Trypsin solution x 1, Sigma: T5650, 2.5g porcine trypsin per litre in HBSS.
' IT-bottomed 96-well microtitre plates,
Urea (NH2CO.NH2), Fisons: U/0500/53, M. wt. 60.06.
Zymosan A, Sigma: Z4250; prepared from Saccharomyces cerevisiae.
7.0 METHODS
7.1 GENERAL TISSUE CULTURE METHODS
In the protocols described, unless otherwise stated, all supernatants were discarded 
following centrifugation steps.
7.1.1 Maintenance of cell lines
The cell lines HL-60 (promelocytic leukaemia, Collins et al, 1977), THP-1 (human 
monocyte, Tsuchiya et al., 1980), U937 (human histiocytic lymphoma, Sundstrom and 
Nilsson, 1976) and E6.1 Jurkat (human T-lymphocyte) were obtained from the 
European Collection of Animal Cell Cultures (Porton Down, Wiltshire). H9 cells 
(human T-lymphocyte, Popovic et al, 1984), originally derived from the HUT78 cell 
line, were obtained from the MRC AIDS directed programme. Thymidine kinase 
negative U937 (U937 TK") cells were a kind gift from Dr Satish Keshav, Sir William 
Dunn School of Pathology, Oxford. Cells were maintained in exponential growth phase 
by frequent sub-culturing into Roswell Park Memorial Institute 1640 (RPMI1640) cell 
culture medium (Sigma Chemical Co. Ltd.) containing 10% foetal calf serum (ICNFIow  
or Sigma Chemical Co. Ltd.) and 10 mM L-glutamine (Sigma Chemical Co. Ltd.; 
complete medium). In certain experiments the medium was supplemented with 50 
pg/ml kanamycin (Sigma Chemical Co. Ltd.). All the cell lines used were grown in 
suspension and were sub-cultured at 3 - 4 day intervals by dilution of the cells to a 
concentration of 1 - 2  x 10 5/ml.
Stocks of each cell line were stored frozen in liquid nitrogen. Cells were frozen at a 
concentration in excess of 1 x 107/ml, using complete medium containing either 10% 
glycerol (BDH) (for THP-1 cells) or 10% DMSO (Sigma Chemical Co. Ltd.) as a 
cryopreservant. When the cells were required, they were quickly defrosted, diluted 
using complete medium (at 37°C) and centrifuged (150g/3 min). The cells were 
resuspended in fresh complete medium and transferred to a 37°C/5% C02, humidified 
incubator. This procedure was designed to minimize the exposure of the cells to the 
toxic cyropreservants.
7.1.2 Production, isolation and maintenance of drug marked cell lines
Mutant cells lacking thymidine kinase (TK") or hypoxanthine guanine phosphofuranosyl 
transferase (HGPRT") enzyme activity can be prevented from replicating if aminopterin
is included in the culture medium. This provides a means of selecting hydridomas from 
parental cell lines. In order to isolate cells with mutations affecting TK activity, the 
available cell lines were cultured in increasing concentrations of 5-bromo-2'~ 
deoxyuridine (5B U ; Sigma Chemical Co. Ltd.). Similarity, exposure of cells to 
increasing concentrations of 2-amino-6-mercaptopurine (6-TG; Sigma Chemical Co. 
Ltd.) was used to select mutants lacking HGPRT activity.
Exponentially replicating cells were diluted to a concentration of 2 x 105/ml. The cells 
were cultured in the presence of 0.5 pg/ml of the appropriate compound, using complete 
medium supplemented with 1 x lO^M  hypoxanthine and 1.6 x 10‘5 M  thymidine (HT 
medium supplement; Sigma Chemical Co. Ltd.). The cells were observed 
microscopically and cell concentrations were monitored daily (using Trypan Blue 
exclusion). When the cell concentration had at least doubled, a 1:2 dilution of the 
culture was prepared, and the cells were exposed to 1.0 fig/ml concentrations of the 
appropriate compounds. This was repeated using 2.0, 4.0, 8.0 and 15.0 |4g/ml 
concentrations of the drugs. When populations of cells had been isolated that could 
replicate in the presence of 15.0 p,g/ml of the compounds, the cells were cloned by 
limiting dilution in 96-well plates containing medium supplemented with 15.0 p,g/ml of 
the appropriate compound. Wells were observed microscopically and any well 
observed to contain a single cell was marked. The plates were incubated (37°C/5% 
C 02), and when cell growth was macroscopically visible in the marked wells, the cells 
were passaged into a larger volume. This cloning and expansion procedure was 
repeated, and stocks of cells were frozen.
Experiments were carried out to confirm that the cells could not replicate in medium 
supplemented with 2 x 10*5M  aminopterin, 1 x 10-4 M  hypoxanthine and 1.6 x 10*5 M  
thymidine (HAT medium supplement; Sigma Chemical Co. Ltd.). Cloned drug- 
resistant isolates were incubated (37°C/5% C02) in 10 ml volumes of RPMI1640 
complete medium supplemented with HAT. Cell concentration was estimated daily 
using Trypan Blue. In order to determine whether any viable cells were present in the 
HAT-treated cells a 1 ml volume of cell suspension was transferred to a centrifuge tube, 
(every day for 10 days). Cells were washed using PBS (250g/3 min) and placed in 1 ml 
fresh medium in a well of a 24-well plate. Each well was observed daily to determine 
whether any cell growth had occurred.
In order to prevent the reversion of mutant cell lines to the parental phenotypes, TK" 
cell lines were routinely maintained in complete medium supplemented with 15 fig/ml 5- 
BU, 1 x 10-4 M  hypoxanthine and 1.6 x 10'5 M  thymidine, and HGPRT" cell lines were
7.1.3 Determination of viable cell concentration
In many of the techniques described it was necessary to determine the concentration of 
viable cells present. The method chosen to quantify cells present was the Trypan Blue 
exclusion test. Trypan Blue is a dye which is excluded from viable cells, but can enter 
dead cells.
Equal volumes of cell suspension and 0.2% Trypan Blue solution (Sigma Chemical Co. 
Ltd.) were mixed. The diluted cell suspension was carefully transferred to an improved 
Neubauer haemocytometer slide. The cells were examined microscopically and the 
number in a defined area of the haemocytometer counted (excluding the cells that had 
stained dark blue).
Adherent cells were resuspended using cold-shock (exposure to -20°C for up to 5 
minutes) prior to being counted by this technique.
7.1.4 Detection of surface antigen expression
Cells were counted (using Trypan Blue exclusion) and an appropriate volume of cell 
suspension (usually containing 5 x 105 cells) was pipetted into the required number of 
centrifuge (or FACScan) tubes (Becton Dickinson). The cells were pelleted by 
centrifugation (150g/3 min) and washed using phosphate buffered saline (PBS; Oxoid) 
(150g/3 min). The cells were resuspended in a 20jjl1 volume of normal human serum 
and the commercially recommended volume of the required monoclonal antibody 
conjugated to a fluorescent probe or appropriate isotype control was added to selected 
samples. A  20|j.l volume of PBS was added to the control samples. All samples were 
gently agitated and incubated on ice for 60 minutes. The cells were washed twice by 
filling the tube with PBS and recovering the cells by centrifugation (150g/3 min). On 
occasion, cells were resuspended at this stage using 20pl normal human serum and then 
incubated on ice for a further 60 minutes with a second monoclonal antibody 
(conjugated to a probe with different fluorecent properties to the first). Again, the cells 
were washed twice with PBS (150g/3 min). All samples were resuspended in 500[±1 of 
PBS and then placed on ice before the cell-associated fluorescence was analysed by flow 
cytometry.
cultured in complete medium containing 15 pg/ml 2-AG, 1 x 1CH M  hypoxanthine and
1.6 x I f f5 M  thymidine.
7.1.5 Flow cytometric analyses
All flow cytometric analyses were performed using a Becton Dickinson FACScan 
(Becton Dickinson, San Jose, California) equipped with an argon ion laser (488nm; 
15mW) and FACScan Research software. Some assays were analysed using Chronys 
and Consort 30 software.
7.2 ISOLATION AND IN  VITRO CULTURE OF HUMAN MONOCYTES
7.2.1 Isolation of mononuclear cells from peripheral human blood 
Mononuclear cells were isolated from peripheral human blood using a Ficoll/Metrizoate 
gradient to separate the cells on the basis of their buoyant densities. Isolation of 
monocytes from the mononuclear population was achieved by adherence in the presence 
of serum for a few hours. Incubation in certain tissue culture plastics in the presence of 
serum , allows monocytes to become adherent thus facilitating their purification, since 
the contaminating lymphocytes can simply be washed off.
Peripheral venous human blood was collected into a tube containing sufficient heparin 
(Sigma Chemical Co. Ltd.) to give a final concentration of 60U/ml. The blood was 
diluted using an equal volume of RPMI1640 medium (Sigma Chemical Co. Ltd.).
Twelve millilitre volumes of 'Lymphoprep' (Nyegaard) were pipetted in to an 
appropriate number of 50 ml Falcon centrifuge tubes (Becton Dickinson). Each -tube 
was tilted to allow the diluted blood to be carefully layered onto the 'Lymphoprep'.
(The resultant ratio of diluted blood to 'Lymphoprep' was approximately 3:1). The 
tubes were carefully transferred to a centrifuge where they were spun at 300g- for 25 
minutes. The majority of the medium above the 'buffy layer' was removed and 
discarded. The 'bufiy layer' cells were collected (using a sterile plastic Pasteur pipette) 
and washed using RPMI1640 medium (300g/10 min). The mononuclear cells were 
washed again using RPMI1640 medium (300g/5 min) and the mononuclear cells were 
resuspended in a little complete RPMI1640 medium. A  viable cell count was performed 
using the Trypan Blue exclusion test. The cells were diluted to a concentration of 5 - 
10 x 105/ml using complete RPMI1640 medium. In experiments where the isolation of 
monocytes was required 200 jj.1 volumes of the cell suspension were dispensed into the 
centre wells of 96-well 'U'-bottomed microtitre plates (Nunc), or appropriate volumes 
were dispensed into tissue culture grade plastic plates or flasks (Nunc; Becton 
Dickinson). Approximately 4 hours after plating the cells were washed twice with 
RPMI1640 (to remove the non-adherent cells) and an appropriate volume of fresh 
complete RPMI1640 medium was added to each well. When suspensions of monocytes
were required, the cells were removed by vigorous washing following cooling of the 
plate(s) (for 5 minutes at -20°C), in order to cold-shock the cells. Alternatively, 
enzyme solutions (e.g. 2.5g/l trypsin; Sigma Chemical Co. Ltd.), were used, but these 
were generally found to be associated with loss of monocyte functional activity or 
viability.
7.2.2 Maturation of human monocytes in vitro
The stimulus of adherence to tissue culture plastic induces human monocytes to 
differentiate into cells which display the phenotypic and functional characteristics of 
macrophages. Isolated human monocytes were incubated at 37°C/5% C02 for upto 15 
days. Every 3 -4  days half of the medium was removed and replaced with fresh 
complete RPMI1640 medium.
7.2.3 Use o f 'Sigmacote' to reduce adherence of monocytes
A  two hundred and fifty microlitre volume of'Sigmacote' (Sigma Chemical Co. Ltd.) 
solution was pipetted into every well in the first column of a 'U'-bottomed 96-well 
microtitre plate (Nunc). After a minimum interval of 1 minute the solution was 
transferred to the second column. This was repeated until every well had been exposed 
to 'Sigmacote1 for at least 1 minute. The plate was then air-dried. Every well was 
washed at least twice using 250 pi of RPMI1640 medium and then air-dried again. The 
plates were wrapped in aluminium foil and held at 4°C until use.
7.2.4 Fusion of human monocyte-derived macrophages
Human mononuclear cells were isolated using density gradient centrifugation, diluted to 
approximately 1 x 106/ml in complete RPMI1640 medium and 200 pi volumes were 
aliquoted into the central wells of 96-well 'U'-bottom microtitre plates (Nunc). 
Monocytes were purified by washing off any non-adherent cells and the plates were 
incubated for an appropriate interval at 37°C/5% C02. The drug-marked cells selected 
as the fusion partner were passaged to ensure that they were replicating exponentially. 
These cells were counted (using Trypan Blue exclusion) and diluted to an appropriate 
concentration. The medium was then carefully aspirated from every well and a 200 pi 
volume of the cell suspension was added to each well. The plate was centrifuged 
(200g/8 min) and the supernatant carefully aspirated. A  sterile solution of PEG 
(average mol.wt. 3350; Sigma Chemical Co. Ltd.) had previously been prepared by 
autoclaving the required weight and mixing with an appropriate volume of complete 
RPMI 1640 when the PEG was cool but still liquid. A  50 pi volume of PEG solution
was added to each well. After incubation for a short time (usually approximately 1 min) 
the PEG was diluted by addition of 150 |utl of complete medium. The plates were then 
centrifuged (200g/8 min) and the supernatant was carefully aspirated from every well. 
The cells were washed by addition of 200 pi of RPMI1640 medium to every well. The 
plates were centrifuged (200g/8 min) and the supernatant carefully aspirated. A  200 pi 
volume of complete medium was added to every well and the plates were incubated at 
37°C/5%C02. The plates were examined at regular intervals and the cells were fed 
every 3 -4  days by exchanging half of the medium for fresh complete medium. When 
appropriate fused cells were selected using medium supplemented with 1 x lO^M 
hypoxanthine, 4 x 10’7M  aminopterin and 1.6 x 10*5M  thymidine (HAT medium 
supplement; Sigma Chemical Co. Ltd.).
7.3 OPTIMIZATION OF FUSION PROTOCOLS USING FLOW CYTOMETRY
7.3.1 Staining of cells with 2\ 7 '-dichlorofluorescin diacetate (DCFH-DA)
A  10 mM stock solution of 2',7'-dichlorofluorescin diacetate(DCFH-DA, Kodak 
Eastman) was prepared in A,7V-dimethylformamide. Shortly before use this stock 
solution was diluted 1:20 using phosphate buffered saline (PBS) to give a 0.5 mM 
working concentration. In an initial experiment cells were exposed to 10 pM DCFH- 
D A  for 15 minutes at 37°C following PEG treatment. In all subsequent experiments, 
cells were washed using PBS (lOOg x 3 min) and then pretreated by incubating in the 
presence of 10 pM DCFH-DA solution for 15 minutes at 37°C prior to exposure to 
PEG. The cell suspension was washed twice with warm PBS (lOOg- x 3 min).
7.3.2 Staining of cells with hydroethidine (HE)
A  63.5 mM stock solution of hydroethidine (HE, Kodak Eastman) was prepared in 
DMSO. Cells to be treated with HE were washed with warm PBS (100g- x 3 min) and 
resuspended in the buffer at a concentration of 4 x 105 cells/ml. Sufficient HE was 
added to the cell suspension to give a final concentration of 0.635 mM and the cells 
were incubated for 15 minutes at 37°C. The cell suspension was washed twice with 
warm PBS (100g x 3 min).
7.3.3 Fusion protocol
Cells were washed in warm PBS (4 - 9 x 105/ml; 100g x 3 min), counted (using 0.4% 
trypan blue solution) and resuspended at a concentration of 4 x 105 cells/ml. When
appropriate cells were pretreated with fluorescent dyes, as described above. Cells were 
mixed in appropriate ratios and were aliquotted, in duplicate, in Falcon FACScan tubes. 
The cells were pelleted by centrifugation (100# x 3 min) and the supernatants were 
discarded. In certain experiments the cells were resuspended in 10‘5 M  sodium 
dodecylsulphate (SDS, Sigma Chemical Co Ltd, Poole, Dorset) and the supernatant was 
discarded following centrifugation (100# x 3 min). The cells in one of each pair of 
tubes were exposed to 200 pi of one of a range of concentrations of PEG solution, 
which were prepared by autoclaving an appropriate amount of PEG (average molecular 
weight 3350, Sigma Chemical Co Ltd, Poole, Dorset), and when nearly cool diluting 
with complete RPMI1640 medium (containing 10% foetal calf serum) to give the 
required v/v concentration. A  5% v/v concentration of dimethylsulphoxide (DMSO, 
Sigma Chemical Co Ltd, Poole, Dorset) was included with the PEG in certain 
experiments. An equal volume of PBS was added to the second tube of each pair.
After 1 minute the tubes were slowly filled with PBS and the cells were washed twice 
with PBS (100# x 3 min). After the final wash, the cells were resuspended in 1.0 ml 
PBS and the tubes were placed on ice until analysed by flow cytometry.
7.4 INVESTIGATION OF CELLULAR NUCLEIC ACIDS
7.4.1 Investigation of the cell cycle using propidium iodide staining
Cells were counted (using Trypan Blue exclusion) and an appropriate volume of cell 
suspension (containing approximately 5 x 105 cells) was transferred to FACScan tube(s) 
(Becton Dickinson). The cells were centrifuged (150#/3 min) and were washed using 
PBS (150#/3 min). The cells were fixed by the vigorous addition of 1.0 ml ice cold 
70% v/v aqueous ethanol 96 (Hayman Limited) and were vortexed. After a minimum 
period of 30 minutes at 4°C, cells were harvested by centrifugation (150#/3 min). The 
cells were resuspended by vortexing in 800|il PBS. A  100jil volume of a 30U/ml 
solution of RNase (DNase-free) (Boehringer Mannheim) was added to each sample. A  
lOOjLil volume of a 400jig/ml solution of propidium iodide (Sigma Chemical Co. Ltd.) 
was added to each sample giving a final concentration of 40fig/ml. Each tube was 
vortexed to mix the contents and then incubated at 37°C for 30 minutes. All samples 
were placed on crushed ice pending analysis by flow cytometry.
7.4.2 Analysis of the cell cycle using incorporation of 5-bromo-2'-deoxyuridine
Cells were counted (using Trypan Blue exclusion) and resuspended at a concentration of 
5 x 105/ml in a sufficient volume of conditioned medium to allow for the number of 
samples. (Conditioned medium was the supernatant prepared from a culture of the
same type of cells that had grown to a concentration of approximately 5 x 105/ml in 
complete RPMI1640 medium). A  5 ml sample of cell suspension was collected (into a 
test tube). 5-bromo--2'-deoxyuridine (BrdU, 5-BU; Sigma Chemical Co. Ltd.) was 
added to the cell suspension to give a final concentration of lOmM and cells were 
incubated at 37°C/5% C02 for 60 minutes. The cells that had been exposed to BrdU 
were pelleted by centrifugation (150g/3 min). The treated cells were resuspended in an 
equal volume of conditioned medium. A  5 ml sample of cell suspension was transferred 
to a test tube. The remaining suspension of treated cells was aliquoted in 5 ml volumes 
into an appropriate number of 25cm3 tissue culture flasks. At appropriate time intervals 
(usually hourly) a flask was removed from the incubator and the cells transferred to a 
test tube. Each sample of cells was pelleted by centrifugation (150g/3 min). The cells 
were washed by resuspending in PBS and centrifuging (150^/3 min). The cells were 
then fixed by the vigorous addition of 2.0 ml 70% v/v ice cold aqueous ethanol (Hayman 
Limited). After a minimum period of 30 minutes at 4°C the cells were harvested by 
centrifugation (150g/3 min). In order to permeabilize the cells they were then 
suspended in 1.0 ml 0.1M hydrochloric acid (Fisons) containing 0.7% v/v Triton X-100 
(Sigma Chemical Co. Ltd.), and kept on ice for 10 minutes. The cells were pelleted by 
centrifugation (150g/3 min) and a 5.0 ml volume of distilled water was used to wash 
each sample. The cells were harvested by centrifugation (150g/3 min) and resuspended 
in 2.0 ml distilled water. All samples were placed in a beaker of boiling water (100°C) 
for 10 minutes and then quickly cooled by plunging into crushed ice. The cells were 
pelleted (150g/3 min) and washed by resuspending in 5 ml PBS containing 0.1% Tween 
20 (Sigma Chemical Co. Ltd.) and centrifuging (150g/3 min). A  20JJ.1 volume of 
undiluted monoclonal anti-BrdU FITC-conjugated antibody (Becton Dickinson) was 
added to every sample. The samples were incubated at 37°C/5% C02 for 60 minutes. 
Excess antibody was washed off by adding 5 ml PBS to each tube and pelleting the cells 
(150g/3 min). The cells were resuspended in 800 (ll PBS. A  100 jil volume of a 1 
jig/ml RNase (DNase flee) (Boehringer Mannheim) solution was admixed to each tube, 
followed by a 100 pi volume of a 400 jag/ml solution of propidium iodide (Sigma 
Chemical Co. Ltd.). The cells were incubated at 37°C for 30 minutes before placing on 
crushed ice. The samples were then run through the flow cytometer using the FACScan 
Research or Consort 30 software.
7.4.3 Acridine Orange staining of nucleic acids
Acridine orange staining was carried out using the method described by Traganos et al 
(1975). Cells were enumerated (using Trypan Blue exclusion) and resuspended at a 
concentration of approximately 2 x 105/ml. One millilitre volumes of the cell
suspension were transferred to the appropriate number of FACScan tubes (Becton 
Dickinson). The tubes were filled with PBS to wash the cells, which were pelleted by 
centrifugation (150g/3 min). The cells were resuspended by vortexing in 200 pi of 
phosphate buffered saline. A  200 pi volume of acid detergent (PBS containing 0.1% 
Triton X-100 (Sigma Chemical Co. Ltd.), 0.15M sodium chloride (Fisons) and 0.08N 
Hydrocholoric acid (BDH)) was added to each tube followed approximately 40 seconds 
later by the addition of 1.2ml of the Acridine Orange staining solution (PBS containing
6.0 pg/ml Acridine Orange (Taab), 10'3 M  EDTA (Sigma Chemical Co. Ltd.) and 0.15 
M  sodium chloride (Fisons). The samples were immediately placed on crushed ice and 
analysed by flow cytometry, as quickly as possible, using the FACScan research 
software.
7.4.4 Karyotype analysis
An exponentially growing culture was centrifuged (150g/3 min) and cells were 
resuspended in 10 ml of fresh complete medium. Sufficient demecolcine (Sigma 
Chemical Co. Ltd.) was added to the culture to give a final concentration of 0.2 pg/ml, 
and the cells were incubated at 37°C/5% C02. The cells were centrifuged (150g/3 min) 
and resuspended in 0.075M potassium chloride (Fisons). Samples were incubated at 
room temperature for 10 minutes. The cells were harvested by centrifugation (150g/3 
min) and fixed by resuspending in a solution containing 3 parts glacial acetic acid 
(Fisons) : 1 part methanol (Fisons) for a minimum of 30 min at 4°C. Samples of the cell 
suspension were then dropped onto an acid-cleaned, wet microscope slide. The 
preparation was stained using 10% Giemsa (pH 6.3; Taab), washed in pH 6.3 buffer 
and air dried. A  coverslip was applied and the preparation was examined using oil 
immersion.
7.5 TREATMENT OF CELLS WITH REVERSIBLE CELL CYCLE INHIBITORS
7.5.1 Blocldng of cells in the cell cycle
All cells used in cell cycle blocking experiments had been passaged 1 -3  days before the 
experiment and were in the exponential phase of growth. The cells were counted, using 
Trypan Blue exclusion, and resuspended at approximately 5 x 105/ml. A  maximum of 
30% fresh complete medium was used to dilute the cells suspensions. The cells were 
incubated for 6 hours at 37°C/5% C02 prior to addition of a cell cycle inhibitor. Cells 
were exposed to appropriate concentrations of reversible cell cycle inhibitors for 18 
hours. At this stage samples of the cells were fixed for propidium iodide analysis, or
were washed with PBS (150#/3 min) prior to analsis of cell phenotype or functional 
capacity.
7.5.2 Analysis of cell cycle distribution
A  software programme, 'Cellfit', specifically designed for flow cytometric analysis of cell 
cycle distribution was available. This programme utilizes mathematical models to 
calculate the number of cells in S phase, by estimating the proportion of S phase cells at 
the Gl/S and G2/M borders. However, in the experiments where potential cell cycle 
inhibitors were titrated, any change in FL2 compared to exponentially replicating cells, 
could have been important. It was therefore decided to use the 'FACScan Research1 
software to set electronic gates on a control population, and keep these gates in the 
same positions for analysis of cell cycle distribution of experimental samples.
7.6 METHODS FOR CHARACTERIZATION OF CELLS OF THE 
MONONUCLEAR PHAGOCYTE LINEAGE
7.6.1 Preparation of samples for transmission electron microscopy 
Cells were washed in PBS (150#/3 min) and the cell pellets were transferred to 
Eppendorf tubes (Nunc). Glutaraldehyde (Grade 1, 25% aqueous stock; Sigma 
Chemical Co. Ltd.) was stored frozen (at -20°C) and was defrosted before use. A  2.5 
% solution of glutaraldehyde was prepared in PBS and 1.0 ml volumes were used to 
resuspend the cell samples. The cells were immediately pelleted by centrifugation 
(200#/3 min). Supernatants were carefully discarded, with minimum disruption of the 
pellets, and fresh 2.5% glutaraldehyde solution was added. The cells were left to fix in 
glutaraldehyde overnight at room temperature. Cells were centrifuged (200#/3 min) 
and resuspended in PBS. A  thorough washing protocol required a minimum of 3 
changes of PBS over a 2 hour period. Post-fixation of the cells utilized a 1 hour 
exposure to 1% osmium tetroxide (Sigma Chemical Co. Ltd.). Cells were again 
thoroughly washed using 3 changes of PBS over a 1 hour period. The samples were 
exposed to a 1% solution of tannic acid (prepared in PBS; Taab) for 30 minutes at 
room temperature. The pellets were washed twice with PBS (200#/3 min). The 
dehydration of samples was then commenced. Cells were resuspended in increasing 
concentrations of alcohol (25%, 50% and 75% aqueous absolute alcohol; Hayman 
Limited) for 30 minutes periods. Cells were pelleted by centrifugation (200#/3 min) 
and the supernatant carefully discarded at each stage. The samples were resuspended in 
absolute alcohol for 60 minutes at room temperarature. After this time the cells were
pelleted (200g/3 min) and resuspended in fresh absolute alcohol (Hayman Limited).
The samples were maintained in absolute alcohol overnight at room temperature. The 
cells were pelleted (200g/3 min) and resuspended in a 1:1 ratio of absolute alcohol: 
acetone (Fisons). After 30 minutes at room temperature the cells were pelleted (200,g/3 
min) and resuspended in acetone (Fisons). The resin was prepared by weighing 12 g 
Epon 812 (Taab), 4.75 g dodecenylsuccinic anhydride (DDSA; Taab) and 8.25 g 
(2,4,6-tri(dimethylaminomethyl)phenol) (MNA; Taab) into a polycarbonate beaker. 
These components were mixed well using a wooden spatula. Shortly before use a 0.5 g 
volume of 2,4,6-tris-(dimethylaminomethyl) (DNP-30; Taab) was admixed to the resin. 
All components were thoroughly mixed. A  2:1 ratio of acetone to resin was prepared 
and specimens were exposed to this for a 60 minute period at room temperature. The 
cells were pelleted (200g/3 min) and a 1:2 ratio of acetone to resin mixture was carefully 
added. After 60 minutes at room temperature the samples were centrifuged (250g/3 
min) and resin was added to every sample, care being taken not to disturb the pellets. 
The samples were held at room temperature for approximately 4 hours, to allow the 
resin to penetrate the samples. The samples were thoroughly disinfected and 
transferred to an oven, where the resin was cured by incubating at 60°C for 16 hours. 
Ultrathin sections were cut using an ultramicrotome and placed onto grids. The 
sections were stained with 2% uranyl acetate (20 minutes at 60°C) and with 4 mg/ml 
lead citrate (room temperature for 7 minutes). All samples were examined in a Phillips 
T400 transmission electron microscope.
7.6.2 Myeloperoxidase assay
Cells were counted (using trypan blue exclusion) and resuspended at approximately 5 x 
105/ml. The cell suspension was aliquoted into an appropriate number of FACScan 
tubes (1.0 ml per tube) and the cells washed with PBS (150g/3 min). The cells were 
fixed by resuspensing in 200 jml of CAF fixing solution (65 ml acetone (Fisons), 8 ml of 
37% formaldehyde (BDH) and 25 ml citrate solution (Sigma) [18 mM citric acid, 9 mM 
sodium citrate, and 12 mM sodium chloride with surfactant]). Each tube was vortexed 
and after approximately 1 minute, was filled with PBS (to wash the cells). The cells 
were pelleted by centrifugation (150g/3 min). A  bottle of peroxidase indicator was 
reconstituted using 1.0 ml Trizmal buffer (pH6.3). Sufficient volume of the following 
solutions were prepared using reagents (that had been prewarmed to 37°C) in the 
following ratios:-
a) 1 part 3% hydrogen peroxide (Fisons): 5 parts peroxidase indicator (Sigma Chemical 
Co. L td .): 250 parts Trizmal buffer (Sigma Chemical Co. Ltd.), (pH6.3);
b) 1 part PBS (Oxoid) : 5 parts peroxidase indicator (Sigma Chemical Co. Ltd.) : 250 
parts Trizmal buffer (Sigma Chemical Co. Ltd.), (pH 6.3).
A  500 jal volume of the appropriate staining solution was added to appropriate tubes.
All samples were vortexed and incubated at 37°C for 30 minutes before being placed on 
ice. (In certain experiments the samples were washed with PBS (150g/3 min)). The 
samples were resuspended in 0.5 ml PBS. Cells were examined microscopically or 
analysed using the flow cytometer and FACScan Research software.
7.6.3 Non-specific esterase activity
The cells were counted (using Trypan Blue exclusion) and resuspended at a 
concentration of approximately 5 x 105/ml. One millilitre aliquots were transferred into 
the required number of FACScan tubes (Becton Dickinson). The cells were washed 
using PBS (150g/3 min). Cells were fixed by addition of 200 pi of CAF fixing solution 
(65 ml acetone (Fisons), 8 ml of 37% formaldehyde (BDH) and 25 ml citrate solution 
(Sigma) [18 mM citric acid, 9 mM sodium citrate, and 12 mM sodium chloride with 
surfactant]). Each tube was vortexed and after approximately 1 minute all tubes were 
filled with PBS to wash the cells which were pelleted by centrifugation (150g/3 min). 
The a-naphthyl acetate esterase staining solution was prepared from reagents that had 
been prewarmed to 37°C. Equal volumes of Fast Blue BB Base solution (15 pg/ml 
Fast Blue BB base in 0.4M Hydrochloric acid; Sigma Chemical Co. Ltd.) and 0.1M 
sodium nitrite solution (Sigma Chemical Co. Ltd.) were admixed in a test tube. This 
solution was held at 37°C for a few minutes. The solution was diluted by the addition 
of 40 volumes of distilled water and 5 volumes of Trizmal buffer concentrate (pH 7.6; 
Sigma Chemical Co. Ltd.). Shortly before use, one volume of a-naphthyl acetate 
esterase solution (12.5 pg/ml a-naphthyl acetate esterase in 0.4M Hydrochloric acid; 
Sigma Chemical Co. Ltd.) was admixed to complete the staining solution. A  200 pi 
volume of the staining solution was added to appropriate tubes. All samples were 
vortexed and incubated at 37°C for 30 minutes. The tubes were then placed in crushed 
ice to stop the reaction. In certain experiments the cells were washed twice using PBS 
(150g/3 min). Samples were analysed by flow cytometry or examined microscopically.
7.6.4 Fluorescein diacetate assay
A stock solution of fluorescein diacetate (FDA; Sigma Chemical Co. Ltd.) was 
prepared at a concentration of 45 pg/ml using glacial acetic acid (Fisons). This stock 
solution was diluted with PBS shortly before use to give a working concentration of 1.8 
x IO*5 M  (7.5 pg/ml). Cells were counted (using Trypan Blue exclusion) and 
resuspended at a concentration of 2 x 105/ml. A  1.0 ml volume of the cell suspension
was pipetted into the appropriate number of FACScan tubes. Each tube was filled with 
PBS and the supernatant was discarded following centrifugation (150#/3 min). The 
cells were resuspended, with vortexing, in a 200 pi volume of PBS. A  3.0 ml volume 
of the working FDA solution was added to each sample, and the time of addition was 
noted. The samples were incubated for an appropriate time at 37°C/5% C02 and the 
reaction was stopped by placing on ice. Samples were analysed as quickly as possible 
by flow cytometry using the FACScan research software. In certain experiments the 
samples were run through the flow cytometer immediately after adding the FDA so that 
the changes in cellular fluorescence with time could be monitored using the Chronys 
software.
7.7 INVESTIGATION OF PHAGOCYTOSIS
7.7.1 Phagocytosis of zymosan particles
A  suspension of zymosan was prepared by adding 20ml of PBS to 400 mg of Zymosan 
A  (Sigma Chemical Co. Ltd.) to give a final concentration of 20 mg/ml. The 
suspension was heated in a boiling water bath for 1 hour and was gently agitated every 
10-15 minutes. Particles were centrifuged out of suspension (150#/3 min) and were 
washed 5 times with PBS. The washed zymosan was resuspended in PBS (50 mg/ml) 
and stored in 1ml aliquots at -20°C. Zymosan particles were opsonized (when .required) 
by incubating for 30 minutes at 37°C with an equal volume of fresh, human serum 
(obtained from a healthy individual). The opsonised zymosan was washed using PBS 
before use (150#/3 min).
Cells to be used in the assay were counted (using trypan blue exclusion) and 
approximately 5 x 105 cells were pipetted into the appropriate number of tubes. After 
centrifugation (150#/3 min), the cells were resuspended by vortexing in 200jll1 PBS. A  
10jj.l volume of an appropriate dilution of stock zymosan, or of opsonized zymosan, was 
added to each sample. Sufficient phorbal myristate acetate (PMA) was added to 
appropriate tubes to give a concentration of 100 jig/ml and the samples were incubated 
for the required time interval at 37°C/5% C02. The tubes were placed on ice and 
samples were analysed by flow cytometry using the FACScan Research software.
Uptake of zymosan particles results in increases in the forward scatter (FSC; cell size) 
and side scatter (SSC; granularity) profiles of the cell population.
A  viable cell count was determined (using Trypan Blue) and cells were resuspended at a 
concentration of 1 x 106/ml. The cells were washed in PBS (150g/3 min) and 
resuspended using PBS or phenol red-free RPMI1640 medium (ICN Flow). The cell 
suspension was aliquoted into wells of a flat-bottomed mitrotitre plate (Nunc), using 
100 pl/well. At this stage of the assay the cells were activated by incubation in the 
presence of appropriate compounds, including 1.6 x lO-TM PMA (Sigma Chemical Co. 
Ltd.). Sheep (Serotec) or human group O erythrocytes were counted (using a 
haemocytometer) and were resuspended at a concentration of 1 x 106/ml using PBS, and 
100 pi was aliquotted into each well. Cells were incubated in the presence of the 
erythrocytes for an appropriate time at 37°C. Following this incubation, the plate was 
centrifuged (150g/5 min) and a 100 pi volume of the supernatant from each well was 
transferred to fresh well. The remaining supernatant was carefully aspirated and a 200 
pi volume of 0.2% sodium chloride solution (Fisons) was added to each of the original 
wells (to lyse the extracellular RBCs). The plate was centrifuged (150g/5 min) and a 
100 pi volume of the supernatant from each well was transferred to a fresh well. The 
remaining supernatant was carefully aspirated and cells were washed twice by adding 
200 pi PBS to each original well and centrifuging the plate (150^/5 min). Cells were 
lysed by adding 100 pi of 0.2M Tris-HCl (Sigma Chemical Co. Ltd.) containing 6M 
Urea (Fisons) to each well. A  stock solution of 2,7- diaminofluorene (DAF) (Sigma 
Chemical Co. Ltd.) was prepared by dissolving 250 mg of the reagent in a 5 ml volume 
of 90% aqueous glacial acetic acid (Fisons). Shortly before use the DAF reagent was 
prepared by admixing a 1 ml volume of the stock DAF solution with a 100 pi volume of 
30% hydrogen peroxide solution (Fisons) and 10 ml of 0.2M Tris HC1 (Sigma Chemical 
Co. Ltd.) containing 6M Urea (Fisons). A  100 pi volume of this DAF reagent was 
added to every well. The plates were kept at room temperature for 5 minutes and the 
optical density at 620 nm recorded.
7.7.2 Assay of cytotoxicity and phagocytosis
7.8 INVESTIGATION OF THE RESPIRATORY BURST
7.8.1 Nitroblue Tetrazolium Reduction Assay
Cells were counted (using Trypan Blue exclusion) and resuspended at a concentration of 
2 x 105/ml. A  1.0 ml volume of the cell suspension was pipetted into the appropriate 
number of FACScan tubes (Becton Dickinson). Each tube was filled with PBS and the 
supernatant was discarded following centrifugation (150g/3 min). The cells were 
resuspended, with vortexing, in 500 pi PBS. An equal volume of 0.1% Nitroblue 
Tetrazolium solution (prepared in PBS; Sigma Chemical Co. Ltd.) was admixed to each
sample. In certain experiments cells were stimulated by the addition of sufficient PMA  
(Sigma Chemical Co. Ltd.) to give a final concentration of 100 ng/ml. The samples 
were incubated at 37°C/5% C02 for 20 minutes. The tubes were then placed on 
crushed ice and the cells examined microscopically or analysed by flow cytometry using 
the FACScan research software.
7.8.2 Hydroethidine assay
Cells were counted (using Trypan Blue exclusion) and resuspended at a concentration 
of 4 x 105/ml. A  1.0 ml volume of the cell suspension was pipetted into an appropriate 
number of pairs of FACScan tubes (Becton Dickinson). Cell were washed with PBS 
(150#/3 min) and resuspended, with vortexing, in 1.0 ml PBS. A  stock 63.5 mM 
solution of hydroethidine (HE; Kodak Eastman) was prepared using DMSO (Sigma 
Chemical Co. Ltd.). A  2.5 pi volume of this stock solution was added to each sample. 
All samples were incubated for 15 minutes at 37°C/5% C02, to allow the cells to take 
up the compound. The cells in one of each pair of duplicate tubes were then stimulated 
by the addition of sufficient PM A (Sigma Chemical Co. Ltd.) to give a final 
concentration of 100 pg/ml. The samples were incubated for a further 20 minutes at 
37°C/5% C02. The tubes were then placed in crushed ice and the cells were analysed 
for red fluorescence using flow cytometry.
7.8.3 2\7'-Dichlorofluorescin diacetate (DCFH-DA) assay
A  10 mM stock solution of 2',7-Dichlorofluorescin diacetate (DCFH-DA; Kodak 
Eastman) was prepared in 7V,/7-dimethylformamide (Sigma Chemical Co. Ltd.). Shortly 
before use, this stock solution was diluted 1:20 using PBS, to prepare a 0.5 mM 
solution. Cells were counted (using Trypan Blue exclusion) and resuspended at a 
concentration of 4 x 105/ml. A  1.0 ml volume of the cell suspension was pipetted into 
the appropriate number of pairs of FACScan tubes (Becton Dickinson). Each tube was 
filled with PBS and following centrifugation (150#/3 min), the cells were resuspended 
in 1.0 ml PBS. A  20 pi volume of 0.5 mM 2',7'-dichlorofluorescin diacetate solution 
was added to each sample. All samples were incubated at 37°C/5% C02 for 15 minutes 
to allow the cells to take up the compound. The cells in one of each pair of duplicate 
tubes were stimulated by the addition of sufficient PMA (Sigma Chemical Co. Ltd.) to 
give a final concentration of 100 ng/ml. The samples were incubated for a further 20 
minutes at 37°C/5% C02. The tubes were then placed on ice and the fluorescence 
associated with the cells analysed using flow cytometry and FACScan research software.
7.9 INVESTIGATION OF THE REPLICATION OF H IV
7.9.1 Production and storage of virus stocks
Isolates of HIV-Irp (ADP103; chronically infected H9 cells; Popovic etal, 1984) and 
H IV -lBa.L (ADP118; a monocytotropic strain; Gartner et al., 1986) were obtained 
from the MRC AIDS directed programme. Stocks of these HIV-1 strains were 
produced by growing the virus in appropriate cell lines. Exponentially replicating cells 
were counted and approximately 2 x 105 cells were transferred to a centrifuge tube.
The cells were pelleted by centrifugation (150g/3 min) and washed using PBS (150g/3 
min). The appropriate strain of HIV was removed from storage at -70°C and quickly 
defrosted. A  100 pi volume of virus suspension was added to the cell pellet, and the 
tube was incubated at 37°C/5% C02 for 90 minutes. The tube was filled with PBS and 
the cells were harvested by centrifugation (150g/3 min). The cells were resuspended in 
5 ml fresh complete medium and transferred to a 25cm3 filter-topped tissue culture flask. 
The infected cell suspension was incubated at 37°C/5% C02 for several days. Cell 
suspensions were observed daily for signs of cytopathic effects and were sub-cultured at 
3 -4  day intervals by dilution of the cells to a concentration of 1 - 2 x 105/ml. When 
cytopathic effects were maximal the cell suspension was transferred to a centrifuge tube 
and the cells harvested by centriguation (150g/3 min). The cells were resuspended in 
10 ml fresh complete medium and incubated at 37°C/5% C02 for a further 24 hours. 
After this time the cells were pelleted (150g/ 3 min) and the supernatant was aliquoted in 
1 ml volumes into cryovials. Each vial was disinfected and transferred to the -70°C 
freezer for storage.
7.9.2 Formazan conversion/MTT assay
This assay was used to give an indication of the affect of H IV -1 replication on cell 
viability. The virus can directly lyse infected cells, or can contribute to cell death 
following syncytia formation. The basis of the assay is that metabolically active cells 
can convert 3~[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to 
insoluble formazan crystals.
All cells used for the MTT assay had been passaged 1 -3  days before the experiment to 
ensure that they were in the exponential phase of growth. In certain experiments the 
cells were treated with reversible cell cycle inhibitors, prior to use in the assay. The 
cells were counted, using Trypan Blue exclusion, and resuspended at approximately 5 x 
105/ml. Sufficient 96-well flat-bottomed 96-well plates were prepared for the assay by 
pipetting 50 pi of complete RPMI 1640 medium into the central wells and 200 pi sterile 
distilled water into the peripheral wells. A  vial of H IV -1 was removed from storage at -
70°C and defrosted. A  50 pi volume of virus stock was added to every well in the first 
column and double-diluted across the plate. A  50 pi volume of cell suspension was 
added to every well. The plates were sealed with tape, disinfected and tranferred to a 
37°C/5% C02 incubator. The plates were examined daily and incubated for a 5 day 
period. The microscopic characteristics of the cells were recorded at this time. A  
solution of MTT (Sigma Chemical Co. Ltd.) was prepared by dissolving sufficient 
compound in PBS to give a final concentration of 7.5 mg/ml. The solution was warmed 
to 37°C to dissolve the MTT, and was then passed through a 0.2 pM poresize filter to 
ensure that no undissolved compound remained. Shortly before use, pyruvic acid 
(Sigma Chemical Co. Ltd.) was admixed give a final concentration of 0.01M. A  50 pi 
volume of this solution was added to every well. The plates were resealed, disinfected 
and returned to the incubator for 90 minutes. Dark formazan crystals could be 
observed in wells containing live cells. Propan-2-ol (iso-propyl alcohol; 150 pi; BDH) 
was added to every well, and the contents were mixed using a multichannel pipette, to 
dissolve any formazan crystals. The plates were observed and the number of wells 
where the yellow MTT solution had been turned blue was noted. The optical density at 
540 nm was recorded for every well.
7.9.3 Investigation of the replication of HIV-1 in cells treated with reversible cell cycle 
inhibitors
Exponentially replicating cultures were counted, using Trypan Blue exclusion, and cell 
concentration was adjusted to approximately 5 x 105/ml. The cells were incubated for 
approximately 6 hours (37°C/5% C02), before appropriate reversible cell cycle 
inhibitors were added. The cells were incubated for 18 hours at 37°C/5% C02 in the 
presence of the cell cycle inhibitors. The cells were transferred to centrifuge tubes and 
were harvested (150#/3 min). The appropriate strain of H IV -1 was removed from 
storage at -70°C and quickly defrosted. A  100 pi volume of undiluted virus suspension 
was added to each cell pellet, and the tubes were incubated (37°C/5% C02) for 90 
minutes. Every tube was filled with PBS and the cells were harvested by centrifugation 
(150#/3 min). The cells were resuspended in 9 ml fresh complete medium and 
transferred to 25cm3 filter-topped tissue culture flasks. The infected cell suspensions 
were incubated at 37°C/5% C02 for several days. Cultures were observed daily for 
signs of cytopathic effects and were sub-cultured at 3 - 4 day intervals by dilution of the 
cells to a concentration of 1 - 2 x 105/ml. Samples of these infected cultures were 
collected for HIV-1 p24 antigen E.L.I.S.A. assay, and for staining for intracellular p24 
antigen. Samples were also fixed, stained and embedded prior to examination using 
transmission electron microscopy.
7.9.4 HIV-1 p24 antigen E.L.I.S.A.
The detection of HIV p24 utilized a commercial kit (Retro-tek HTV-1 p24 antigen 
E.L.I.S.A. kit; Cellular Products Inc.) based on an antigen capture E.L.I.S.A. The 
assay was carried out according to the manufacturer’s instructions, but brief details are 
given below.
All reagents were warmed to room temperature. Virus particles were disrupted by 
mixing each sample (225 pi) with lysing buffer (25 pl)which contains the biological 
detergent Triton X-100. Wells of a 96-well microtitre plate had been pre-coated with 
monoclonal anti-p24 antibody. Sufficient pre-coated wells were placed in a plastic 
frame, washed with assay diluent, and blotted dry using tissues. A  two hundred 
microlitre volume of assay diluent was placed in a control well, and an equal volume of 
samples or diluted standard placed in other wells. The plate was covered and incubated 
for 2 hours at 37°C. The contents of each well was carefully aspirated, and the plate 
was washed six times with the assay diluent. The plate was blotted dry and 100 pi of 
the detector antibody solution was placed in every well, with the exception of the assay 
blank. The plate was covered and incubated for 1 hour at 37°C. The contents of every 
well was carefully aspirated, and the wells were washed six times with the assay diluent, 
and blotted dry. Streptavidin-peroxidase solution was added to every well (100 pi), 
except the blank well, to which an equal volume of assay diluent was added. The plate 
was covered and incubated for 30 minutes at 37°C. A one hundred microlitre volume 
of the substrate solution was added to every well and the plate was incubated, 
uncovered, at room temperature for 30 minutes. At this stage, the development of a 
dense blue colour indicates the presence of viral antigen. The reaction is stopped by 
addition of 100 pi 2M sulphuric acid solution to each well. The assay is quantified by 
reading the optical density at 450 nm within 15 minutes of stopping the reaction.
7.9.5 Detection of intracellular p24 antigen
HIV infection of mononuclear phagocytes may result in accumulation of virus in 
intracellular vacuoles, with little or no viral antigens expressed on the host cell surface. 
The KC57 monoclonal antibody can be used to detect the core antigens present inside 
cells using flow cytometry.
Cells to be tested for presence of intracellular p24 antigen were harvested by 
centrifugation and washed with PBS (150g/3 min). The cells were fixed by addition of 
of 1 ml of 20 pg/ml lysolecithin inl% paraformaldehyde (Sigma Chemical Co. Ltd.). 
After 2 minutes at room temperature the cells were pelleted by centrifugation (300g/5 
min). Absolute methanol (Sigma Chemical Co. Ltd.) was removed from storage at -
20°C and a two millilitre volume was added to every sample. The cells were incubated 
on ice for 10 - 15 minutes before harvesting by centrifugation (300g/5 min). Each 
sample was held on ice for 5 minutes in the presence of 1.0 ml 0.1% Nonidet P-40 
(Sigma Chemical Co. Ltd.). The cells were pelleted by centrifugation (300g/5 min). A  
5 pi volume of monoclonal KC57 antibody solution (Coulter Electronics Ltd.) or 
appropriate isotype control (Sigma Chemical Co. Ltd.) and a 195 pi volume of PBS was 
added to the appropriate samples. Samples were incubated for 15 minutes at room 
temperature. A  one millilitre volume of PBS was added to each tube and cells were 
harvested by centrifugation (300g/5 min). Cells were resuspended in 1 ml PBS and 
samples were held on ice before the cell-assocoated fluorescence was analysed using 
flow cytometry.
7.10 STATISTICS
Unless otherwise stated differences between median flow cytometric values or mean 
optical density results were assessed statistically using Student's t test.
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8.1 ISOLATION OF FUSION PARTNERS
8. J. 1 Selection of drug-markedfusion partners
The selection of a hypoxanthine guanine phospho ribosyltransferase negative 
(HGPRT”) mutant of the murine macrophage cell line P388D1 had been described by 
Uchida et ai (1985). These authors cultured the cells in the presence of increasing 
concentrations (0.5, 1.0, 2.0, 4.0, 7.0 and 10.0 pg/ml) of 6-thioguanine (6-TG) for 
periods of 7 - 14 days. It was decided to adopt this protocol in order to select for 
HGPRT” mutants of the human myeloid cell lines U937, HL-60 and THP-1. The same 
protocol was also used with the chemical 5-bromo-2'-deoxyuridine (5-BU) in order to 
select for thymidine kinase negative (TK“) mutants of the HL-60 and THP-1 cell lines.
Microscopic examination of HL-60 and U937 cells that had been exposed to either of 
the two compounds at a concentration of 0.5 pg/ml indicated that the cells had quickly 
became very granular. Trypan blue cell counts showed that cellular replication rate had 
decreased and the cell counts were observed to stabilize, before beginning to decrease. 
All cells eventually died. A  TK" mutant of the U937 cell line was available, so no 
further attempts to produce other TK” cell lines were made.
The growth rate of THP-1 cells was unaffected by the inclusion of 0.5 pg/ml 6-TG in 
the growth medium. After 3 days exposure to 0.5 pg/ml 6-TG the cells were passaged 
(using a 1:2 dilution with fresh complete RPMI1640 medium). Half of the cells were 
maintained in the presence of 0.5 pg/ml 6-TG, and the remaining cells were exposed to
1.0 pg/ml 6-TG. Trypan blue counts indicated that exposure to the higher 
concentration of the chemical resulted in a slight decrease of cellular growth rate. The 
cells were passaged (1:10 dilution) after a further 4 days into fresh medium containing 
either 1.0 pg/ml or 2.0 pg/ml 6-TG. At this stage the microscopic appearance of the 
cells was granular and the cell counts showed little evidence of replication. However, 
after approximately 2 weeks of exposure to either 1.0 pg/ml or 2.0 pg/ml 6-TG, an 
increase in cell concentration was recorded. Passage into 4.0 pg/ml 6-TG resulted in a 
temporary growth arrest, but after 7 days exposure to this concentration cell counts 
indicated that cellular replication was occurring. At this stage, passage into medium 
containing higher concentrations of the compound was not observed to affect the 
growth rate of the cells. Figure 8.1 shows the cell concentrations of the THP-1 cells
shows the cell concentrations of the THP-1 cells exposed to 6-TG. Cells that could 
replicate in the presence of 15 fig/ml 6-TG were cloned by limiting dilution. The 6-TG 
resistant cells were routinely maintained in medium supplemented with 15 pg/ml 6-TG 
to prevent reversion to the parental phenotype.
THP1 cells were more resistant to exposure to 5-BU. Trypan blue cell counts indicated 
that cell replication was relatively unaffected by addition of 0.5 or 1.0 pg/ml 5-BU to the 
culture medium. However, when the concentration of 5-BU was raised from 1.0 pg/ml 
to 2.0 pg/ml a reduction in replication rate occurred. Microscopical examination 
indicated that the cells remained looking healthy. When cells were passaged into 
medium containing 4.0 pg/ml, 8.0 fxg/ml or 15.0 pg/ml 5-BU the normal rate of growth 
was resumed. Figure 8.2 shows the cell counts recorded for THP1 cells exposed to 5- 
BU. Once cells that could replicate in medium supplemented with 15 pg/ml 5-BU had 
been isolated, they were cloned by limiting dilution. THP-2 TK" clones were 
maintained in medium supplemented with 15 pg/ml 5-BU to prevent reversion to the 
parental phenotype.
8.1.2 Sensitivity of the drug-resistcmt cells to selective medium 
Growth of cells in the presence of 6-TG is insufficient to ensure that cells have no 
HGPRT enzyme activity, and similarily replication of cells in the presence of 5-BU does 
not indicate that the cells have no TK activity. However, in the context of these 
investigations, the aim of obtaining drug-resistant clones was to render the cells sensitive 
to the selective HAT medium. The terminology is therefore used for convenience to 
differentiate the cell types and does not infer that these enzymes are inactive in the drug- 
resistant cells.
Experiments were carried out to determine the ability of the cells to survive in selective 
medium. Both U937 TK" and THP-2 TK" cells were found to be sensitive to HAT 
medium. Trypan blue indicated that cell viability was markedly reduced after 4 days 
exposure to HAT medium, although a few viable cells could still be isolated up to 8 days 
after addition of HAT. The THP-1 HGPRT" cells were much more sensitive to HAT 
medium. Trypan blue indicated that the majority of the cells were dead after just 48 
hours exposure to medium containing 2 x 10'5 M  aminopterin, and no viable cells could 
be isolated following 3 days incubation in HAT medium.
30-,
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Figure 8.1
Growth curves showing replication rate of THP-1 cells incubated in the presence of 
increasing concentrations of 6-thioguanine. Cell counts were determined by the Trypan blue 
exclusion test. Cells that could replicate in 15.0 itg/ml 6-thioguanine were isolated and 
cloned. These cells were sensitive to HAT medium suggesting that they had an HGPRT" 
phenotype.
0.5 ng/ml 5-bromo-2'-deoxyuridine —0 — 4.0 ng/ml 5-bromo-2'-deoxyuridine
—e  -  1.0 ng/ml 5-bromo-2'-deoxyuridine —®— 8.0 ng/ml 5-bromo-2'-deoxyuridine
— 2.0 ng/ml 5-bromo-2'-deoxyuridine 15.0 ng/ml 5-bromo-2'-deoxyuridine
Figure 8.2
Growth curves showing replication rate of THP-1 cells incubated in the presence of 
increasing concentrations of 5-bromo-2'-deoxyuridine. Cell counts were determined by the 
Trypan blue exclusion test. Cells that could replicate in 15.0 jig/ml 5-bromo-2'-. 
deoxyuridine were isolated and cloned. These cells were sensitive to HAT medium 
suggesting that they had an TK~ phenotype.
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8.1.3 Choice of cell lines for fusion partners
Initial experiments were carried out using U937 TK" cells as a fusion partner, as this was 
the only available cell line that was sensitive to selective medium. However, the high 
sensitivity of THP-1 HGPRT" cells to HAT medium indicated that these cells would be 
very suitable for use as fusion partners. A  selection protocol that only required a short 
exposure to HAT medium would minimize the risk of the selective medium being toxic 
to any fusion products. Therefore, when they became available the THP-1 HGPRT" 
cells were used for the majority of fusions. The THP-2 TK" cells offered no advantage 
in comparison to U937 TK" cells in regard to sensitivity to selective medium, so the use 
of these cells for fusions was restricted. This was fortuitous at it was subsequently 
shown that these cells were tetraploid (see section 9.4.2) and the high initial number of 
chromosomes would not make these cells suitable as fusion partners.
8.1.4 Time in normal medium before selective medium
Protocols for the fusion of rodent lymphocytes to appropriate myeloma cells (for the 
production of monoclonal antibodies) are well described. Normally, cells are placed 
into selective medium directly after fusion, to prevent overgrowth of the myeloma cells. 
However, rodent cells are associated with much higher rates of both replication and 
PEG-induced fusion, than would be expected for human cells. Recently, Kudo et al 
(1991) have described enhanced isolation of human hybridomas when the use of HAT 
medium was delayed until 24 hours after fusion. Therefore, in order to enhance the 
chance of isolating a human macrophage hybridoma a protocol was adopted where 
addition of HAT medium supplement was delayed until growth of cells was observed 
(usually 1 week post-fusion). The cells were exposed to the selective medium for a 
minimim period, determined to be 2 days for THP-1 HGPRT" cells or 7 days for U937 
TK" cells. Cells were then returned to incubation in complete RPMI1640 medium 
supplemented with HT.
8.2 FUSION OF HUMAN MONOCYTE-DERIVED MACROPHAGES
8.2.1 Cell fusion protocols
A  wide range of cell types have been fused with PEG, but cells vary widely in their 
susceptibility to the fusogenic effects of the polymer (Pontecorvo et al., 1977). The 
frequency of fusion depends on both partners - the fusibility of cells in homogenous 
culture can be of great predictive value in maximizing fusion. If one partner is more 
susceptible to fusion than the other, there is an increased probability of self-hybridization
occurring. In order to minimize this, it was reccommended that cells are mixed in 
unequal ratios, plating the less fusible cell line in 10-fold excess (Davidson and Ephrussi, 
1970).
An experiment was therefore carried out to determine the fusibility of human monocytes 
and of U937 TIC" cells exposed to a range of PEG solutions. Human mononuclear cells 
were separated using density gradient centrifugation. The cells were suspended at a 
concentration of 1 x 106/ml and 200pl volumes were dispensed into the central wells of 
two 96-well plates. Non-adherent cells were removed by washing and the monocytes 
were cultured in vitro for 7 days. The cells were exposed to solutions of PEG (with 
concentrations ranging from 30-55% w/v) for a period of 1 - 2 minutes. The PEG 
was removed by dilution, and the cells cultured at 37°C/5% C02 for 10 days. The 
plates were observed daily for signs of cell fusion or cytotoxicity. The experiment was 
repeated using exponentially replicating U937 TK" cells. Cell concentrations ranging 
from 3 x 103 - 2 x 105/ml were used.
Evidence of fusion was observed in some wells containing monocytes that had been 
treated with 45%, 50% and 55% PEG. Treatment of monocytes with 55% PEG  
solution was, however, associated with toxicity. Use of this concentration of PEG also 
presented practical problems owing to its high viscosity. Many of the non-adherent 
TK" U937 cells were lost, during attempts to remove the higher concentrations of PEG 
by dilution. The fusion rate amongst the TK" U937 cells was observed to be higher 
than that recorded for the monocytes. Fusion of TIC" U937 cells had occurred in wells 
treated with 40%, 45%, 50% and 55% PEG. The results therefore indicated that TK" 
U937 cells were more susceptible to PEG-mediated fusion than human monocytes. The 
protocol for further experiments would therefore utilize a ratio of 10 monocytes to 1 
U937 TK" cell, using an exposure to 45% or 50% PEG solution for 1 - 2 minutes.
8.2.2 Use of different tissue culture plastics to enhance differentiation 
Monocytes are freqently isolated from peripheral blood mononuclear cells by their ability 
to adhere to tissue culture plastics, allowing contaminating cells to be simply washed 
away. This adherence to plastic acts as a stimulus to initiate cellular differentiation 
(Johnson et al., 1977; Zuckerman et al, 1979). In vitro maturation of monocytes 
requires the presence of serum and can be affected by cell concentration (Musson,
1983). The cells are extremely fastidious and low cell numbers can result in poor 
maturation and loss of viability. The precise reasons for this are not understood, but it 
is likely that the monocytes can produce factors, which are required during
differenitation, to be present at a minimum concentration. The ideal conditions for 
fusion would therefore utilize a high number of monocytes, which would combine a high 
probability of obtaining a fusion product with conditions where the presence of many 
cells may provide conditions that encourage the growth of any fusion products.
Initial experiments were carried out to determine which tissue culture plastics were most 
suitable for the isolation, maturation and subsequent fusion of human monocytes.
Human mononuclear cells were isolated by Ficoll gradient centrifugation and 
resuspended at concentrations of 1 - 5 x 106/ml in complete RPMI1640 medium. 
Appropriate volumes of the cell suspension were aliquoted into a variety of tissue 
culture plastic vessels. Non-adherent cells were washed away after a period of 4 hours, 
and the adherent monocytes were incubated at 37°C/5% C02. The cells were observed 
daily using an inverted microscope. As monocytes mature in vitro to macrophages, 
they tend to spread and increase their surface area (Johnson et al., 1977). This can be 
observed microscopically and was used to indicate the success of maturation in the 
different vessels. Monocytes cultured in 'U'-bottomed 96-well plates were seen to 
mature well. The cells tended to migrate to the bottom of the wells where they spread 
and remained healthy over a period of weeks in culture. However, use of these plates 
has the disadvantage that the cell number in each well is relatively low and therefore a 
large number of wells must be used in order to maximise the probability of successful 
fusion.
When flat-bottomed 96-well plates were used, the cells tended to congregate around the 
edge of the wells, with few cells remaining in the centre of the wells. Spreading of 
these cells was poor. This effect was also observed when the cells were cultured in 
either 24-well plates or in 6-well plates. Maturation of human monocytes in hybridoma 
plates was also investigated. These plates have 24 square wells, that each contain a 
raised grid, in order to increase the surface area. Again the monocytes tended to 
aggregate at the vertices, and differentiation was poor. The differentiation of 
monocytes in 25cm3 tissue culture flasks suffers from the same problems. However, 
flasks with increased surface area were obtained from IS VP. The increased surface 
area of these flasks had been achieved by using an uneven surface on the side of the flask 
that the cells were to be cultured on. Observation of the monocytes was difficult as the 
optical properties of the plastic was poor. However, the cells tended to aggregate 
around the vertices and no significant improvement in maturation was observed. These 
results indicated that human monocytes matured best in ’U'-bottomed 96-well plates, 
probably because they that did not have vertices where the cells could congregate at
very high densities. A  protocol using 96-well 'U'-bottomed plates was used in all 
attempts to isolate a human monocyte hybridoma cell line.
8.2.3 Use of different media to support the maturation of human monocytes 
Macrophages are particularity fastidious cells, and are particularity sensitive to 
fluctuations in pH (Musson, 1983). The buffering in RPMI1640 medium is provided by 
sodium bicarbonate. Another medium, termed High Growth Enhancement Medium 
(HGEM), is reported to maintain pH more effectively than many media, and can provide 
higher cell yields. This medium is a modification of Dulbecco's modification of Eagle's 
medium in which 3.6g/L fructose is substituted for glucose. The buffering in a third 
medium, termed Leibovitz L-15 medium (Leibovitz, 1963), is provided by the free bases 
of the amino acids in place of sodium bicarbonate. In addition, the glucose in this 
medium is replaced by galactose. Leibovitz L-15 medium can be used for the growth of 
tissues in free gaseous exchange with the atmosphere.
These media were utilized to support the maturation of human monocytes in 96-well 
microtitre plates. The Leibovitz L-15 medium became very yellow when it had been 
incubated in a 5% C02 atmosphere for a few hours. The medium contained the 
indicator Neutral Red, so the yellow colouration showed that the medium had become 
acidic. The monocytes failed to mature in this medium.
RPMI 1640 and HGEM media supplemented with 10% foetal calf serum both supported 
the maturation of human monocytes. No significant differences in the in vitro 
differentiation of the human monocytes were observed between the two media. 
Microscopic examination of the cells after 8 days incubation at 37°C/5% C02 showed 
that the cells had spread and looked healthy. Complete RPMI1640 medium (containing 
10% foetal calf serum) was selected for in vitro culture of human monocytes prior to 
fusion.
The properties associated with the biological membrane are obviously important in the 
context of cell fusion experiments. Some experiments have shown that by growing cells 
in media that has been enriched with certain lipids the fusion efficiency can be enhanced 
(Roos and Choppin, 1985). However, the aim of the fusion experiments was to derive 
an immortal cell line with as many characteristics of human monocytes/macrophages as 
possible. The expression of monocyte specific surface antigens has been shown to alter 
when cells are grown in medium supplemented with lipid depleted foetal calf serum.
The expression of CD 14 and CD64 were both reported to decrease when human 
monocytes were cultured under these conditions, and CD64 expression was not restored
following addition of cholesterol (Esfahani et al., 1993). Changes in surface antigen 
expression due to changes in lipid content of the medium have also been reported for 
U937 cells (Bigler et al, 1990). It was therefore possible that attempts to enhance 
fusion efficieny by enhancing the lipid content of the medium may affect the phenotype 
of any resulting hybridomas, and this approach was not therefore attempted.
8.2.4 Range of times of exposure to PEG
Exposure of cells to PEG concentrations in the range of 30 - 40% w/v can result in 
toxicity if the treatment is longer than a period of minutes. At these concentrations of 
PEG, protocols usually reccommend a period of 8 - 10 minutes, before removal of PEG 
by dilution. Cells can tolerate higher PEG concentrations (40 - 50% w/v) for shorter 
periods and if these are used a treatment period of approximately 1 minute is 
recommended, followed by careful slow dilution of the polymer. Shimoda et al (1988) 
and Woo et al (1988) describe the production of novel human monocyte cell lines by 
fusion using a short exposure (approximately 1 minute) to a 45% PEG solution. Unless 
otherwise stated, a protocol using a relatively high concentrations of PEG (45% - 50%), 
with a short exposure time (1 min), was adopted for the fusion experiments.
8.2.5 Range of times to fusion
In initial fusion experiments a protocol where human monocytes were isolated by density 
gradient centrifugation, and then purified by adherence to the plastic wells of U '- 
bottomed 96-well plates, was used. The cells were incubated for 7 - 9 days, in 
RPMU640 medium supplemented with 10% foetal calf serum, at 37°C/5% C02. This 
allowed the cells to differentiate into cells with characteristics of macrophages (MDM). 
Attempts to fuse MDM in situ to U937 TIC" cells used short (1 minute) exposure to 
45% PEG, using a ratio approximating to 10 MDM : 1 U937 TK" cell. Microscopical 
examination immediately after fusion indicated the presence of a few large cells. The 
plates were observed daily, and some cell replication was observed. The medium was 
replaced with HAT medium, for a period of 7 days, and no further replication was 
observed. The large cells remained looking healthy, but there was little evidence that 
any of these large cells were replicating, even upto 12 weeks post-fusion. This 
experiment was repeated on two occasions using THP-1 HGPRT" cells, but again 
although large cells apparently remained viable for many weeks post-fusion, no signs of 
replication were observed.
Macrophages represent a terminally differentiated phenotype and when these initial 
experiments failed to produce hybridomas, monocytes that had been matured in vitro for
shorter times were used. It was hoped that these less differentiated cells would be more 
metabolically active, and therefore both easier to fuse and more capable of replication 
subsequent to fusion. However, there was again little evidence that any potential fusion 
products were replicating. In one experiment fusion of 7-day M DM with U937 TK* 
cells (10:1 ratio; 45% PEG/1 min) resulted in large cells that were apparently able to 
slowly replicate. However, the cells were very adherent and when attempts to isolate 
these cells using cold shock (-20°C/3 min) or trypsin were used, viability was lost.
8.2.6 'Sigmacoating' the plates
In an initial fusion experiment it appeared that several wells contained adherent fusion 
products. However, several problems were encountered when trying to isolate these 
possible hybridomas. The cells were attached too firmly to be dislodged by vigorous 
washing and use of a 2.5 g/1 solution of the enzyme trypsin resulted in loss of viability. 
'Sigmacote' can be used to treat glass and plastic surfaces. The solution forms a tight 
microscopically thin film of silica on glass which has water repellant properties. It was 
hoped that wells coated with silica would reduce the adherence of the monocytes 
sufficiently to allow potential adherent fusion products to be isolated by vigorous 
washing procedures. Experiments showed that normal human monocytes could be 
removed more easily from 'Sigmacoated' plates, and this coating was therefore used on 
several of the plates used for fusions.
8.2.7 Surfactant enhancement ofpolyethylene-inducedcell fusion
It is generally accepted that an early effect of PEG treatment on cell membranes is the 
redistribution of intramembrane particles, which results in the formation of large 'bare' 
patches (Boni and Hui, 1987). This may result from a localized precipitation of protein 
caused by dehydration and a decrease in the polarity of the medium. Commercially 
available detergents have been shown to induce the fusion of sonicated liposomes 
(Urbaneja, 1988) and may cause the effects associated with the PEG-induced clustering 
of IMP described above. The possibility of enhancing PEG-induced fusion of B16 
melanoma cells, using a range of detergents, was investigated by Prado et al (1989). 
These authors showed that if the cells were pre-treated with low concentrations of 
certain surfactants the PEG-induced fusion efficiency could be greatly enhanced, without 
significantly reducing cell viability. The ionic detergent sodium dodecylsulphate (SDS) 
was found to be the most effective of the surfactants tested, when a concentration of 5 x 
10-5M  was used. In several attempts to fuse human monocytes with human monocytic 
cell lines, the monocytes were washed with PBS containing 5 x 10-5M  SDS. Cells that
had been treated with SDS and then 45% PEG remained healthy for several weeks, 
however, there was no evidence of cellular replication.
8.2.8 Use of DMSO
The inclusion of 5% dimethyl sulphoxide (DMSO) in PEG solutions has been reported 
to enhance the efficiency of fusion (Norwood et al., 1976). In several attempts to fuse 
human monocytes 5% DMSO was added to the PEG preparation. Microscopic 
observations of the cells showed no signs of toxicity associated with the inclusion of 5% 
DMSO. However, no advantages of including DMSO with PEG were observed. 
Fusions between 7-day human monocytes and THP-1 HGPRT- cells were mediated 
using 45% PEG in the presence or absence of 5% DMSO. The presence of some 
unusually large cells was observed following fusions. A  proportion of these large cells 
were observed to remain healthy, during incubation in HAT medium, and for several 
weeks post-fusion. Although, these large cells presumably remained viable, no evidence 
of replication was observed, either in the 45% PEG or the 45% PEG/5% DMSO treated 
populations.
8.2.9 Use of GM-CSF
Granulocyte-macrophage colony stimulating factor (GM-CSF) is a haemopoietic factor 
which stimulates the proliferation of multipotential progenitor cells. Macrophages 
express specific GM-CSF receptors of high affinity on their surface. Exposure of 
macrophages to GM-CSF is able to enhance several functional properties of myeloid 
cells. GM-CSF has been reported to activate monocyte-derived macrophages for 
enhanced intracellular killing of parasites (Weiser et al., 1987) or to become cytotoxic to 
certain tumour cell lines (Cannistra et al., 1988). Cultured monocytes usually remain 
viable in vitro for around 4 weeks, but survival was significantly enhanced by exposing 
the cells to 50 U/ml GM-CSF (Eishen et al., 1991). These authors report observing the 
occasional mitotic cell in the GM-CSF treated cutures, which suggests that a 
subpopulation of monocyte-derived human macrophages can proliferate in response to 
the cytokine. In two experiments monocytes were isolated and cultured in the presence 
of 50 U/ml GM-CSF for 7 days. The monocyte/macrophages were observed to be 
healthy and were mixed with U937 TK" cells in a 10:1 ratio. The cells were exposed to 
either 45% PEG or to 45% PEG/5% DMSO for 1 minute. However, although several 
large cells remained viable upto 9 weeks following fusion there was no evidence of any 
replication, and no hybridomas were isolated.
Bennett et al (1992) reported that when monocytes were isolated by adherence and 
maintained in serum-free medium a limited extent of cell proliferation could be observed 
in the un-treated cell population. When exogenous GM-CSF was added this monocyte 
proliferation was delayed for up to 17 days. Cell proliferation is frequently assessed as 
the uptake of radiolabelled thymidine, required for DNA replication, or by 
microscopically counting cells using a haemocytometer. Thymidine incorporation 
assays may not be sufficiently sensitive to detect replication in a low number of cells. 
Microscopic methods of cell counting usually require the cells to be present in 
suspension. Monocytes adhere very firmly to plastic and most methods that are 
commonly used to release the cells, donot release all of the cells. It would be necessary 
to resuspend all of the cells in order to assess if any replication had occurred. Accurate 
in situ enumeration of monocytes isolated into 96-well 'U'-bottomed plates was not 
possible because of the relatively high cell densities used (to maximize the probability of 
successful fusion) and the ability of the cells to move. Obviously, replication of 
monocytes prior to fusion procedures would be advantageous, as use of metabolically 
active cells may enhance the probability of obtaining a hybridoma capable of subsequent 
replication. As it was not possible to determine whether GM-CSF treatment affected 
monocyte proliferation in our system the factor was not used prior to subsequent 
fusions.
8.2.10 IFN-y treatment of human monocyte-derived macrophages 
In order to maximise the chance of a successful fusion, it would be advantageous to use 
both fusion partners in a metabolically active state. The cytokine interferon-y (IFN-y) 
was used to activate human monocyte-derived macrophages. A  concentration of 0.1 
U/ml rhuIFN-y was used to stimulate 5-day cultures of plastic adherent monocytes for a 
period of 24 hours prior to fusion. This concentration of IFN-y had been reported by 
Nathan et al. (1984) to cause a good stimulation of macrophages. However, when 
monocytes/macrophages are activated by exposure to IFN-y they undergo changes, 
including modulation of surface antigen expression. It was hoped that any hybridomas 
isolated would maintain as much of the parental myeloid phenotype as possible. For 
this reason, EFN-y was only used to activate cells in one experiment. Although cells 
remained healthy for several weeks, there was no evidence of replication following 
fusion (using a 1 minute exposure to 45% PEG and a 10:1 monocyte to THP-1 
HGPRT" cell ratio).
8.2.11 Use of'sticky' (PMA-treated) U937 TK" cells
The fusion of cells requires the occurrence of two events. Contact between cells must 
be established and then a transient destablization of the biological membrane must occur. 
Enhancement of fusion efficiency has been reported by using lectins or specially 
engineered antibodies against cell surface antigens to bring the cells into close proximity 
prior to treatment with PEG. Human monocytes and monoycte-derived macrophages 
express a family of molecules, termed integrins, that function as adhesion molecules.
The U937 TK" cell line normally grows in suspension. However, it was noted that 
when these cells were exposed to 1.6 x 10-7 M  PMA they rapidly (within 1 hour) 
became adherent to plastic. Flow cytometry was used to used to examine the 
expression of the integrin lympocyte function associated-1 (LFA-1; CD 11 a/CD 18) 
molecule on the PMA treated U937 TK" cells. The results showed that the acquistion 
of the adherent phenotype was associated with significant upregulation of CD1 la on the 
surface of U937 TK“ cells (p < 0.05; see section 9.2.3). Experiments confirmed that 
PM A treated U937 TK" cells could be resuspended by cold-shock (3 -5  minutes at - 
20°C), and that after the PMA had been removed by washing and the cells returned to 
tissue culture plastic, the adherent phenotype was retained. The protocol that had been 
developed to fuse cells in 96-well plates involved several centrifugation stages. The use 
of PM A activated U937 TK" cells had the advantages that as both cell types were 
stongly adherent, the washing stages of the protocol did not require centrifugation.
Also, the the cells were held in close contact prior to PEG treatment. However, 
treatment of U937 TK" cells with the phorbol ester will induce these cells to 
differentiate. Whilst, this may have the advantage, that similar to murine cells, fusion 
rates are highest when cells are at a similar stage of differentiation, it may also be 
disadvantageous to use cells that are replicating at a slower rate. Two experiments 
were carried out using U937 TK" cells that had been pre-treated with PMA. Again, 
although cells remained healthy for several weeks post-fusion, there was no evidence of 
replication.
8.3 DEVELOPMENT OF METHODS TO QUANTIFY FUSION EFFICIENCY
8.3.1 PEG treatment enhances cellular permeability
The leakage of 45Ca2+ into erythrocyte ghosts after a 1 minute incubation with PEG 
1500 rapidly increased at concentrations above 30% PEG (Blow et al., 1978). The 
increase of permeability was reported to coincide with an increase in fusion efficiency.
A  series of experiments was carried out to investigate whether permeability changes, 
detected using fluorescent dyes, could indicate conditions favouring fusion of
mononuclear phagocytes. A  fluorescent dye precursor (2,7-dichorofluorescin diacetate, 
DCFH-DA) was selected for these experiments. This compound is reported to be non- 
fluorescent, but it can be taken up by viable cells (Keston and Brandt, 1965). Once 
inside a cell, cytosolic enzyme reactions can covert DCFH-DA to a green fluorescent 
product. If cellular permeability, and coincidentally fusibility, are increased by exposure 
to PEG, then it would be expected that the treated cells would be associated with 
enhanced fluorescence.
An initial experiment was carried out in order to investigate whether changes in 
permeability, induced by exposure to PEG, could be detected as alterations in uptake of 
the fluorescent dye precursor, DCFH-DA. Approximately 4 x 105 THP-1 cells were 
treated with PEG solutions (ranging between 0 and 55% w/v) for 1 minute. The PEG 
was removed by dilution and the cells washed with PBS (250g/3 min) prior to 
incubation with 10 pM DCFH-DA at 37°C for 15 minutes. The cells were placed on 
ice prior to running through a flow cytometer, and samples were observed 
microscopically. Some unusually large cells were observed in the PEG-treated samples. 
Flow cytometry results showed an increased range of forward scatter (size) for the 
PEG-treated cells in comparison with the control cells. This would be consistent with 
the average cell size decreasing due to the dehydration effects associated with PEG, and 
of the formation of some larger fused cells. The green fluorescence (FL1) associated 
with the PEG-treated cells was higher than that recorded for the controls, for all 
concentrations except 55% (Figure 8.3). The decreased fluorescence observed at the 
highest concentration of PEG may have occurred as a result of leakage of the product 
from the cells. These results suggested that PEG-induced changes of permeability 
could be monitored by observing intracellular accumulation of a fluorescent derivative of 
DCFH-DA. However, it was possible that the PEG treatment had altered the activity of 
the cytosolic enzymes which prevented or modulated the production of the fluorescent 
moiety.
An experiment was therefore designed to investigate whether the results described 
above were due to changes of cellular permeability or to alteration of the activity of 
cytosolic enzymes. THP-1 cells were incubated with 10 p.M DCFH-DA for 15 minutes 
at 37°C. These pre-treated cells were then mixed in various ratios with un-treated cells, 
prior to treatment with 45% PEG. The fluorescence of the cells was analysed by flow 
cytometry. When 100% of the cells had been pre-treated with DCFH-DA, the median 
FL1 associated with the control cells was unchanged by PEG treatments. This 
suggested that once cytosolic enzymes had converted DCF H-DA to the fluorescent
Figure 8.3
Permeability of THP-1 cells treated with a range of concentrations of PEG solution prior 
to exposure to DCFH-DA. Exponentially replicating cells were harvested and treated 
with the appropriate concentration of PEG for 1 minute. PEG was carefully removed by 
dilution, and cells were exposed to 10 mM DCFH-DA. High intensity fluorescence 
indicates uptake of DCFH-DA. PEG treatments (35% - 50%) enhanced uptake of 
DCFH-DA. PEG-induced changes in cell permeability are reported to correlate with 
conditions favouring fusion. Data from a representative experiment are shown.
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product, it had became trapped inside the cell and that 45% PEG was neither affecting 
enzyme activity, nor loss of product from the cell.
Results for the mixtures of cells indicated that when any proportion of the cells had been 
pre-treated with DCFH-DA, the entire cell population became associated with green 
fluorescence (FL1). This was surprising as populations of cells, where none had been 
exposed to DCFH-DA, did not exhibit any autofluorescence under the experimental 
conditions. The un-treated cells were associated with a low intensity, and those that 
had been pre-treated with a much higher intensity of FL1. This indicated that the un­
treated cells had taken up some of the compound. The optimum ratio for detecting 
changes in FL1 was a mixture of 20% pre-treated and 80% un-treated cells. When 
more than 20% of the cells had been pre-treated with DCFH-DA, the high intensity 
green fluorescence tended to mask the changes. The green fluorescence associated 
with a control population of THP-1 cells (solid line) is compared to the FL1 profile o f a 
duplicate population of cells that have been treated with 45% PEG for 1 minute (dotted 
line) in Figure 8.4. A  large increase in the number of cells associated with an 
intermediate intensity of fluorescence can be seen. It is probable that this increase in 
number ofPEG-treated cells associated with an intermediate intensity of fluorescence, 
reflects permeability changes that have allowed more of the dye to enter the cells.
Fusion between pre-treated and un-treated cells may also contribute to this region of 
intermediate fluorescence. Consistent with this is the observation that the mean FSC of 
the cells with intermediate levels of fluorescence was observed to be higher (136) than 
that of the control cells (121). Any increase in numbers of cells with intermediate 
fluorescence intensity may indicate conditions that favour fusion.
The optimum conditions for the fusion of THP-1 HGPRT", THP-1 TIC and U937 TIC 
cells were investigated. A  20% proportion of the cells were pre-treated with DCFH- 
D A  and the cells were exposed to various concentrations of PEG 4000 (in the presence 
or absence of 5% DMSO). The results showed that similar to the previous experiment 
the control population was associated with two peaks of high and low intensity green 
fluorescence. The PEG treated THP-1 cell derivatives showed a particularily marked 
increase in cells displaying an intermediate intensity of green fluorescence. It was 
probable that the cells contributing to this intermediate peak were cells that had taken up 
low levels of DCFH-DA, released from the treated cells, owing to enhanced 
permeability associated with the PEG treatment. The maximum intensity of FL1 for 
THP-1 HGPRT" and THP-1 TICcells was recorded when ceils were treated with 45% 
PEG. Addition of 5% DMSO did not affect the intensity of FL1, suggesting that the 
fusion efficiency was not likely to be enhanced by inclusion of the compound. U937
 ----- — Control THP-1 cells
................  45% PEG
Figure 8.4
Comparison of the green fluorescence associated with 45% PEG treated THP-1 cells and 
control, untreated cells. A proportion of the cells had been pre-treated by incubation for 
15 minutes at 37°C with DCFH-DA. These pre-treated cells are associated with high 
intensity green fluorescence. These cells were mixed with untreated THP-1 cells (20% 
DCFH-DA : 80% untreated) and either exposed to PBS (controls) or 45% PEG for 1 
minute. The increase of cells with intermediate fluorescence intensity in the PEG-treated 
population is thought to reflect an increase of cellular permeability, and indicate that the 
conditions favour fusion.
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TK" cells had maximum intensity of FL1 at 50% PEG. However, in contrast to the 
THP-1 derivatives inclusion of DMSO reduced the intensity of FL1, suggesting that the 
compound was inducing toxicity. Assuming that the maximal fluorescence intensity 
correlates with conditions favouring fusion, this method indicated whether conditions 
that would enhance fusion efficiency. The results are summarized in Figure 8.5.
8.3.2 Direct demonstration of fusion
Although this method could be used to indicate the conditions that were likely to 
facilitate fusion, cellular permeability and not actual fusion was being measured. The 
only direct evidence that the conditions which enhanced permeability also increased 
fusion efficiency was the observation that the cells associated with the intermediate 
fluorescence tended to have higher forward scatter that the mean for the total cell 
population. The quantitation of fusion efficiencies would require direct demonstration 
of fusion. In an attempt to achieve this, cells treated as described above were 
immediately fixed (using either 70% ice cold aqueous ethanol or citrate-acetone- 
formaldehyde solution). The cells were then incubated in the presence of 40 fig/ml 
propidium iodide, and cell associated red fluorescence examined using flow cytometry. 
Unfortunately, the fixing stage, that was necessary to allow the penetration of propidium 
iodide, resulted in the loss of the green fluorescent product.
In order to directly demonstrate fusion, it was decided to treat a certain proportion of 
cells with hydroethidine (HE). This compound can be taken up by viable cells and 
converted by cytosolic enzymes to ethidium bromide. Ethidium bromide can intercalate 
into DNA and fluoresce red (Rothe and Valet, 1990). In an initial experiment THP-1 
HGPRT" cells stained green (using DCFH-DA) were mixed with similar cells that had 
been stained red (using HE) and un-treated THP-1 HGPRT" cells in various ratios. The 
most appropriate ratio was determined to be 20% red : 20% green : 60% non- 
fluorescent, as any changes in fluorescence tended to be masked in experiments where 
higher proportions of labelled cells were used. In control populations < 0.1% of cells 
were associated with both red and green fluorescence (Figure 8.6). However, when 
fluorescence associated with duplicate cell populations, that had been treated with 45% 
PEG, was compared with that of the un-treated populations, it was consistently 
observed that there was an increase in the number of cells that were associated with dual 
fluorescence (Figure 8.7). This indicated that fusion had been successful, and that 
fusions between DCFH-DA and HE pre-treated cells could be quantified. However, as 
fusions between two cells that have been pre-treated with the same compound, or with 
cells that have not been treated cannot be recorded, the method only provides a semi- 
quantitative measure of fusion. In a series of three independent experiments, the
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Permeability of THP-1 HGPRT-, THP-2 TK- and U937 TK" cells treated with 45% PEG in 
the presence or absence of 5% DMSO. A proportion of each cell type were pre-treated by 
incubating in the presence of 10 ftM DCFH-DA. These cells were mixed with un-treated 
cells in a 20% : 80% ratio. Samples were treated by exposure to either 45% PEG, 45% 
PEG/5% DMSO or PBS (Controls) for 1 minute. Green fluorescence of each sample was 
assessed by flow cytometry. Median fluorescence of each sample is shown. Increase of cell 
permeability indicates conditions favouring fusion. Results indicate that inclusion of DMSO 
does not enhance fusibility of THP-1 HGPRT- and THP-2 TK- cells and may be toxic to 
U937 TK- cells.
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Red Fluorescence 
caz)
Figure 8.6
Dot plot showing the fluorescence associated with control THP-1 HGPRT" cells. A 
20% proportion of the cells had been stained green (DCFH-DA), 20% had been stained 
red (HE) and 60% were unstained. Very few cells with dual fluorescence were detected.
Figure 8.7
Dot plot showing the fluorescence associated with 45% PEG-treated THP-1 HGPRT" 
cells. A 20% proportion of the cells had been stained green (DCFH-DA), 20% had been 
stained red (HE) and 60% were unstained. In a series of three independent experiments, 
signficantly more cells with dual fluorescence were observed in the PEG-treated 
population in comparison to the controls (p < 0.05) The fusion efficiency was estimated 
to be in excess of 0.1% in the experiment shown.
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number of dual-positive events in the PEG-treated populations was significantly higher 
compared with the appropriate controls (p < 0.05). The fusion rate was estimated to be 
in excess of 0.1%.
9.0 DEVELOPM ENT OF TESTS TO INVESTIGATE_THEJgHENQTYPE OF  
M O NO NUCLEAR  PH AGOCYTIC  CELL LINES
The differentiation of monocytes to macrophages is accompanied by changes in a range 
of phenotypic characteristics and functional capacities. The stage of maturation can be 
determined by a combination of morphological examination and by monitoring 
functional properties that are acquired as the cells mature. Experimental protocols to 
analyse and (where possible) quantify these myeloid-associated characteristics were 
developed, or adapted from reported methodology.
Myeloid cell lines were utilized during the development of assays to provide a relatively 
homogeneous source of cells, and to give an insight into the maturation status of the cell 
lines. Once standardised, the tests were used to investigate changes in phenotypic and 
functional characteristics of the available cell lines following treatment with compounds 
to prevent normal progression through the cell cycle. The results obtained are 
described in the following chapter.
9.1 GENERAL CELL MORPHOLOGY
9.1.1 Morphological examination
THP-1 ceils grew as loose clumps in suspension culture. The cells were mainly round 
but some polygonal cells were observed. Average cell diameter was estimated to be 12 
-14 f±m. The slightly smaller THP-1 HGPRT" cells grew as tighter clumps, but the 
larger THP-1 TK" cells grew individually. U937 and U937 TK" cells grew individually 
in suspension. The U937 TK" cells were predominantly polygonal, with occasional 
round cells. Parental U937 cells tended to be more rounded. HL-60 cells and the T- 
cell lines H9 and E6.1 Jurkat also consisted of predominantly round cells that grew in 
loose clumps.
9.1.2 Investigation of cellular ultrastructure
Samples of THP-1, U937 and U937 TK“ cells were fixed, stained, embedded in Epon 
812 resin and examined using transmission electron microscopy (Section 7.6.1). THP-1 
cells typically contained a large nucleus surrounded by a thin layer of heterochromatin. 
The cytoplasm frequently contained many vesicles, some mitochondria and occasionally
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endoplasmic reticulum was observed. An ultramicrograph of a typical THP-1 cell is 
shown in Plate 9.1. U937 TK" and the parental U937 cells were observed to have a 
similar structure. These cells contained relatively large, lobate nuclei which often 
contained a prominent nucleolus. The nucleus was typically surrounded by a thin layer 
of heterochromatin. Cytoplasm tended not to be as rich as that observed in the slightly 
more mature THP-1 cells. Few vesicles and mitochondria could be identified in most 
cells, and endoplasmic reticulum was sparse. Ultramicrographs showing typical U937 
and U937 TK" cells are shown in Plates 9.2 and 9.3 respectively.
9.2 CHARACTERIZATION OF SURFACE ANTIGEN EXPRESSION
9.2.1 Surface antigen expression
Functions associated with some of the surface antigens characteristically expressed on 
the surface of myeloid cells have been determined. A  range of commercially available 
monoclonal antibodies conjugated to fluoresecent molecules were used to identify 
selected antigens on the surface of the available cell lines using flow cytometry. All 
staining of cells with monoclonal antibodies was carried out on ice to prevent capping. 
The surface antigen expression of the available cell lines is summarized in Table 9.1.
9.2.2 Expression of CD4
CD4 interacts with MHC Class II molecules during antigen presentation (Gay et al., 
1987). The molecule has also been confirmed as the major receptor for H IV -1 
(Maddon et al., 1986). Available cells lines were stained with FITC-conjugated 
monoclonal anti-CD4 and the resulting fluoresence investigated using flow cytometry. 
U937 TIC" and the parental U937 cells expressed similar levels of surface CD4 (mean 
FL1 260), which were significantly higher than any of the THP-1 cell line derivatives (p 
< 0.01). THP-1 cells expressed a moderate level of CD4 (mean FL1 177). However, 
the intensity of green fluorescence recorded for THP-2 TK" and THP-1 HGPRT" cells 
stained with monoclonal anti-CD4 was not significantly different from that recorded for 
the appropriate isotype controls (p < 0.025). The T-cell lines H9 and E6.1 Jurkat were 
shown to express significant but low levels of CD4 (p < 0.01 and p < 0.05, respectively).
9.2.3 Expression of integrin molecules
Certain integrin molecules consist of a complex formed between an a-chain, (CD 11 a, b 
or c), and a common p-chain, CD 18. Lymphocyte function associated antigen-1
Plate 9.1
An ultramicrograph of a typical THP-1 cell. Exponentially replicating cells were fixed 
using 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, stained with 1% tannic 
acid, and dehydrated through an ethanol series. Samples were embedded in Epon 812 
resin and ultrathin sections were cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy showed a large nucleus, surrounded by 
a thin margin of heterochromatin. The cytoplasm contains several mitochondria, some 
endoplasmic reticulum and several vesicles. THP-1 cells tended to appear rounded with a 
few lamellipods projecting from the cell surface, (x 6 000)
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Plate 9.2
An ultramicrograph of a typical U937 cell. Exponentially replicating cells were fixed 
using 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, stained with 1% tannic 
acid, and dehydrated through an ethanol series. Samples were embedded in Epon 812 
resin and ultrathin sections were cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy indicated that cells contained a relatively 
large, lobate nuclei which often contained a prominent nucleolus. The nucleus was 
typically surrounded by a thin layer of heterochromatin. Few vesicles and mitochondria 
could be identified in the cytoplasm of most cells, and endoplasmic reticulum was sparse.
(x  6 000)
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Plate 9.3
An ultramicrograph of a typical U937 TK‘ cell. Exponentially replicating cells were fixed 
using 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, stained with 1% tannic 
acid and dehydrated through an ethanol series. Samples were embedded in Epon 812 
resin and ultrathin sections were cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy indicated that cells contained a relatively 
large, lobate nuclei which often contained a prominent nucleolus. The nucleus was 
typically surrounded by a thin layer of heterochromatin. Few vesicles and mitochondria 
could be identified in the cytoplasm of most cells, and endoplasmic reticulum was sparse
(x 8 000)
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(LFA-1, GDI 1 a/CD 18) participates in many interactions between monocytes and 
lymphocytes to mediate intercellular adhesion, and maintain close cellular contact during 
immunological reactions (Dougherty and Hogg, 1987). Surface expression of the 
CD1 la molecule on the available cell lines was studied. The results showed that THP-1 
(diploid) and THP-2 (tetraploid) cells expressed the highest level of GDI la. 
Fluorescence intensity associated with THP-1 (mean FL1 279) and THP-2 (mean FL1 
228) cells stained for GDI la was significantly higher than all other cell lines tested (p < 
0.005). U937 cells expressed an intermediate level of GDI la (mean FL1 188) that was 
significantly higher than that expressed by the thymidine kinase derivatives (p < 0.025; 
U937 TK" mean FL1 115; THP-2 TK” mean FL1 123) and THP-1 HGPRT" cells 
(mean FL1 119). However, the intensity of fluoresence associated with the latter cell 
lines, stained for GDI la expression, was significantly higher than the appropriate isotype 
controls (p < 0.025), indicating that the cells were expressing a significant, but low, level 
of the antigen.
It had been observed that when U937 and U937 TK" cells were activated by exposure to
1.6 x lCKM PM A they became adherent to tissue culture plastic within a period of 
hours. An experiment indicated that the adherent phenotype observed just 3 hours after 
exposure of U937 TIC cells to the phorbol ester correlated with a significant 
upregulation of surface CD1 la expression (p < 0.05), with an increase of in mean FL1 
of 66 units.
Expression of CD1 lb is restricted to human monocytes, macrophages, granulocytes and 
natural killer cells (Pahl et al, 1992). The antigen functions both during intercellular 
adhesion interactions, and as a receptor for complement component C3bi (Beller et al, 
1982). The CD1 lb/CDl 8 complex can mediate phagocytosis of complement- 
opsonized particles (Ross et al, 1985). Investigation of the red fluorescence associated 
with cells that had been stained with a phycoerythrin-conjugated monoclonal anti- 
CD 1 lb antibody indicated that only THP-1 and U937 TK" had fluoresence intensities 
significantly higher than the isotype controls (p < 0.005). U937 TK" cells expressed 
significantly higher levels of this antigen (mean FL2 435) than THP-1 cells (mean FL2 
254; p < 0.01).
Another integrin molecule, GDI lc, has specificity for the iC3b complement component 
and can mediate phagocytosis of complement-opsonized particles, in addition to 
mediating intercellular adhesion. Expression of this antigen has been observed to 
increase during the in vitro differentiation of human monocytes (Myonnes et al, 1988). 
This antigen is primarily expressed on human tissue macrophages, but some circulating
monocytes have also been shown to express CD1 lc (Brown, 1991). Low levels of 
CD1 lc were expressed by THP-1, cells (mean FL1 137). Antigen expression by this 
cell line was low but significantly higher than that of appropriate isotype controls (p <
0.10). In comparison to the appropriate isotype controls the other cell lines did not 
express significant levels of CD1 lc indicating the immaturity of these myeloid cell lines.
In comparison with the appropriate isotype controls, all of the cell lines expressed 
significant levels of CD 18, the p-chain of integrin molecules (p < 0.005). This result 
was expected, because all of the monocytic cell lines had expressed significant levels of 
at least one of the a-chains. The highest level of expression was associated with THP-1 
and H9 cells (mean FL1 286). Interestingly, U937 TK" cells expressed significantly 
higher levels of CD 18 than the parental U937 cells (mean FL1 277 and 220, 
respectively; p < 0.025). Tetraploid THP-2, THP-1 HGPRT" and E6.1 Jurkat cells all 
expressed similar levels of CD 18 (mean FL1 141).
9.2.4 Expression of CD 14
The CD 14 antigen (expressed by a variety of cell types including monocytes, 
Langerhan's cells, granulocytes, and macrophages), is a receptor for complexes of 
lipopolysaccharide (lps) and lps binding protein (Wright et al., 1990). Expression of 
CD 14 is frequently associated with a differentiated phenotype. In keeping with the cell 
lines having characteristics associated with immature myeloid cells, none of the cells 
tested were observed to express the CD 14 antigen.
9.2.5 Expression of CD 15
CD 15 was expressed at high levels on the surface of both THP-1 and U937 cells (mean 
FL2 428 and 346 respectively). U937 TK" cells also expressed significant levels of this 
antigen (mean FL2 217; p < 0.10 compared to isotype controls). THP-2 and THP-1 
HGPRT" cells did not express significant levels of CD 15 on their surface.
9.2.6 Expression of CD25 ($-chain of IL-2 receptor)
THP-1 and U937 TIC cells were the only cell lines that expressed significant levels of 
the CD25 antigen (p < 0.05 and p < 0.1, respectively). Unstimulated U937, THP-2 and 
THP-1 HGPRT" cells did not express CD25. This antigen is reported to be expressed 
by activated T cells, B cells and macrophages, and functions as the p-chain of IL-2 
receptor (O'Laughlin et al, 1992).
9.2.7 Expression of Fey Receptors
CD 16, the low-affinity receptor for monomeric IgG (FcyRHI), is expressed by mature 
tissue macrophages, monocytes recruited to sites of inflammation, granulocytes and NK  
cells (Bordessoule et al, 1993). The antigen is absent from human peripheral blood 
monocytes (Clarkson and Ory, 1988), but is expressed during serum-induced in vitro 
maturation (Andreesen et al, 1990). No evidence was recorded that any of the cell 
lines constitutively expressed CD 16 (FcyRIII), providing further evidence for the 
immature nature of these cell lines.
Another antibody receptor, CD64 (FcyRI), is expressed by macrophages and some 
circulating monocytes. This receptor binds monomeric IgG with high affinity (Wong et 
al, 1991). CD64 (FcyRI) was not expressed on the surface of U937 or U937 TK" 
cells. THP-1 cells, (or their derivatives), were not tested for expression of this antigen.
9.2.8 Expression of CD71 (transferrin receptor)
All the cell lines tested expressed relatively high levels of CD71. In every case the 
green fluorescence of cells stained with FITC-conjugated anti-CD71 was significantly 
higher than the isotype controls (p < 0.005). This observation was not unexpected. 
CD71 is the transferrin receptor which, due to its involvement in the uptake of iron, is 
essential for cellular replication (Judd et al., 1980).
9.2.9 Expression of HLA-DR
THP-1 cells expressed a significant level of HLA-DR, an MHC Class II antigen (p < 
0.05). The other cell lines tested (U937, U937 TK", THP-2 and THP-1 HGPRT") were 
not found to express this antigen. Expression of HLA-DR has been reported to 
increase during the in vitro differentiation of human monocytes (Valentin et al, 1990a).
9.3 INVESTIGATION OF MYELOID ENZYME ACTIVITY
9.3.1 Non-specific esterase activity: The fluorescein diacetate assay 
Esterases comprise a series of enzymes which act on a range of substrates including the 
hydrolysis of a large number of uncharged carboxylic esters. Cellular esterase activity is 
ubiquitous as it results from a series of enzymes acting on a range of substrates. 
Published data suggests that non-specific esterase activity is a good indicator of the
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myeloid origin of a cell. The use of fluorescein diacetate to investigate the non specific 
esterase activity associated with monocytic cells was described by Szollosi et al (1981). 
Fluorescein diacetate is a non-fluorescent compound that can readily penetrate viable 
cells. Intracellular esterases can convert the compound to fluorescent molecular 
fluorescein which can then be detected by flow cytometry.
In an initial experiment exponentially replicating myeloid cells were washed with PBS 
and incubated in the presence of 1.8 x 10‘5 M  fluorescein diacetate (FDA) for 20 
minutes at 37°C. The samples were run through the flow cytometer to determine the 
level of green fluoresence (FL1) associated with the FDA-treated cells. Control 
samples that had been incubated in the presence of PBS alone were not associated with 
FL1 in this experiment. However, the results showed that all FDA-treated samples 
gave a single peak of green fluoresence. The intensity of fluorescence varied between 
the cell lines (Figure 9.1), with the U937 and U937 TK" cells associated with the highest 
intensity of fluorescence.
The rate of FDA conversion to fluorescein was investigated in a further experiment.
Cells were counted, and approximately 2 x 105 were placed in a FACScan tube. The 
cells were washed (using PBS) and 3.0 ml of the working concentration of FDA (1.8 x 
10'5 M ) was added. The tube was immediately placed on the flow cytometer, with 
aquistition of data commencing after approximately 30 seconds. Using the Chronys 
software, data was collected over 10 second periods, with intervals of 20 seconds. The 
fluorescence associated with U937 cells (Figure 9.2) was compared to that of the T-cell 
line E6.1 Jurkat (Figure 9.3), incubated under the same conditions. Both cells lines 
were observed to convert FDA to fluoresecein, although the rate and maximum intensity 
of fluorescence associated with U937 cells (maximum FL1 412) was much higher than 
that recorded for E6.1 Jurkat cells (262). Cellular esterase activity is ubiquitous, but as 
expected more FDA was converted to fluorescein by the myeloid cell line compared to 
the T-lymphoid cell line. However, the poor specificity associated with FDA 
conversion limits the usefulness of this compound, and no further work was carried out.
9.3.2 Non-specific esterase activity: Development of flow cytometric method 
Cellular esterase activity is ubiquitous but under defined reaction conditions the activity 
of specific esterase enzymes can be used to identify certain cell types (Yam etal., 1971). 
Activity of the enzyme a-naphthyl acetate esterase is primarily detected in monocytes 
and macrophages (Bennett and Reed, 1975). The basis of a cytochemical test 
frequently used to detect a-naphthyl acetate esterase (a-NAE) activity relies on the
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Figure 9.1
Non-specific esterase activity of cell lines indicated by conversion of fluorescein diacetate 
to a green fluorescent product. Approximately 4 x 105 cells were harvested and washed 
with PBS. The cells were resuspended in a working solution of fluorescein diacetate (1.8 
x 10'5M) and run through a flow cytometer. Intensity of green fluorescence indicates 
non-specific enzyme activity. U937 and U937 TK" cells were associated with the highest 
esterase activity, and THP-1 HGPRT" cells the lowest. THP-2, THP-2 TK" and HL-60 
cells displayed and intermediate levels of enyzme activity. Data from a representative 
experiment is shown.
THP-2
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Figure 9.2 Time (Seconds)
Conversion of fluorescein diacetate to a green fluorescent product by U937 cells in 
relation to time. Approximately 4 x 105 U937 cells were harvested and washed with 
PBS. The cells were resuspended in a working solution of fluorescein diacetate (1.8 x 
10'5M ) and immediately aquistition of flow cytometry data was commenced. The 
Chronys software was used to acquire data of 10 second intervals, with periods of 20 
seconds between data collection. The increase of FL1 with time indicates uptake of 
fluorescein diacetate and subsequent disacetylation to produce a fluorescent product. 
However, maximum intensity of fluorescence was higher than recorded for E6.1 Jurkat 
cells, indicating that these myeloid cells were associated with a higher level of esterase 
activity.
Conversion of fluorescein diacetate to a green fluorescent product by E6.1 Jurkat cells in 
relation to time. Approximately 4 x 105 E6.1 Jurkat cells were harvested and washed 
with PBS. The cells were resuspended in a working solution of fluorescein diacetate (1.8 
x 10_5M ) and immediately aquistition of flow cytometry data was commenced. The 
Chronys software was used to acquire data of 10 second intervals, with periods of 20 
seconds between data collection. The increase of FL1 with time indicates uptake of 
fluorescein diacetate and subsequent disacetylation to produce a fluorescent product. 
However, maximum intensity of fluorescence was lower than recorded for U937 cells, 
indicating that these T-cells had a lower level of esterase activity.
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appropriate enzyme to hydrolyse specific ester linkages and liberate naphthol 
compounds. When the latter are released in the presence of freshly formed diazonium 
salts, highly coloured, insoluble complexes are deposited at sites of enzymatic activity.
A  commercially available kit provided chemicals for staining cells fixed to microscope 
slides. Experiments were carried out to investigate whether the cytochemical method 
could be adapted to allow the cells to be stained in suspension, so that any increase of 
cellular granularity, of the stained cells, could be analysed as an increase in light 
scattered at 90° (side scatter; SSC) in the flow cytometer.
A  suspension of freshly isolated human peripheral blood mononuclear cells (PBMC) was 
fixed and stained for a-NAE activity. The cells were examined microscopically and the 
largest cells appeared darkly stained. Cells containing intracellular granules were 
counted and found to account for approximately 10% of the population. Fixed, 
unstained PBMC did not contain any granules. When PBMC stained for a-NAE  
activity were analysed by flow cytometry, the population as a whole showed a slight 
increase in 90° light scattering (SSC). Monocytes were identified by staining with an 
FITC-conjugated anti-CD 14 monclonal antibody. The CD 14 positive cell population 
accounted for approximately 15.5% of the PBMC (n = 5, range 12.2 - 16.4) and were 
found to be amongst the largest present (i.e they had high FSC values, Figure 9.4). The 
SSC of the CD 14 expressing cells was examined by setting electronic gates on the large 
cells associated with green fluoresecence (Figure 9.5). The CD14 expressing cells were 
associated with a significant increase in granularity (SSC) after staining for a-NAE  
activity. Subsequent experiments showed that inclusion of sodium fluoride ablated the 
a-NAE staining associated increase of SSC.
When human cell lines of monocytic origin were stained for a-NAE activity and 
examined microscopically, they were observed to contain dark intracellular granules. 
However, the average number of intracellular granules varied considerably between the 
cell lines indicating possible differences in the levels of a-NAE activity. Similar to the 
results of the FDA experiments described above THP-1 cells showed the weakest 
esterase activity, with 1 -5  granules per cell. HL-60 cells demonstrated an intermediate 
level of a-NAE activity, containing 8 -17 intracellular granules in each cell. The 
highest a-NAE activity was observed in the U937 cells, which were often so densely 
stained that the number of granules per cell could not be counted. Microscopic 
examination of E6.1 Jurkat cells stained for a-NAE activity showed no evidence of 
intracellular granules. Flow cytometric analyses from several experiments showed that 
the mean SSC of a-NAE stained cells correlated with the pattern of staining observed 
microscopically, i.e. the THP-1 cells showed a modest increase in SSC, HL60- cells
Log Green 
Fluorescence
Figure 9.4
Typical FACScan profile of human mononuclear cells stained with CD 14 monoclonal 
antibody. Peripheral blood mononuclear cells were stained with monoclonal anti-CD 14 
directly conjugated with fluorescein isothiocyanate and analysed of the FACScan. The profile 
shows the distribution of cdll size (forward scatter, FSC; X axis) and fluorescence intensity 
(FL1; Y axis). Region A includes all the large, CD14+ cells, which includes the majority of 
monocytes. This region was determined for each sample and used as a 'gate' to analyse the 
side scatter of these cells.
Number of events
Figure 9.5
Demonstration of a-NAF! activity in CD14 positive mononuclear cells. 1 he side scatter (SSC; 
X axis) distribution of control, or a-NAE stained, CD14+ cells was analysed. I hese cells 
showed a wide range of SSC values but stained cells showed higher mean granularity (SSC) 
values than control cells.
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showed an intermediate increase and U937 cells showed the highest increase and 
variability (Figure 9.6).
9.3.3 Myeloperoxidase activity: Development of a flow cytometric method 
Myeloperoxidase activity regulates the duration of superoxide/hydrogen peroxide 
formation via the NADPH oxidase (Locksley et al., 1987). The enzyme can catalyse 
the oxidation, by hydrogen peroxide, of chloride ions to free chlorine and hypochlorous 
acid, but the major in vivo role of myeloperoxidase is thought to be the degradradation 
of hydrogen peroxide to water (Edwards and Swan, 1986). The demonstration of 
myeloperoxidase activity is considered to be a marker for cells of the myelomonocytic 
lineage, although some monocytes may only display weak enzyme activity. A  
commerically available kit (Sigma Chemical Co. Ltd.) uses an indicator system, first 
described by Hanker et al (1977), where myeloperoxidase catalyses a reaction between 
p-phenylenediamine, catechol and hydrogen peroxide to produce a brown-black 
insoluble reaction product. The kit was designed for the cytochemical localization of 
myeloperoxidase activity, but as the deposition of an insoluble product within a cell 
should produce an increase of cellular granularity. Experiments were carried out to 
investigate whether the procedures could be adapted in order to stain cells in suspension 
so that the reaction could be quantitated using flow cytometry.
In an initial experiment suspensions of human peripheral blood mononuclear cells 
(PMBC) were stained for myeloperoxidase activity. Microscopical examination 
indicated that the largest cells present, thought to be monocytes, had stained darkly. A  
few cells had stained, but the intensity of staining was somewhat less. The majority of 
small cells (presumably lympocytes) had not stained for myeloperoxidase activity. A  
representative sample of PBMC stained for MPO activity is shown in Plate 9.4.
In a further study U937 TK" cells, and similar cells that had been induced to mature into 
cells with macrophage-like characteristics by incubating in the presence of 1.6 x 10'7M  
PMA for 3 days, were stained for myeloperoxidase activity. Microscopical examination 
indicated that cells treated with the cytochemical stain, in the absence of exogenous 
hydrogen peroxide, contained a light brown deposit, evenly distributed throughout the 
cytoplasm. However, cells that had been stained in the presence of exogenous 
hydrogen peroxide could be clearly identified as they contained dark brown deposits 
(Plate 9.5). In many cells the nucleus appeared black, and was surrounded by 
cytoplasm that was stained dark brown. Large amounts of extracellular black insoluble
Number of Events (A )
Side Scatter (SSC; Linear units)
Figure 0 6
Demonstration of <x-NAE activity in human monocytoid cell lines. Figure9.6a 
shows a typical side scatter profile for Fixed, control, and u-NAE stained THP-1 
cells. Stained cells showed a slight but consistent increase in side scatter when 
compared to controls. Figure 9.6b shows the greater increase observed with IJ937 
cells.
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Plate 9.4
Light micrograph of human peripheral blood mononuclear cells (PBMC) stained for 
myeloperoxidase activity PBMC were separated from human peripheral blood by Ficoll 
density centrifugation Cells were fixed (using citrate-acetone-formaldehyde solution) 
and stained for myeloperoxidase activity using reagents from a Sigma cytochemical kit, in 
the presence of exogenous hydrogen peroxide. The darkly stained cells are amongst the 
largest present, suggesting that they are monocytes.
Light micrograph of U937 TK" cells stained for myeloperoxidase activity Exponentially 
replicating cells were fixed (using citrate-acetone-formaldehyde solution) and stained for 
myeloperoxidase activity using reagents from a Sigma cytochemical kit, in the presence of 
exogenous hydrogen peroxide The cells are darkly stained, with the nucleus appearing 
black in many cells Large amounts of extracellular black insoluble material can also be 
seen This extracellular deposit could not be measured by flow cytometry, so the extent 
of staining could not be quantified.
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material was also observed, frequently in close association with clusters of cells. No  
differences in the intensity of this staining could be observed by light microscopy.
When samples of cells stained for myeloperoxidase activity were run through the flow 
cytometer, it was clear that in comparison to the controls, stained cells were associated 
with increased levels of SSC (Figure 9.7). The accumulation of a deposit in cells 
stained in the absence of exogenous hydrogen peroxide was associated with a modest 
increase in SSC. Such staining presumably indicates that the cells either contain 
endogenous hydrogen peroxide, or suitable enzymes for conversion of the substrate into 
an insoluble product. Staining in the presence of exogenous hydrogen peroxide was 
associated with the highest levels of granularity, with PMA-matured cells associated 
with higher levels of SSC than control U937 TK" cells.
In a series of five experiments it was observed that FSC of cells stained for MPO activity 
in the presence of exogenous hydrogen peroxide was significantly reduced (p < 0.05) 
when compared to fixed control cells. It is thought that the intensity of staining was 
preventing light from passing through the cytoplasm and reaching the FSC 
photomultiplier. Flow cytometry is limited to investigation of cellular parameters. 
Extracellular accumulation of an insoluble product was observed microscopically, but 
such deposits cannot be quantified by flow cytometry. It has been reported that during 
in vitro maturation of monocytes, the characteristic of peroxidase activity in the 
monocyte lysosomes is lost, but that the enzyme activity later reappears in association 
with the nuclear envelope and rough endoplasmic reticulum (Nakagawara et al., 1981; 
Rosmarin et al., 1989). It is possible that during the phorbol ester induced maturation 
of U937 TK" cells intracellular myeloperoxidase activity associated with the nucleus is 
enhanced, and more of the insoluble product is produced and retained in the cells, 
causing the observed increase in granularity. However, useful comparisons of 
myeloperoxidase activity between cell lines cannot be performed because of the 
limitations outlined above.
9.4 INVESTIGATION OF NUCLEIC ACIDS
9.4.1 Acridine orange staining of nucleic acids
Acridine orange (AO ) is a metachromatic fluorescent dye. When the dye is intercalated 
(as a monomer) into double-stranded nucleic acids (e.g.DNA) and illuminated using a
B 2BB 4BB EBB
Side Scatter (SSC)
E B B 1 B B B
   Fixed control
.............. MPO
.................  MPO + H20 2
Figure 9.7
Granularity of U937 TK" cells stained for myeloperoxidase (MPO) activity.
Exponentially replicating cells were fixed (using C.A.F. solution) and stained in 
suspension using the reagents supplied in a cytochemical kit. Granularity of the cells was 
recorded by flow cytometry. The histogram compares the side scatter (SSC) of fixed 
U937 TK" cells with identical cells that have been stained for MPO activity in the 
presence (MPO + H20 2) or absence (MPO) of exogenous hydrogen peroxide. The 
increase of SSC for MPO stained cells presumably indicates a level of endogenous 
hydrogen peroxide activity. Microscopic observations indicated that staining in the 
presence of hydrogen peroxide resulted in high levels of extracellular material, which 
could not be detected by flow cytometry.
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blue light source, it fluoresces green (emission near 530 nm). By contrast, the dye 
stacks on single stranded nucleic acids (e.g. RNA) resulting in red fluorescence 
(emission near 640 nm; Darzynkiewicz et al., 1975). Non-fixed cells can be rendered 
permeable to the dye using a non-ionic detergent at low pH (Traganos et al., 1977). 
Differentiation of native DNA, from RNA can be enhanced by the inclusion of chelating 
agents with the acridine orange, such as EDTA, to ensure that the RNA is denatured 
prior to, or during the staining procedure. This green-red fluorescence is accepted as a 
measure of DNA-RNA content of a cell, but it actually only measures of the 
fluorescence of the bound dye (Darzynkiewicz et al., 1984) and may vary therefore with 
changes in the accessibility of the dye to nucleic acids (which is restricted by proteins, 
including histones). It has recently been reported by Myc et al (1992) that in certain 
cell systems the binding of AO to nucleic acids correlates with structural modifications 
in chromatin that accompany cellular differentiation. These authors showed that human 
monocytes cultured for a few days in plastic tissue culture plates increased in both red 
and green fluorescence intensity during cultivation.
An experiment was set up to investigate the in vitro maturation of isolated human 
monocytes. Mononuclear cells were isolated by density gradient centrifugation from 
peripheral venous blood. The cells were incubated (37°C/5% C02) in 96-well 'U1- 
bottomed plates, and non-adherent cells were washed off after 4 hours. Samples of 
adherent cells were removed by using cold-shock (exposure to -20°C for 5 minutes) on 
a daily basis. The cells were fixed using acid detergent, washed with PBS, and stained 
using acridine orange. Samples were analyzed by flow cytometry as quickly as possible. 
Results showed that there were no obvious differences between the 4 and 24 hour 
samples. Monocytes were associated with median FSC of 61 and SSC of 92 at these 
times. However, in later samples a general increase of both FSC and SSC was 
observed and a distinct population of large, granular cells could be identified. This 
correlated with the microscopical observation that the cells tended to spread during in 
vitro differentiation induced by adherence to plastic. After 72 hours incubation, 74% of 
the monocytes had a median FSC of 75 and a median SSC of 106; with 26% of the cells 
constituting a larger (FSC =  132), more granular (SSC =  224) population.
Interestingly, fluorescence intensity (FL1 and FL2) associated with acridine orange 
stained samples was also observed to increase in a similar manner. Electronic gating 
showed that the large granular population, accounting for 25% of the cells at 72 hours, 
was associated with a higher intensity of red (RNA-associated; median FL2 402) and 
green (DNA-associated; median FL1 442) fluorescence (Figure 9.8). The smaller cells 
had median FL1 of 355 and FL2 of 325 which were similar to the values recorded for 
the 4 hour population of monocytes. It is unlikely that a quarter of the cell population
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Figures 9.8 a and 9.8 b
Acridine orange staining of human monocytes matured in  v itro .  Human peripheral blood 
monocytes were isolated by Ficoll density gradient centrifugation and cultured adherent 
to plastic (37°C/5% C02) in medium containing 10% foetal calf serum. Samples were 
resuspended using cold-shock after 4, 24, 48 and 72 hours in vitro culture. Cells were 
stained with acridine orange and resulting fluorescence analysed using flow cytometry. 
Figure a shows the FL1 (DNA) profile and Figure b shows the FL2 (RNA) profile. Both 
histograms show that a population of cells with a more open configuration of nucleic 
acids appears after 24 hours in culture. Electronic gating indicated that these cells were 
associated with higher FSC and SSC than the remainder of the population.
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was synthesizing DNA, particularity as no increase in cell number was observed during 
the experiment. It is therefore probable that the higher intensity of staining reflected a 
more open conformation of the nucleic acid. The in vitro maturation of human 
monocytes is known to be accompanied by many changes in phenotype, and it is 
therefore a reasonable assumption that cellular nucleic acids become more accessible 
during such a period of enhanced transcription.
A  similar experiment was carried out to investigate changes in nucleic acid conformation 
during the DMSO-induced granulocytic differentiation of HL-60 cells. In contrast to 
the myeloid differentiation described above, the maturation of HL-60 cells into 
granulocytes was associated with a decrease in intensity of acridine orange-associated 
fluorescence. Two peaks were recorded for the FL1 (DNA-associated fluorescence) of 
the exponentially replicating control HL-60 cells. Approximately 30% of the cells 
contributed to lower intensity fluorescence peak, (median fluoresence intensity 562) and 
70% to the high intensity fluorescence peak (median 619). Following 24 and 48 hours 
exposure to 1.5% DMSO approximately half of the cells contributed to each peak.
After 6 days exposure to 1.5% DMSO the HL-60 cells had matured into cells capable of 
undergoing maximum stimulus-induced respiratory burst activity (see section 9.6.2). At 
this stage 75% of the cells were contributing to the low intensity FL1 peak (median 524) 
and 25% to the higher intensity peak (median 581). Propidium iodide staining of HL- 
60 cells indicated that cell replication had arrested in G1/G0. The FL2 (RNA- 
associated fluorescence) profile also had two peaks. Acridine orange staining of control 
cells showed that 65% of the cells were associated with the lower intensity peak (median 
453) and 35% with the higher intensity peak (median 507). As the maturation of the 
cells progressed, the proportion of cells contributing to the high intensity peak decreased 
until at 6 days less than 5% of the cells were associated with this peak (median 508) and 
95.5% of the cells were associated with lower intensity fluorescence (median 436).
9.4.2 Karyotype analysis
THP-1 cells are reported to have a diploid number of chromosomes (Tsuchiya et al., 
1980). However, when one clone of these cells was stained with propidium iodide an 
unusual profile, with five peaks, instead of the usual three was recorded (Figure 9.9). 
This suggested that the cell population contained a mixture of diploid and tetraploid 
cells. This clone, termed THP-2 cells had been drug-marked by exposure to 
appropriate chemicals (see section 8.1.1). THP-1 derivatives with TK" and HGPRT" 
phenotypes were likewise stained with propidium iodide. The intensity of red 
fluorescence (FL2) associated with the HGPRT" cells was approximately half that
2 5  B
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Fluorescence 2
---------------THP-1
...............  THP-2
Figure 9.9
Comparison of the propidium iodide profiles of TFIP-1 and THP-2 cells. Exponentially 
replicating cells were fixed (using icecold 70% ethanol) and stained with propidium 
iodide. The profiles were unusual in that three peaks, instead of the usual two, could be 
distinguished. The majority of the THP-1 cells were diploid. However, the high 
intensity of PI staining indicated that the THP-2 cells were predominantly tetraploid.
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recorded than for the TK' cells (Figure 9.10). This observation could be explained if 
the HGPRT" cells were diploid and the majority of the TK" cells were tetraploid.
In non-dividing cells the chromosomes are not visible, even with the aid of histological 
stains for DNA. However, during mitosis the chromosomes condense and with use of 
stains, including Giemsa, become visible under the light microscope. In order to 
determine the average number of chromosomes present in cells of a particular cell 
population it is necessary to prepare the cells so that a high proportion of the cells are in 
metaphase. Samples of exponentially replicating THP-1 cells and derivatives were 
treated with demecolcine to increase the number of cells in metaphase. Samples were 
fixed and chromosomes stained using Giemsa. The cells were examined 
microscopically and the number of chromosomes in 100 metaphase nuclei of each cell 
type were counted. Chromosomes of a representative dipoid cell are shown in Plate 9.6 
and from a typical tetraploid cell in Plate 9.7. The results show that the proportion of 
diploid and tetraploid cells estimated by chromosome enumeration correlated well with 
the percentages estimated using propidium iodide staining (Table 9.2).
9.5 DEVELOPMENT OF ASSAYS TO INVESTIGATE PHAGOCYTOSIS
9.5.1 Phagocytosis of particles
Phagocytosis is frequently monitored by microscopical examination of cells that have 
been incubated in the presence of appropriate particles. Many phagocytes express 
surface receptors that can mediate binding and subsequent phagocytosis of sheep 
erythrocytes (SRBC). These relatively large particles can easily be observed 
microscopically, and the number of erythrocytes ingested by each phagocyte can be 
enumerated. However, this method is very labour intensive, so a preliminary 
experiment was designed to investigate whether phagocyosis of sheep red blood cells 
could be quantified using flow cytometry. U937 and THP-1 cells were incubated for 90 
minutes (at 37°C) with SRBC, in the presence or absence of PMA. Samples were run 
through the flow cytometer and cells were observed microcsopically. Visually, it was 
clear that the THP-1 cells had bound SRBC, with cells surrounded by 'rosettes' of 
erythrocytes (Plate 9.8). The binding interaction of SRBC to THP-1 cells was 
sufficiently strong to prevent dissociation of the bound erythrocytes during repeated 
washing. However, no intracellular SRBC were observed, even in the cells that had 
been incubated in the presence of PMA, indicating that the particles had not been 
phagocytosed. This is in contrast to the U937 cells which neither bound nor
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Figure 9.10
Propidium iodide profiles of a) TFIP-1 HGPRT" and b) THP-2 TIC cells compared to 
THP-1 cells. Exponentially replicating cells were fixed (using icecold 70% ethanol) and 
stained with propidium iodide. The profiles indicated that THP-1 HGPRT" cells were 
virtually all diploid, but the high intensity of PI staining indicated that TFIP-2 TK" cells 
were predominantly tetraploid. This result was confirmed using a karyotype analysis.
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Plate 9.6
Light micrograph of chomosomes in a diploid THP-1 cell nucleus Exponentially 
replicating THP-1 cells were exposed to 0.2 /xg/ml demecolcine for 2 hours at 37°C. The 
cells were washed and resuspended in 0 075M KC1 solution for 10 minutes prior to 
fixation using a 1 part glacial acetic acid 3 parts methanol solution. The preparation was 
tranferred to a microscope slide and stained with 10% Giemsa solution. Microscopical 
examination showed that approximately 21% of the metaphase nuclei contained a diploid 
number (48 +/- 5) of chromosomes.
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Plate 9.7
Light micrograph of chomosomes in a tetraploid THP 2 cell nucleus. Exponentially 
replicating THP 2 cells were exposed to 0.2 /xg/ml demecolcine for 2 hours at 37°C. The 
cells were washed and resuspended in 0.075M KC1 solution for 10 minutes prior to 
fixation using a 1 part glacial acetic acid 3 parts methanol solution The preparation was 
tranferred to a microscope slide and stained with 10% Giemsa solution Microscopical 
examination showed that approximately 79% of the metaphase nuclei contained just under 
a tetraploid number (88 +/- 4) of chromosomes
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Plate 9 8
Light micrograph of a rosette of sheep red blood cells surrounding a pair of THP-1 cells. 
Exponentially replicating THP-1 cells were incubated for 90 minutes (at 37°C/5 % C02) 
with SRBC Microscopic examination indicated that THP-1 cells had bound SRBC, with 
cells surrounded by 'rosettes' of erythrocytes
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phagocytosed SRBC These results correlate well with those obtained by flow 
cytometry. Size (FSC) and granularity (SSC) of U937 cells were not significantly (p < 
0.005) altered by incubation of the cells with SRBC. However, the results from three 
independent experiments indicate that THP-1 cells had significantly (p < 0.025) 
increased SSC (70.3 +/- 2.1) following incubation with SRBC, compared to control 
THP-1 cells (47.0 +/- 6.5). No change in the forward scatter of THP-1 cells was 
observed in these experiments.
A  further experiment investigated the ability of U937 cells to phagocytose zymosan.
This is a preparation of yeast cell walls, which contains large, easily seen particles, that 
are rapidly taken up by phagocytic cells. A  stock of zymosan was rehydrated, aliquoted 
and stored at -20°C. A  preliminary experiment was set up to determine the most 
appropriate concentration of zymosan for demonstration of phagocytic activity. In 
order to enhance the phagocytic potential of U937 cells, the cells were induced to 
differentiate into macrophage-like cells by incubation in the presence of 1.6 x 10*7M  
PMA for 3 days, prior to incubation for 90 minutes at 37°C in the presence of 
increasing dilutions of zymosan. Microscopically U937 cells that had been incubated 
with zymosan appeared larger and more granular than appropriate controls.
Intracelluar zymosan particles were observed in some U937 cells that had been matured 
by incubation with PM A for 3 days, indicating that phagocytosis had occurred. Flow 
cytometry showed that FSC and SSC associated with U937 cells that had been 
incubated in the presence of zymosan were higher than the control cells. The 
differences were greatest when a 1:40 dilution of the stock zymosan suspension was 
used, indicating that this concentration was optimal for use in subsequent experiments.
A  series of three replicate experiments indicated that in comparison to the controls 
(FSC: 104.5 +/- 2.6; SSC: 37.8 +/- 2.0), incubation of PMA-difFerentiated U937 cells in 
the presence of zymosan resulted in significant (p < 0.025) increases of FSC (125.3 +/- 
8.7) and of SSC (96.0 +l- 23.3) detected using flow cytometry.
Freshly isolated human peripheral blood mononuclear cells were likewise incubated in 
the presence of zymosan. Microscopic examination showed that the largest cells 
present contained granules, indicating that zymosan had been phagocytosed by these 
cells. Flow cytometry results indicated that there was a slight overall increase in median 
FSC and SSC of mononuclear cell populations that had been incubated in the presence 
of zymosan. Certain samples were stained with FITC-conjugated monoclonal anti- 
CD 14, following incubation with zymosan. Electronic gating of these samples 
confirmed that the CD 14 positive cells were the major contributors to increase in size 
and granularity following incubation in the presence of zymosan. Significant increases
in FSC and SSC were recorded for the CD 14 expressing cells that had been incubated 
with zymosan (p < 0.05; median 113.2 +/- 9.8 and SSC 156.3 +/~ 21.5, respectively), 
compared with CD14 +ve controls (FSC: 88.1 +/- 8.7; SSC: 89.7 +/- 32.6).
The results described above indicate that incubation of cells in the presence of zymosan, 
or of SRBC, can result in binding and/or phagocytosis of the particles which can be 
detected as significant increases of FSC and SSC using flow cytometry. However, 
application of this technique was limited, as there was no provision for discrimination 
between particles bound to the cell surface from those that had been ingested. A  
fluorescence quenching technique developed to allow microscopical discrimination of 
bound and phagocytosed (intracellular) fluorescently labelled bacteria (Hed et al, 1987) 
has been successfully adaptated for use with flow cytometry (Fattorossi et al, 1989). 
Further development of a flow cytometric method to quantify phagocytosis would have 
investigated the use of this method. However, more recently, a microtitre method that 
allows simultaneous assessment of cytotoxicity and of phagocytosis has been reported 
(Gebran et ah, 1992) and it was decided to attempt to develop this method, rather than 
investigate the flow cytometric method.
9.5.2 Cytotoxicity and phagocytosis assay
The demonstration of phagocytosis requires an indicator system. Gebran et al (1992) 
described a technique that allowed both the extracellular cytotoxicity and the phagocytic 
ability of a population of cells to be investigated simultaneously. Release of 
haemoglobin from erythrocytes can be detected by utilizing the pseudoperoxidase 
activity of the molecule to alter the properties of 2,7-diaminofluorene and increase the 
optical density at 620 nm. When cells are incubated in the presence of erythrocytes 
they may be capable of directly lysing them. Alternatively, the red blood cells (RBCs) 
may be phagocytosed. In order to establish whether the erythrocytes have been lysed, 
the pseudoperoxidase activity of samples of the supernatant obtained after the cells have 
been incubated in the presence of RBCs is compared to a control of RBCs alone. 
Extracellular RBCs can then be lysed and the cells washed. Any RBCs that have been 
internalized will be released when the cells themselves are lysed. Any pseudoperoxidase 
activity associated with the lysate will indicate that phagocytosis has occurred. A  
standard curve can be used to make the assay semi-quantitative.
Human monocytes (that had been cultured in vitro for 2 days) and U937 cells were 
selected for an initial experiment to investigate the cytotoxic and phagocytic potential of 
these cells. The results demonstrated that very little, if any, phagocytosis was detected,
-155-
even in wells that contained cells that had been stimulated by exposure to 1 x 10-7 M  
PM A for 60 minutes, prior to addition of sheep erythrocytes. The standard curve 
indicated that even at relatively low concentrations the optical density maintained a 
linear relationship with the estimated number of lysed erythrocytes. The detection limit 
of the assay was in the region of 1 x 103 erythrocytes. The results for the U937 cells 
were in agreement with the flow cytometric results described above, which indicated 
that U937 cells neither bound nor phagocytosed SRBC, presumably as they did not 
express appropriate surface receptors. It is possible that the lack of phagocytic activity 
detected in the monocytes reflected the sensitivity of the assay. It was calculated that 
each well probably contained in the region of 1 - 2 x 103 viable monocytes. Therefore, 
unless every monocyte had phagocytosed at least one SRBC in the 60 minute period, 
pseudoperoxidase activity of these cells would not be detected above background. This 
indicated that a higher cell concentration, and longer incubation period would be 
required.
In the preliminary experiment described above, it was noted that control wells containing 
medium alone were associated with higher optical density, than wells containing buffer. 
This indicated that either the serum in the culture medium was associated with 
peroxidase activity, or that the phenol red was interfering with the optical density 
measurements. Further experiments showed that if serum- and phenol red-free medium 
was utilized, the background optical density was much lower. Cells were washed in 
PBS and incubated in serum- and phenol red-free medium for the duration of all 
subsequent experiments to overcome this problem.
In a subsequent experiment human monocytes were isolated and cultured in vitro at a 
concentration equating to approximately 2000 monocytes/well for 8 days. The 
monocyte-derived macrophages were incubated in the presence of human group 'O’ 
erythrocytes for 4 hours. The results showed no evidence of either cytotoxicity or 
phagocytosis. The lack of detectable levels of phagocytic activity may have reflected a 
low concentration of monocytes that had survived for the 8 day period, or could have 
resulted either from an insufficient incubation period with SRBC or lack of opsonization 
of the SRBC. It is also possible that incubating the cells with SRBC in the absence of 
serum had interfered with the normal functioning of the cells. Media containing heat- 
inactivated foetal calf serum was subsequently shown to be associated with low levels of 
peroxidase activity, and was therefore not suitable for replacing the serum-free medium. 
However, further experiments were planned to investigate whether higher cell 
concentrations and longer incubation periods would allow the detection of phagocytic 
activity.
Approximately 5% of THP-1 cells are reported to be phagocytic in the absence of 
further stimulation (Tsuchiya et al, 1982). An assay was set up to determine whether 
phagocytosis of these cells could be detected. Using a cell concentration of 1 x 
105/well, THP-1 cells were incubated in the presence of human group *0’ erythrocytes 
for 18 hours. The standard curve was again linear, with the limit of detection estimated 
to be 1 x 103 erythrocytes. The optical density results indicated that phagocytosis had 
occurred in the absence of detectable cytolysis. Extrapolation from the standard curve 
indicated that approximately 7.5 x 103 erythrocytes had been phagocytosed by 
unstimulated cells, and 1.5 x 104 by cells that had been stimulated by incubation in the 
presence of 1 x 10*7 M  PM A for 1 hour prior to the start of the experiment. If it is 
assumed that only one red blood cell is phagocytosed by each THP-1 cell, then 7.5% of 
the unstimulated cell population have phagocytic capacity compared to 15.0% of the 
stimulated cells. It is probable that some cells phagocytose more than one erythrocyte, 
and that the estimated percentages of phagocytosing cells are actually lower than quoted 
above. However, the results compare favourably with rates of spontaneous 
phagocytosis reported by Tsuchiya et al (1982), indicating that the assay could be used 
to measure phagocytic activity of the available cell lines.
9.6 DEVELOPMENT OF ASSAYS OF RESPIRATORY BURST ACTIVITY
9.6.1 Investigation of respiratory burst activity
Phagocytosis or stimulation of certain cell types can induce a metabolic or 'respiratory 
burst'. The non-mitrochondrial oxygen consumption increases, and a variety of reactive 
oxygen metabolites are released into the phagosome and into the extracellular 
environment. The superoxide anion (O2-) is the primary metabolite generated through a 
one-electron reduction of molecular oxygen, catalysed by a membrane-bound NADPH  
oxidase. Superoxide ions dismute either spontaneously, or are catalysed by superoxide 
dismutase, to hydrogen peroxide (H20 2). Myeloperoxidase can catalyse the conversion 
of H20 2 to hypohalous acids. Most of these products have microbicidal activity and 
can protect the cell against infection. Several methods have been described that 
investigate different stages of the respiratory burst. The oxygen metabolites can 
catalyze the reduction of many compounds. Nitroblue tetrazolium (NBT) can penetrate 
viable cells and its reduction leads to the formation of highly coloured insoluble granules 
which indicate the presence of respiratory burst activity. Experimental data reported by 
Rothe and Valet (1990) showed that use of different compounds could differentiate 
between the early and late metabolites produced during the respiratory burst.
Hydroethidine (HE) was oxidised at an early stage of the reactive oxygen metabolism of 
phagocytic cells, and 2',7l-dichlorofluorescein (DCFH) was oxidized at a later stage.
9.6.2 Nitroblue tetrazolium reduction assay
Nitroblue tetrazolium (NET) dissolves to form a yellow solution that can be taken up by 
viable phagocytic cells. If these cells are induced to undergo a respiratory burst, the 
released oxygen metabolites can reduce NET, leading to the intracellular accumulation 
of insoluble formazan granules. Microscopic determination of the percentage of cells 
that reduce NET is a commonly used functional measure of the extent of differentiation 
(Collins et al., 1980). Mature granulocytes display higher levels of NBT reduction than 
their myeloid counterparts, and were therefore selected for development of the assay. 
The differentiation of HL-60 cells into mature granulocytes can be induced by exposure 
to chemicals including DMSO (Collins et al., 1978; Brietman et al., 1980).
Microscopic determination of the percentage of cells that have reduced NBT is 
commonly used as a measure of the extent of such granulocytic differentiation. This 
method is very labour intensive. However, a semi-quantitative method which correlated 
increases of granularity (SSC) detected using flow cytometry with NBT reduction was 
reported by Blair et al. (1985, 1986). A  series of experiments were carried out to 
determine the suitability of this method for assessing the respiratory burst activity of 
myeloid cells.
HL-60 cells were induced to differentiate into mature granulocytes by exposing to 1.5% 
DMSO for 7 days. Samples of cells were washed and resuspended in 0.5 ml PBS. A  
five hundred microlitre volume of 0.1% NBT solution was added to the samples which 
were incubated (+/- 1 jig/ml PMA) for 20 minutes at 37°C. Samples were fixed using 
ice-cold 70% aqueous ethanol. The results showed that although the colour of the 
solution in the tubes containing DMSO-matured and PMA-stimulated cells had turned 
dark blue, there was no significant alteration in the side scatter associated with these 
cells compared to the control undifferentiated cells. Certain samples were stained with 
propidium iodide and subsequent analysis demonstrated that 84% of the DMSO-treated 
HL-60 cells had accumulated in G1/G0 of the cell cycle. Such arrest of cells in G1/G0 
is commonly associated with differentiation. The protocol used for this experiment was 
identical to that described by Blair et al (1985) with exception of the fixation procedure. 
These authors reported experiments that utilized 2% paraformaldehyde solution to fix 
the cells, except for the cell cycle analysis where NBT treated samples had been stained 
with propidium iodide and run without fixation. It was therefore decided to repeat the 
experiment without fixing the cells.
The experiment described above was repeated, but the samples were not fixed. Visual 
examination of the tubes showed that the NBT solution had remained yellow in the 
tubes containing undifferentiated cells, but was dark blue in the tubes containing DMSO- 
matured, PMA-stimulated HL-60 cells. The presence of dark formazan granules in the 
differentiated cells was confirmed microscopically. Flow cytometry indicated that FSC, 
and to a lesser extent SSC, profiles of control HL-60 cells were markedly different from 
that of the DMSO-matured cells. The control cells were associated with a single peak 
of FSC, indicating that the cells were of similar sizes. However, two peaks of FSC 
were observed in the DMSO-matured cells. Populations accounting for 68% of the 
cells were smaller, and 32% of the cells were larger than the undifferentiated cells. All 
of the DMSO-matured cells had slightly increased SSC in comparison to the controls. 
Approximately 46% of the cells contributed to a significant (p < 0.005) increase in SSC 
(median 259 +/- 26; control median 156 +/- 32) when differentiated cells incubated with 
NBT were stimulated with PMA. Electronic gating of these samples indicated that the 
major contribution to this increase of SSC was from a population of cells with higher 
FSC than the control undifferentiated cells. These results suggest that a 7 day exposure 
to 1.5% DMSO has resulted in a proportion of the cells acquiring the capacity to 
undergo stimulus-induced respiratory burst activity. The responsive cells can be 
detected with significantly increased side scatter following reduction with NBT in the 
presence of PMA (Figure 9.11) and are associated with increased size (FSC).
In a subsequent experiment, the acquistion of capacity to undergo a stimulus-induced 
respiratory burst was studied in relation to the time that HL-60 cells were exposed to 
1.5% DMSO. The change in phenotype was first apparent after 4 days, when 17.9% of 
the cells were associated with very high SSC following incubation with 0.1% NBT and 
100 ng/ml PMA. The proportion of responding cells increased to a maximum of 48.2% 
at 6 days (Figure 9.12). These results suggest that only around half of the HL-60 cells 
can be matured into cells with granulocyte-like cells by exposure to DMSO. It is 
possible that a population of HL-60 cells contains a mixture of cells with potential to 
mature into cells with granulocytic or with myeloid characteristics, and cells that 
differentiate in response to DMSO may not mature in response to agents that induce 
myeloid differentiation.
Myeloid differentiation of U937 cells was induced by exposure to 1.6 x 10*^ PMA. 
Samples collected after 0, 24, 48 and 72 hours exposure to the phorbol ester were 
incubated in the presence of 0.1% NBT (+/- 100 ng/ml PMA) for 20 minutes at 37°C. 
Visual examination indicated that the solution in every tube had remained yellow, 
suggesting that NBT reduction had not occurred. This was confirmed by microscopic
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Side scatter 
- Control HL-60 cells 
HL-60 cells + 1.5% DMSO 6 days
Figure 9.11
Nitroblue tetrazolium (NBT) reduction by HL-60 cells. HL-60 cells were induced to 
mature into cells with granulocytic characteristics by incubation with 1.5% DMSO for six 
days. These differentiated cells and non-differentiated control HL-60 cells were 
stimulated by addition of 1 x 10_6M PMA, and then incubated in the presence of 0.1% 
NBT solution for 20 minutes at 37°C. The histogram compares the granularity of 
differentiated and non-differentiated HL-60 cells. Approximately 60% of the 
differentiated cells could undergo a stimulus-induced respiratory burst and reduce NBT. 
Intracellular accumulation of granules resulted in increased side scatter
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Figure 9.12
HL-60 cells were induced to differentiate into cells with granulocytic characteristics by 
exposure to 1.5% DMSO. Approximately 5 x 105 cells were removed on a daily basis, 
washed and resuspended in 0.5ml PBS. A 500 microlitre volume of 0.1% nitroblue 
tetrazolium (prepared in PBS) was added to each sample. The cells were stimulated by 
addition of 1.0 /xg/ml PMA. Samples were incubated at 37°C for 20 minutes and then 
placed on ice, prior to analysis of granularity by flow cytometry. The results indicated 
that initially only few undifferentiated cells (<5%) were associated with high granularity. 
However, as the cells matured into granulocytes the proportion of cells that could reduce 
NBT to insoluble formazan significantly increased. The histogram shows the percentage 
of HL-60 cells with capacity for NBT reduction in relation to the time of exposure to 
1.5% DMSO. Data from a representative experiment is shown.
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examination, and by flow cytometric analysis which indicated that although U937 cells 
that had been incubated with PMA were slightly more granular than the controls, there 
was no evidence of increases in SSC owing to NBT reduction, even when cells had been 
stimulated by further addition of the phorbol ester. It was possible that the PMA- 
matured U937 cells had not taken up NBT, or that PMA did not provide a suitable 
stimulus for NBT reduction.
The addition of plasma to NBT solution is reported to result in the formation of NBT- 
heparin and NBT-fibrinogen complexes, which can be ingested by cells with phagocytic 
capacity (Hudson and Hay, 1989). Phagocytosis of such complexes may be followed 
by respiratory burst activity and result in reduction of NBT to insoluble formazan. An 
experiment was therefore set up to investigate the uptake of NBT/plasma suspension by 
PMA-matured U937 cells, with or without exogenous stimulation using 10 jig/ml PMA. 
Microscopic examination indicated that following incubation with 0.1% NBT/20% 
human plasma a proportion U937 cells, that had been matured in the presence of 1.6 x 
10-7M  PMA for 4 days, contained dark formazan crystals. Flow cytometry indicated 
that these cells were associated with significantly increased FSC (p < 0.025; median FSC 
130.8 +/- 5.2; control median FSC 116.5 +/- 4.9). The SSC of these cells was also 
significantly increased (p < 0.01; median SSC 121 +/ -16.7; control median SSC 88.3 
+/- 0.6). These results indicate that U937 cells induced to mature into macrophage-like 
cells by exposure to phorbol ester can phagocytose NBT/plasma complexes and reduce 
the NBT. Addition of PMA did not influence the ability of the cells to undergo a 
respiratory burst. U937 cells which had been matured by exposure to 1.6 x 10_7M  
PMA for 10 days were associated with a high background granularity. Microscopic 
examination showed that a proportion of these cells contained formazan granules, but no 
increase of SSC was detected using flow cytometry, probably as a result of the high 
background SSC obscuring any further increases of SSC occurring as a result of NBT  
reduction.
The influence of phagocytosis on respiratory burst activity was further studied by 
incubating U937 cells in the presence of 0.1% NBT and opsonized zymosan. 
Unstimulated U937 cells showed no evidence of ingesting opsonized zymosan.
However, cells that had been matured by exposing to 1.6 x lO-'flVI PMA for 4 days prior 
to incubation with 0.1% NBT and opsonized zymosan were associated with increased 
FSC and SSC. This suggested that phagocytosis of opsonized zymosan was stimulating 
oxidative burst activity and reduction of NBT. Taken together with the previous 
results, this suggests that U937 cells could take up NBT. Phagocytosis was necessary 
to induce respiratory burst activity, by a pathway that PMA stimulation alone, could not
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activate in U937 cells that had been matured in the presence of the phorbol ester. The 
induction of respiratory burst activity in DMSO-matured HL-60 cells (with 
characteristics of granulocytes) appeared to be regulated by a different pathway, as 
PM A could activate oxidative burst activity in the absence of any other stimuli.
9.6.3 Use of hydroethidine to study the respiratory burst
Hydroethidine (HE) is the non-fluorescent sodium borohydride-reduced derivative of 
ethidium bromide (EB), and is reported to be predominantly oxidized by superoxide 
anions (O2-) . HE, in contrast to EB, can permeate the membrane of viable cells and be 
directly oxidized to red fluorescent EB, which becomes trapped in the nucleus by 
intercalation into DNA  (Rothe and Valet, 1990).
U937 cells that had been matured into cells with myeloid characteristics by 4 days 
exposure to 1.6 x lO-’M  PMA were selected for an initial experiment. The PMA- 
matured cells, and control U937 cells were incubated in the presence of 160 pM HE for 
35 minutes at 37°C. Cells were then placed on ice and run through the flow cytometer 
as quickly as possible. Control cells (that had not been exposed to HE) were associated 
with low levels of autofluorescence. However, all of the cells that had been incubated 
in the presence of HE were associated with relatively high levels of red fluorescence.
The intensity of FL2 recorded for HE treated cells was independent of PMA stimulation. 
The most probable explanation of this result was that non-specific enzyme activity was 
reducing HE to ethidium bromide, as the latter compound, which fluoresces red when 
intercalated into DNA, cannot itself enter viable cells. It was therefore decided that 
further experiments to investigate the use of this assay should not be carried out.
9.6.4 Use of DCFH-DA to study the respiratory burst
The later reactive oxygen intermediates can be detected using a method decribed by 
Rothe and Valet (1990). These authors based their assay on a compound, 2\T- 
dichlorofluorescein diacetate (DCFH-DA), which can penetrate viable cells and be 
disacetylated to 2',7'-dichlorofIuorescein (DCFH) by cytosolic enzymes. DCFH is a 
non-fluorescent compound that becomes trapped inside the cells due to the polarity of 
the molecule. DCFH can be oxidized to fluorescent 2',7,-dichlorofluorescin (DCF) by 
oxygen metabolites generated during the respiratory burst. DCFH is partly oxidized by 
hydrogen peroxidase (H20 2) and partly by phagosomal peroxidases (Rothe and Valet, 
1990).
An initial experiment was set up to determine whether it was feasible to use DCFH-DA 
to study the respiratory burst of human cell lines. Previous results had indicated that a 
proportion of HL-60 cells matured into cells with granulocytic characteristics by 
exposure to 1.5% DMSO, could undergo a stimulus-induced respiratory burst (as 
indicated by NBT reduction, see section 9.6.2), so these cells were selected for 
development of this assay. HL-60 cells that had been matured by incubation in the 
presence of 1.5% DMSO for 6 days, and control undifferentiated cells, were prestained 
by incubation in the presence of 10 foM DCFH-DA for 15 minutes at 37°C. A  father 
30 minute incubation was carried out in the presence or absence of 100 ng/ml PMA, 
prior to the cells being placed on ice and analysed by flow cytometry. The results 
indicated that all control HL-60 cells incubated in the presence of DCFH-DA were 
associated with much higher levels of green fluorescence (median FL1 440) than the low 
level of autofluoresence recorded for unstained controls (median FL1 86). The 
intensity of FL1 was enhanced by stimulation of these cells with PM A (median FL1 
463). DMSO-differentiated cells were observed to be associated with two peaks of 
FSC. Interestingly, the DMSO-matured population was also observed to have a 
bimodal distribution of FL1 intensity. Electronic gating indicated that higher 
fluorescence intensity was associated with cells of larger size. Treatment with PMA  
enhanced the fluorescence intensity of all cells.
In order investigate the possibility that non-specific cellular enzyme activity was 
converting DCFH-DA to a fluorescent derivative during incubation, the experiment was 
repeated, incubating cells on ice to slow enzymic activity. However, the results were 
similar to those described above, with all DCFH-DA exposed cells associated with high 
intensity FL1. Treatment with PM A caused a small enhancement of fluorescence 
intensity in every sample. Similarity, a population of human mononuclear cells 
incubated with DCFH-DA on ice was observed to fluoresce with intensities of green 
fluorescence that appeared to correlate with cellular size (FSC).
A  cell-free assay confirmed that low levels of green fluorescence could be detected when 
a freshly prepared DCFH-DA solution was illuminated with light of 488 nm in a 
spectrophotometer. The compound appeared to break down rapidly producing a 
fluorescent product, as high levels of green fluorescence were recorded after 15 minutes 
at room temperature. It therefore appears that stock DCFH-DA could breakdown to a 
fluorescent product, which could penetrate all cells tested. Cellular fluorescence was 
probably related to cell volume, and did not reflect respiratory burst activity. It is 
possible that the increased intensity of fluorescence associated with PMA treatment may
reflect enhanced cellular permeability. No alternative suppliers of the compound could 
be found, so it was decided not to investigate the use of this assay any further.
19.0 JQSE_QE_CHEMICALS_TQ_1NTERIIPT REPLICATION QF_MQNQCYTIC  
C EL L  LIN ES.
It is generally accepted that HIV can only productively infect activated T-lymphocytes 
(Stevenson et al, 1990a; Zack etal, 1990). However, correlations between infectivity 
and the replication state of mononuclear phagocytes are less clear. Experiments were 
planned to investigate the importance of the cell cycle of myeloid cells on replication of 
HTV. Preliminary tests were carried out to gain detailed knowledge of the kinetics of 
cell replication of the lines available. This allowed rational design of protocols for 
experiments to arrest the normal progression through the cell cycle by treatment of cells 
with various chemicals. A  series o f experiments was carried out to titrate compounds 
and select concentrations that reversibly inhibited the cell cycle. The phenotypic and 
functional characteristics associated with cells blocked at various stages in the cell cycle 
could then be investigated.
10.1 REPLICATION RATE OF MONOCYTIC CELL LINES
10.1.1 Investigation of the growth rate of U937 and U937 TK" cells
The myeloid cell lines U937 and U937 TK" were maintained in exponential growth phase 
in suspension cultures by dilution with fresh medium every 3 -4  days. Preliminary 
experiments were carried out to investigate the replication rate of these cells. Daily cell 
counts estimated by the Trypan Blue exclusion test were compared to results obtained 
from flow cytometric cell cycle analysis using propidium iodide staining. The results are 
shown graphically in Figures 10.1 and 10.2.
The cell enumeration study showed that when the U937 and the U937 TK" cells were 
diluted to a concentration of approximately 1 x 105 cells/ml, they underwent a lag phase 
that lasted approximately 24 hours. The replication of the cells then entered an 
exponential phase, where cell counts doubled approximately every 24 hours. The 
growth rate of U937 TK" cells was slightly faster than that recorded for the parental 
cells, and a higher cell concentration was reached within the period of study. These 
results correlated with the previous observationslhat old cultures of U93 7 TK" cells 
could contain in the region of 2 x 106 cells/ml, while the concentration ofU937 cells 
rarely exceeded 1.5 x 106 cells/ml. The original report of the isolation and
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Figure 10 1
Replication of U937 cells. A 72 hour culture of U937 cells was diluted with fresh 
complete medium to give a cell concentration of approximately 1 x 105 cells/ 
ml. Cell concentrations were estimated daily using the Trypan Blue exclusion test 
(—• —). Every day a sample of the culture was washed with PBS and fixed using 
70% ice-cold aqueous ethanol. Samples were stained with propidium iodide and 
analysed using flow cytometry. The resulting FL2 profiles were analysed using 
the Cellfit software to determine the cell cycle distribution. The data shown was 
from a representative experiment.
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Figure 10.2
Replication of U937 TK- cells. A 72 hour culture of U937 TK- cells was diluted 
with fresh complete medium to give a cell concentration of approximately 1 x 105 
cells/ml. Cell concentrations were estimated daily using the Trypan Blue 
exclusion test (-■ w )• Every day a sample of the culture was washed with PBS 
and fixed using 70% ice-cold aqueous ethanol. Samples were stained with 
propidium iodide and analysed using flow cytometry. The resulting FL2 profiles 
were analysed using the Cellfit software to determine the cell cycle distribution. 
The data shown was from a representative experiment.
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characterization of the U937 cell line recorded a population doubling time of 95 hours 
(Sundstrom and Nilsson, 1976). However, recent passages of the line have been 
reported to grow more quickly, with synchronized cultures completing the cell cycle in
20.5 to 21.5 hours (Hass etal., 1992b).
Analysis of the samples that had been stained with propidium iodide gave a more detailed 
insight into the replication of the U937 and U937 TK" cells. At 24 hours after passage 
56% of the U937 cells and 45% of the U937 TK" cells were replicating their DNA  (i.e. 
in S phase). The cell count data at this stage showed that the cells were in a lag phase 
with minimal cell division occurring. The cell counts first started to increase at 48 hours 
after passage. At this time point the proportion of U937 cells in S phase had decreased 
to 45%, but the proportion of U937 TK- cells with intermediate levels of DNA had 
increased to 58% of the population. Although, the cell counts continued to increase 
exponentially, the percentage of both cell types in S phase began to decrease as cells 
began to accumulate in G1/G0. This indicated that the rate of growth was beginning to 
slow, probably as a result of decreasing concentrations of nutrients and growth factors in 
the medium. At the peak of replication the proportion of cells in G2/M reached 15% 
and this level was not exceeded. This suggests that cells spend relatively little time in 
this phase in comparison to the other cell cycle phases.
10.1.2 Investigation of the length of S phase using 5-bromo-2'-deoxyuridine 
A  more detailed study was required to determine the approximate length of time that the 
myeloid lines took to traverse the S phase of the cell cycle. Propidium iodide staining 
can be used to estimate the number of cells in each cell cycle phase, but the results are 
inaccurate as it is difficult to distinguish cells in early S phase from those in G1/G0 and 
likewise those in late S from those in G2/M. Mathematical models have been used to 
estimate the proportions in each phase of the cell cycle. However, if the cells in S phase 
could be differentiated from cells not replicating their DNA, the accuracy of the 
technique would be increased. A  protocol that combined propidium iodide staining with 
the specific labelling of cells in S phase was described by Gratzner et al. in 1982. Cells 
that are replicating their D N A  can take up the uridine analogue 5-bromo-2l-deoxyuridine 
An place- of thymidine,-and the S phase cells can-then be specifically identified using a 
monoclonal antibody directed against 5-bromo-2'-deoxyuridine conjugated to FITC. In 
order to use this technique sucessfully, the cells have to be treated to make them 
permeable to the anti-bromodeoxyuridine antibody. This antibody will only bind to
single-stranded DNA, so the cells also have to be treated to denature the DNA. Using 
two-colour flow cytometric analysis an accurate estimate of the numbers of cells in S 
phase is possible. Furthermore, if the movement of cells through S phase is linear then 
the duration of DNA synthesis and the potential doubling time can be accurately 
determined from a single sample (Begg et al., 1985).
An initial experiment studied the movement through S phase of exponentially replicating 
BrdU-labelled cells over a total of 20 hours. Samples were taken hourly and cell counts 
were estimated using the Trypan Blue exclusion test. The increase of cell number over 
time was plotted graphically (Figure 10.3). Extrapolation from this graph indicated that 
the doubling time of HL-60 cells was 12.5 hours, and 15 hours for U937 cells.
Flow cytometic analysis of samples that had been fixed and dual-stained with both 
propidium iodide and FITC-conjugated anti-BrdU showed that most of the cells with an 
intermediate amount of D N A  had incorporated BrdU. The progression of cells (that 
had incorporated BrdU into their DNA ) was monitored though the cell cycle. Initially 
all o f the cells exhibiting green fluorescence (FL1; BrdU positive) were associated with 
an intemediate level of D NA  (i.e. all cells were in S phase). The two hour sample 
indicated that some of the cells that had incorporated BrdU had entered G2/M. One 
hour later it was observed that some of the labelled cells had divided and entered G1/G0. 
The first cells appeared to re-enter S phase 14 hours after the start of the experiment (11 
hours after the first cells had been observed in G1/G0). At this stage, there were still a 
few residual cells in late S or G2/M of the cell cycle. The sample collected 18 hours 
after the start of the experiment showed that the majority of BrdU-positive cells had 
completed mitosis, and a significant proportion had returned to S phase. Representative 
dot plots are shown in Figure 10.4 (a - f).
The preparation and analysis of samples to investigate the time course of DNA  synthesis 
by following the progress of BrdU-labelled cells through the cell cycle is very labour 
intensive. However, the duration of DNA synthesis can be estimated from the results of 
a single sample using a mathematical equation reported by Begg et al. (1985).
Electronic gating is used to quantify movement of BrdU-labelled cells through S phase. 
The mean intensity of FL21 associated with the BrdU-labelled (FL1 positive) cells is 
compared with that exhibited by the cells present in the G1/G0 and G2/M peaks.
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Figure 10.3
Increase of HL-60 and U937 cell concentrations (determined using Trypan Blue 
exclusion counts) with time. Exponentially replicating cultures of HL-60 and U937 
cells were exposed to 10 gM BrdU for 60 minutes, and were then washed and 
resuspended in conditioned medium. Aliquots of 10 ml volume were incubated in 25 
cm3 tissue culture flasks. A flask of each cell type was removed hourly and samples 
were enumerated using Trypan Blue exclusion. Data from a representative 
experiment is shown.
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Figure 10.4
Progression of U937 cells through the cell cycle. The dot plots show the green (FL1) and 
red (FL2) fluorescence associated with U937 cells that have been fixed and stained with 
monoclonal FITC-conjugated anti-BrdU and propidium iodide. All the cells (apart from 
the controls) were incubated for 1 hour in the presence of 10 pM BrdU. The compound 
was washed off, and cells were incubated in conditioned medium at 37°C/5% C02. 
Samples were fixed at hourly intervals. Control cells show a normal cell cycle distribution 
in the absence of green fluorescence (a). Immediately after incubation with BrdU, it can 
be seen that FL1 (indicating incorporation of BrdU) is restricted to cells traversing S 
phase (intermediate levels of FL2) (b). The BrdU labelled cells continued to progress 
thorough the cell cycle and by 2 hours some cells have reached G2/M (c). One hour later 
(3 hours after removal of BrdU) the first labelled cells have divided and entered G1/G0 
(d). The cells continued to progress though S phase, divide and accumulate in G1/G0. 
The sample shown in (e) is representative of the cells that have been incubated for 8 hours. 
The first cells appeared to re-enter S phase 14 hours after the start of the experiment (11 
hours after the first cells had been observed in G1/G0). At this stage, there were still a 
few residual cells in late S or G2/M of the cell cycle (f).
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Figure 10.4 Progression of BrdU-labelled cells through the cell cycle
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The relative movement (RM ) o f the cells through the cell cycle can be calculated using 
the following equation:-
RM =  EL2a r FL2onm
FL2g2/m - FL2gi/go
where FL2s is the mean red fluorescence of the green-labelled cells, and FL2gi/go and 
FL2g2/m are the mean red fluorescence values of G1/G0 and G2/M cells, respectively. 
Immediately after BrdU treatment it would be expected that the mean fluorescence 
associated with the labelled cells would be at an intermediate level, with the ratio 
approximating to 0.5. As the labelled cells continue to synthesize DNA, the mean FL2 
will increase and the ratio will approach unity. Thus, the relative movement o f the 
labelled cells through the cell cycle can be followed as the mean intensity of red 
fluorescence increases. Assuming that the relative movement of the cells through S 
phase is linear with time, the time taken to synthesize the total cellular DNA (Ts) can be 
calculated, with results from a single sample taken several hours after labelling with 
BrdU, using the following formula: -
Ts — 0.5 x t
RM - 0.5
Results for some representative samples are shown in Table 10.1.
In a subsequent experiment a single 6 hour sample was used to estimate the time that 
diploid THP-1, THP-1 HGPRT" cells, and tetraploid THP-2 cells required to traverse S 
phase. U937 cells were used as a control and these cells were estimated to spend 9.5 
hours replicating their DNA, which was in agreement with the previous experiment. 
THP-1 cells were estimated to require 10.4 hours for DNA synthesis, and THP-2 cells
9.2 hours. Interestingly, the results for THP-1 HGPRT" cells indicated that no BrdU 
had become incorporated into the cellular DNA, although the cells were replicating 
exponentially (as determined by cell counts and the propidium iodide profile).
Thymidine kinase negative derivatives of the cell lines had originally been isolated by 
growing in increasing concentrations of BrdU, and therefore this test was not used to 
determine length S phase in these cells. It was possible that the mutation that allowed 
THP-1 HGPRT" mutants to grow in the presence of 6-thioguanine, may also have 
affected the thymidine kinase enzyme activity. This hypothesis was confirmed by 
demonstration that THP-1 HGPRT" cells could replicate at normal rates in medium 
containing 15 jig/ml BrdU. In the absence o f a suitable method to accurately determine 
the length of S phase for the drug-marked derivatives, it was assumed that as the 
replication rates determined by Trypan Blue exclusion cell counts tended to be slightly
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faster than for the parental cell lines, that the duration of S phase was the same or 
shorter.
10.2 INHIBITION OF REPLICATIONMONOCYTIC CELL LINES
10.2.1 Titration of cell cycle inhibitors
Several compounds are reported to reversibly inhibit the normal division cycle of cells.
A  series of experiments was carried out to titrate such compounds in order to determine 
concentrations that were tolerated well by the cells, whilst inducing accumulation in 
certain phases of the cell cycle. Each compound was titrated in U937 or U937 TK" and 
THP-1 HGPRT" cells. I f  the preliminary results demonstrated that the compound was 
affecting the normal replication cycle, it was titrated in at least one other myeloid cell line 
and one T-lymphoid cell line (H9 or E6.1 Jurkat). This would indicate whether any 
effects on the cell cycle could be attributed to the origin of the cell lines. Further 
experiments were carried out to investigate recovery of cells following removal of the 
chemicals. The experiments reported in this section were aimed at investigating which 
compounds could be used to interupt the replication of the available cell lines. The 
effects of the selected chemicals on the function and phenotype of the cells are described 
in the following chapter.
Information obtained from the experiments described earlier in this chapter gave an 
insight into the replication of the cell lines available. When replicating exponentially, the 
cells had been shown to take a maximum of 11.5 hours to replicate their DNA. The 
time spent in G2/M was much shorter, estimated at 1 - 2 hours, with the total doubling 
time estimated to be in the region of 20 hours. This indicated that for experiments 
designed to investigate the effects of known cell cycle inhibitors on the replication of 
these cells, the exposure to compound should exceed 13.5 hours, thus allowing all cells 
that were progressing through the cell cycle at the time of compound addition to 
complete S phase and divide. A  standard protocol was adopted where exponentially 
replicating cultures were exposed to compounds for 18 hours. All experiments were 
repeated a minimum of three times to allow a statistical analysis of the results.
Most of the compounds that have been reported to interrupt the cellular replication cycle 
act by interfering with the synthesis of DNA. This will either prevent cells from entering
S phase, leading to an accumulation at the Gl/S border, or will prevent cells from 
completing DNA replication, leading to an increase in the number of cells in S phase,
10.2.2 Mimosine titration
Few compounds inhibit cells in G l, but one such compound, mimosine, was reported by 
Hofrman et al. (1991). These authors demonstrated that a concentration of 300 pM  
could block the replication of HL-60 cells approximately 1 -2  hours prior to the Gl/S 
border. In the present study, the compound was initially titrated in U937 TK" and THP- 
1 HGPRT" cells using concentrations ranging between 75 pM and 1200 pM. 
Microscopic observation indicated that some of the cells that had been treated with the 
highest concentrations of mimosine were more granular than the controls. Cell counts 
indicated that treatment with 75 pM and 150 pM mimosine had not affected replication, 
but at the higher concentrations no increase in cell number was observed. Ethanol fixed, 
propidium iodide stained cells were examined using flow cytometry. The results of the 
cell cycle analysis indicated that incubation for 18 hours in the presence of mimosine had 
caused significant accumulation of both cell types at 300 pM, 600 pM and 1200 pM, but 
had no effect on the replication of the cells at 75 pM or 150 pM (p < 0.025and p <0.05, 
respectively; Figures 10.5 and 10.6). A  further titration in H9 cells indicated that these 
T-lymphoid cells were slightly more sensitive to the compound, with significantly more 
cells in G l, compared to the control population, following treatment with 150 pM, 300 
pM, 600 pM and 1200 pM mimosine (p < 0.05; Figure 10.7). Incubation of H9 cells 
with 75 pM mimosine had no significant effect on cellular replication.
These results indicated that high concentrations of mimosine were poorly tolerated. It 
was therefore decided to use a 300 pM concentration of mimosine to block cells in 
G1/G0 in further experiments. (This was the lowest concentration of compound that 
significantly affected the replication of all three cell lines tested).
10.2.3 Ciclopirox olamine titration
Ciclopirox olamine is another compound that is reported to block cells in G l (Hoffman 
et al (1991). These authors demonstrated that a concentration of 10 pM  could block 
the replication of HL-60 cells, at the same point as mimosine, approximately 1 -2  hours 
prior to the Gl/S border. The mechanism of action associated with this compound has 
not been elucidated. In an initial experiment, the compound was titrated in U937 TK"
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Figure 10.5
Mimosine titration in U937 TK" cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the mimosine treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 30( 
pM, 600 pM and 1200 pM mimosine has caused a significant (p < 0.025) accumulation of 
cells in G1/G0, whilst the lower concentrations (75 /xM and 150 pM) have not affected 
replication of U937 TK" cells.
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Gl/GO G2/M
Control
1200 pM Mimosine 
600 pM Mimosine
300 pM Mimosine 
150 pM Mimosine 
75 pM Mimosine
Figure 10.6
Mimosine titration in THP-1 HGPRT" cells. Exponentially replicating cells were diluted 
to a concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on G1/G0 and G2/M peaks 
of a representative control population. These markers were used to determine the cell 
cycle distribution of the mimosine treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 30< 
pM, 600 pM and 1200 pM mimosine has caused a significant (p < 0.05) accumulation of 
cells in G1/G0, whilst the lower concentrations (75 pM and 150 pM) have not affected 
replication of THP-1 HGPRT" cells.
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Gl/GO G2/M
^  Control
1200 pM mimosine 
600 pM mimosine
300 pM mimosine 
150 pM mimosine 
75 pM mimosine
Figure 10.7
Mimosine titration in H9 cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of mimosine for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the mimosine treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 15 
pM, 300 pM, 600 pM and 1200 pM mimosine has caused a significant (p < 0.05) 
accumulation of cells in G1/G0, whilst the lowest concentration (75 pM) has not affected 
replication of H9 cells.
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and THP-1 HGPRT" cells. These cells were exposed to concentrations of the 
compound ranging between 5 pM and 100 pM for 18 hours. Samples were fixed (using 
ethanol), stained with propidium iodide, and cell-associated fluorescence was 
investigated using flow cytometry. High concentrations of ciclopirox olamine (50 pM  
and 100 pM) were obviously toxic to the cells. Microscopic examination showed that 
cells treated with these concentrations of the compound had become very granular. Cell 
counts indicated a slight reduction o f cell counts at these high concentrations.
However, exposure to either 5 pM  or 10 pM ciclopirox olamine did not appear to have 
affected cellular growth as estimated by Trypan blue counts. Results of the propidium 
iodide staining indicated that compared to controls U937 TK“ treated with 20 pM, 50 
pM  and 100 pM ciclopirox olamine had accumulated in G l (p < 0.025). Similarity, 
THP-1 HGPRT" cells exposed to high concentrations of ciclopirox olamine had tended 
to accumulate in G1/G0, with exposure to a 20 pM concentration resulting in a 
significant accumulation in this phase of the replication cycle (p < 0.10). However, 
treatment with 5 pM and 10 pM concentrations of the compound had not resulted in any 
significant alterations of cell cycle distribution of either cell type when compared to the 
untreated controls (Figures 10.8 and 10.9). Many of the cells treated with high 
concentrations of ciclopirox olamine were observed to have a lower intensity of 
fluorescence than the control G1/G0 peak. An example of this is shown in Figure 
10.10. This probably indicated that a proportion of cells were undergoing apoptosis. 
Although a 20 pM solution of ciclopirox olamine could block the cells in Gl, the poor 
tolerance at higher concentrations, and possible effects on the conformation of the host 
chromosomes limited the usefulness of this compound. No further studies were 
therefore carried out using ciclopirox olamine.
10.2.4 Aphidicolin titration
The progression of cells through the Gl/S border can be prevented by treatment with 
aphidicolin. HL-60 cells exposed to a concentration of 2 pg/ml for 16 hours were 
blocked in late Gl/early S phase (Hoffman et al., 1991). It is thought that the chemical 
blocks entry into S phase by competing with deoxynucleotides for binding to DNA  
polymerase a and inhibiting enzyme activity. Exponentially replicating cultures of U937 
TK" and THP-1 HGPRT" cells* were incubated in the presence of-0.6 pg/mk 1 pg/ml, 2— * 
p,g/ml, 5 pg/ml and 10 pg/ml aphidicolin for 18 hours. Microscopical observation 
indicated no obvious signs of toxicity. However cell counts revealed that in contrast to 
the control cell concentration which had doubled, numbers of aphidicolin-treated cells
Gl/GO G2/M
Control
100 11M Ciclopirox olamine
H  50 pM Ciclopirox olamine
20 pM Ciclopirox olamine 
10 pM Ciclopirox olamine 
5 pM Ciclopirox olamine
Figure 10.8
Ciclopirox olamine titration in U937 TK' cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours. 
The cells were examined microscopically, and those exposed to the highest concentrations 
of the compound were seen to be very granular, indicating that the compound was poorly 
tolerated. Samples were fixed and stained with propidium iodide, and fluores cence was 
detected by flow cytometry. Electronic markers were set on the G1/G0 and G2/M peaks 
of a representative control population. These markers were left in the same position and 
used to determine the cell cycle distribution of the ciclopirox olamine treated cells. The 
histogram shows the mean and standard deviation of three replicate experiments. 
Compared to controls, exposure to 20 gM, 50 /xM and 100 fxM ciclopirox olamine has 
caused a significant (p < 0.025) accumulation of cells in G1/G0, whilst the lower 
concentrations (5 /xM and 10 /xM) have not affected replication of U937 TK' cells.
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Gl/GO S G2/M
Control
100 uM Ciclopirox olamine 
50 pM Ciclopirox olamine
20 pM Ciclopirox olamine
10 pM Ciclopirox olamine
5 pM Ciclopirox olamine
Figure 10.9
Ciclopirox olamine titration in THP-1 HGPRT' cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours.
The cells were examined microscopically, and those exposed to the highest concentrations 
of the compound were seen to be very granular, indicating that the compound was poorly 
tolerated. Samples were fixed and stained with propidium iodide, and fluores cence was 
detected by flow cytometry. Electronic markers were set on the G1/G0 and G2/M peaks 
of a representative control population. These markers were used, in the same positions, 
to determine the cell cycle distribution of the ciclopirox olamine treated cells. The 
histogram shows the mean and standard deviation of three replicate experiments. 
Compared to controls, exposure to 20 pM, ciclopirox olamine has caused a significant (p 
<0.10) accumulation of cells in G1/G0, whilst the lower concentrations (5 juM and 10 
pM) have not affected replication of THP-1 HGPRT" cells
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Figure 10.10
Propidium iodide profile of 100 pM ciclopirox olamine treated U937 TIC cells is 
compared to that of an exponentially replicating control population. Cells were 
incubated in the presence of either 100 pM ciclopirox olamine or PBS (controls) for 18 
hours (37°C/5% C02). Samples were fixed (using icecold 70% ethanol) and stained 
with propidium iodide. The reduced intensity of fluorescence associated with the 
compound treated cells suggests that the cells are undergoing apoptosis. This result 
correlates with the microscopic granular appearance of the cells indicating that the 
compound was poorly tolerated.
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had only increased slightly. Propidium iodide staining indicated that treatment with all 
but the lowest (0.5 Jig/ml) concentration of aphidicolin had resulted in a general increase 
in mean numbers of U937 TK" and THP-1 HGPRT" cells in late G1/early S (Figures 
10.11 and 10.12, respectively). However, only treatment of THP-1 HGPRT" cells with 
20 jig/ml aphidicolin had caused a significant in accumulation in G1 (p < 0.10). As the 
increases in the mean proportions of these cells in G1 were not significant, this 
compound was not used in any further experiments.
10.2.5 Hydroxyurea titration
A  compound that prevents DNA  synthesis is hydroxyurea (Adams et al., 1967). This 
compound is reported to specifically inhibit normal replication of DNA, without affecting 
RNA or protein synthesis (Yarbro, 1968). Hydroxyurea is thought to inhibit the enzyme 
ribonucletide reductase, which is the key enzyme involved in the balanced regulation of 
deoxynucleoside triphosphate (dNTP) pools (Reichard et al., 1983). In a preliminary 
experiment hydroxyurea was titrated in U937 TK" and THP-1 HGPRT" cells using 
concentrations ranging from 0.25 mM to 4 mM. Following an 18 hour exposure to 
hydroxyurea, microscopical examinination revealed that cells exposed to 4mM appeared 
slightly granular, but otherwise there was no evidence of toxicity. Propidium iodide 
analysis revealed that exposure to hydroxyurea had a more marked effect on the 
replication of U937 TK" cells than on THP-1 HGPRT" cells. Significant accumulations 
of U937 TK" in G1/G0 were recorded for cells treated with 2 mM and 4 mM 
hydroxyurea (p < 0.025). Surprisingly, a concentration dependent accumulation of the 
cells in S phase was recorded as the compound was further diluted (Figure 10.13). 
Significant accumulation of cells in S phase were recorded for U937 TIC" cells treated 
with 0.25 mM and 0.5 mM hydroxyurea (p < 0.025). However, high variability in the 
response of THP-1 HGPRT" cells meant that althought there was a general trend 
towards accumulation of cells exposed to high concentrations of hydroxyurea in G1/G0, 
and in S phase for cells exposed to lower concentration, none of the changes were 
significant (Figure 10.14).
The experiment was repeated using THP-1 and E6.1 Jurkat cells and further dilutions of 
- hydroxyurea (concentration range 0,031 mM -- 4.mM). IncubatioELof these cell lines in 
the presence of 2 mM or 4 mM hydroxyurea caused significant accumulations in G1/G0 
(p <  0.05). Similar to the results for U937 TK" cells described above, exposure to 
lower concentrations blocked these cell lines in S phase. THP-1 cells were quite
Gl/GO S G2/M
Control
20 pg/ml Aphidicolin 
■  10 pg/ml Aphidicolin
5 pg/ml Aphidicolin 
2 pg/ml Aphidicolin 
1 pg/ml Aphidicolin
Figure 10.11
Aphidicolin titration in U937 TK" cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of aphidicolin for 18 hours. The cells were 
examined microscopically and no evidence of toxicity was observed. Samples were fixed 
and stained with propidium iodide, and fluores cence was detected by flow cytometry. 
Electronic markers were set on the Gl/GO and G2/M peaks of a representative control 
population. These markers were used to determine the cell cycle distribution of the 
aphidicolin treated cells. The histogram shows the mean and standard deviation of three 
replicate experiments. Although treatment with all but the lowest concentration of 
aphidicolin caused an increase in the mean number of cells in Gl/GO, these increases were 
not statistically significant
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Gl/GO S G2/M
^  Control
20 pg/ml Aphidicolin 
10 pg/ml Aphidicolin
5 pg/ml Aphidicolin 
2 pg/ml Aphidicolin 
1 pg/ml Aphidicolin
Figure 10.12
Aphidicolin titration in THP-1 HGPRT" cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of aphidicolin for 18 hours. The 
cells were examined microscopically and no evidence of toxicity was observed. Samples 
were fixed and stained with propidium iodide, and fluores cence was detected by flow 
cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the aphidicolin treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Compared to controls, exposure to 20 gg/ml 
aphidicolin caused a significant (p < 0.10) accumulation of cells in Gl/GO, whilst the 
lower concentrations (1 /xg/ml, 2 gg/ml, 5 gg/ml and 10 /xg/ml) have not significantly 
affected replication of THP-1 HGPRT" cells.
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Gl/GO S G2/M
^  Control
4.00 mM hydroxyurea 
■  2.00 mM hydroxyurea
1.00 mM hydroxyurea 
0.50 mM hydroxyurea 
0.25 mM hydroxyurea
Figure 10.13
Hydroxyurea titration in U937 TK" cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 370C/5%CO2. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 2 
mM and 4 mM hydroxyurea has caused a significant (p < 0.025) accumulation of cells in 
G1/G0, whilst lower concentrations (0.25 mM and 0.5 mM) have caused a significant (p < 
0.025) accumulation of U937 TK" cells in S phase.
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Gl/GO S G2/M
Control
4.00 mM hydroxyurea 
■  2.00 mM hydroxyurea
1.00 mM hydroxyurea 
0.50 mM hydroxyurea 
0.25 mM hydroxyurea
Figure 10.14
Hydroxyurea titration in THP-1 HGPRT" cells. Exponentially replicating cells were 
diluted to a concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed wit! 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Although the general trend is for high 
concentrations of hydroxyurea to cause accumulation of THP-1 HGPRT" cells in G1/G0, 
and for lower concentrations to block cells in S phase, the relatively high levels of inter- 
experimental variation mean than none of the changes are statistically significantly 
different from the controls.
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variable in their response, although exposure to 0.125 mM and 0.25 mM hydroxyurea 
caused a significant proportion of THP-1 cells to accumulate in S phase (p <0.10;
Figure 10.15). E6.1 Jurkat cells appeared to be more homogenous in their response to 
hydroxyurea, (Figure 10.16) with significant accumulation of cells in S phase following 
treatments with 0.125 mM, 0.25 mM and 0.5 mM (p < 0.025). Further experiments 
indicated that exposure to 4 mM hydroxyurea caused a significant accumulation of U937 
and of H9 cells in Gl/GO, and that at 0.25 mM the compound caused cells to accumulate 
in S phase (p <  0.05 and p < 0.10, respectively; Figures 10.17 and 10.18).
Although the entry of hydroxyurea treated cells into S phase has been recorded (Walters 
et al., 1976), the use of different concentrations of a single compound to block cells in 
different phases of the cell cycle has not been previously reported. Cells would be 
treated with 4 mM hydroxyurea (to block in Gl/GO) and 0.25 mM hydroxyurea (to 
block in S phase) in further studies. An advantage of using the same compound to 
block in different phases of the cell cycle is that non-specific compound-related 
alterations to cellular physiology, apart from effects on cellular replication, should be 
similar.
10.2.6 5-fluoro-2 '-deoxyuridine titration
The synthesis of DNA  in eukaryotic cells can also be inhibited by 5-fluoro-2'- 
deoxyuridine (Ruechart and Mueller 1960). The mechanism of action of this compound 
is thought to involve inhibition of the enzyme thymidylate synthase. The initial report 
indicated that the growth of HeLa cells was totally prevented by exposure to 1 x 10*6 M  
5-fluoro-2'-dexoyuridine. This was selected as the highest concentration of compound 
to be used in the titration experiment, as higher levels were likely to be poorly tolerated. 
Exponentially replicating U937 and THP-1 HGPRT" cells were exposed to 
concentrations of 5-fluoro-2'-deoxyuridine between 5 x 10-8 M  and 1 x 10-6 M  for 18 
hours. The cells were examined microscopically and then fixed and stained with 
propidium iodide. Cells treated with the highest concentrations of compound were 
granular in appearance. A  limited, but not statistically significant, accumulation of U937 
cells in late Gl/early S was detected when the cells were treated with the highest 
concentrations ofthe compoundj(Figure^ 10.19).. Analysis of the cpll cycle distribution 
indicated that there were no significant differences between the untreated control and 
compound treated THP-1 HGPRT" cells (Figure 10.20). The absence of significant
Gl/GO G2/M
Control
4.00 mM Hydroxyurea
2.00 mM Hydroxyurea
1.00 mM Hydroxyurea 
0.50 mM Hydroxyurea
0.25 mM Hydroxyurea 
0.13 mM Hydroxyurea 
0.062 mM Hydroxyurea 
0.031 mM Hydroxyurea
Figure 10.15
Hydroxyurea titration in THP-1 cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 2 
mM and 4 mM hydroxyurea has caused a significant (p < 0.05) accumulation of cells in 
G1/G0, whilst lower concentrations (0.125 mM, 0.25 mM and 0.5 mM) have caused a 
significant (p <0.10) accumulation of THP-1 cells in S phase.
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Gl/GO S G2/M
Control 1H 0.25 mM hydroxyurea
4.00 mM hydroxyurea §i§ 0.13 mM hydroxyurea 
M  0.062 mM hydroxyurea 
iH  0.031 mM hydroxyurea
11 2.00 mM hydroxyurea
HD 1.00 mM hydroxyurea
H§ 0.50 mM hydroxyurea 
Figure 10.16
Hydroxyurea titration in E6.1 Jurkat cells. Exponentially replicating cells were diluted to 
a concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 2 
mM and 4 mM hydroxyurea has caused a significant (p < 0.05) accumulation of cells in 
G1/G0, whilst lower concentrations (0.125 mM, 0.25 mM and 0.5 mM) have caused a 
significant (p < 0.025) accumulation of E6.1 Jurkat cells in S phase.
Gl/GO G2/M
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4.00 mM hydroxyurea
2.00 mM hydroxyurea
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0.50 mM hydroxyurea 
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Figure 10.17
Hydroxyurea titration in U937 cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 2 
mM and 4 mM hydroxyurea has caused a significant (p < 0.05) accumulation of cells in 
G1/G0, whilst lower concentrations (0.25 mM and 0.5 mM) have caused a significant (p < 
0.05) accumulation of U937 cells in S phase.
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4.00 mM hydroxyurea
2.00 mM hydroxyurea
1.00 mM hydroxyurea
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0.25 mM hydroxyurea
Figure 10.18
Hydroxyurea titration in H9 cells. Exponentially replicating cells were diluted to a 
concentration of 4 - 6 x 105/ml and incubated in the presence of appropriate 
concentrations of hydroxyurea for 18 hours at 37°C/5%C02. Samples were washed with 
PBS and fixed using 70% ice cold aqueous ethanol. Cellular DNA was stained using 
propidium iodide and the cell cycle distribution was calculated from the profiles 
determined by flow cytometry. Electronic markers were set on the G1/G0 and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the hydroxyurea treated cells. The data represent the mean and 
standard deviation of three replicate experiments. Compared to controls, exposure to 4 
mM hydroxyurea has caused a significant (p < 0.05) accumulation of H9 cells in G1/G0, 
whilst at a lower concentration of 0.25 mM a significant (p < 0.10) accumulation of H9 
cells in S phase was recorded.
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Figure 10.19
5-fluoro-2'-deoxyuridine titration in U937 cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours 
(37°C/5% C02). The cells were examined microscopically and at the highest 
concentrations many were seen to be very granular, indicating that the compound was 
poorly tolerated. Samples were fixed and stained with propidium iodide, and 
fluoresecence was detected by flow cytometry. Electronic markers were set on the 
Gl/GO and G2/M peaks of a representative control population. These markers were used 
to determine the cell cycle distribution of the 5-fluoro-2'-deoxyuridine treated cells. The 
histogram shows the mean and standard deviation of three replicate experiments.
Statistical analysis revealed that treatment of U937 cells with 5-fluoro-2'-deoxyuridine did 
not significantly affect the cell cycle distribution of the cells.
Gl/GO S G2/M
1.0 x 10'6M 5-FdU
Control
■  5.0 x 10 7M 5-FdU
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Figure 10.20
5-fluoro-2'-deoxyuridine titration in THP-1 HGPRT- cells. Exponentially replicating cells 
were incubated in the presence of appropriate concentrations of the compound for 18 
hours (37°C/5% C02). The cells were examined microscopically and following exposure 
to the highest concentrations were seen to be very granular, indicating that the compound 
was poorly tolerated. Samples were fixed and stained with propidium iodide, and 
fluoresecence was detected by flow cytometry. Electronic markers were set on the 
G1/G0 and G2/M peaks of a representative control population. These markers were used 
to determine the cell cycle distribution of the 5-fluoro-2'-deoxyuridine treated cells. The 
histogram shows the mean and standard deviation of three replicate experiments.
Statistical analysis revealed that treatment of U937 cells with 5-fluoro-2'-deoxyuridine did 
not significantly affect the cell cycle distribution of the cells.
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effects on the cycling of the two cell lines, and poor tolerance, limited the interest in this 
compound. No further experiments were carried out using 5-fluoro-2,-dexoyuridine.
10.2.7 Thymidine titration
A  double thymidine block has been used to induce synchronicity in the division cycle of 
cells in many experiments (Xeros, 1962). The incorporation of high concentrations of 
thymidine in the culture medium causes a gross imbalance in the intracellular dNTP pools 
which restricts synthesis of DNA (Gentry et al., 1965). Thymidine (at concentrations 
ranging between 0.25 mM and 4 mM) was initially titrated in U937 TK" and THP-1 
HGPRT" cells. Microscopical observation indicated that the compound was well 
tolerated even at the highest concentration (4 mM). Analysis of the cell cycle 
distribution of samples of propidium iodide stained cells showed that significant 
accumulation of U937 TK” cells in S phase had occurred when the cell were exposed to 
either 2 mM or 4 mM thymidine (p < 0.05; Figure 10.21). The THP-1 HGPRT- cells 
appeared to be less sensitive to thymidine with a modest accumulation of cells in S phase 
following treatment 4 mM thymidine (p < 0.10; Figure 10.22).
Further experiments were carried out to investigate the effects of thymidine on the 
replication of other cell lines. Results for U937 indicated that in contrast to the drug- 
marked derivatives, the most significant thymidine-induced accumulation of cells in S 
phase occurred with the lowest (0.25 mM) concentration of thymidine (p <  0.025;
Figure 10.23). The other concentrations of thymidine also resulted in significant 
increases in the proportion of cells in S phase (p < 0.05). The reasons for this difference 
remain unclear. Significant increases in the proportion of THP-1 cells in S phase were 
recorded following treatment with all concentrations of thymidine, except for 0.25 m M  ( 
(p < 0.025 and p < 0.05, respectively, Figure 10.24). The mean number of the T-cell 
lines E6.1 Jurkat (Figure 10.25) and H9 (Figure 10.26) cells in S phase following 
treatment with 0.5 mM, 1 mM, 2 mM or 4 mM thymidine, were significantly higher than 
the appropriate controls (p < 0.05).
These experiments indicated that thymidine was effective at blocking a range of cells in S 
-  phase~ As .thexompound was.apparently__w-dliolerated,it.was~decided to use the 
compound at a 4 mM concentration in further experiments, as cells this concentration 
had resulted in significant increases in the proportion of cells in S phase for all o f the 
cells, with the notable exception of U937.
Gl/GO S G2/M
Control
4.00 mM thymidine
U  2.00 mM thymidine
1.00 mM thymidine
0.50 mM thymidine
0.25 mM thymidine
Figure 1
Thymidine titration in U937 TK" cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of the compound for 18 hours (37°C/5% C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the thymidine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Treatments with 2 mM and 4 mM thymidine had 
resulted in statistically significant (p < 0.05) increases in proportion of cells in S phase, 
and correspondingly decreased proportions of U937 TK" cells in Gl/GO.
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Figure 10-22
Thymidine titration in THP-1 HGPRT' cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours 
(37°C/5% C02). The cells were examined microscopically and no evidence of toxicity 
was observed. Samples were fixed and stained with propidium iodide, and fluores cence 
was detected by flow cytometry. Electronic markers were set on the Gl/GO and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the thymidine treated cells. The histogram shows the mean and - 
standard deviation of three replicate experiments. Treatment of THP-1 HGPRT" cells 
with 4 mM thymidine resulted in a significant (p < 0.10) accumulation of cells in S phase.
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Figure 10.23
Thymidine titration in U937 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5% C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the thymidine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Intestingly, the most significant (p < 0.025) 
accumulation of cells in S phase resulted treatment of U937 cells with the lowest 
concentration of thymidine (0.25 mM). Treatment with other concentrations of the 
compound also resulted in significant (p < 0.05) increases in the numbers of cells in S 
phase.
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Figure 10.24
Thymidine titration in THP-1 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5% C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected b 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the thymidine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant (p < 0.025) accumulations of cells i: 
S phase were recorded for all concentrations of thymidine, except 0.25 mM were the 
accumulation was less marked (p < 0.05).
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Figure 10.25
Thymidine titration in E6.1 Jurkat cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of the compound for 18 hours (37°C/5% C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the G1/G0 and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the thymidine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant (p < 0.025) accumulations of E6.1 
Jurkat cells in S phase were recorded for every concentration of thymidine, except 0.25 
mM (p < 0.05).
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Figure 10.26
Thymidine titration in H9 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5% C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the thymidine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant (p < 0.025) accumulations of H9 
cells in S phase were recorded for every concentration of thymidine, except 0.25 mM 
which did not significantly affect replication of this T-lymphoid cell lines.
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10.2.8 Colchicine titration
The mechanism of action of one compound that was titrated did not involve interference 
with the synthesis of DNA. Colchicine (1.4 x IO6 M ) was first reported to block 
Chinese hamster ovary cells in metaphase in 1965 (Stubblefield and Klevecz). These 
authors noted that prolonged exposure (> 2 hours) was associated with toxicity because 
of an increase of aberrent mitoses. The compound acts by binding to tubulin subunits 
thus preventing subsequent polymerization (Osborn and Weber, 1976). In the absence 
of microtubule formation the spindle formation and subsequent migration of 
chromosomes is defective. A  low concentration the compound can reversibly inhibit 
cellular replication, for example HeLa cells exposed to a concentration of 2.1 x IO8 M  
were reversibly blocked in metaphase (Romsdahl, 1968). In order to reduce potential 
toxicity it was decided to treat the cells with low concentrations of colchicine. In an 
initial experiment U937 TK" and THP-1 HGPRT" cells were exposed to concentrations 
of colchicine ranging from 1 x IO-9 M  to 2.5 x IO 8 M. Microscopic observation 
following the 18 hour treatment period indicated that the compound had been relatively 
well tolerated, although some granular cells were observed in the populations that had 
been treated with the highest concentrations of the compound. Cell counts indicated 
that replication had been inhibited at the highest concentration of colchicine, but not at 
the lower concentrations. As had been noted for other compounds the U937 TK" cells 
were more sensitive to effects on the cell cycle than THP-1 HGPRT" cells. Greater than 
50% of the former cells had accumulated in G2/M in response to incubation with 1 x 10'8 
M  or 2.5 x 10-8 M  and more than 40% following treatment with 5 x IO'9 M  colchicine (p 
< 0.025 and p < 0.05, respectively), whereas significant perturbations of the cell cycle 
were only recorded at the highest (1 x 10*8 M  and 2.5 x 10‘8 M; p < 0.05) 
concentrations for the latter cell line (Figures 10.27 and 10.28).
The results were encouraging, so further experiments were carried out to titrate 
colchicine in U937 and THP-1 cells. These parental cell lines showed a response similar 
to that previously recorded for the drug-marked derivatives (Figures 10.29 and 10.30). 
Statistically significant accumulations of U937 cells in S phase resulted from incubation 
of the cells with 1 x 10*8 M  or 2.5 x 10'8 M  colchicine (p < 0.01). Similarity incubation 
of THP-1 cells in the presence of 2.5 x 10 8 M  or 1 x 10*8 M  colchicine resulted in 
significant increases in 4hcnumbers-©f cells blocked in-G2/M- (p-< 0:01 and p < 0.05, 
respectively). The results of further experiments (shown in Figures 10.31 and 10.32) 
demonstrated that similar to THP-1 cells, the T-lymphoid cell lines H9 and E6.1 Jurkat
IGl/GO G2/M
Control
2.5 x 108 M colchicine
1.0 x 10'8 M colchicine
5.0 x 10 9 M colchicine
2.5 x 10 9 M colchicine
1.0 x lO 9 M colchicine
Figure 10.27
Colchicine titration in U937 TK' cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of colchicine for 18 hours (37°C/5%C02).
The cells were examined microscopically and a few granular cells were observed in the 
cells that had been incubated with the highest concentration of compound. Samples were 
fixed and stained with propidium iodide, and fluores cence was detected by flow 
cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the colchicine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant proportions of U937 TK' cells had 
accumulated in G2/M following treatment of the cells with 1.0 x 10 8 M (p < 0.025), 2.5 x 
10'8 M (p < 0.025) and 5 x 10‘9 M (p < 0.05) colchicine.
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Figure 10.28
Colchicine titration in THP-1 HGPRT" cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours 
(37°C/5%C02). The cells were examined microscopically and some granularity was 
observed in the cells treated with the highest concentration of the compound. Samples 
were fixed and stained with propidium iodide, and fluores cence was detected by flow 
cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the colchicine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant (p < 0.05) proportions of THP-1 
HGPRT" cells had accumulated in G2/M following treatment of the cells with 1.0 x 10-8 A 
and 2.5 x 10'8 M colchicine.
Gl/GO
Control
2.5 x 10 8 M colchicine
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G2/M
5.0 x 10 9 M colchicine
2.5 x 10~9 M colchicine
1.0 x 10 9 M colchicine
Figure 10.29
Colchicine titration in U937 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of colchicine for 18 hours (37°C/5%C02). The 
cells were examined microscopically and no evidence of toxicity was observed. Samples 
were fixed and stained with propidium iodide, and fluores cence was detected by flow 
cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the colchicine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant proportions of U937 cells had 
accumulated in G2/M following treatment of the cells with 1.0 x 10 8 M (p < 0.01) and 2.5 
x 10'8 M (p < 0.025) colchicine.
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Figure 10.30
Colchicine titration in THP-1 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02).
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the colchicine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant proportions of THP-1 cells had 
accumulated in G2/M following treatment of the cells with l.Ox 108 M (p < 0.05) and 2.5 
x 10‘8 M (p < 0.01) colchicine.
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Figure 10.31
Colchicine titration in H9 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02). 
The cells were examined microscopically and a few granular cells were observed in 
samples treated with the highest concentration of colchicine. Samples were fixed and 
stained with propidium iodide, and fluores cence was detected by flow cytometry. 
Electronic markers were set on the Gl/GO and G2/M peaks of a representative control 
population. These markers were used to determine the cell cycle distribution of the 
colchicine treated cells. The histogram shows the mean and standard deviation of three 
replicate experiments. Significant proportions of H9 cells had accumulated in G2/M 
following treatment of the cells with 2.5 x IO*8 M (p < 0.10) colchicine.
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Figure 10.32
Colchicine titration in E6.1 Jurkat cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of the compound for 18 hours (370C/5%CO2). 
The cells were examined microscopically and no evidence of toxicity was observed 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the colchicine treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Significant proportions of E6.1 Jurkat cells had 
accumulated in G2/M following treatment of the cells with 2 .5 x 10'8 M (p < 0.05) 
colchicine
-  2 1 0  -
were only significantly blocked in G2/M by exposure to a concentration of 2.5 x Iff8 M  
colchicine (p < 0.01).
These titrations with colchicine demonstrated that in the presence of sufficient colchicine 
(1 - 2.5 x 10*8 M ) a high proportion (50 - 70%) of cells could be blocked in G2/M. 
However, at colchicine concentrations lower than 1 x 10"8M  there were no observable 
effects on cellular replication. In order to minimize possible toxicity, it was decided to 
use 1 x 10*8 M  colchicine to block cells in G2/M in further experiments.
10.2.9 GR39457A titration
A  water-soluble compound, GR39457A had previously been tested and shown to inhibit 
cells in G2/M, by an unknown mechanism of action (unpublished observation). This 
compound was titrated in U937 TK" and THP-1 HGPRT" cells. The compound was 
initially titrated using concentrations ranging from 1 (iM to 20 pM. At these 
concentrations no changes in the microscopic appearance of the cells, or pertubations in 
their replication were recorded. Further experiments examined the effect of exposing 
the cells to GR39457A at concentrations ranging between 25 pM and 150 pM. 
Microscopical observations indicated that the highest concentration was poorly tolerated 
with many cells appearing granular. Treatment of U937 TK" cells with concentrations 
of GR39457A ranging between 25 pM and 150 pM resulted in significant accumulations 
of cells in S phase (p < 0.025) and in G2/M (p < 0.10), with corresponding decreases in 
numbers of cells in Gl/GO (p < 0.05) (Figure 10.33). THP-1 HGPRT" cells showed 
similar trends towards decreases in the proportion of cells in Gl/GO, with corresponding 
increases in numbers of cells in S and G2/M (Figure 10.34). However, the higher inter- 
experimental variation meant that the only significant increase of cell number in G2/M 
was in the group treated with 25 pM GR39457A (p < 0.10).
Further experiments investigated effects of GR39457A on replication of U937 and 
THP-1 cells. Treatment of U937 cells with concentrations of GR39457A ranging 
between 25 pM and 150 pM resulted in significant accumulations of cells in S phase (p 
< 0.025), with corresponding decreases in numbers of cells in Gl/GO (p < 0.05) (Figure 
10.35). In contrast, treatment with the same range of concentrations of GR39457A had 
no significant effects on the replication of THP-1 cells (Figure 10.36). Titration of 
GR39457A in the T-cell lines E6.1 Jurkat (Figure 10.37) and H9 (Figure 10.38) gave 
similar results. Exposure of these cell lines to concentrations of GR39475A ranging
Gl/GO G2/M
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75 pM GR39457A 
50 \iM GR39457A 
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Figure 10.33
GR39475A titration in U937 TK“ cells. Exponentially replicating cells were incubated i 
the presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02 
The cells were examined microscopically and a few cells treated with the highest 
concentration of compound were observed to be granular. Samples were fixed and 
stained with propidium iodide, and fluores cence was detected by flow cytometry. 
Electronic markers were set on the Gl/GO and G2/M peaks of a representative control 
population These markers were used to determine the cell cycle distribution of the 
GR39457A treated cells. The histogram shows the mean and standard deviation of thre 
independent experiments. The results showed that all concentrations of GR39457A
(ranging between 25 and 150 /xM) caused statistically significant increases in proportion4 
of cells in S (p < 0.025) and in G2/M (p < 0.10), with corresponding decreases in 
proportions in Gl/GO (p < 0.05).
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Figure 10.34
GR39475A titration in THP-1 HGPRT" cells. Exponentially replicating cells were 
incubated in the presence of appropriate concentrations of the compound for 18 hours 
(37°C/5%C02). The cells were examined microscopically and no evidence of toxicity 
was observed. Samples were fixed and stained with propidium iodide, and fluores cence 
was detected by flow cytometry. Electronic markers were set on the Gl/GO and G2/M 
peaks of a representative control population. These markers were used to determine the 
cell cycle distribution of the GR39457A treated cells. The histogram shows the mean and 
standard deviation of three independent experiments. The only statistically significant (p 
< 0.10) increase in proportion of cells in a particular phase of the cell cycle was an 
accumulation of cells treated with 25 pM GR39457A in G2/M.
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Figure 10.35
GR39475A titration in U937 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02).
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the GR39457A treated cells. The histogram shows the mean and standard 
deviation of three independent experiments. All concentrations of GR39457A used in this 
experiment caused statistically significant accumulations of U937 cells in S phase (p < 
0.025), and corresponding decreases in Gl/GO (p < 0.05).
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Figure 10.36
GR39475A titration in THP-1 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02).
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the GR39457A treated cells. The histogram shows the mean and standard 
deviation of three independent experiments. Treatment of THP-1 cells did not 
significantly affect the replication of these cells.
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Figure 10.37
GR39475A titration in E6.1 Jurkat cells. Exponentially replicating cells were incubated in 
the presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02). 
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the GR39457A treated cells. The histogram shows the mean and standard 
deviation of three replicate experiments. Treatment ofE6.1 Jurkat cells with 
concentrations of GR39457A ranging between 25 pM and 150 pM resulted in statistically 
significant accumulations of cells in S phase (p < 0.05). As the concentration of 
compound was decreased, there was a tendency for the mean number of cells in G2/M to 
increase. Exposure to 25 pM GR39457A resulted in a significant (p < 0.05) 
accumulation of E6.1 Jurkat cells in G2/M.
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Figure 10.38
GR39475A titration in H9 cells. Exponentially replicating cells were incubated in the 
presence of appropriate concentrations of the compound for 18 hours (37°C/5%C02).
The cells were examined microscopically and no evidence of toxicity was observed. 
Samples were fixed and stained with propidium iodide, and fluores cence was detected by 
flow cytometry. Electronic markers were set on the Gl/GO and G2/M peaks of a 
representative control population. These markers were used to determine the cell cycle 
distribution of the GR39457A treated cells. The histogram shows the mean and standard 
deviation of three independent experiments. Treatment of H9 cells with concentrations of 
GR39457A ranging between 25 pM and 150 pM resulted in statistically significant 
accumulations of cells in S phase (p < 0.05). As the concentration of compound was 
decreased, there was a tendency for the mean number of cells in G2/M to increase. 
Exposure to 25 pM GR39457A resulted in a significant (p < 0.05) accumulation of H9 
cells in G2/M.
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between 25 pM and 150 pM caused a statistically significant increase in proportion of 
cells in S phase (p < 0.025). However, as the concentration of compound was reduced 
from 150 pM to 25 pM there was a concentration dependent increase in the number of 
cells blocked in G2/M. Treatment with 25 pM GR39457A resulted in a significant 
accumulation of both cell types in G2/M (p < 0.05).
10.2.10 Selection of compounds for use in further studies 
The aim of this series of titration experiments was to identify the appropriate 
concentrations at which compounds could be used to block cell replication at specific 
stages of the cell cycle. It was intended that two inhibitors of each phase, associated 
with different mechanisms of action, would be selected for further experiments. The 
results of the experiments described above indicated that an 18 hour treatment of cells 
with 300 pM mimosine or 4 mM hydroxyurea could be used to cause a significant 
accumulation of cells in Gl. The compounds selected to block the cells in S phase were 
a 0.25 mM concentration of hydroxyurea and a 4 mM solution of thymidine. 
Accumulation of cells in G2/M would be carried out by incubating the cells in the 
presence of 1 x 10 8M  colchicine or 75 pM GR39457A. Most of the compounds were 
reported to be associated with non-permanent effects on replication. The removal of the 
chemicals should result in the cells to returning to normal rates of asynchronous 
replication. Experiments were carried out to investigate the reversible nature of 
treatment with the compounds that had been selected to block the cells in specific cell 
cycle phases.
10.3 REVERSIBLE NATURE OF CELL CYCLE INHIBITION
An initial study to investigate the reversible nature of the selected cell cycle inhibitors 
indicated that the distribution of U937 cells, which had been allowed to recover in fresh 
medium for 24 hours, following incubation in the presence of hydroxyurea (0.25 mM to 
4 mM) for 18 hours at 37°C/5% C02, had not returned to levels comparable with the 
- control (exponential^ replicating cells): However,' the- accumulation of cells in certain - 
phases of the cell cycle observed following hydroxyurea treatment was less apparent 
indicating that the cells had started to move through the cell cycle. Exponentially 
growing U937 cell populations double approximately every 24 hours. However, if cells
are diluted into fresh medium growth slows, presumably as a result of the cells adjusting 
to the conditions. It is probable that if the treated cells had been left to recover for a 
longer period, the normal level of asynchrony would have returned and the cell cycle 
distributions would have been similar to that observed for the control cells. The lag in 
replication resulting from dilution into fresh medium may have been minimized if 
conditioned medium had been used.
A  further experiment investigated the recovery of THP-1 cells, blocked in G1 by 
incubating in the presence of 300 pM mimosine for 18 hours. The mimosine treated 
cells were washed and resuspended in conditioned medium. Samples were collected 
every hour and a propidium iodide analysis was used to investigate the cell cycle 
associated with the recovering cells. The results indicated that the cells had started to 
cycle by 8 hours, and cycle distribution was indistinguishable from the control cells by 24 
hours. However, during the preparation of the conditioned medium it had been 
observed that centrifugation of the medium alone was insufficient to remove all of the 
cells. Filtration of the medium was required to ensure that no cells were transferred.
As sterile filtration of large volumes of medium was impractical, it was decided that 
further experiments to investigate the recovery of cells would utilize a longer incubation 
period in fresh medium.
The reversible nature of hydroxyurea, mimosine, thymidine, colchicine and GR39457A 
was studied in a further experiment. U937 cells were incubated at 37°C/5% C02 in the 
presence of 4 mM hydroxyurea, 0.25 mM hydroxyurea, 1 x 10*8 M  colchicine, 300 pM  
mimosine, 4 mM thymidine or 75 pM GR39457A for 18 hours. Control cells were 
incubated in the presence of an equal volume of PBS. A  sample of each cell treatment 
was washed and fixed using ice-cold 70% aqueous ethanol. These samples were kept 
refridgerated (4°C), so that propidium iodide staining could be carried out 
simultaneously with the samples of recovering cells. The remaining cells of each 
treatment were washed twice using PBS and resuspended in fresh complete RPMI1640 
medium. Previous experimental results had indicated that when placed in fresh medium 
the cells required a period of approximately 24 hours before entering exponential 
growth. It was decided to incubate the cells for 72 hours (37°C/5% C02). At this 
stage it was observed that the medium had turned yellow, indicating that cell replication 
had occurred, so samples were washed with PBS and fixed with 70% ethanol. All 
samples were stained with propidium iodide and run through the flow cytometer. 
Electronic markers were set on the Gl/GO and G2/M peaks of the control populations.
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The cell cycle distributions of the cells immediately after treatment with the selected 
compounds and after the cells had been allowed to recover for 72 hours were 
investigated. Results indicated that the treatments had blocked cells in the expected 
phases of the cell cycle. However, the cell cycle distribution following 72 hour 
incubation in fresh medium was not significanly different from that recorded for the 
controls for any treatment. The results are shown graphically in Figure 10.39. These 
results demonstrate the reversible nature of the compounds selected to inhibit the 
replication cycle of the cell lines.
A  further series of experiments investigated the recovery from colchicine treatment in 
more detail. In a preliminaiy experiment, U937 TK" cells were incubated at 37°C/5% 
C 02 in the presence of 1 x 10*8 M  colchicine for 18 hours. The cells were washed 
twice, using PBS, and resuspended in fresh complete RPMI1640 medium. Samples of 
the cells were collected immediately post-treatment and following recoveiy for 15 
minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours. Analysis of the cell 
cycle distribution of control U937 TK” cells showed 45% in Gl/GO, 36% in S and 19% 
in G2/M. This can be compared with 11% in Gl/GO, 25% in S and 64% in G2/M 
recorded for the colchicine treated population. No obvious changes in the cell cycle 
distribution were recorded for the cells recovering for periods up to 6 hours in the fresh 
medium. The samples collected at 6 hours indicated a small decrease in the number of 
cells accumulated in G2/M. The previous experiments had demonstrated that cells had 
fully recovered by 72 hours. The recovery of U937 TK" cells and THP-1 HGPRT" cells 
between 6 and 72 hours was investigated. The cells were incubated at 37°C/5% C 02 in 
the presence of 1 x 10"$ M  colchicine for 18 hours. The cells were washed twice, using 
PBS, and resuspended in fresh complete RPMI1640 medium. Samples of cells were 
collected immediately post-treatment and following recovery for 6 hours, 24 hours, 30 
hours, 48 hours and 72 hours. Similar to the preliminary experiment the results showed 
that a 6 hour incubation in fresh medium had resulted in a small decrease in the number 
of cells accumulated in G2/M. After 24 and 30 hours recovery in fresh medium the 
majority of both cell types were traversing Gl/GO or S phase. Samples at 48 and 72 
hours indicated that the cells had recovered and were cycling normally.
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Figure 10.39 a and 10.39 b
Recovery of U937 cells following treatment with cell cycle inhibitors. Exponentially 
replicating U937 cells were incubated in the presence of the appropriate compounds for 18 
hours (37°C/5%CC>2). Samples were fixed and stained with propidium iodide to confirm 
that cellular replication had been blocked (10.39 a). The remaining cells were washed (using 
PBS) and resuspended in fresh medium. The cells were allowed to recover for 3 days. 
Further samples were fixed and stained with propidium iodide (10.39 b). Analysis of cell 
cycle indicated that the U937 cells had recovered and none of the cell cycle distributions of 
treated cells were significantly different from the control population.
1L0-CHABACJERISTICS OF CELLS TREATED W ITH  REVERSIBLE CELL  
CYCLE INHIBITORS
Results from experiments described in the previous chapter identified concentrations at 
which several compounds could be used to reversibly block the replication of monocytic 
cell lines. It was planned to treat cells with these cell cycle inhibitors for studies aimed 
at investigating the effects of myeloid host cell proliferation on replication of H IV -1. 
Obviously any alterations in cell physiology resulting from treatment with the selected 
compounds, other than accumulation of cells in the selected phase of the cell cycle, 
could affect viral replication. Therefore, a series of experiments was carried out to 
investigate whether treatments were affecting a variety of physiological parameters that 
could potentially affect ability of the cells to support replication of H IV-1. The results 
of these experiments are described below.
1L1 SURFACE ANTIGEN EXPRESSION
11.1.1 Effect of membrane fluidity on surface antigen expression 
A  study reported by de Laat et al. (1977) demonstrated cell cycle related changes in the 
fluidity of neuroblastoma plasma membranes. Membrane fluidity reached a transient 
minimum during G2/M, and was maximum in Gl/GO. Such changes in membrane 
fluidity are believed to influence functional availability of receptors, inducing reduced 
binding of vasoactive intestinal peptide (VIP) and HIV-1 to CD4 (Lehr et al., 1990). It 
was therefore decided to carry out an experiment to determine whether any differences 
in intensity of staining for two surface antigens (CD4 and CD71) could be detected 
(using flow cytometry) on cells that had been treated with chemicals to enhance 
membrane fluidity, in comparison with control exponentially replicating cells. The 
compounds selected to increase plasma membrane fluidity were butylated 
hydroxytoluene (BHT; Eletr et al., 1974) and phenytoin (Harris and Bruno, 1985; 
Twombly et al., 1988). Fluorescence anisotropy studies had been used in the reports 
demonstrating that these compounds increased plasma membrane fluidity. However, as 
no instruments for this technique were available, it was decided to use an indirect 
measurer of membrane mobility. Gangliosides are a cOfnpoilent o f biologicaTrrrembranes * 
that are thought to function in the regulation of membrane fluidity by forming selective 
hydrophobic associations with membrane proteins and influencing molecular mobility 
(Bimbaumer, 1973). The presence of one such ganglioside, GM1, acts as a receptor for 
the p-subunit of cholera toxin (Cuatrecasas, 1973). Expression of GM1 was therefore 
used to indicate any potential changes in membrane fluidity, using the assumption that
plasma membranes would be more fluid when GM1 expression was reduced, and that 
membrane mobility would be lowered when higher levels of GM1 bound integral 
membrane proteins.
THP2 cells were incubated in the presence of either 20 pg/ml phenytoin or 1 x lO^M 
BHT for 18 hours at 37°C/5% C02. Samples of cells were washed and incubated, on 
ice for 1 hour, in the presence of FITC-conjugated monoclonal antibodies (to detect 
CD4 and CD71 expression) or FITC-conjugated cholera toxin (3-subunit (to detect 
GM1). Unbound antibody or toxin was washed off and cell-associated green 
fluorescence was determined using flow cytometry. Further samples were fixed (icecold 
70% ethanol) and stained with propidium iodide to determine whether these treatments 
had affected the cell replication cycle. This experiment was repeated on three 
independent occasions so that the results could be compared statistically.
Microscopical examination indicated that 20 pg/ml phenytoin had been well tolerated by 
THP-2 cells. Flow cytometry showed that treatment with the compound had induced 
reductions in median FL1 associated with CD4, CD71 and GM1 (Table 11.1).
However, none of these reductions were significantly different from the controls.
Analysis of cell cycle distribution indicated that significantly less phenytoin treated cells 
were in S phase compared to the controls (p < 0.10), but although the mean proportion 
in Gl/GO had increased due to phenytoin treatment, it was not significantly higher than 
the controls. These results (non-significant increase in proportion of cells in Gl/GO and 
corresponding general decreases in CD4 and CD71 expression) are consistent with the 
observations reported by de Laat et al (1977) that membrane fluidity was maximal in 
Gl/GO. The non-significant reduction in binding of cholera toxin p-subunit to GM1 
also suggested that membrane fluidity had been enhanced.
Cells incubated in the presence of 1 x lO^M BHT (37°C/5% C02) were observed to be 
very granular, suggesting that the compound had been poorly tolerated. The increase in 
cellular granularity was confirmed by flow cytometry where a significant increase in SSC 
of BHT treated cells compared to the controls, was recorded in the absence of any 
change in FSC (p < 0.10). Mean expression of CD4, CD71 and GM1 were lower 
than for controls (Table 11.1), although due to high interexperimental variation only the 
reduction in CD71 expression was significant (p < 0.10). Proportions of BHT-treated 
cells in different phases of the cell cycle were not significantly different from the 
controls, although the mean number in Gl/GO was lower, and those in S and G2/M 
higher. These results suggest that BHT treatment was enhancing plasma membrane 
fluidity, and that this reduced either expression of surface antigens, or interfered with
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binding of specific monoclonal antibodies to the selected antigens. It is possible that the 
high levels of variation were in part due to the poor tolerance of this compound.
In a further experiment expression of GM1 was investigated on U937 cells following 18 
hours incubation (37°C/5% C 02) with selected cell cycle inhibitors. Samples of treated 
cells were fixed and stained with propidium iodide, in order to confirm that the cells had 
been blocked in appropriate phases of the cell cycle. Results from three independent 
experiments indicated that treatment with 4 mM hydroxyurea had caused a significant 
accumulation of cells in Gl/GO, 0.25 mM hydroxyurea had resulted in a significant 
increase in S phase cells, whilst 1 x 10'8M  colchine treatment had caused more than half 
of the cells to accumulate in G2/M (p < 0.01 and p < 0.005, respectively). Interestingly, 
incubation of cells with 1 x 10"8M  colchicine had caused significant decreases in mean 
FL1 associated with both GM1 and CD4 (Table 11.2). However, no significant changes 
in binding of FITC-conjugated cholera toxin p-subunit, or selected monoclonal 
antibodies could be detected, when compared to the controls, for any of the other 
treatments. These results suggest that in contrast to the results reported by de Laat et 
al (1977), U937 cells accumulated in G2/M following incubation with colchicine appear 
to have enhanced membrane fluidity, which interferes with binding of monoclonal anti- 
CD4 antibodies.
However, when these experiments were repeated using U937 TK“ cells a significant 
increase in binding of FITC-conjugated cholera toxin p-subunit was detected on cells 
that had been incubated with 0.25 mM hydroxyurea for 18 hours at 37°C/5% C02 (p < 
0.05; Table 11.3). This correlated with a significant increase in binding of monoclonal 
anti-CD4 antibody, suggesting that treatment with 0.25 mM hydroxyurea was decreasing 
plasma membrane fluidity and enhancing receptor availability (p < 0.025). Although 
treatment with 0.25 mM hydroxyurea had caused an increase in the proportion of cells 
present in S phase, it was not significant in this series of experiments. Treatment of 
U937 TIC cells with 4 mM hydroxyurea or accumulation of cells in G2/M (following 
treatment with 1 x 10-8M  colchicine, p < 0.05) did not significantly alter binding of 
FITC-conjugated cholera toxin p-subunit to U937 TK“ cells.
11.1.2 Expression of CD4
It is widely accepted that CD4 is the major receptor for HIV-1 (e.g. Maddon et al, 
1986). Therefore, any alteration in expression of CD4 could potentially interfere with 
the initial stages of viral replication. In the previous section (11.1.1) it was shown that 
binding of monoclonal anti-CD4 antibodies, seemed to correlate with expression of
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GM1, used to indicate plasma membrane fluidity. CD4 and GM1 expression were 
significantly enhanced on U937 TK" cells treated with 0.25 mM hydroxyurea, and 
decreased on U937 cells blocked in G2/M following incubation with 1 x 10_8M  
colchicine for 18 hours (37°C/5% C02; p < 0.05 and p < 0.10, respectively). However, 
a significant decrease in expression of CD4 was observed on U937 TK" cells that had 
been incubated with 300 pM mimosine for 18 hours, in the absence of any 
corresponding decrease of GM1 (p < 0.10; Table 11.3). Expression of CD4 is reported 
to decrease during in vitro differentiation of human monocytes into macrophage-like 
cells (Kazazi et al, 1989; Valentin et al, 1991). It is therefore possible that mimosine 
treatment had initiated cellular differentiation and an associated growth arrest, rather 
than specifically blocking cellular replication in Gl/GO. (The proportion of mimosine 
treated cells in Gl/GO was not significantly higher than that of control cells in Gl/GO in 
this series of experiments).
11.1.3 Expression of integrins: CD 11a, CD lib  and the common $-chain CD 18 
Integrin molecules, including CD 11 a/CD 18 (LFA-1), can mediate cell adhesion and are 
involved in initiation of immune responses (Dougherty and Hogg, 1987). The 
demonstration that monoclonal anti-CD 18 antibodies can interfere with cell free HIV-1 
infection of U937 cells, indicates that these molecules also play a role early in the viral 
infection cycle (Valentin et al, 1990). Complement receptor 3 (CR3; CD1 lb/CD 18) 
can mediate phagocytosis, and infection of phagocytic cells by complement opsonized 
HIV-1 (Beller et al., 1982; Thieblemont et al, 1993). Interestingly, CR3 
(CD1 lb/CD 18) is reported to associate with the cytoskeleton in an interaction which can 
regulate function and mobility of this receptor (Ross et al., 1992).
In an initial series of experiments expression of CD1 la, CD1 lb and CD 18 on THP-1 
cells that had been incubated (18 hours at 37°C/5% C02) in the presence of either 4 mM 
or 0.25 mM hydroxyurea was investigated (Table 11.4). Microscopic observation 
indicated that THP-1 cells that had been treated with 4 mM hydroxyurea appeared 
granular, suggesting that the compound had not been well tolerated. This observation 
correlated with a significant increase of SSC recorded by flow cytometry (p < 0.10).
 ^ Treatmentwith 4 mM hydroxyurea- had <resu.Ued4n^sigrifiGant -aceumulatiomof THP-1 
cells in Gl/GO (p < 0.10). These cells had lowered mean CD1 lb, and significantly 
decreased expression of both CD1 la and CD 18 (p < 0.10). In contrast, treatment with 
0.25 mM hydroxyurea had caused a significant accumulation of cells in S phase (p <  
0.10), but no significant changes in expression of CD1 la, CD1 lb or CD 18 were 
recorded.
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In a further series of experiments binding of FITC-conjugated monoclonal anti-CD 1 la 
and anti-CD 18 to U937 cells treated with cell cycle inhibitors was investigated 
(Table 11.2). (The expression of CD1 lb was not investigated as these cells had previously 
been demonstrated not to express this antigen (see section 9.2). In this experiment 
significant accumulation of cells in Gl/GO, S and G2/M had resulted from treatments 
with 4 mM hydroxyurea, 0.25 mM hydroxyurea and 1 x 10_8M  colchicine, respectively 
(p < 0.05). Treatment with either concentration of hydroxyurea had not caused any 
significant changes in binding of the two monoclonal antibodies. However, treatment of 
U937 cells with 1 x 10-8M  colchicine resulted in significant decreases in binding of 
monoclonal anti-CD 18 and a lowered mean FL1 resulting from binding of anti-CD 1 la. 
These results correlated with a significant decrease of binding of cholera toxin p-subunit 
to U937 cells (p < 0.10), suggesting that receptor availability was decreased due to 
enhanced plasma membrane fluidity.
When these experiments were repeated using a range of compounds to block the 
replication of U937 TK" cells, none of the treatments caused significant changes of FSC 
or SSC when compared to the controls, and only one treatment (0.25 mM 
hydroxyurea, 18 hours at 37°C/5% C02) caused a significant change to the binding of 
cholera toxin p subunit (Table 11.3). The significant increase in GM1 expression 
(indicating decreased membrane fluidity) correlated with significantly enhanced binding 
of anti-CDl lb and anti-CD 18 (p < 0.05). Treatment with 0.25 mM hydroxyurea 
resulted in a non-significant increase of cells in S phase. No other treatment resulted in 
a significant change in GM1 expression (indicating that membrane fluidity was similar to 
that of control exponentially replicating cells). However, significant accumulation of 
U937 TK" cells in G2/M, following incubation with 75 pM GR39457A, caused a 
significant increase in CD 18 expression (p < 0.05 and p < 0.10, respectively). This 
suggests that CD18 is expression is up-regulated on these cells. As CD 18 is the p-chain 
of integrin molecules, and expression of the CD1 lb a-chain did not change, presumably 
expression of one of the other a-chains (e.g. CD1 la or CD1 lc) was likewise enhanced. 
Significantly decreased binding of anti-CDl lb, in the absence of any change in GM1 
expression, indicated down-regulation of this antigen on U937 TK" cells treated with 
300 pM mimosine or with 4 mM thymidine (p < 0.05). Both treatments had increased 
the proportion of cells in Gl/GO, with 4 mM thymidine causing a significant 
accumulation of cells in this phase (p < 0.10). CD1 lb expression is reported to increase 
during myeloid differentiation (Beller et al., 1982). It is therefore particularity suprising 
to observe down-regulation of this antigen on U937 TK" cells treated with 300 pM 
mimosine in view of the results for CD4 expression that suggested the treatment had
initiated differentiation. The reasons for the down-regulation of GDI lb expression 
were not determined.
11.1.4 Expression of CD 71
Iron is essential for cellular replication. CD71, the transferrin receptor, is involved in 
uptake of iron, and is expressed by proliferating cells (Judd et al., 1980). Lalande and 
Hanauske-Able (1990) report that CD71 expression was enhanced when a T-cell line 
was blocked in late G l using a novel cell cycle inhibitor. However, although more 
U937 TK" cells treated with 4 niM hydroxyurea were present in Gl/GO than the 
controls, and mean FL1 associated with treated cells stained for CD71 was higher, the 
changes were not significant (Table 11.3). Expression of CD71 was observed to be 
significantly enhanced on U937 TK" cells treated with 300 pM mimosine and with 0.25 
mM hydroxyurea (p < 0.10 and 0.025, respectively). Although these treatments had 
resulted in accumulation of cells in Gl/GO and S phase, respectively, the increases were 
not significant (Table 11.3). Interestingly, staining for GM1 was significantly increased 
on 0.25 mM hydroxyurea treated cells, indicating that stabilization of the plasma 
membrane may be responsible for increased availability of CD71 receptors (p < 0.05). 
However, no significant changes in GM1 expression were recorded for U937 TK" cells 
blocked inGl/GO following treatment with 300 pM mimosine, suggesting that CD71 
expression had been upregulated on these cells.
11.2 ENZYME ACTIVITY
11.2.1 Myeloperoxidase activity
Myeloperoxidase (MPO) activity is associated with microbicidal activity of cells 
(Rosmarin et al., 1989). It was therefore of interest to determine whether treatment of 
cells with reversible cell cycle inhibitors affected myeloperoxidase activity. Results 
described in a previous chapter (section 9.3.3) had indicated that whilst cells treated with 
approriate cytochemical stains to demonstrate MPO activity had stained darkly, and 
were associated with increased SSC when analysed by flow cytometry, MPO activity 
could not be quantified owing to a high level of extracellular reaction product.
However, when the reaction had been carried out in the absence of exogenous hydrogen 
peroxide, staining had been restricted to within the cells. A  series of three independent 
replicate experiments was carried out in order to investigate whether any differences in 
MPO activity of four monocytic cells lines (U937, U937 TK", THP-1 and THP-1
HGPRT") treated with either 4 mM or 0.25 mM hydroxyurea could be identified 
microscopically, or by flow cytometry.
Cells were treated with 4 mM or 0.25 mM hydroxyurea for 18 hours. Samples were 
fixed and stained for MPO activity, in the presence or absence of exogenous hydrogen 
peroxide. Microscopical observation indicated that all cells stained in the absence of 
exogenous hydrogen peroxide contained a light brown deposit, presumably indicating 
endogenous hydrogen peroxide activity. No difference could be observed by eye in the 
intensity of staining. Similarly, all of the cells stained in the presence of hydrogen 
peroxide were observed to be heavily stained, but no differences in the intensity of 
staining could be detected. Large amounts of extracellular black deposits were 
observed in all samples of cells stained in the presence of hydrogen peroxide. Flow 
cytometry of fixed cells indicated that for all four cell lines incubation in the presence of 
either concentration of hydroxyurea had significantly increased the SSC of the cells (p < 
0.05). This high background SSC made farther increases of granularity difficult to 
detect. In fact, no significant increases of SSC were detected between any of the 
hydroxyurea treated cells that had been stained for MPO activity in the absence of 
exogenous hydrogen peroxide and the appropriate fixed controls. The high levels of 
extracellular material observed in the samples stained in the presence of exogenous 
hydrogen peroxide indicated that flow cytometry could not be used to quantify level of 
enzyme activity.
However, it can be concluded from the microscopical observations that MPO activity 
was not inhibited to any great extent following treatment of cells with hydroxyurea.
The observation that all cells stained in the absence of exogenous hydrogen peroxide 
contained a light brown deposit suggested that hydroxyurea treatment probably did not 
have significant effects on levels of endogenous hydrogen peroxide.
11.3 PHAGOCYTIC ACTIVITY
11.3.1 Phagocytic and cytotoxic capacity
An experiment was carried out to determine whether treatment of cells with reversible 
cell cycle inhibitors affected the phagocytic and cytotoxic capacities of four monocytic 
cell lines (U937, U937 TK", THP-1 and THP-1 HGPRT") using the method described 
by Gebran et al (1992). Cells were incubated in the presence of appropriate 
concentrations of cell cycle inhibitors for 18 hours (37°C/5% C02). Treatments with 4 
mM hydroxyurea, 0.25 mM hydroxyurea and 1 x 10‘8M  colchicine were used to arrest
cells in Gl/GO, S and G2/M, respectively (p < 0.05). Following treatment with these 
compounds, cells were washed and resuspended at a concentration of 5 x 105 cells/ml in 
phenol red-free RPMI 1640 medium. Two hundred millilitre aliquots were transferred to 
microtitre plates, where the cells were stimulated by incubation in the presence or 
absence of 1 x 10-7 M  PMA for approximately 1 hour. Cells were incubated in the 
presence of sheep erythrocytes (SRBCs) for 18 hours (37°C/5% C02). Haemoglobin 
released from lysed erytrocytes was detected by utilizing the pseudoperoxidase activity 
of the molecule to alter the properties of 2,7-diaminofluorene, allowing detection as an 
increase in optical density at 620 nm. Thus, cytotoxic activity could be detected by 
measuring activity of haemoglobin present in samples of culture supernatant. 
Phagocytosed SRBCs could likewise be detected as pseudoperoxidase activity in the 
supernatant of lysed cells, (that had been washed and treated with a mild lysing solution 
to remove any bound or extracellular SRBCs). Previous assays had indicated that the 
assay detection limit was approximately 1 x 103 lysed SRBC (9.5.2). Results from three 
independent experiments, (in which every sample had been repeated in triplicate), are 
described below.
There was no indication that any SRBC had been phagocytosed by control or treated 
U937 cells, when plates containing cells that had been incubated with SRBC for 18 
hours were examined microscopically. Results from the cytotoxicity/phagocytosis assay 
confirmed this observation, with no significant increases in optical density recorded in 
any well containing lysed U937 cells (p > 0.10). This result correlated with previous 
data (9.5.1) that had indicated U937 cells neither had capacity to bind or phagocytose 
SRBC. Assay of culture supernatants indicated that none of the cell treatments were 
associated with detectable levels of cytotoxicity.
Plates containing U937 TIC" cells that had been incubated with SRBC for 18 hours were 
examined microscopically. All cells had settled at the bottom of the wells, with some of 
the U937 TK" cells surrounded by clear zones. A  number of U937 TK" cells were 
observed to contain intracellular SRBC indicating phagocytosis had occurred.
However, due to the high number of cells in each well, the proportion of cells that had 
phagocytosed SRBC could not be enumerated. The optical density of wells containing 
- lysed U937 TK" ■cdls was compared to that of controlwells- (containing lysed U937 TKA 
cells that had been incubated under the same conditions, but in the absence of SRBC). 
Significant increases in optical density, compared to control wells, were recorded for all 
of the control and treated U937 TK" cells (p < 0.025). Extrapolation from the standard 
curve indicated that control U937 TK" cells had phagocytosed in the region of 6 x 104 
SRBC. Assuming that each cell had only phagocytosed a single SRBC, it can be
calculated that 60% of the cells had undergone phagocytosis. However, it is probable 
that some cells had phagocytosed more that one SRBC, and that the proportion of cells 
that had phagocytosed SRBC was actually less than 60%. Results for cells treated with 
either 4 mM or 0.25 mM hydroxyurea indicated that the phagocytic capacity of these 
cells was not significantly different from the controls. However, mean optical density of 
wells containing lysed 1 x 10'8M  colchicine treated cells tended to be slightly, but not 
significantly higher, than recorded for the control cells. Analysis of the results for the 
culture supernatants indicated that control U937 TK" cells had not lysed any SRBC. 
Treatments with reversible cell cycle inhibitors had not significantly increased the 
cytotoxic capacity of U937 TK" cells. The results also showed that incubation of cells 
with PMA prior to addition of SRBC caused no significant changes to the phagocytic or 
cytotoxic potential of control or treated U937 TK" cells.
THP-1 cells that had been incubated overnight in the presence of SRBC were examined 
microscopically. SRBC were clustered around the monocytoid cells making it difficult 
to determine whether any cells contained intracellular SRBC. However, analysis of 
results from the assay indicated that neither phagocytosis nor cytotoxicity had occurred. 
This result was surprising in view of the results of a previous assay (see .9.5.2) that had 
shown approximately 5% of THP-1 cells could phagocytose human group 'O' 
erythrocytes. Stimulation of control and cell cycle inhibitor-treated cells with PM A was 
not observed to enhance either phagocytic or cytotoxic capacity.
THP-1 HGPRT" cells grow in loose clumps, which made it difficult to observe whether 
any SRBC had been internalized by these cells. Comparison of assay results for lysed 
THP-1 HGPRT" cells that had been incubated in the presence or absence of SRBC 
indicated significant increases in optical density were associated with cells that had been 
incubated with SRBC (p <0.05). Extrapolation from the standard curve showed that 
approximately 3.8 x 103 SRBC had been phagocytosed, indicating that upto 4% of the 
cells were associated with capacity to phagocytose. This compares well with results 
reported by Tsuchiya et al. (1982) that indicate 5% of THP-1 cells are phagocytic for 
SRBC in the absence of further stimulation. However, the result is somewhat surprising 
when compared with the lack of phagocytosis recorded for the parental THP-1 cells in 
this assay. Analysis of the results for the culture supernatants indicated that control 
THP-1 HGPRT" cells had not lysed any SRBC. Treatments with reversible cell cycle 
inhibitors had not altered the cytotoxic capacity associated with THP-1 HGPRT" cells. 
The results also showed that incubation of cells with PMA prior to addition of SRBC 
caused no significant changes to the phagocytic or cytotoxic potential of control or 
treated U937 TK" cells.
11.4 U L T R A S T R U C T U R A L  S T U D IE S
11.4.1 Ultrastructure of cells treated with reversible cell cycle inhibitors 
The effects of a range of reversible cell cycle inhibitors on the ultrastructure of U937 
TK" cells was studied. Cells were treated by incubating with appropriate concentrations 
of selected compounds for 18 hours (37°C/5% C02). The propidium iodide 
fluorescence profile of samples from every cell treatment was investigated using flow 
cytometry to confirm that treatments had blocked cells in appropriate phases of the 
replication cycle. Treated cells were fixed using 2.5% glutaraldehyde and post-fixed 
with 1% osmium tetroxide. Samples were treated with 1% tannic acid, prior to dehydration 
through an ethanol series (Section 7.6.1). The cells were embedded in epoxy resin,
(Epon 812), and then ultrathin sections were cut. Sections were stained using uranyl 
acetate and lead citrate before examination using a transmission electron microscope 
(TEM).
Examination of ultrathin sections of U937 TK" cells indicated that cells displayed 
morphological similarities to human monocytes. The cells were rounded with a few 
short lamellipods. The nuclei o f most cells appeared to be bean-shaped, had an 
eccentric position, and were surrounded by a thin margin of heterochromatin. The 
nucleolus tended to appear well developed. The cytoplasm typically contained sparse 
endoplasmic reticulum and few mitochondria. Vesicles were occasionally present in the 
cytoplasm. An electron micrograph of a typical U937 TK" cell is shown in Plate 11.1.
Propidium iodide analysis showed that 70% of U937 TK" cells treated with 4 mM 
hydroxyurea were present in Gl/GO in this experiment. The average FL2 of 4 mM 
hydroxyurea treated cells contributing to the Gl/GO peak was slightly higher than that 
recorded for Gl/GO peak of exponentially replicating control cells, indicating that a 
proportion of these cells had accumulated at the Gl/S border. Transmission electron 
microscopy showed that the nuclei of U937 TK" cells that had been treated with 4 mM 
hydroxyurea for 18 hours, had a similar appearance to the control cells. Typically the 
nuclei were irregularity shaped and surrounded by a thin margin of heterochromatin.
The nucleolus was frequently prominant. However, a particularity striking difference 
was observed between the cytoplasm of the 4 mM hydroxyurea treated cells and that of 
the controls. Numerous well-defined structures, comprising of multiple layers of plasma 
membrane, were seen in a high proportion of the 4 mM hydroxyurea treated cells In 
other respects, cytoplasm of 4 mM hydroxyurea treated cells was similar to controls, 
with sparse endoplasmic reticulum, few mitochondria and few vesicles. A  typical 4 mM 
hydroxyurea treated U937 TK" cell, containing several of these smooth membrane- 
derived structures is shown in Plate 11.2. The structures were slightly larger than
Plate 111
An ultramicrograph of a control U937 TK" cell. Exponentially replicating cells were 
fixed using 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, stained with 1% 
tannic acid, and dehydrated through an ethanol series. Samples were embedded in Epon 
812 resin and ultrathin sections were cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy indicated that cells contained a relatively 
large, lobate nuclei which often contained a prominent nucleolus. The nucleus was 
typically surrounded by a thin layer of heterochromatin. Few vesicles and mitochondria 
could be identified in the cytoplasm of most cells, and endoplasmic reticulum was sparse, 
(x 6 000)
-235 -
Plate 1 • -2
Ultramicrograph of a U937 TK- cell treated with 4 mM hydroxyurea. Exponentially 
replicating U937 TK" cells were incubated in the presence of 4 mM hydroxyurea at 
37°C/5% CO? for 18 hours. Cells were fixed using 2.5% glutaraldehyde, postfixed with 
1% osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated 
through an ethanol series prior to embedding in Epon 812 resin. Thin sections were 
prepared and stained using a combination of lead citrate and uranyl acetate. Electron 
microscopy revealed that 4 mM hydroxyurea treated cells appeared similar to the control 
cells, with sparse endoplasmic reticulum and few mitochondria present in the cytoplasm 
However, structures consisting of layers of plasma membrane, thought to be paired 
cisternae were obvious in the cytoplasm of many cells. The plate shows a typical 4 mM 
hydroxyurea treated U937 TK" cell, where many paired cisternae are present in the 
cytoplasm, (x 4 600)
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would be expected for mitochondria (0.1 - 0.5 pM x 1 - 2 fiM), sometimes up to 3 pM  
in diameter. High magnification revealed that layers of plasma membrane were 
regularity spaced either in discrete areas of cytoplasm (Plate 11.3 a) or apparently 
bridging cytoplamic vesicles (Plate 11.3b). These structures are believed to be similar 
to those termed paired cistemae by Sato et al (1982).
Exposure to 0.25 mM hydroxyurea for 18 hours had resulted in nearly half of the cell 
population being present in S, or early G2/M of the cell cycle. Examination of ultrathin 
sections of these cells indicated that the nuclear: cytoplasmic ratio appeared to be higher 
than observed in the control cells. The nucleus frequently had a fairly ’patchy' 
appearance, suggesting an alteration in the conformation of chromatin. Similar to the 
control population, the nucleous tended to be large and well defined. The cytoplasm 
was sparse with few organelles or vesicles observed. In contrast to the cells treated 
with the higher concentration (4 mM) of hydroxyurea, plasma membranous stuctures 
resembling paired cistemae were infrequently observed. An ultramicrograph of a typical 
cell that has been treated with 0.25 mM hydroxyurea for 18 hours is shown in Plate 11.4.
In this experiment, approximately 30% of U937 TK” cells were calculated to be present 
in G2/M following treatment with 1 x 10-8M colchicine for 18 hours. Median intensity 
of red fluoresence was slightly higher than for the G2/M peak of the controls, indicating 
that more of the colchicine treated cells contributing to this peak had completely doubled 
their DNA  content. Examination of ultrathin sections prepared from colchicine treated 
U937 TK" cells showed that around two thirds of cells had a very similar appearance to 
the control cells. Large, lobate nuclei, containing prominent nucleoli, were typically 
surrounded by cytoplasm containing few organelles or vesicles. A  typical U937 TK" 
cell that has been treated with 1 x 10'8M  colchicine for 18 hours is shown in Platel 1.5. 
However, approximately one third of the cells examined were observed to be in 
metaphase. These cells could be identified by containing dark areas of condensed 
chromatin in place of a distinct nucleus. The proportion of cells observed to be in 
metaphase correlated well with the number that were estimated to be present in G2/M by 
propidium iodide staining. Colchicine is reported to block replication during metaphase 
without affecting chromosome condensation (Osborn and Weber, 1975). The 
compound is believed to act by-binding to tubulin+mckprsvent spindle fermation. This 
interferes with movement of the chromosomes towards the poles of the cell. Structures 
resembling paired cistemae were frequently observed in the cytoplasm surrounding the 
condensed chromosomes. A  typical metaphase cell is shown in Platel 1.6.
Plates 11.3A andl 1.3B
Ultramicrographs showing high magnification detail of paired cisternae in the cytoplasm 
of a 4 mM hydroxyurea treated U937 TK" cell. U937 TK" cells were incubated in the 
presence of 4 mM hydroxyurea at 37°C/5% C02 for 18 hours. Cells were fixed using 
2.5% glutaraldehyde, postfixed with 1% osmium tetroxide and stained with 1% tannic 
acid. Samples were dehydrated through an ethanol series prior to embedding in Epon 
812 resin. Thin sections were prepared and stained using a combination of lead citrate 
and uranyl acetate. Paired cisternae consist of two or more flattened, membrane-bound 
saccules which are stacked in parallel arrays in the cytoplasm. (A: x 60 000; B: x 46 000)
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Plate 11.4
Ultramicrograph of a typical U937 TK" cell treated with 0.25 mM hydroxyurea. 
Exponentially replicating U937 TK" cells were incubated with 0.25 mM hydroxyurea at 
37°C/5% C02 for 18 hours. Cells were fixed using 2.5% glutaraldehyde, postfixed with 
1% osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated 
through an ethanol series prior to embedding in Epon 812 resin. Thin sections were 
prepared and stained using a combination of lead citrate and uranyl acetate. Electron 
microscopy revealed that ultrastructure of U937 TK" cells treated with 0.25 mM 
hydroxyurea was similar to the control cells. The large lobate nucleus typically 
contained a prominent nucleolus, and was surrounded by a thin margin of 
heterochromatin. The cytoplasm contained sparse endoplasmic reticulum and few 
mitochondria. In contrast to the 4 mM hydroxyurea treated cells, paired cisternae were 
rarely observed, (x 6 000)
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Plate 11.5
Ultramicrograph of a U937 TK- cell treated with 1 x 10‘8M colchicine. Exponentially 
replicating U937 TK" cells were incubated with 1 x 10*8M colchicine at 37°C/5% C02 for 
18 hours. Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium 
tetroxide and stained with 1% tannic acid. Samples were dehydrated through an ethanol 
series prior to embedding in Epon 812 resin. Thin sections were prepared and stained 
using a combination of lead citrate and uranyl acetate. Electron microscopy revealed 
that 1 x 10'8M colchicine treated cells were similar to the control cells. The cell shown 
contains a large lobate nucleus surrounded by a thin layer of heterochromatin, with a 
typically prominent nucleolus. The cytoplasm contains few mitochondria and vesicles.
(x 6 000)
-240 -
%<M
Plate 1 1.6
Ultramicrograph of a U937 TK- cell treated with 1 x lCHM colchicine. Exponentially 
replicating U937 TK" cells were incubated with 1 x 10'8M colchicine at 37°C/5% C02 for 
18 hours. Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium 
tetroxide and stained with 1% tannic acid. Samples were dehydrated through an ethanol 
series prior to embedding in Epon 812 resin. Thin sections were prepared and stained 
using a combination of lead citrate and uranyl acetate. Electron microscopy revealed 
that treatment with 1 x 10‘8M colchicine had blocked approximately one third of the cells 
in metaphase. The plate shows a metaphase cell with condensed chromatin in place of a 
defined nucleus. Some paired cisternae can be seen in the cytoplasm, (x 6 000)
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Results of the propidium iodide analysis indicated that approximately 70% of U937 TK" 
cells that had been exposed to 300 pM mimosine for 18 hours were in Gl/GO.
However, mean FL2 was slightly lower than for the controls, indicating that the cells 
were blocked at an earlier stage of Gl, than had been observed for 4 mM hydroxyurea. 
Transmission electron microscopy indicated that the nucleus of these cells was very 
similar to the controls. A  prominent nucleolus was frequently observed in lobate nuclei, 
that were typically surrounded by a thin layer of heterochromatin. The cytoplasm 
contained more vesicles than observed with any of the other treatments. Endoplasmic 
reticulum was more frequently observed, although mitochondria were rare. The surface 
of the cells tended to be more irregular than that of control cells, with short lamellipods 
frequently observed. These results suggest that mimosine treatment had initiated 
myeloid differentiation of U937 TK" cells. Interestingly, similar to the 4 mM 
hydroxyurea treated cells, numerous well-defined structures, comprising of multiple 
layers of plasma membrane, were seen in a high proportion of mimosine treated cells.
An ultramicrograph of a typical U937 TK" cell after 18 hours exposure to 300 pM  
. mimosine (containing many paired cistemae in the cytoplasm) is shown in Plate 11.7.
Treatment with 4mM thymidine for 18 hours had also caused cells to accumulate in 
Gl/GO in this experiment. Propidium iodide staining showed that approximately 83% 
of cells were determined to be in Gl/GO, with a mean fluoresence identical to the 
controls. Examination of thin sections showed that the ultrastructure of these cells was 
similar to the controls. A  large lobate nucleus was surrounded by a thin layer of 
heterochromatin, and the nucleolus was well developed. The cytoplasm contained a few 
vesicles, but mitochondria and endoplasmic reticulum were rarely observed. Structures 
resembling paired cistemae were not observed in the cytoplasm of any thymidine treated 
cells. Platel 1.8 shows a typical U937 TK" cell that has been exposed to 4 mM 
thymidine for 18 hours.
A  35% proportion of U937 TK" cells that had been exposed to 75 pM GR39457A for 
18 hours were calculated to be in G2/M, following propidium iodide staining. The 
mean intensity of FL2 was similar to the controls, and slightly lower than for the 
colchicine treated population. Thin section electron microscopy revealed that the 
nuclear structure was similar to control cells. The nucleus was irregular in shape, and 
defined by a thin layer of heterochromatin. A  nucleolus was frequently prominent. The 
cytoplasm typically contained few mitochondria or vesicles, and sparse endoplasmic 
reticulum. Interestingly, a high proportion of the cells contained paired cistemae in 
their cytoplasm. It was estimated that less than 5% of the cell population contained 
condensed chromosomes, indicating that in contrast to colchicine treatment, only a low
Plate 11.7
Ultramicrograph of a U937 TK- cell treated with 300 pM mimosine. Exponentially 
replicating U937 TK" cells were incubated with 300 pM mimosine (37°C/5% C02, 18 
hours). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium 
tetroxide and stained with 1% tannic acid Samples were dehydrated through an ethanol 
series prior to embedding in Epon 812 resin. Thin sections were prepared and stained 
using a combination of lead citrate and uranyl acetate. Electron microscopy revealed 
that mimosine treated cells tended to have a slightly more mature appearance than the 
controls. Mitochondria were more frequent and more common and vesicles were 
observed in the cytoplasm of most cells. Well-developed paired cisternae, such as can be 
seen in the cytoplasm of the cell shown above, were frequently observed, (x 8 000)
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Plate 11.8
Ultramicrograph of a typical U937 TK- cell treated with 4 mM thymidine. Exponentially 
replicating U937 TK“ cells were incubated with 4 mM thymidine at 37°C/5% C02 for 18 
hours. Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide 
and stained with 1% tannic acid. Samples were dehydrated through an ethanol series 
prior to embedding in Epon 812 resin. Thin sections were prepared and stained using a 
combination of lead citrate and uranyl acetate. Electron microscopy revealed that 
ultrastructure of U937 TK" cells treated with 4 mM thymdine was similar to that of 
control exponentially replicating cells. No paired cisternae were seen in the cytoplasm of 
any U937 TK" cells treated with 4 mM thymidine, (x 6 000)
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proportion of cells were arrested in metaphase. As the propidium iodide staining 
indicated that one third of the cell population had doubled the amount of DNA, and few 
cells were observed to have entered metaphase, it is concluded that GR39457A acts at 
the end of S phase, prior to condensation of the chromatin. A  dividing cell that has 
been treated for 18 hours with 75 pM GR39457A is shown in Platel 1.9. It has been 
proposed that paired cistemae, which are thought to be restricted to mitotically active 
cells, function in the generation of nuclear membrane of daughter cells (Sato et al, 
1982). It is therefore interesting to note that structures resembling paired cistemae are 
present in the cytoplasm of the dividing cell shown in Plate 11.9, even though the 
daughter nuclei are surrounded by an intact nuclear membrane.
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Plate 11.9
Ultramicrograph of a U937 TK- cell treated with 75 pM GR39457A. Exponentially 
replicating U937 TK' cells were incubated with 75 pM GR39457A (37°C/5% C 02, 18 
hours). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium 
tetroxide and stained with 1% tannic acid. Samples were dehydrated through an ethanol 
series prior to embedding in Epon 812 resin. Thin sections were prepared and stained 
using a combination of lead citrate and uranyl acetate. Electron microscopy revealed 
that GR39457A treated cells were similar to the control cells, except for the presence of 
paired cisternae in the cytoplasm of the majority of cells. The plate shows a dividing cell, 
where although the nuclear membrane has formed around the daughter nuclei, paired 
cisternae are still present in the cytoplasm, (x 4 600)
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12,0 INVESTIGATION OF HIV-1 REPLICATION IN MONOCYTIC CELL 
LINES
12.1 REPLICATION OF H IV-1 IN  MONOCYTIC CELL LINES
12.1.1 Titration of virus stocks
In order to determine the dilution of virus stocks appropriate for use in subsequent 
experiments, stocks of IiIV -lRF and H IV -lBa_L were titrated in the available monocytoid 
cell lines. Stock virus was defrosted and diluted (using complete medium) across a 
microtitre plate. Equal volumes of cell suspension (THP-1, U937 or U937 TK", 5 x 105 
cells/ml) were added to wells containing diluted virus. Control plates containing a 
volume of complete medium equal to that of the diluted virus were also set up. The 
cells were incubated (37°C/5% C02) in the presence of the diluted virus for a total of six 
days. All plates were examined regularly during this incubation period. When the 
plates had been incubated for six days, MTT solution was added to every well, and the 
cells were incubated for a further 90 minutes in the presence of this solution. 
Metabolically active cells can convert the solution to produce insoluble formazan 
crystals. An organic solvent is used to dissolve the dark blue crystals, and the optical 
density of wells indicates the biological activity of the cells.
THP-1 cells remained looking healthy throughout the incubation period and no signs of 
cytopathic effects were noted. Incubation of THP-1 cells in the presence of either HTV- 
Irp or HTV-1 Ba_L did not significantly affect the ability of these cells to convert MTT into 
formazan (p < 0.05; Figures 12.1 and 12.2), indicating that either these virus strains 
could not replicate in THP-1 cells, or that replication of the virus did not affect the 
metabolic activity of the cells. In view of these observations, it was decided not to use 
THP-1 cells in any further experiments.
In the wells containing the highest concentrations of H lV -lg ^  or HIV-1RF, U937 TK" 
and U937 cells were observed to be quite granular and there was little evidence of an 
increase of cell number during the incubation period. Apart from this apparent 
- reduction of growth rate, at high virus concentrations..,, no signs^afcytopathicjeffects were 
observed. Virus concentration-dependent decreases of formazan conversion were 
recorded when either strain of virus was incubated in the presence of U937 (Figures 12.3 
and 12.4) or U937 TK" cells (Figures 12.5 and 12.6). At comparable dilutions of stock
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Figure 12.1
Titration of HIV-IRF in THP-1 cells. Exponentially replicating cultures of 
THP-1 cells were incubated in the presence of increasing dilutions of virus 
for 6 days at 37oC/5% C02. MTT solution was added to every well, and 
the cells were incubated for a further 90 minutes. Formazan crystals were 
solubilized using propan-2-ol and the optical density of each well was 
measured at 540 nm. The mean and standard deviation of three
independent experiments is shown.
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Ba-LFigure 12.2
Titration of HIV-lBa-L in THP-1 cells. Exponentially replicating 
cultures of THP-1 cells were incubated in the presence of increasing 
dilutions of virus for 6 days at 37oC/5% C02. MTT solution was 
added to every well, and the cells were incubated for a further 90 
minutes. Formazan crystals were solubilized using propan-2-ol and 
the optical density of each well was measured at 540 nm. The mean 
and standard deviation of three independent experiments is shown.
Op
tic
al
 d
en
sit
y 
(54
0 
nm
) 
Op
tic
al
 d
en
sit
y 
(54
0 
nm
)
0.8 
0.7- 
0.6- 
0.5- 
0.4- 
0 3 -  
0.2- 
0.1-
:x::c::x:x::x ::x:: x::x
:x::x::xx::x::x::::x::x::xx::x::x::,:x::x::xx::x::x::::x::x::xx::x::x::::x::x::x
Control 1.4 1.8 1.16 
Dilution of HIV-1
1.32 1.64
R\ stock
Uninfected control 
1 : 4 HIV-Irf 
1 : 8 HIV-Irf 
1 : 16 HIV-Irf 
1 : 32 HIV-Irf 
1 :64 HIV-Irf
Figure 12 3
Titration of HIV-IRF in U937 cells. Exponentially replicating cultures of 
U937 cells were incubated in the presence of increasing dilutions of virus 
for 6 days at 37oC/5% C02. MTT solution was added to every well, and 
the cells were incubated for a further 90 minutes. Formazan crystals were 
solubilized using propan-2-ol and the optical density of each well was 
measured at 540 nm. The mean and standard deviation of three
independent experiments is shown.
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Figure 12.4
Titration of HIV-lBa-L in U937 cells. Exponentially replicating 
cultures of U937 cells were incubated in the presence of increasing 
dilutions of virus for 6 days at 37oC/5% C02. MTT solution was 
added to every well, and the cells were incubated for a further 90 
minutes. Formazan crystals were solubilized using propan-2-ol and 
the optical density of each well was measured at 540 nm. The mean
and standard deviation of three independent experiments is shown.
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Rl*Figure 12.5
Titration of HIV-1RF in U937 TK- cells. Exponentially replicating cultures 
of U937 TK- cells were incubated in the presence of increasing dilutions of 
virus for 6 days at 37oC/5% C02. MTT solution was added to every well, 
and the cells were incubated for a further 90 minutes. Formazan crystals 
were solubilized using propan-2-ol and the optical density of each well was 
measured at 540 nm. The mean and standard deviation of three 
independent experiments is shown.
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Titration of HIV-lBa-L. in U937 TK- cells. Exponentially replicating 
cultures of U937 TK- cells were incubated in the presence of 
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solution was added to every well, and the cells were incubated for a 
further 90 minutes. Formazan crystals were solubilized using propan- 
2-ol and the optical density of each well was measured at 540 nm.
The mean and standard deviation of three independent experiments is 
shown. . 250.
virus suspension, greater reductions in formazan conversion were recorded for cells 
incubated with the IHV-1RF strain compared with cells incubated in the presence of the 
monocytotropic H IV -lBa_L strain. This indicated that either more virions were present 
in the HIV-1RF stock or that this virus had a greater capacity to replicate in U937 cells 
and their thymidine kinase derivatives.
12.2 EFFECT OF HOST CELL CYCLE ON REPLICATION OF HIV-1
12.2.1 Titration of HIV-1 in U937 TK~ cells reversibly blocked in the cell cycle 
Initial experiments were carried out to investigate whether treatment of cell lines with 
reversible cell cycle inhibitors affected the replication of either a lymphotropic or 
monocytotropic strain of virus (HIV--1RF and H IV -lBa.L, respectively) in U937 TK" cells. 
The previous experiments had indicated that incubating the cells in the presence of either 
a 1:8 dilution of stock H IV -l^  or of a 1:4 dilution of H IV -lBa.L gave comparable 
reductions in formazan conversion. U937 TK" cells were exposed to appropriate 
concentrations of cell cycle inhibitors for a period of 18 hours at 37°C/5% C02. The 
treated cells were transferred to centrifuge tubes, harvested (lOOg- x 3 min), and 
resuspended at a concentration of 5 x 105/ml in fresh medium. Stock virus was diluted 
across microtitre plates and appropriately treated cell suspensions were added. Control 
plates containing an equal concentration of uninfected cells were also set up. The cells 
were incubated, (37°C/5% C02), in the presence, or absence, of the appropriate strain of 
HIV-1 for a total of 6 days. All plates were examined microscopically and a 50 pi 
volume of a 7.5 pg/ml solution of MTT was added to every well. The plates were 
incubated for a further 90 minutes to allow metabolically active cells to convert MTT to 
insoluble formazan crystals. The formazan crystals were solubilized by careful mixing of 
the contents of each well, following addition of 150 pi of propan-2-ol. The optical 
density of every well at 540 nm was recorded using a microtitre plate reader. The 
results are shown graphically in Figure 12.7.
The results of the MTT assay indicated that treatment of uninfected U937 TK" cells with 
4 mM hydroxyurea, 300 jTM mimosine and to a lesser extent 1 x 10*8M  colchicine for 18 
hours, prior to a 6 day recovery in complete medium, resulted in reduced, capacity for 
MTT reduction by these cells. (These reductions were not significantly different from 
the controls). This may indicate a lasting effect of the compounds on cellular 
metabolism, but it is more likely to indicate a reduction in the numbers of cells present.
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Although roughly equal numbers of cells were placed in every well at the start of the 
experiment, any delays whilst cells recover to normal rates of replication would mean 
that less cells would be present at the end of the incubation period, compared to the 
exponentially replicating control population.
Incubation of U937 TK" control cells for 6 days in the presence of either a 1:8 dilution of 
stock H IV -1RF, or a 1:4 dilution of stock HIV- lBa_L resulted in a 30% reduction in the 
capacity of these cells to produce formazan, compared with an uninfected population (p 
< 0.025). Cells that had been treated with 0.25 mM hydroxyurea, 4 mM thymidine or 
75 JiM GR39457A for 18 hours prior to incubation with H IV -lBa_L showed a similar 
decrease in formazan reduction capacity compared to appropriate controls. HTV-lBa_L 
infection of 4 mM hydroxyurea, 300 pM mimosine or 1 x 10'8M  colchicine treated U937 
TK" cells resulted in greater reductions in capacity to produce formazan (37%, 48% and 
51% respectively). Statistical analysis showed that these reductions were not 
significantly different from the H IV -lBa_L infected controls. However, the results 
suggest that these treatments either enhance infection, or exert some lasting effects on 
cellular metabolism.
Compared to the appropriate controls, treatments of U937 TK" cells with either 0.25 
mM hydroxyurea, 4 mM thymidine or 75 jxM GR39457A did not cause any significant 
alterations in capacity of HIV-1RF infected cells to reduce MTT. However, all other 
treatments did perturb the production of formazan. In comparison to the uninfected 
cells, infection of U937 TK" cells pre-treated with 4 mM hydroxyurea, 1 x 10'8M  
colchicine or 300 pM mimosine with HIV-1RF, resulted in a reduction of the capacity of 
cells to reduce MTT by approximately 50%. Conversion of MTT to formazan was 
significantly lower in H3V-1RF infected U937 TK" cells that had been pre-treated with 
either 300 pM mimosine or 1 x 10'8M  colchicine in comparison to infected control cells 
(p < 0.10 and p <0.025, respectively).
12.2.2 Investigation of HIV-1 replication in U937 TK" cells blocked in the cell cycle 
U937 TK" cells were exposed to appropriate concentrations of cell cycle inhibitors for a 
period of 18 hours at 37°C/5% C02. The treated cells were transferred to centrifuge 
tubes and harvested (lOOg x 3 min). The cell pellets were incubated in the presence of 
stock HIV-1 for 90 minutes at 37°C/5% C02. Any excess virus was washed off (using 
PBS, 100gx 3 min) and the cells were resuspended in fresh complete medium and
incubated at 37°C/5% C02 for 25 days. In an initial experiment U937 TK" cells were 
infected with the monocytotropic strain HIV-1 but in subsequent experiments the 
lymphocytotropic strain HTV-Irj? was used. During the incubation period all cultures 
were regularity observed microscopically. Cellular replication appeared to be unaffected 
by infection with HIV-1, and cells were sub-cultured by dilution into fresh medium every 
3 -4  days. No cytopathic effects were observed following infection of U937 TK" cells 
with H IV -lBa_L. However, some cells with swollen appearance and a few syncytia were 
observed in cultures of U937 TK" cells between 20 and 25 days after infection with HIV- 
Irp. These results should be compared with those recorded following infection of the 
T-cell line (H9) with H1V-1RF Initially, the replication rate of H9 cells appeared to be 
unaffected by the presence of the virus. However, six days after infection with the HIV- 
Irp strain, the cells were observed to be markedly clumped. Close examination revealed 
that larger, fused cells tended to be present at the centre of the clumps, indicating 
formation of syncytia. In H9 cells the appearance of cytopathic effects correlated with a 
reduction of growth rate. Ten days after the cells had been infected with HTV-Irj? 
many, large, multinucleate, giant cells, or syncytia, were present. In order that the cells 
could be fixed and stained at the same time as the myeloid cells, the cells were passaged 
into fresh medium containing 2 x 105/ml uninfected H9 cells.
12.2.3 Ultrastructure of U937 TKr infected with HIV-lBa_L
In an initial experiment a population of exponentially replicating U937 cells was infected 
with ff lV -lBa.L, and incubated for a total of 11 days. Samples of the cells were fixed, 
embedded, stained and examined by transmission electron microscopy. The infection 
was very low level, with very few cells (<  1%) estimated to be infected with this 
monocytotropic isolate of HIV-1. The virions that were observed tended to have the 
appearance of immature HIV-1; although a few particles with more mature 
characterisctics were observed within intracellular vesicles. HXV-I^.l present within an 
intracellular vesicle is shown in Plate 12.1. A  few virus particles were observed to be 
associated with host cell plasma membranes, although it was not clear whether the 
virions were actually budding through the surface membranes. However, despite the 
apparent low level of infection, the appearance of the cells was dramatically different 
from that of uninfected cells. An ultramicrograph of an uninfected U937 cell was shown 
in Plate 9.2 and this should be compared with the HTV-1 Ba_L infected U937 cells shown 
in Plate 12.2. Uninfected cells are typified by cytoplasm containing a few mitochondria 
and sparse endoplasmic reticulum. However, the cytoplasm of cells incubated in the
Plate 12.1
Ultramicrograph of a vesicle in the cytoplasm of a U937 cell 1 ldays after infection with 
H IV -lBa_L. Exponentially replicating U937 cells were incubated in the presence of HIV- 
1 B a - L  f ° r 90 minutes. Infected cells were incubated for a total of 21 days (37°C/5% 
C 02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide 
and stained with 1% tannic acid. Samples were dehydrated through an ethanol series 
prior to embedding in Epon 812 resin. Thin sections were prepared and stained using a 
combination of lead citrate and uranyl acetate. The ultrastructure of these cells was 
observed to be very similar to the controls. Two HIV-1 virions are shown inside an 
intracellular vesicle, (x 100 000)
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Plate 12.2
Ultramicrograph of a typical U937 cell 11 days after infection with H IV -lBa.L. 
Exponentially replicating U937 cells were infected with H IV -lBa_L, and incubated for a 
total of 11 days. Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium 
tetroxide and stained with 1% tannic acid. Samples were dehydrated through an ethanol 
series prior to embedding in Epon 812 resin. Thin sections were prepared and stained 
using a combination of lead citrate and uranyl acetate. Transmission electron microscopy 
showed that uninfected U937cells were typified by cytoplasm containing a few 
mitochondria and sparse endoplasmic reticulum. However, the cytoplasm of cells 
incubated in the presence of H IV -lBa_L for 11 days contained many vesicles and large 
amounts of plasma membrane, probably endoplasmic reticulum. Mitochondria were also 
more numerous in the virus infected cells. Although very few cells were observed to be 
infected with HIV-1, the increase in intracellular membrane was seen in virtually all U937 
cells. ( x 4 600)
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presence of HTV-1 Ba.L for 11 days contained many vesicles and large amounts of plasma 
membrane, probably endoplasmic reticulum. Mitochondria were also more numerous in 
the virus infected cells. Although very few cells were observed to be infected with HIV- 
1, the increase in intracellular membrane was seen in virtually all U937 cells.
In a subsequent experiment U937 TK" cells were infected with H IV -lBa_L, and incubated 
for 19 days, in order to allow for any infection to become more established. Certain 
U937 TK" cells were treated with reversible cell cycle inhibitors prior to infection with 
HTV-lBa_L. The samples were fixed, embedded, stained and examined by transmission 
electron microscopy. Infection level was very low, estimated at < 1% of cells seen to 
contain virus in any of the samples examined. Treatment with reversible cell cycle 
inhibitors was not observed to have any obvious effects on the replication of the virus. 
The few infected cells that were observed, contained low numbers of virions in 
intracellular vesicles. Occasional virions were recorded to be present in association with 
the host cell plasma membrane. However, no evidence that particles were maturing by 
budding through this membrane was observed. The only significant difference between 
the treated and control cells was recorded for the population of U937 TK" cells that had 
been blocked in Gl/GO, by exposure to 4 mM hydroxyurea for 18 hours, prior to 
incubation with stock HTV-1 Ba_L. Many of these cells contained more plasma membrane 
in their cytoplasm than the controls and a few of these cells were observed to contain 
structures which appeared to consist of concentric rings of plasma membrane.
Structures similar to these had been observed in a macrophage present in a human 
alveolar lavage (Carstens, 1993). No virus was observed in association with these 
membranous structures. A  typical U937 TK" cell that had been treated with 4 mM 
hydroxyurea for 18 hours prior to infection with HTV-lBa_L is shown in Plate 12.3.
12.2.4 Investigation ofp24 antigen release from HTV-1 Ba_L infected U937 TK- cells 
Replication of HTV-1 is frequently followed by monitoring release of the viral core 
antigen (p24) into the culture supernatant (e.g. Haffer et al., 1992). The concentration 
of p24 core antigen can be determined using a commercially available E.L.I.S.A.-based 
assay. An initial experiment investigated the level of p24 present in supernatants derived 
from TJ937 TK" cells that had been cultured in the presence of H lV -lg ^  for 14 days. 
Levels of p24 antigen in the supernatants of cells that had been treated with reversible 
cell cycle inhibitors prior to infection with the monocytotropic strain of HTV-1, were 
compared with those of exponentially replicating control cells. Optical densities for all
Plate 12.3
Ultramicrograph of a 4 mM hydroxyurea treated U937 TK" cell 21days after infection 
with HIV-lHl.,. Exponentially replicating U937 TK" cells were incubated in the 
presence of 4 mM hydroxyurea for 1 8 hours. The cells were harvested and incubated 
with HIV-1R1 for 90 minutes. Infected cells were incubated for a total of 21 days 
(37°C/5% C02) Cells were fixed using 2.5% glutaraldehyde, post fixed with 1% 
osmium tetroxide and stained with l°o tannic acid Samples were dehydrated through an 
ethanol series prior to embedding in bpon 812 resin 1 hm sections were prepared and 
stained using a combination ol lead citrate and uranyl acetate. I he plate shows a typical 
cell, with unusual formations of plasma membrane around the edge of the cell (x 6 000)
samples of culture supernatants from cells that had been infected with HTV-lBa_L for 14 
days were higher than recorded for the assay blanks, although readings were close to the 
detection limit of the assay. Extrapolation from a standard curve estimated that the 
concentration of p24 antigen was in the region of 2 pg/ml, indicating a very low level of 
infection. No significant differences between the cell treatments were observed.
In a subsequent experiment U937 TK" cells were likewise treated with reversible cell 
cycle inhibitors prior to infection with H IV -lBa.L. However, the incubation period was 
extended to 21 days in order to determine whether a higher level of infection would be 
established after this time. The results showed that all samples of supernatants obtained 
from H IV -lBa_L infected cultures, except from cells that had been pretreated with the 
metaphase arrest agent GR39457A, had significantly higher optical densities when 
compared with supernatants from uninfected U937 TK" control cultures (p < 0.005). 
Extrapolation from a standard curve indicated that the concentration of p24 in the 
culture supernatants was higher than in the initial experiment, with most of the cell 
treatments associated with 6 -8  pg/ml. The notable exception to this was supernatant 
isolated from the cells that had been treated with 1 x 10-8M  colchicine. This sample 
contained 76.6 pg/ml p24, which was significantly higher than recorded for the control 
infected cultures (p < 0.05). Cells which had been exposed to 0.25 mM hydroxyurea 
prior to infection with H IV -lBa_L were also observed to have increased levels of p24 
antigen in the culture supernatants. It was estimated that these cultures contained 
approximately 23 pg/ml p24 antigen, although this was not significantly higher than the 
control infected cultures (p >0.1). A  histogram showing the relative concentrations of 
p24 antigen in the treated cells is shown in Figure 12.8.
These results indicate that a low level infection of the monocytotropic isolate H IV -lBa.L 
had been established in U937 TK" cells, and suggest that prior treatment with 1 x 10_8M  
colchicine may either enhance or accelerate the infection. The low levels of p24 antigen 
detected in the culture supernatants correlated with electron microscopical observations 
that very few virions were present in the H IV -1 Ba.Linfected cultures. .^ . . . . . .  ....
12.2.5 Ultrastructure of cell lines infected with HIV-1 pp
H9 cells that had been infected with HIV-1RF for 21 days were examined by transmission 
electron microscopy. This T-cell line was seen to be heavily infected with the virus.
The majority of the cells observed were associated with virions budding from the plasma
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Figure 12.8
Assay of HIV-l p24 released into culture supernatants. U937 TK- cells were treated 
with reversible cell cycle inhibitors for 18 hours, prior to infection with HIV-lBa { . 
Samples of culture supernatant from infected cells that had been incubated for 21 days 
were assayed for p24 concentration using a commercial E.L.I.S.A.-based kit. Results 
from a representative experiment are shown.
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membrane. The cytoplasm of infected cells contained some mitochondria, and 
occasional vesicles. Although such intracellular vesicles were observed, they were never 
associated with any virus. A  typical infected cell is shown in Plate 12.4. Large, 
multinucieated, giant cells, (or syncytia), were also observed. Typically, such cells 
tended to have an appearance characteristic of dying cells, with granular cytoplasm and a 
very thin plasma membrane. A  representative multinucleated cell is shown in Plate 12.5.
Control, exponentially replicating, U937 TK" cells that had been infected with H IV -1RF 
for 21 days were examined by transmission electron microscopy. A  striking feature of 
these cells was the presence of many paired/confronting cisternae within the cytoplasm 
of infected cells which were not present in uninfected U937 TK" cells. In other 
respects, the infected and uninfected U937 TK" cells appeared similar. The nucleus in 
most of the cells was surrounded by a margin of heterochromatin, and the nucleolus was 
frequently prominent. The cytoplasm typically contained few mitochondria and sparse 
endoplasmic reticulum. H IV -Irp was observed to be budding from the plasma 
membrane of approximately 50% of the cells. Virus can be seen budding from the 
plasma membrane of a typical IIIV-1RF infected U937 TK" cell in Plate 12.6. A  few 
metaphase cells were observed. The cytoplasm of these dividing cells contained well- 
defined paired cisternae, and virus was observed budding from the plasma membrane of 
these dividing cells. A  typical metaphase cell is shown in Plate 12.7. Interestingly, 
many of the cells contained paired/confronting cisternae, and these cells were also 
observed to contain intracellular accumulations of HIV-1rf. However, virions were 
never observed in direct association with paired cisternae in any of the infected cells. 
Virus budding into intracellular vesicles was observed in more than half of the infected 
cells that were seen to have H IV -Irp budding from the plasma membrane surrounding 
the cell. A  U937 TK" cell containing a large intracellular accumulation of virus is shown 
in Plate 12.8.
U937 TK" cells, that had been blocked on the Gl/S border, by exposure to 4 mM 
. hydroxyurea for 18 hours prior to incubation with stock virus, were examined using 
transmission electron microscopy 21 days after infection with H IV -l^ . Many of these 
cells were observed to have virions budding from the cell surface. The cells frequently 
had large accumulations of virions around areas of the cell surface. Few cells (<  10%) 
contained paired/confronting cisternae, but the cells which did contain these structures 
were also observed to contain intracellular vesicles containing virus. A  representative 
cell is shown in Plate 12.9.
Plate 12.4
Ultramicrograph of an HIV-1RF infected H9 cell. Exponentially replicating H9 cells were 
incubated with HIV-1RF for 90 minutes. Excess virus was washed off and cells were 
incubated for a total of 21 days (37°C/5% C02). Cells were fixed using 2.5% 
glutaraldehyde, postfixed with 1% osmium tetroxide and stained with 1% tannic acid. 
Samples were dehydrated through an ethanol series prior to embedding in Epon 812 
resin. Thin sections were prepared and stained using a combination of lead citrate and 
uranyl acetate. Electron microscopy revealed that the cell is surrounded by budding 
virions, and although vesicles can be seen within the cytoplasm there is no intracellular 
viais. (x 6 000)
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Plate 12.5
Ultramicrograph of a syncytium formed between HIV-1RF infected H9 cells.
Exponentially replicating H9 cells were incubated with HIV-1RF for 90 minutes. Excess 
virus was washed off and cells were incubated for a total of 21 days (37°C/5% C02).
Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide and 
stained with 1% tannic acid. Samples were dehydrated through an ethanol series prior to 
embedding in Epon 812 resin. Thin sections were prepared and stained using a 
combination of lead citrate and uranyl acetate. A single syncytium is shown. Cells 
comprising this syncytium are probably dead, as they are surrounded by an thin, 
incomplete, plasma membrane, (x 3 600)
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IPlate 12.6
Ultramicrograph of a U937 TK" cell 21 days after infection with H IV - Ir f . Exponentially 
replicating U937 TK" cells were incubated with H IV - Irf for 90 minutes (37°C/5% CCA). 
Excess virus was washed off and cells were incubated for a total of 21 days. Cells were 
fixed using 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide and stained with 1% 
tannic acid. Samples were dehydrated through an ethanol series prior to embedding in Epon 
812 resin. Thin sections were prepared and stained using a combination of lead citrate and 
uranyl acetate. Transmission electron microscopy showed that at least half of the cells were 
infected with HIV-1. Virus was observed to be budding from the surface of many of the 
infected cells, although virions were frequently observed to be budding into intracellular 
vesicles. The cell shown in this plate contains a particularity large intracellular 
accumulation of HIV-1. Interestingly, the cytoplasm contains many paired cisternae, 
although these were never observed in association with virions, (x 4 600)
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Plate 12.7
Ultramicrograph of a control U937 TK" cell 21 days after infection with HIV-1RF. 
Exponentially replicating U937 TK" cells were incubated in the presence of HIV-1RF for 
90 minutes. Excess virus was washed off and cells were incubated for a total of 21 days 
(37°C/5% C02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% 
osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. The micrograph shows a 
metaphase cells, with condensed chromatin in place of a distinct nucleus. The cytoplasm 
contains some paried cisternae. HIV-1 can be seen budding from the plasma membrane 
of this replicating cell, (x 6 000)
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Plate 12.8
Ultramicrograph of HIV-1 budding into an intracytoplasmic vesicle of a U937 TK" cell 21 
days after infection with HIV-Irf. Exponentially replicating U937 TK" cells were incubated 
with H IV -Irf f°r 90 minutes (37°C/5% CO2). Excess virus was washed off and cells were 
incubated for a total of 21 days. Cells were fixed using 2.5% glutaraldehyde, postfixed with 
1% osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. Transmission electron 
microscopy showed that at least half of the cells were infected with HIV-1. Virus was 
observed to be budding from the surface of many of the infected cells, although virions were 
frequently observed to be budding into intracellular vesicles. A high magnification view of 
one such intracellular vesicle is shown, (x 46 000)
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Plate 12.9
Ultramicrograph of a 4 mM hydroxyurea treated U937 TK" cell 21 days after infection 
with HIV-1rf. Exponentially replicating U937 TK' cells were incubated in the presence 
of 4 mM hydroxyurea for 18 hours. The cells were harvested and incubated with HIV- 
1RF for 90 minutes. Excess virus was washed off and cells were incubated for a total of 
21 days (37°C/5% C 02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% 
osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. The ultrastructure of 
these cells was observed to be very similar to the controls. HIV-1 was observed to be 
budding from the cell membrane of approximately half of the cells. The plate shows a 
typical cell (x 6 000)
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Approximately 50% of U937 TK“ cells were present in S phase, following treatment of 
the cells with 0.25 mM hydroxyurea for 18 hours. However, the treated cells remained 
permissive for infection with the H IV -Irp strain. At 21 days post-infection at least half 
of the cells were observed to have virions maturing by budding from the host cell 
membranes. However, a lower proportion of cells were observed to be associated with 
intracellular accumulation of virus, than had been recorded for the control (exponentially 
replicating) cell population. Few of the 0.25 mM hydroxyurea treated cells were 
observed to contain paired cistemae in their cytoplasm. A  U937 TK" cell that had been 
treated with 0.25 mM hydroxyurea for 18 hours prior to infection with HIV-Irp is 
shown in Plate 12.10.
An 18 hour exposure of U937 TK" cells to 1 x 10_8M  colchicine had caused 
approximately 20% of the cells to accumulate in G2/M phase of the cell cycle. 
Examination of colchine treated U937 TK" cells, that had been incubated for 21 days 
following infection with H IV -Irp, indicated that at least 40% of the cells were 
productively infected with the virus. Virions were observed budding from the surface of 
many of the infected cells. Low numbers of virions were seen in small intracytoplasmic 
vesicles in many cells. Although virtually all of the cells contained many paired 
cistemae, HIV was never observed to be associated with these structures. A  typical cell 
that has been incubated in the presence of HIV-Irp for 20 days following treatment with 
1 x 10'8M  colchicine is shown in Plate 12.11. Interestingly, approximately 5% of the 
cells appeared to be undergoing apoptosis, as evidenced by highly condensed chromatin 
in the nucleus, very granular cytoplasm and a thin cellular membrane. These apoptotic 
cells did not appear to be infected with H IV -Irp, as virions were not observed either 
within intracellular vesicles, or budding from the surface of these dying cells.
U937 TK" cells that had been exposed to300 pM mimosine for 18 hours were 
predominantly, (approximately 70%) blocked in Gl/GO. Examination of cells that had 
been incubated for 21 days following infection by HIV-Irp, indicated that some of the 
cells were associated with a more differentiated appearance than the. control cells.
These cells which tended to appear larger than the control cells were frequently 
surrounded by many pseudopodia. Infected cells were associated with both 
accumulation of HIV-Irp within intracellular vesicles, and with maturation of vims by 
budding from the cell membrane. A  typical cell is shown in Plate 12.12.
Plate 12.10
Ultramicrograph of a 0.25 mM hydroxyurea treated U937 TK' cell 21 days after infection 
with HIV-1rf. Exponentially replicating U937 TK“ cells were incubated in the presence 
of 0.25 mM hydroxyurea for 18 hours. The cells were harvested and incubated with 
HIV-1rf for 90 minutes. Excess virus was washed off and cells were incubated for a 
total of 21 days (37°C/5% C02). Cells were fixed using 2.5% glutaraldehyde, postfixed 
with 1% osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated 
through an ethanol series prior to embedding in Epon 812 resin. Thin sections were 
prepared and stained using a combination of lead citrate and uranyl acetate. The 
ultrastructure of these cells was observed to be very similar to the controls. HIV-1 was 
infrequently observed to be budding into intracellular vesicles in these cells. The plate 
shows a typical cell with virions budding from the plasma membrane, (x 6 000)
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Ultramicrograph of a 1 x K>8M colchicine treated U937 TK- cell 21 days after infection 
with HIV-1RF- Exponentially replicating U937 TK" cells were incubated in the presence 
of 1 x 10_8M colchicine for 18 hours. The cells were harvested and incubated with HIV- 
1RF for 90 minutes. Excess virus was washed off and cells were incubated for a total of 
21 days (37°C/5% C02). colchicine. Cells were fixed using 2.5% glutaraldehyde, 
postfixed with 1% osmium tetroxide and stained with 1% tannic acid Samples were 
dehydrated through an ethanol series prior to embedding in Epon 8 12 resin Thin 
sections were prepared and stained using a combination of lead citrate and uranyl acetate 
The plate shows a typical HIV-1 infected colchicine treated U937 TK' cell with many 
paired cisternae in the cytoplasm. Virus was observed both in intracytoplasmic vescicles 
and budding from the cell membrane, (x 6 000)
Plate 12.11
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Plate 12.12
Ultramicrograph of a 300 pM mimosine treated U937 TK“ cell 21 days after infection 
with HIV-1rf. Exponentially replicating U937 TK" cells were incubated in the presence 
of 300 pM mimosine for 18 hours. The cells were harvested and incubated with HIV- 
1RF for 90 minutes. Excess virus was washed off and cells were incubated for a total of 
21 days (37°C/5% C02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% 
osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. TEM indicated that these 
cells tended to appear slightly more mature than the control cells with mitochondria and 
endoplasmic reticulum more frequently observed. Virus was observed both in 
cytoplasmic vesicles and associated with the plasma membrane, as shown in this plate.
(x 6 000)
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In this experiment, exposure of U937 TK" cells to 4 mM thymidine caused 
approximately 70% of the cells to accumulate at the Gl/S border. Examination of cells 
by transmission electron microscopy 21 days after infection with H IV -Irp, indicated that 
at least half of the cells had been infected with the virus. The infected cells were 
predominantly associated with virions maturing by budding from the cell surface. Very 
few intracellular vesicles containing H IV -Irp were observed. No paired cisternae were 
observed in the cytoplasm of these cells. A  cell that appears to be phagocytosing 
clusters of virions is shown in Plate 12.13.
U937 TK" cells that had been exposed to75 pM GR39457A for 18 hours had tended to 
accumulate in G2/M. Ultrathin sections of the cells were prepared 21 days after 
infection with H IV -Irf, and examined by transmission electron microscopy. The cells 
were observed to contain many small vesicles within the cytoplasm. Many cells also 
contained paired/confronting cisternae. Infection of these cells was characterized by 
accumulation of H IV -1RF within intracellular vesicles. Virions were observed maturing 
by budding directly from the cell membrane and into intracellular vesicles (Plates 12.14 
and 12.15). A  typical cell is shown in Plate 12.16.
12.2.6 Investigation of intracellular p24 antigen levels associated with HIV-1RF 
infected U937 TKr cells
Myeloid cells, in contrast to T-lymphocytes, are associated with intracellular 
accumulation of HIV (Gendelman et al., 1990). Conventional assays for detection of 
viral p24 core antigens detect the level of antigen released into the supernatant of 
infected cell cultures. However, a monoclonal antibody that has specificity for 
intracellular p24 is now commercially available. If cells are fixed and treated with 
appropriate chemicals to render them permeable, this monoclonal can be used to indicate 
intracellular levels of the viral core antigen. U937 TK" cells were exposed to 
appropriate concentrations of cell cycle inhibitors for a period of 18 hours at 37°C/5% 
C02. (Samples of treated cells were fixed and stained with propidium iodide, in order to 
confirm that the treatments had caused cells to accumulate in the appropriate phases of 
the cell cycle). The treated cells were transferred to centrifuge tubes and harvested 
(100# x 3 min). Resulting cell pellets were incubated in the presence of stock HTV-Irf 
for 90 minutes at 37°C/5% C 02. Any excess virus was washed off*(using PBS, 100# x 
3 min) and the cells were resuspended in fresh complete medium and incubated at 
37°C/5% C02 for a total of 25 days. During the incubation period all cultures were
Plate 12.13
Ultramicrograph of a 4 mM thymidine treated U937 TK" cell 21 days after infection with 
HIV-1rf. Exponentially replicating U937 TK" cells were incubated in the presence of 4 
mM thymidine for 18 hours. The cells were harvested and incubated with HIV-1RF for 
90 minutes. Excess virus was washed off and cells were incubated for a total of 21 days 
(37°C/5% C02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% 
osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. The ultrastructure of 
these cells was observed to be very similar to the controls. HIV-1 was observed to be 
budding from the cell membrane of approximately half of the cells, but virions were rarely 
seen within intracellular vesicles. The plate shows a cell which appears to be 
phagocytosing some virions, (x 6 000)
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Plate 12.14
Ultramicrograph of HIV-1 budding from the surface of a 75 pM GR39457A treated 
U937 TK" cell 21 days after infection with HIV-1RF. Exponentially replicating U937 TK" 
cells were incubated in the presence of 75 pM GR39457A for 18 hours. The cells were 
harvested and incubated with HIV-1RF for 90 minutes. Excess virus was washed off and 
cells were incubated for a total of 21 days (37°C/5% C02). Cells were fixed using 2.5% 
glutaraldehyde, postfixed with 1% osmium tetroxide and stained with 1% tannic acid. 
Samples were dehydrated through an ethanol series prior to embedding in Epon 812 
resin. Thin sections were prepared and stained using a combination of lead citrate and 
uranyl acetate. This high magnification micrograph shows the detail of HIV-1 budding 
from the host cell plasma membrane, together with some cell free virions, (x 130 000)
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Plate 12.15
Ultramicrograph of HIV-1 budding into an intracytoplasmic vesicle of a 75 pM 
GR39457A treated U937 TK" cell 21 days after infection with HIV-1RF. Exponentially 
replicating U937 TK" cells were incubated in the presence of 75 pM GR39457A for 18 
hours. The cells were harvested and incubated with H1V-1RF for 90 minutes. Excess 
virus was washed off and cells were incubated for a total of 21 days (37°C/5% C02).
Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide and 
stained with 1% tannic acid. Samples were dehydrated through an ethanol series prior to 
embedding in Epon 812 resin. Thin sections were prepared and stained using a 
combination of lead citrate and uranyl acetate. This high magnification micrograph 
shows in detail HIV-1 accumulating in an intracellular vesicle. The dark cresents at the 
edges of the vesicle indicate new virions budding into the vesicle. Virions, containing 
cone-shaped cores typical of HIV-1 can be observed in this vesicle, (x 17 000)
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Plate 12.16
Ultramicrograph of a 75 pM GR39457A treated U937 TK" cell 21 days after infection 
with HIV-1rf. Exponentially replicating U937 TK" cells were incubated in the presence 
of 75 pM GR39457A for 18 hours. The cells were harvested and incubated with HIV- 
1RF for 90 minutes. Excess virus was washed off and cells were incubated for a total of 
21 days (37°C/5% C02). Cells were fixed using 2.5% glutaraldehyde, postfixed with 1% 
osmium tetroxide and stained with 1% tannic acid. Samples were dehydrated through an 
ethanol series prior to embedding in Epon 812 resin. Thin sections were prepared and 
stained using a combination of lead citrate and uranyl acetate. Transmission electron 
microscopy revealed that the cytoplasm contained many paired cisternae, and more 
vesicles than the control cells. HIV-1 was frequently observed to be budding both from 
the plasma membrane and into intracellular vesicles. The plate shows a typical cell with 
virions budding from the plasma membrane, (x 6 000)
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regularity observed microscopically and cultures were diluted with fresh complete 
medium every 3 -4  days. At 15 and 25 days after the cells had been infected with HIV- 
I r p  samples of cells were fixed and stained with FITC-conjugated monoclonal antibody 
KC57 (anti-p24). The samples were run through the flow cytometer to investigate the 
level of green fluorescence (FL1) associated with the infected cells.
Flow cytometric analysis of control cells that had been stained for intracellular p24 
antigen expression 15 days after infection with HIV-Irp were observed to have small 
(but not significant) reductions of mean forward scatter (FSC), and corresponding 
increases of side scatter (SSC), compared to that recorded for uninfected control U937 
TK" cells. This indicated that the infected cells tended to be slightly smaller and more 
granular than the uninfected population. Control U937 TK" cells, (that had not been 
pre-treated prior to infection with H IV -Irp), were associated with a significantly higher 
intensity of green fluorescence (FL1) than the uninfected control cells (p < 0.025). A  
higher mean intensity of FL1 was likewise recorded for cells that had been exposed to 
either 4 raM hydroxyurea or 0.25 mM hydroxyurea prior to infection with HIV-Irp, but 
the fluorescence intensity was not significantly different from that of the virus infected 
controls. Treatment of U937 TIC" cells with 300 pM mimosine caused a significant 
accumulation of cells in Gl/GO (p < 0.05). Staining of the mimosine pre-treated cells 
for intracellular p24 indicated that the cells contained a significantly higher level of p24 
antigen than HIV-Irp infected controls (p < 0.05). Interestingly, exposure of cells to 4 
mM thymidine had also caused cells to accumulate in Gl/GO (p < 0.05, when compared 
to the controls). However, unlike treatment with 300 pM mimosine, intracellular p24 
antigen levels were significantly lower than recorded for the H IV -Irp infected controls (p 
< 0.05). In this experiment, treatment of the cells with either 1 x 10*8M  colchicine or 
with 75 pM GR39457A had resulted in a significant accumulation of cells in late S phase 
(p < 0.01). Both of these treatments had also resulted in significantly higher median 
FL1 intensity than recorded for the infected controls, indicating higher levels of 
intracellular p24 antigen, and presumably virus (p < 0.10). The median green 
fluorescence associated with the treated cells 15 days after infection with HIV-Irp is 
shown in Figure 12.9.
Following incubation for a further 10 days, flow cytometric analysis revealed significant 
levels of intracellular p24 antigen within all cultures tested (p < 0.005; Figure 12.10). 
However, no significant differences between the fluorescence intensities associated with 
the different cell treatments were observed. Interestingly, the HIV-Irp infected cells
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Control
4.00 mM Hydroxyurea 
0.25 mM Hydroxyurea 
1 x 10‘8 M Colchicine
300 uM Mimosine 
4 mM Thymidine 
75 pM GR39457A
Figure 12.9
Intracellular p24 antigen expression 15 days after U937 TK- cells were infected 
with HIV-lRp. Cells were treated with reversible cell cycle inhibitors for 18 
hours prior to infection with virus. Cells were fixed with paraformaldehyde 
and stained using an FITC-conjugated monoclonal anti-p24 antibody (KC57). 
Cell associated green fluoresence was detected using flow cytometry. I he 
mean and standard deviation from three independent experiments are shown.
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Figure 12.10
Intracellular p24 antigen expression 25 days after U937 TK- cells were infected 
with HIV-lRp. Cells were treated with reversible cell cycle inhibitors for 18 
hours prior to infection with virus. Cells were fixed with paraformaldehyde 
and stained using an FITC-conjugated monoclonal anti-p24 antibody (KC57). 
Cell associated green fluorescence was detected using How cytometry. The 
data shows mean and standard devidation from three independent experiments.
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tended to have higher forward scatter, (size), and were associated with significantly 
higher side scatter than the uninfected control U937 TK" cells (p < 0.05). This indicates 
that the granularity of the infected cells was increased by the high level of intracellular 
virions.
13,0 DISCUSSION
13.1 OPTIMIZA TION OF FUSION PROTOCOLS
13.1.1 Quantitation of fusion efficiency
The success of a particular fusion protocol is usually monitored by enumerating the 
hybridomas isolated (Kappler et al., 1981). The selection of fusion protocols that result 
in the maximum isolation of hybridomas is relatively simple when their growth can be 
detected within a few days of fusion. However, the reported successful isolations of 
macrophage hybridomas indicate that growth was observed first around 8 weeks post­
fusion (e.g. Woo et al., 1988). In the current study, initial experiments utilized the 
procedures described by Shimoda et al. (1988) for the production of human macrophage 
hybridomas. The protocol achieved fusion by exposing cells to a relatively high 
concentration of PEG for a short time. However, despite numerous attempts to fuse 
human monocytes with either U937 TK" or THP-1 HGPRT" cells, no fusion products 
were isolated. In most experiments a few large cells were observed to remain viable for 
many weeks post-fusion, but no evidence of cell replication was observed. Therefore, it 
was decided that it would be necessary to develop a method to quantify fusion 
efficiency, so that protocols could be optimized to maximize the chance of isolating a 
human hybridoma.
Development of an assay to select conditions favouring fusion was based on the results 
reported by Blow et al. (1978). These authors reported that increased leakage of 
45Ca2+ into PEG-treated erythrocyte ghosts correlated with an increase in fusion 
efficiency. In the current study, results from an initial experiment demonstrated that 
uptake of DCFH-DA could be used to indicate cellular permeability and therefore, 
indirectly indicate conditions that favoured PEG-induced fusion. The results showed 
that the intensity of green fluorescence,(resulting from the intracellular accumulation of 
polar DCF), increased in a dose-related manner with the concentration of PEG, reaching 
a maxium intensity with 40% PEG. This correlates to the range of PEG concentrations 
— (35 -50%)-that are reported to induce^Mgh fusion rafesrin association with-minimal 
toxicity (e.g. Galfre et al., 1977). The reported successful fusions of human 
macrophages and U937 HGPRT" cells utilized 45% (Sperber etal., 1990a) and 50% 
PEG (Woo et al., 1988), which are also within the range observed to enhance cellular 
permeability. The concentrations at which PEG is reported to mediate fusion (35 - 
50%) coincide with the concentration at which PEG can bind all of the water molecules
present in the solution (38 - 45%; Baran et al, 1972). Interestingly, at the highest 
concentration of PEG (55%) median fluorescence intensity was observed to be lower 
than for the controls. This indicates that at such high concentrations PEG was poorly 
tolerated by the cells. The basis for this toxicity may relate to the osmotic pressure 
exerted by the high concentration of PEG, which would tend to dehydrate the cells. 
However, it is also possible that high concentrations of PEG induced damage to the cell 
membrane, allowing the polar fluorescent product to leach out of the cells. These 
results indicated that flow cytometry could be used to monitor conditions that enhance 
cellular permeability and therefore, indirectly indicate conditions favouring fusion. The 
method could also distinguish protocols that may result in cytotoxicity, by indicating 
conditions that resulted in loss of the fluorescent product from cells.
13.1.2 Use of DMSO to enhance fusion efficiency
The inclusion of 5% dimethyl sulphoxide (DMSO) in PEG solutions has been reported 
to enhance the efficiency of fusion (Norwood et al., 1976). Although DMSO is 
potentially toxic to cells, these authors showed that the viability of human diploid cells 
was not significantly decreased by a 1 minute exposure to medium containing 44% 
polyethylene glycol and 10% DMSO. In the present studies, results of experiments 
where 5% DMSO was included with 45% PEG, also indicated that during a short 
exposure the compounds were tolerated at this concentration. The precise mechanism 
by which DMSO enhances fusion efficiency has not been elucidated. However, 
treatment of monolayers of phosphatidyl choline and phosphatidyl ethanolamine with 
both PEG and DMSO has been reported to lead to a decrease of the surface potential 
(Maggio et al., 1976). This could facilitate close contact of cells, a prerequisite for 
fusion, which would normally be inhibited by electrostatic repulsion. In the current 
study, an experiment was carried out to investigate conditions that favoured fusion of 
three monocytic cell lines. DCFH-DA and untreated cells were mixed in a 20 : 80 ratio 
and then exposed for 1 minute to 45% PEG in the presence or absence of 5% DMSO. 
The results indicated that inclusion of 5% DMSO did not enhance permeability of THP- 
1 HGPRT" or of THP-2 TIC" cells to DCFH-DA (when compared to cells treated with 
45% PEG alone) suggesting that DMSO was not enhancing fusibility of these cells.
- However, when the experiment was repeated using U937 TK" cells, the fluorescence of 
cells treated with 45% PEG/5% DMSO was much lower than that of similar populations 
that had been treated with 45% PEG alone. This decrease in fluorescence indicated that 
that cells treated with 45% PEG/5% DMSO contained less fluorescent product than the 
appropriate control population. It is possible that inclusion of DMSO had interfered 
with enzyme activity in the U937 TK" cells, restricting conversion of DCFH-DA to the
fluorescent product. However, it is more likely that the reduced fluorescence intensity 
indicated that polar DCF was leaching from the cells, either as a result of the osmotic 
gradient exerted by the solution, or as a result of damage to cell membranes. This 
suggested that treatment of U937 TK" cells with 45% PEG/5% DMSO induced toxicity 
that was not seen when the same cells were treated with 45% PEG alone. These results 
indicate that the inclusion of 5% DMSO would not enhance fusion efficiency of either 
THP-1 HGPRT" or THP-2 TK" cells and would be poorly tolerated by U937 TK" cells. 
These conclusions are similar to those reported by Fazekas de St. Groth and 
Scheidegger (1980). These authors reviewed the success of fusion protocols and 
concluded that DMSO should only be included where fusion conditions were 
suboptimal. A  further point to note is that DMSO can induce myeloid cells to 
differentiate. Exposure of HL-60 cells to 1.5% DMSO induces growth arrest and 
subseqent differentiation into cells with granulocytic characteristics (Collins et al,
1978). Also, results reported by Kitano et al (1990) suggest that DMSO can induce 
differentiation of THP-1 cells. Obviously, arresting cell growth would reduce the 
chances of isolating hybridomas capable of replication. It is therefore recommended 
that DMSO should not be included with PEG for fusions carried out in an attempt to 
isolate novel human macrophage hybridomas.
13.2 FAILURE TO ISOLATE HUMAN MACROPHAGE HYBRIDOMAS
13.2.1 Direct demonstration of fusion
In the present studies, a series of experiments investigated the permeability changes of 
PEG-treated cells. The results indicated that a 1 minute exposure of THP-1 HGPRT" 
cells to 45% PEG 4000 resulted in maximum uptake of DCFH-DA, suggesting that 
these conditions would be optimal for mediating fusion. In a further series of 
experiments, fusions were directly demonstrated by mixing cells stained with DCFH-DA 
(green) and with HE (red). Exposure to PEG resulted in the formation of hybrid cells, 
that could be identified by dual colour fluorescence. The method was only semi- 
quantitative as only fusions of green- to red-labelled cells could be detected. However, 
when THP-1 HGPRT" cells were treated using the protocol that had been identified as 
optimal using permeability studies, (45% PEG/1 min), the minimum fusion rate was 
estimated to be in the region of 0.1%. This compares well to the highest fusion rate 
(0.03%) achieved by Sperber et al (1990a). However, although unusually large cells 
were observed to remain viable for periods of many weeks following fusion using the 
conditions outlined above, no replication of hybridomas was observed in the current 
studies.
13.2.2 Isolation ofHAT-sensitive fusion partners
Reports of successful isolation of human macrophage hybridomas have all utilized U937 
cells reported to have HGPRT" phenotypes, as the fusion partners. Woo et al. (1988) 
and Shimoda et al. (1988) isolated their drug-resistant clone of U937 cells following 
culture in increasing concentrations of 8-azaguanine. Other authors increased the 
probability of obtaining drug-resistant clones by treating U937 cells with the mutogen, 
ethylmethanesulfonate, prior to growth of cells in high concentrations of 6-thioguanine 
(Sperber et al., 1990a; Shaked etal., 1991). In the current study, a similar protocol 
exposing THP-1 cells to either increasing concentrations of 6-thioguanine or to 5- 
bromo-2-deoxyuridine, in the absence of a mutagen, was successfully used to isolate 
HGPRT" and TK" clones, respectively. All groups reported that the HGPRT” nature of 
isolated U937 clones was confirmed by demonstration of sensitivity to HAT medium.
In comparison to the results reported for the U937 HGPRT" clones, the THP-1 
HGPRT" clone isolated in the present study appeared more sensitive to HAT medium. 
Exposure of THP-1 HGPRT" cells to HAT medium resulted in cell death within 2 days, 
whereas the U937 HGPRT" cells were reported to die within 5 days (Bohbot et al.,
1993; Woo et al., 1988). Karyotype analysis revealed differences in the number of 
chromosomes present in the drug-marked U937 cells isolated by the different groups. 
Shimoda et al. (1988) report that the modal chromosomal number was 57 (range 40 - 
70), whilst a range of 43 - 83 chromosomes were recorded by Sperber et al. (1990a).
In the present studies THP-1 HGPRT" clones were observed to have a diploid number 
of chromosomes (45 +/- 9). This is similar to the diploid (46, XY ) number of 
chromosomes recorded 8 months after the initial isolation of parental THP-1 cells 
(Tsuchiya et al., 1980). By contrast, the THP-2 TIC" cells were predominantly 
tetraploid (88 +/- 4). This highlights the possibility of obtaining an enhancement of 
chromosome number during experiments designed to select drug-resistant clones. 
Another group, that reported failed attempts to isolate macrophage hybridomas, indicate 
that the modal number of chromosomes in U937 HGPRT" cells was 62 (Bohbot et al.,
1993). Such inter-laboratory variations in cell lines are not unusual. It is well known 
that over a period of years in culture, cells lines can alter their phenotype and give rise to 
different strains which may contain different numbers of chromosomes (De Carli and 
Lariza, 1978). Changes in chromosome number may occur spontaneously during 
qulture as a result of duplication or distribution errors (Pera and Rainer, 1973; Rizzoni 
etal., 1974).
Demostration of sensitivity to HAT medium is insufficient to prove that a clone is 
HGPRT”. Expression of the HGPRT gene can be inhibited by methylation of cytosine 
residues in the gene sequence (Yen et al, 1984). In cell culture, genes inactivated by
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methylation can be partially or totally reactivated in the presence of the methylation 
inhibitor 5-azacytidine (Jones, 1985; Vesely, 1985). There is evidence that cells with 
HGPRT" phentotypes and HGPRT+ genotypes can re-express the silent HGPRT gene as 
a result of reactivation during the selection procedure (Milman et a l 1976). It is 
possible that such gene reactivation could account for at least some of the reported 
successful isolations of human macrophage hybridomas. An example of this would be 
the ’hybridomas’ described by Woo et al. (1988). The hybrid nature of their fusion 
products was confirmed by recording higher chromosome numbers and different surface 
antigen expression of the hybridomas compared to the controls. Thus, it cannot be 
ruled out that two U937 HGPRT" cells had fused resulting in the reactivation of a silent 
HGPRT" gene to produce a cell with a higher number of chromosomes than the parental 
cells and the capacity for autologous replication. A  change in the expression of one 
gene could easily be accompanied by changes in others, accounting for the differences in 
the phenotype of the hybridomas compared to that of the parental cells. Bohbot et al. 
(1993) suggest that treatment of cells with 5-azacytidine prior to exposure to HAT 
medium could be used as a simple method to confirm the HGPRT" status of a drug- 
resistant clone.
13 2.3 Macrophages may negatively regulate the replication of hybridomas 
Fusion of human cells generally results in the production of unstable hybrids. A  
common feature of prolonged in vitro culture of human-human hybrids is a random loss 
of chromosomes (Mayer et al., 1982). Obviously, loss of chromosomes can 
significantly alter the phenotype of hybrid cells, and in particular loss of the 
chromosomes controlling replication will result in loss of capacity for autologous 
growth. This could account for the failure of some fusion products to grow, but it is 
normal to observe at least some rounds of replication during which the genes are lost.
In the present studies, large cells that were observed following fusion of human 
monocytes with THP-1 HGPRT" cells showed no evidence of replication during several 
weeks in culture. Similarity, Bohbot et al. (1993) reported the successful fusion of 
U937 HGPRT" cells with human macrophages giving rise to heterokaryons which 
survived for weeks in HAT medium without dividing. However, despite over 50 
attempts and the use of various methods, these authors were unable to isolate human 
macrophage hybridomas. The HGPRT" status of their U937 fusion partners had been 
confirmed, indicating that the cells capable of surviving in selective medium must have at 
least some human macrophage genes. These results indicate that macrophage genomes 
can exert a negative regulatory mechanism on the proliferative capacity of the monocytic
tumour cells, and suggest that it may not be possible to isolate a true human macrophage 
hybridoma cell line.
13.2.4 Meihylation of DNA
It is of interest to note that mechanisms similar to those described for regulation of 
HGPRT gene expression, have been postulated to play a role in the maintenance of HIV  
D NA  in a latent state in HTV-1 infected individuals. Such individuals characteristically 
have a long period of clinical latency before the development of overt disease, and it is 
possible that viral expression is regulated by DNA methylation. A  cellular model has 
been developed to study the biochemical basis of HIV latency. Reporter genes (under 
the control of the HIV LTR) were introduced transiently or permanently into cells by 
electroporation. These reporter genes were stably transfected into U937 cells (Patel et 
al, 1992). DNA methylation may be involved in protecting DNA against restriction 
endonucleases, regulating gene expression in eukaryotes, enhancement of mutation and 
recombination rates and may influence viral replication and viral latency. The control of 
expression of a number of genes, including HGPRT, has been shown to be modulated by 
the degree of methylation (Milman et al., 1986). Treatment of HIV latently or 
chronically infected human monocytic cell lines with 5-azacytidine can induce or 
enhance viral replication (Mikovits et al, 1990). 5-azacytidine is a nucleoside analogue 
that was originally developed as a cancer chemotherapeutic agent, that can prevent 
methylation of DNA, but also can alter other biochemical events within the cell (Vesely, 
1985). DNA methylation affects DNA-protein interactions and is thought to preserve 
the functionally latent state of HIV. The regions of the HTV LTR sequences sensitive 
to inactivation by methylation were mapped by deletion analysis and were shown to 
contain the NFkB binding sites. Bednarik et al (1990) demonstrated the existence of 
two CpG sites in the HIV LTR which can silence transcription of both reporter genes 
and infectious proviral DNA when methylated. The transcriptional block was overcome 
by the presence of tat without significant methylation of the HIV LTR.
13.3 MEMBRANOUS STRUCTURES-IN THE-GYTOPLASM OF CELLS 
BLOCKED IN  Gl/GO AND IN  G2/M
13.3.1 Paired cistemae
Since attempts had failed to isolate a novel macrophage hybridoma with more mature 
characteristics than the available myeloid cell lines, it was decided that the immature cell 
lines would be used for further experiments in the current studies. A  series of titration
experiments identified a range of compounds that could be used to reversibly inhibit 
cellular replication at various stages of the cell cycle. The functional phenotype of cells 
was investigated, in order to identify any changes that may affect the ability of H IV -1 to 
infect the cells. The ultrastructure of treated cells was also investigated using 
transmission electron microscopy. The results indicated that when U937 TK" cells 
were blocked in the cell cycle by incubation in the presence of a variety of chemicals (18 
hours, 37°C/5% C02), the ultrastructure was generally similar to that of exponentially 
replicating control populations. However, a striking difference was the presence of 
numerous structures consisting of layers of smooth membrane in the cytoplasm of cells 
that had been blocked either in Gl/GO (by 4 mM hydroxyurea or 300 JiM mimosine) or 
in G2/M (by 1 x 10_8M  colchicine or 75 JiM GR39457A). The presence of similar 
structures has been previously been observed in Chinese Hamster Ovary cells that had 
been treated with colcemid (Brinkley et al, 1967). These structures resembled paired 
cisternae (PC) which are defined as consisting of two or more flattened, membrane- 
bound saccules (cisternae), stacked in parallel arrays within the cytoplasm and separated 
by 15 - 20 nm wide intercistemal partitions of cytoplasm (Epstein, 1961). PC have 
been observed in a wide variety of rapidly proliferating normal and neoplastic cells in 
vivo, as well as in similar cells in vitro (Leak et al, 1967; Kamio et al, 1977; Taura, 
1978). These membranous organelles are described as conspicuous within the 
cytoplasm of mitotically active cells (Hanaoke and Friedman, 1970). Apart from paired 
cisternae, the structures have been assigned a variety of other names, most commonly 
intracytoplasmic confronting cisternae (Kumegawa et al, 1968; Palisano, 1993). 
However, other terms ascribed to the structures include pentalaminar membranous 
structures (Napolitano and Gange, 1963), spindle lamellas (Warren et al, 1972), 
stacked remnants of nuclear envelopes (Barer et al, 1959; Chang and Gibley, 1968), 
intracistemae membranes (Chew et al, 1986) and a peculiar structure of membranes 
(Procicchiani etal, 1968).
13.3.2 Function of paired cisternae
Considerable uncertainty exists regarding the origin, evolution and potential function of 
PC in the cell cycle. The presence of PC in mitotically active cells has been associated 
with the dissolution <and regeneration of nuclear envelopes, duringjliyisiaa o f neoplastic 
cells (Buck, 1961; Taura, 1978). Evidence that a minimum of 60% of nuclear 
envelope proteins and 50% of nuclear envelope phospholipids are present during G2 of 
the cell cycle and are reutilized in the reformation of nuclear envelope following mitosis 
in Chinese Hamster Ovary cells supports this hypothesis (Conner et al, 1980). A  
model linking the genesis of paired cisternae with replication of nuclear membrane has
been proposed by Sato et al (1982). Based on their observations these authors suggest 
that grouped intracytoplasmic vesicles observed in the cytoplasm of mitotically active 
tumour cells derive from the nuclear membrane of early prophase cells. These vesicles 
flatten and assume the stacked conformation typical of PC. During late anaphase and 
early telophase, PC surround condensing daughter chromatin and subsequently undergo 
transformation into vesicles with prominent intervesicular septa. Coalescence of these 
vesicles results in the formation of perinuclear cisternae, which create the nuclear 
membranes surrounding the nuclei of daughter cells.
However, in the present studies, PC were observed in the cytoplasm of a dividing cell, 
where the daughter nuclei were surrounded by intact nuclear membranes. This suggests 
that PC may be associated with other functions. Several other investigators have 
likewise reported observing PC in interphase cells immediately after mitosis, and it has 
been suggested that PC provide a source of rough endoplasmic reticulum (RER) in the 
daughter cells (Epstein, 1961; Chang and Gibley, 1968; Hanaoka and Friedman, 1970). 
The cytoplasm of the dividing cell observed in the present studies contained little or no 
RER, giving support to this hypothesis. However, an investigation of the formation of 
PC in HeLa cells indicated the presence of PC in interphase cells, despite the presence of 
both intact nuclear membranes and extensive RER (Palisano, 1993). Chew (1986) 
suggested that newly synthesized membranous protein and phospholipid molecules may 
polymerize spontaneously. If these new membranes joined to existing endoplasmic 
reticulum they would form separate cisternae, and the result would be the multiplication 
of endoplasmic reticulum. Similar events could also account for the replication of 
nuclear membranes. It is likely that spontaneous polymerization of phospholipids and 
proteins may contribute to the formation of PC within the cytoplasm. These 
membranous organelles may then provide a reservoir of plasma membrane that could be 
used during cell replication in the genesis of nuclear membranes, endoplasmic reticulum, 
or even cell membranes.
13.3.3 Genesis of paired cisternae in cells treated with thymidine or hydroxyurea 
In the present studies, PC were infrequently observed in exponentially replicating U937 
. TK"-~g©11s .£>jun the cytoplasm of-similar ceflsThatJiadhee^treate4~with-0.25-mM . 
hydroxyurea, to block the cells in S phase. These results are consistent with reports of 
PC in interphase cells, and suggest that PC are transient stuctures (Epstein, 1961; Sato 
et al., 1982). The complete absence of PC from the cytoplasm of cells treated with 4 
mM thymidine in the present study correlates with the findings reported by Palisano 
(1993). PC are prominent organelles in dividing HeLa cells, but when the cells were
synchronized using a double exposure to 2 mM thymidine, PC were eliminated. These 
authors suggest that formation of PC reflected the speed that HeLa cells entered mitosis. 
The rapid cycling of these cells may provide insufficient time for the normal breakdown 
of nuclear envelope. Instead, the nuclear envelope may persist and fold-back on itself, 
as has been described for some human tumour cells (Hanaoka and Friedman, 1970). It 
is possible that PC are infrequently observed in most mitotic cells because normally cell 
division is highly regulated, and break down of nuclear membrane occurs. However, it 
is difficult to envisage a mechanism by which high concentrations of exogenous 
thymidine could promote the breakdown of nuclear membranes. Excess thymidine 
blocks the cell division cycle at the Gl/S border, and depresses uridine incorporation 
into both nucleolar and cytoplasmic RNA (Kasten et al, 1965). It is possible that 
excess thymidine interferes with the breakdown of nuclear envelopes by interfering with 
RNA synthesis and, therefore, protein synthesis of one or more proteins which may be 
necessary for membrane diassembly. Alternatively, if PC form as a result of 
spontaneous polymerization of membrane proteins and phospholipids, then excess 
thymidine may prevent the synthesis of an essential protein(s). The latter hypothesis is 
supported by the observations made during the present study that treatment with high 
concentrations of hydroxyurea blocked U937 TK" cells in Gl/GO and resulted in the 
formation of well developed PC; whilst treatment with 0.25 mM hydroyxurea caused 
cells to accumulate in S phase, but was not associated with enhanced levels of PC. 
Similar to thymidine, high concentrations of exogenous hydroxyurea can inhibit DNA  
synthesis by disrupting deoxyribonucleotide pools (Skoog and Nordenskjold, 1971). 
However, hydroxyurea treatment results in little or no reduction in protein synthesis and 
therefore cells with low DNA but high protein content accumulate (Adams et al, 1986). 
Results indicated that large numbers of PC had formed in the cytoplasm of 4 mM 
hydroxyurea treated U937 TK" cells, suggesting that synthesis of membrane constituents 
had not been interupted by treatment with the chemical. Furthermore, at a reduced 
concentration of hydroxyurea (0.25 mM) the rate of DNA synthesis was greatly 
reduced, with cells tending to accumulate in S phase. Similar results were reported by 
Walters et al (1975) who used high concentrations of hydroxyurea (4 mM) to block 
Chinese hamster ovaiy cells in Gl, but failed to prevent entry into S phase. Cells 
treated with 0.25 mM hydroxyurea were observed to contain few PC suggesting that 
delayed'progression through the cell cycle had allowed normal breakdewn- offtho nudea? 
membrane.
13.3.4 Paired cistemae in cells blocked in G2/M
Further reports indicate that depolymerization of microtubules, induced by treatment of 
cells with navelbine, was associated with hypertrophy of endoplasmic reticulum and
formation of PC (Paintrand and Pignot, 1983). Similarity, in the present studies, when 
colchicine (which inhibits mitosis by depolymerizing microtubules) was added to U937 
TK" cells, PC were frequently observed in the cytoplasm. These results suggest a link 
between polymerization of microtubules and formation of PC. PC were also frequently 
observed in U937 TK" cells blocked in G2/M following treatment with 75 pM  
GR39457A. The mechanism of action associated with the ability of this compound to 
inhibit metaphase has not been elucidated. It is not therefore possible to speculate 
whether formation of PC is related to cell cycle stage or to induction of defects in 
cellular metabolism including defective microtubule polymerization.
In summary, the results discussed above suggest several possible mechanisms by which 
PC may form. It would however, appear that formation of PC is either related to the 
rate of progression through the cell cycle or to abnormal cellular metabolism, rather than 
being induced in specific phases of the cell cycle. It is possible that PC form from 
fragments of the nuclear envelope that persist because they are not degraded during 
prophase, as they would normally be in cells that undergo slower, more regulated cycles 
of mitosis. PC fail to form when chemicals, including thymidine and low concentrations 
of hydroxyurea, are used to slow the rate of replication, allowing normal breakdown of 
nuclear membranes. However, when DNA  synthesis is prevented by high 
concentrations of hydroxyurea, it is likely that the uninterupted synthesis of membrane 
components would lead to spontaneous polymerization and result in the formation of 
PC. The observation that PC are present in cells treated with agents that interfere with 
microtubule polymerization suggests that the cytoskeleton may also play a role in the 
formation of PC. However the importance of this observation, and possible 
mechanisms of action remain unclear.
13.3.5 Relevance of paired cisternae to HIV infection
In the current study, analysis of cell cycle distribution indicated that treatment of U937 
TK" cells with 4 mM hydroxyurea, 300 pM mimosine and 4 mM thymidine had all 
blocked cells in Gl/GO. PC were abundant in the cytoplasm of cells treated with the 
first two compounds, but in contrast were completely absent from the 4 mM thymidine 
Treated cells, Jnterestiagty,. examination-of these. trea.ted.celL populations 21. Mays after 
infection with H IV -Irf revealed that although PC were still prominent in the cytoplasm 
of the 4 mM hydroxyurea and 300 pM mimosine treated U937 TK" cells, they remained 
absent from 4 mM thymidine treated cells. HIV-1 virions budding into intracytoplasmic 
vesicles were commonly observed in cells that had been treated with either 4 mM 
hydroxyurea or 300 pM mimosine. However, very few such cytoplasmic virus-
containing vesicles were observed in the 4 mM thymidine treated cells. Similarity, cells 
blocked in S phase by exposure to 0.25 mM hydroxyurea contained relatively few PC at 
the time of infection, and low levels of intracellular virus 21 days post-infection. 
Treatment of cells that resulted in accumulation of cells in G2/M, induced PC to form 
and subsequently contained many intracellular virus-containing vesicles. These results 
suggest that presence of PC in the cytoplasm of U937 TK" cells during infection with 
H IV -Irf enhances intracellular replication of virions. However, virions were never 
observed associated with PC, suggesting that they were not budding into these 
membranous organelles. The significance of this observation is not known.
The control exponentially replicating U937 TK" cells provided an unexpected result. At 
the time of infection these cells contained few PC. However, when samples were 
examined 21 days after infection with HIV-1RF many PC were present in the cytoplasm, 
and intracellular virus-containing vesicles were common. This indicates that HIV-1 
infection could induce PC to form. If PC formation is linked to rapid cellular 
replication rate, this would suggest that the doubling time of H IV -1 infected cells was 
reduced in comparison to the controls. This seems unlikely, as uninfected U937 TK" 
cells were associated with high replication rates, being capable of doubling every 24 
hours. It is more likely that replication of HTV-1 was affecting cellular metabolism. 
Spontaneous polymerization of newly synthesized membrane was suggested to 
contribute to the formation of PC in cells that have been treated with compounds that 
prevent DNA synthesis, without affecting protein synthesis. Viral replication may slow 
replication of host nucleic acid by competing for deoxynucleotides. dNTPs, required 
for reverse transcription and the replication of DNA are obtained by scavenging 
exogenous dNTPs, and reduction of endogenous ribonucleoside diphosphates. The 
concentrations of dNTPs in eukaryotic cells are highly asymmetric (Cohen et al, 1983), 
vary greatly between cell types and fluctuate during the cell cycle (Mun and Mathews, 
1991). Competition for dNTPs could slow the replication of host DNA, without 
affecting protein synthesis, resulting in the formation of PC by the same mechanisms that 
occur in 4 mM hydroxyurea treated cells.
13.4 EFFECT OF CHANGES IN  dNTP POOLS ON REPLICATION OFHIV-1
13.4.1 Effect of hydroxyurea treatment on HIV-1 RF replication in U937 TK" cells 
In the present study, a significantly higher intensity of fluorescence was recorded for 
U937 TK" cells that had been treated for 18 hours with 0.25 mM hydroxyurea prior to
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incubation with FITC-conjugated monoclonal anti-CD4 antibody, in comparison to that 
recorded for 4 mM hydroxyurea treated or control exponentially replicating cells. The 
results also suggested that the membrane of the 0.25 mM hydroxyurea treated cells was 
less fluid than that of the control population, a factor which may contribute to increased 
receptor availability. The reason for the enhanced binding of monoclonal anti-CD4 by
0.25 mM hydroxyurea treated cells was not elucidated. However, in comparison to the 
controls and 4 mM hydroxyurea treated U937 TK" cells, significantly enhanced binding 
of monoclonal antibodies to CD lib, CD 18 and CD71 was also observed on the 0.25 
mM hydroxyurea treated population. It is unlikely that treatment with 0.25 mM 
hydroxyurea would up-regulate expression of all these unrelated antigens, especially as 
expression was not enhanced on the 4 mM hydroxyurea treated cells. This indicates 
that enhanced binding of monoclonal anti-CD4 was likely to relate to a decrease in 
membrane fluidity and a resultant increase in receptor availability. No other myeloid 
characteristics of the hydroxyurea treated cells were observed to be significantly 
different from that of the control population.
Despite enhanced binding of monoclonal anti-CD4 antibodies, infection studies indicated 
that in 0.25 mM hydroxyurea treated U937 TK" cells the levels of intracellular p24 
antigen at 15 and 25 days post-infection with HIV-Irp were not significantly different 
from the controls. Likewise, treatment with either 4 inM hydroxyurea or 4 niM 
thymidine did not significantly affect replication of HIV--1RF in U937 TK" cells. This 
suggests that CD4 expression was not affecting replication of the virus and was not 
therefore acting as the major receptor mediating HIV-Irp infection of U937 TK" cells. 
However, it is possible that treatment of cells with hydroxyurea was interfering with 
viral replication, thus masking any possible increase in infection due to enhanced CD4 
expression.
13.4.2 Mechanism of action of hydroxyurea and thymidine
Hydroxyurea is a potent inhibitor of the enzyme ribonucleotide reductase which is a key 
enzyme in the balanced regulation of dNTP pools. The enzyme catalyses the reduction 
of ribonucleoside diphosphates (CDP, ADP, GDP, and UDP) to their corresponding 
— deoxyribonudeoside diphosphates (Rsichard-and Ehrenberg, 1-9831 -  Addition of 
exogenous deoxyribonucleosides to culture medium can alter intracellular dNTP pools. 
For example, the addition of thymidine results in a 5 - 10-fold reduction in dCTP and a 
corresponding increase in TTP levels (Dahbo and Eriksson, 1985). Addition of 
thymidine to H9 and U937 cell lines results in a depletion of intracellular dCTP which 
can be reversed by the addition of deoxycytidine. Replication of HTV-1 LAI was shown
to be sensitive to the intracellular concentrations of dNTPs (Meyerhans et al, 1994). A  
dramatic reduction of virus replication in thymidine treated H9 and U937 cells could be 
reversed by the addition of dCyd. Treatment of human PBMC with hydroxyurea 
resulted in a reduction of 90% of dATP pools, 40 - 80% of dCTP and dGTP pools and 
an increase in TTP levels. Infection of human PBMC with HIV-1 was carried out such 
that hydroxyurea was present during the first 5 hours, the period when provirus 
synthesis was occurring. Viral replication, assessed by RT activity in the supernatant, 
was abolished by this treatment, but the effect could be reversed by deoxyadenosine 
(Meyerhans et al, 1994). It is possible that a highly biased ratio of dCTP/TTP may lead 
to an increased frequency of mutation, as has been shown for adenosine 
phosphoribosyltransferase in mammalian cells (Pheare* al, 1987; Meuth, 1989). 
Retroviruses are uniquely sensitive to the mutagenic effects of dNTP precursor 
imbalances. Reverse transcriptase has no 3* exonuclease activity and only positive- 
strand DNA synthesis is subject to proofreading by cellular enzymes after proviral 
translocation to the nucleus. Whilst replication fidelity produces many antigenic 
variants, it may also result in production of higher levels of defective progeny, as well as 
altering the overall viral replication kinetics. It has been suggested that guanine to 
adenosine hypermutation of the HIV genome is associated with dNTP pool imbalances 
(Vartanian etal, 1991).
In the present studies, hydroxyurea and thymidine were selected to block cellular 
replication in Gl/GO at high concentrations, and in S phase using lower concentrations. 
As mentioned before, these compounds can interfere with DNA  replication by causing 
imbalances in intracellular dNTP pools (Reichard and Ehrenberg, 1983; Dahbo and 
Erikkson, 1985). Thus, at high concentrations DNA synthesis can be prevented, and at 
lower concentrations the rate of DNA  synthesis is greatly reduced. This would increase 
the time taken for cells to progress through S phase and result in the observed 
accumulation of S phase cells. Inhibition of DNA synthesis can prevent reverse 
transcription of H IV -1 nucleic acids and prevent viral replication (Meyerhans et al,
1994). In the current studies, the protocol for infection of cells was carefully selected 
in order to avoid potential anti-viral activity. In all MTT assays cells were washed 
immediately prior to addition of H IV -1 and in all other assays, compounds were 
removed by dilution/centrifugation after incubation of cells in the presence of virus for 
90 minutes. These protocols ensured that extracellular compound was removed prior 
to reverse transcription of viral nucleic acids. The results indicated that in comparison 
with controls, infection of U937 TK" cells treated with either 0.25 mM or 4 mM 
hydroxurea, or 4 mM thymidine, with HTV-Irf did not result in any significant changes 
to levels of intracellular p24 antigen at 15 or 25 days post-infection. This suggested
that the selected protocols had not interfered with replication of HIV-1. However, it is 
possible that limited antiviral activity associated with hydroxyurea and thymidine 
treatments of the cells may have masked any enhancement of infection related to the 
stage of cell cycle.
13.5 RELATIONSHIP OF SURFACE ANTIGEN EXPRESSION TO INFECTION 
WITH HIV-1
13.5.1 Expression of CD4
The CD4 molecule has been identified as the receptor for HIV-1 (Maddon et al., 1986). 
In vivo the CD4 glycoprotein is mainly expressed on T-lymphocytes (that are MHC class 
II-restricted in their functions) and by cells of the mononuclear phagocytic lineage 
(Sattentau and Weiss, 1988). Expression of CD4 by peripheral blood monocytes is 
much lower in comparison to levels expressed by T-lymphocytes (Filion et al., 1990). 
Early studies suggested that susceptibility to HIV infection correlated with the level of 
CD4 expression on host cells (Asjo et al., 1987). However, further studies have 
indicated that expression of this molecule does not necessarily correlate with 
susceptibility of host cells to infection with HIV. Indeed, certain CD4 negative cells 
can be infected by the virus (e.g. Tateno et al., 1989). In the current studies, THP-1 
cells were shown to express CD4, confirming the observations reported by Faltynek et 
al. (1989). Data from the current study indicated that in comparison to THP-1 cells, 
U937 and U937 TIC" cells expressed higher levels of CD4. U937 cells have previously 
been reported to have high intensity CD4 expression (Stewart et al., 1986). It has been 
shown that productive HIV-1 infection of THP-1 cells with monocytotropic isolates can 
only be established only when these cells have been induced to differentiate, a process 
that results in the down-regulation of CD4 (Meylan et al, 1993). This highlights the 
complex nature of the initial interaction between the virus and the host cell receptor.
Uninfected U937 cells are reported to form syncytia when mixed with HIV-1 producing 
cells, a process that can be blocked using anti-CD4 antibodies (Clapham etal, 1987). 
However, such cytopathology was rarely seen during examination of H IV -1 infected 
cultures of U937 cells in the present studies. U937 TK" cells that had been shown to 
express high levels of surface CD4 rarely formed syncytia, despite the observation that 
HTV-Irp virions were maturing by budding from the host surface membranes, and that 
not all cells were infected. Interestingly, H9 cells, which were susceptible to HTV- 
induced cytopathology, were shown to express significantly lower levels of CD4 than 
U937 TK" cells. This suggests that either the formation of syncytia is dependent on a 
property of CD4 associated with the type of cell that it is expressed on, or that other
mechanisms are important. It is known that CD4 expression is differentially regulated 
in lymphoid and myeloid cells. The antigen is maintained on the surface of lymphocytes 
by exclusion from coated pits; this is thought to occur as a result of the non-covalent 
association of the molecule with p56,ck (Veillette et al, 1988). By contrast, in myeloid 
cells where the molecule is not associated with this tyrosine kinase, CD4 is constitutively 
internalized and recycled (Sorio et al., 1993). However, formation of syncytia requires 
fusion of cell membranes and it is possible that monocyte cell lines fuse less readily than 
T-cell lines.
Infection of cells by HIV-1 is followed by the disappearance of CD4 from the host cell 
membrane (Geleziunas et al, 1991; Hoxie et al, 1986). Alterations in the expression 
of other surface antigens has been associated with HIV infection e.g. HLA antigens, 
(Eales et al, 1988; Schols et al, 1992) and the CD3, CD8 and CD11 antigens 
(Stevenson et al, 1987). The surface antigen expression of H9 cells, and of similar 
cells that had been infected with HIV-1 was investigated using immuno-electron 
microscopy (Meerloo et al, 1993). These authors showed that the level of 
immunolabelling for CD1 la and CD54 on infected cells was greater than on uninfected 
cells, presumably as a result of activation during viral synthesis. Furthermore, these 
authors demonstrated that virions generated in HIV-1 infected cells concentrated host- 
derived molecules, including the integrin molecules into their envelopes. The CD54 
antibodies used in the study recognize epitopes involved in cellular adhesion (Bloemen 
et al, 1992). Incorporation of host-derived molecules into viral envelopes may 
therefore provide a potential mechanism by which virions could mediate cytopathology. 
The LFA-1 molecule, which is the ligand for CD54, has been shown to be involved in in 
vitro syncytium formation by HIV-1 infected cells (Hildreth and Orentas, 1989;
Valentin et al, 1990b), but not in HIV spread and virus replication (Pantaleo et al, 
1991).
13.5.2 Contribution of integrins to formation of syncytia
The phorbol ester PMA strongly inhibits HIV-1 induced syncytium formation. It has 
been suggested that this inhibitory effect is due to transient down-modulation of CD4 
(Chowdhury et al, 1.993). - However, hybrid cells expressing truncated or hybrid CD4- 
molecules (which are not down-regulated in response to PMA; Bedinger et al, 1988), 
failed to fuse with CD4" cells expressing HTV-1 gp 120/gp41 or with chronically infected 
H9 cells (Golding et al, 1994). The inhibitory effect of PM A has been blocked by 
staurosporine in a dose-dependent fashion, suggesting that it is mediated by protein 
kinase C. These results indicate that PMA inhibits CD4/gpl20/gp41 fusion by
modulating an accessory molecule in the target CD4 positive cells. It has been 
suggested that integrin molecules may contribute to syncytium formation by mediating 
intracellular adhesion and phorbol ester treatment can induce significant alteration in the 
expression of integrin molecules. For example, results obtained in the current study 
indicated that within hours of exposure to PMA, U937 cells become adherent to plastic. 
This alteration of phenotype correlated with a significant upregulation of CD1 la 
expression. CD1 lc was not found to be expressed on unstimulated U937 cells. 
However, expression of this antigen by U937 cells can be induced by treatment with 
PM A (Bellon et al, 1994). Expression of CD 18 by human monocytes was observed to 
increase by 40% in response to PMA (Wallis et al, 1985). By contrast, expression of 
CD54 (ICAM-1) by THP-1 cells (Perez etal, 1993) and of CD49d/CD29 (VLA-4) by 
U937 cells (Bellon et al, 1994) was down-modulated following exposure to PMA.
Monoclonal antibodies to the integrins, CD1 la - c/CD 18, have also been demonstrated 
to inhibit formation of syncytia (Hildreth and Orentas, 1989). Close contact of cells 
would be required for fusion to occur and it is possible that steric hindrance, resulting 
from the binding of anti-CD 1 la to the cell surface, could maintain cells at a distance too 
great to allow fusion to occur. However, it is more likely that the integrin molecules 
exert a specific contribution to syncytial formation by functioning as adhesion molecules, 
thereby stabilizing cells in close association. This is upheld by the observations reported 
by Panteleo etal (1991) that C D lla  monoclonal antibodies blocked syncytium 
formation without interfering with HIV-1 gp!20/CD4 interactions. Monoclonal 
antibodies to CD 18, the integrin p-chain, can prevent cell free infection of U937 cells. 
These antibodies can also inhibit the formation of syncytia between HTV-1 infected 
U937 cells and CD4+ T-lymphocytes (Valentin et al, 1990b). However, the 
monoclonal anti-CD 18 antibodies did not interfere with CD4/gpl20 binding.
13.5.3 Activation of integrin molecules
Interestingly, expression of the integrin molecules CD1 la - c/CD 18 was not found to 
correlate with the microscopical growth characteristics of the monocytic cell lines. 
THP-1 and THP-1 HGPRT" cells were observed to grow as loose clumps, whereas 
THP-2 TK",- THP-2, U937 and U937 TK“ -v/sre-seen4ogr©w-as.individual cells. All of. 
the cell lines expressed both CD1 la and CD18, but only THP-1 and U937 TK" cells 
expressed CD1 lb. THP-1 and THP-2 cells expressed similar levels of CD1 la. Thus, 
the expression of CD1 lb by THP-1 cells could be related to the more adherent 
phenotype exhibited by these cells. However, U937 TK" cells expressed significantly 
higher levels of CD1 lb than THP-1 cells, whilst maintaining a non-adherent phenotype.
It should be noted that GDI lb has been identified within intracellular vesicles of 
phagocytes (Calafat et al., 1993) indicating that surface expression may not reflect the 
capacity of the cells to transcribe the protein. Only modest levels of CD1 la and CD 18 
were expressed by THP-1 HGPRT" cells suggesting that expression of other molecules 
may account for the characteristic clumped appearance of the cultured cells. However, 
there is evidence that post-translational modification of GDI 1 a/CD 18 may be required in 
order for the molecules to mediate adhesion. Hedman and Lundgren (1992) 
demonstrated alterations in the binding of CD11 a/CD 18 to its ligand CD54 in the 
absence of changes of surface antigen expression. It is now generally accepted that 
integrin molecules must be activated in order to mediate various functions. An example 
of this is that the avidity of CD11 a/CD 18 binding can be upregulated by CD 14 
(Beekhuizen etal., 1993).
13.6 H IV  INFECTION OF MONOCYTIC CELL LINES
The m V -lBa_L strain of virus can infect and integrate into host chromosomes of human 
monocytes (Weinberg et al., 1991). However, in the current study, the monocytic cell 
line U937 TK" failed to support significant levels of replication of this monocytotropic 
HIV-1 strain. This is in keeping with previous reports which have indicated that the 
parental U937 cells only support productive infection when they have been treated with 
chemicals to induce differentiation (Kitano et al, 1990). In contrast, a productive 
infection was established by the lymphotropic HIV-1RF isolate in these cells. An 
increase of permissiveness for the monocytotropic H IV -lBa.L isolate was likewise 
reported for a proportion of PMA-treated THP-1 cells. This increase in permissiveness 
for H IV -lBa_L was reported to correlate with a decrease in permissiveness for the 
lymphotropic isolate IUV-1LAI (Meylan et al, 1993). Monocytotropic strains of HIV-1 
are thought to be present in peripheral blood throughout the course of clinical infection 
(Schuitemaker et al, 1991). These virus strains are not associated with syncytia 
formation and may not replicate in T-lymphocyte cell lines. However, recent results 
suggest that monocytotropic strains of H IV -1 can be isolated from a population of T- 
lymphocytes expressing low levels of CD4 (Schmdein-JBickwafoL^1992)l.
13.6.1 Replication of HIV-1 in U937 cells
Microscopical examination of U937 cells 11 days after infection with the 
monocytotropic HTV-lBa.L isolate indicated that the virus was not inducing host cell 
lysis. Transmission electron microscopy (TEM) indicated that the level of viral
infection was very low, reflecting a deliberately low multiplicity of infection. Use of 
high titres of virus to infect cells may give artefactual results since in vivo it is unlikely 
that cells will be exposed to a high level of virus in the absence of exogenous factors 
such as interferons. Only occasional cells were observed to contain H IV -lBa.L virions. 
Stringent control of replication of another strain of virus, I IIV-1LAV, in U937 cells was 
reported by Pauza et al (1988). A  low-multiplicity of infection resulted in viral 
replication for 2.5 days, before virus production ceased. The dramatic decrease in HIV- 
1 release was shown to be due in part to reduced accumulation of cytoplasmic viral 
RNA.
In the present studies a low proportion of U937 cells was observed to be infected, with 
low numbers of H IV -1 virions present in the infected cells. Therefore, it was surprising 
that the ultrastructure of U937 cells incubated in the presence of HTV-1 Ba_L was 
strikingly different to that of equivalent uninfected cells. Numerous mitochondria and 
large amounts of plasma membrane (possibly endoplasmic reticulum) were observed in 
the cytoplasm of cells that had been incubated with H IV -lBa.L. These observations are 
similar to those reported by Pautrat et al. (1990), who describe TEM studies of U937 
cells 11 days after infection with HIV-1BRU. In contrast to uninfected cells, most HIV-1 
infected cells were seen to contain large vacuoles delineated by smooth membranes. 
Concomitant budding of virions from the host cell membrane and into cytoplasmic 
vesicles was observed. In our studies, the few H IV -lBa4 virions that were observed in 
infected U937 cells were present within intracytoplasmic vesicles. This monocytotropic 
strain of H IV -1 has also been reported to bud into intracellular vacuoles during infection 
of human macrophages (Gartner et al, 1986). Ultrastructural studies of human 
monocytes, cultured in vitro prior to infection with HIV-1, indicated that the cells were 
highly vacuolized, and that virions were restricted to intracellular vesicles (Blom et al, 
1993). Intravacuolar assembly and accumulation of H IV-1 in human macrophages, 
infected in vitro, has also been reported by Orenstein et al (1988). These authors 
identified the vacuoles as Golgi elements.
13.6.2 Infection with HIV induces cellular differentiation 
JEhe Increased number^of mitochondria and extensive-formation oCendoplasmie 
reticulum observed in the cytoplasm of U937 cells incubated in the presence of H IV -lBa. 
L suggested that the virus may have induced the monocytic U937 cells to differentiate 
into cells with more mature characteristics. Previous reports have also indicated that 
U937 cells can be induced to differentiate in response to infection with HIV-1. Petit et 
al (1987) investigated surface antigen expression of U937 cells following infection with
HTV-lm.B. These authors showed that apart from down-regulation of MHC Class II 
antigens, the results were consistent with HIV infection inducing differentiation of U937 
cells. Another report indicates that U937 cells chronically infected with HIV-1 are 
more differentiated than their uninfected counterparts, suggesting that viral gene 
expression can trigger the maturation process (Gazzolo and Mace, 1990). Further 
studies indicate that HTV infection can alter expression of the c-myc gene in U937 cells 
(Pauza et al., 1988). Expression of this gene normally relates to cellular differentiation 
status, but in infected cells the level of c-myc expression was shown to correlate with 
level o f viral RNA accumulation and not to cellular differentiation. This provides 
further evidence for a relationship between HIV replication and maturation of U937 
cells. In contrast, clinical studies have indicated that HIV infection in vivo impairs 
monocyte to macrophage differentiation. Peripheral blood monocytes isolated from 
seropositive individuals were demonstrated to have characteristics of more immature 
monocytes than equivalent cells isolated from seronegative individuals (Offenberger et 
al., 1986). However, it is conceivable that monocyte precursors could be infected in 
vivo leading to interference with subsequent maturation into monocytes.
13.6.3 Infection of U93 7 TK" cells with HIV-lBa_L
In the present study, U937 TK” cells were treated with reversible cell cycle inhibitors 
(18 hours, 37°C/5% C02) prior to infection with IlIV -lBa.L. The cells were incubated 
for 19 days, during which time the cells had continued to replicate at normal rates, and 
no signs of infection were observed. An assay for detection of p24 core antigen was 
used to investigate release of the antigen into culture supernatants at 14 days post­
infection. Results indicated that all of the cells, apart from those treated with 
GR39457A, had released low levels of the viral antigen into the culture medium. 
However, release of p24 was significantly higher in the cells that had been pre-treated 
with 1 x 10"8M  colchicine.
Ultrastructural studies of U937 TK“ cells fixed 19 days post-infection indicated that 
similar to U937 cells, infection was low level with few virions observed in occasional 
infected cells. Smooth membrane was prominent within the cytoplasm of U937 TK"
. cellsJhat had beenincubated in the presence,of HLVM^a.L.  ^.However, in th&jample that 
had been treated with 4 mM hydroxyurea prior to infection with virus, smooth 
membrane appeared to be particularily prominent, and was frequently seen to be 
blebbing from the surface of the cells, forming circular vesicles. In a few cells 
structures consisting of concentric rings of plasma membrane were observed. It is 
thought that concentric rings were identical to the structures present in the cytoplasm of
a macrophage isolated from a pleural effusion described by Carstens (1993). It is not 
known whether these structures have a function, although Carstens suggests that they 
represent a temporary storage of excess plasma membrane. It is not known whether 
these concentric rings of plasma membrane have any relationship to paired cisternae.
13.6.4 Replication of HIV-1 in 1 x 10~8M  colchicine treated U937 TK~ cells 
In all of the present studies of H IV -1 replication in colchicine treated U937 TIC cells, 
results consistently indicated a significant enhancement of viral replication. In the MTT 
assay, significant down regulation of formazan production indicated that infection of 
colchicine treated cells with either H IV -lBa.L or ITIV-1RF either reduced cellular 
metabolism, or had prevented cell replication. This correlated with the TEM  
observation that approximately 5% of the cells incubated with HIV-1RF showed the 
typical morphology of cells undergoing apoptosis 21 days after first exposure to the 
virus. In comparison to exponentially replicating cells or to cells treated with other 
compounds, p24 antigen release was shown to be significantly higher in the THV--lBa_L 
infected colchicine treated cells. Similarity, intracellular levels of H IV -lIlF were 
significantly enhanced in the colchicine treated population at 15 days post-infection.
Cell cycle analysis indicated that treatment with the compound had caused a significant 
proportion of the cells to accumulate in G2/M, but otherwise characterization of the 
cells showed no significant differences from the control exponentially replicating U937 
TK“cells. This was expected because colchicine is reported to block replication during 
metaphase without affecting chromosome condensation. The compound interferes with 
tubulin polymerization and prevents spindle formation, preventing movement of the 
chromosomes towards the poles of the cell (Osborn and Weber, 1975). Interestingly, 
treatment of the same cells with another cell cycle inhibitor (GR39457A) also caused a 
significant increase in intracellular p24 antigen expression 15 days after infection with 
HXV-Irp The mechanism of action associated with this compound is not known, but 
the compound blocked cells at a slightly different stage in G2/M than colchicine, as 
TEM studies indicated that less cells contained condensed chromosomes. These results 
suggest that HIV-1 replication is enhanced by accumulation of cells in G2/M.
.A study reported by Lehr etal. ( l99Cfysb.owed that..when-concentrated BIY-1 was 
incubated with exponentially replicating H9 cells, the majority of the virus specifically 
bound to cells in G2/M. Further experiments utilized fluorescence anisotropy to 
measure membrane fluidity of phenytoin treated and untreated peripheral blood 
lymphocytes. The results indicated that treatment with phenytoin enhanced the 
membrane fluidity of the lymphocytes, and this was associated with decreased binding of
the unrelated ligands, HIV-1 and vasoactive intestinal peptide (VIP) to the CD4 
receptor. These authors suggested that enhanced binding to cells in G2/M may reflect 
increased receptor availability due to the minimal membrane fluidity that has been 
associated with this stage of the cell cycle (de Laat et al, 1977). The present study has 
showed that treatment of cells with the membrane fluidizing agent phenytoin could 
reduce binding of monoclonal anti-CD4 antibodies. By contrast, we could not detect 
any significant differences in binding of monoclonal anti-CD4 between U937 TK" cells 
blocked in G2/M (1 x 1()-8M  colchicine or 75 }lM GR39457A) and exponentially 
replicating populations. The binding of monoclonal anti-CD4 antibodies to similar cells 
that had been treated with 0.25 mM hydroxyurea was significantly enhanced in 
comparison to the control U937 TK" cells. However, increased binding of anti-CD4 
was not found to correlate with increased susceptibility to infection with HIV-Irp or 
H IV -lBa„L (see section 13.4.1). These results indicate that in our experiments, increased 
availability of CD4 was not responsible for enhancing HIV-1 replication in U937 TK" 
cells blocked in S phase (0.25 mM hydroxyurea) or in G2/M (1 x 10 8M  colchicine or 75 
|±M GR39457A). HIV-1 can use a variety of other receptors to enter myeloid cells, and 
it is possible that expression of another receptor or of a fusion protein was induced or 
enhanced on the U937 TK" cells blocked in G2/M.
13.6.5 Replication of HIV-1 in 300 \\M mimosine treated U937 TK~ cells 
The results of several experiments in the current study indicated that treatment of U937 
TK" cells with 300 pM mimosine blocked cellular replication in Gl/GO. However, 
examination of samples of treated cells by transmission electron microscopy suggested 
that the compound had induced differentiation of the cells and an associated arrest of 
growth. This was further supported by the significant down-regulation of surface CD4 
expression. Further studies indicated that the cells were permissive for infection with 
HTV-1 rf- Cells stained for intracellular p24 antigen expression were shown to contain 
significantly more antigen than all other treatments, with the exception of 1 x 108M  
colchicine. This result is in keeping with previous reports that have indicated that HTV- 
1 replication in U937 cells is dependent on the state of cellular replication and that 
treatment of the cells with differentiation-inducing agents can enhance infection 
(Gazzolo and Mace, 1990; Kitano et al, 1990). .
The in vitro maturation of human monocytes to macrophages was characterized by 
Valentin et al. (1990a). These authors showed that differentiation of human monocytes 
was accompanied by upregulation of lysozyme secretion and expression of CD1 lc, 
CD54, CD 16 and HLA-DR. The cells were susceptible to infection with HTV-1 at all
stages of maturation, with more efficient virus production (monitored by RT levels) 
recorded for the more immature monocytes. Macrophages were characterized by a low 
persistent production of viral p24 (Valentin et al., 1991). Rich et al. (1992) compared 
p24 release from human monocytes, alveolar macrophages and monocyte-derived 
macrophages (MDM) infected with HIV-1 in vitro. These authors showed that p24 
release was greatest from MDM and lowest from monocytes. By contrast, another 
report indicated that freshly isolated human peripheral blood monocytes were not 
permissive for replication of H IV-1 in vitro until the cells had been cultured adherent to 
plastic for at least 2 days (Schuitemaker et al., 1992a). Results from the present study 
indicated that after 48 hours in vitro maturation, a distinct population of larger, more 
granular human monocytes could be detected by flow cytometry. The numbers of cells 
contributing to this population had increased from 17% at 48 hours to 25% at 72 hours. 
This population of monocytes characterized by increased size and granularity, was 
shown to exhibit increased fluorescence following acridine orange staining. This 
suggests that the nucleic acids were in a more open configuration in the differentiating 
cells. The appearance of the population of cells with the more open nucleic acid 
conformation correlated with the time that monocytes were reported to become 
permissive for productive HIV-1 infection (Scuhitemaker et al., 1992). The differences 
in the reported susceptibility of monocytes and macrophages probably reflects both the 
strains of virus used and the methods used to assay viral replication. However the 
general trend suggests that monocytes and macrophages are permissive for infection 
with HIV-1 and that differentiation can affect viral release. This correlates with in vivo 
studies which indicate that monocytes are rarely infected, in comparision to terminally 
differentiated macrophages which represent the most commonly infected cells in many 
tissues (Poli and Fauci, 1992). No previous reports have associated mimosine with 
differentiation of monocytic cell lines, but the results suggest that treatment of U937 
cells with the compound has induced maturation and enhanced replication of H IV -1.
13.7 FURTHER INVESTIGATIONS
13.7.1-Genesis of paired cisternae . . . . . .
Further studies are required to investigate the genesis of paired cisternae. A  series of 
samples taken at selected intervals after addition of hydroxyurea to U937 TK“ could be 
used to investigate time course of formation of paired cisternae and may provide 
information relevant to the formation of these structures. The biogenesis of membranes 
is an important area of investigation as membranes are widely occurring basic structures.
The genesis of intracellular membranes may be of particular importance for studies 
investigating control of H IV -1 replication in mononuclear phagocytes. In this cell type 
HIV-1 virions can mature by budding into intracellular vesicles, rather than undergoing 
normal maturation.
13.7.2 Surface antigen expression on treated U937 and U937 TK~ cells 
Results described in the present study indicated interesting differences between 
expression of antigens on U937 TK ' and U937 cells treated with reversible cell cycle 
inhibitors. Binding of monoclonal antibodies to U937 TK' cells indicated that treatment 
of cells with 0.25 mM hydroxyurea to block the cells in G2/M had enhanced expression 
of the unrelated CD4, CD1 lb, CD 18 and CD71 antigens. The results also suggested 
that the enhanced expression of these antigens correlated with a decrease in membrane 
fluidity. In comparison to control U937 TK" cells, no significant changes of surface 
antigen expression were recorded for cells blocked in Gl/GO using 4 mM hydroxyurea 
or in G2/M using 1 x 10*8M  colchicine. In contrast to these results, binding of 
monoclonal antibodies to U937 cells treated with the same reversible cell cycle inhibitors 
indicated that treatment with 1 x 10*8M  colchicine resulted in significant alteration in 
antigen expression. Results suggesting that treatment of U937 cells with 1 x 10‘8M  
colchicine had increased plasma membrane fluidity correlated with significantly 
decreased expression of both CD4 and CD 18, and a reduced expression of CD1 la. It 
would be interesting to carry out fluorescence anisotropy studies to confirm that 
incubation of U937 cells with 1 x 10'8M  colchicine could increase membrane fluidity and 
that incubation of U937 TK“ cells with 0.25 mM hydroxyurea could decrease plasma 
membrane fluidity.
It would also be very interesting to compare the replication of H IV -Irp in U937 cells 
treated with reversible cell cycle inhibitors with replication of the virus in U937 TK“ 
cells treated in the same way. Results had suggested that enhanced replication of HIV- 
Irp in U937 TK” cells blocked in G2/M by treatment with 1 x 10'8M  colchicine was not 
related to expression of either CD4 or membrane fluidity. Further information 
regarding the contribution of these factors to infection with H IV -Irp could be gained by 
investigating replication of this viral strain in 1 x 10*8M  colchicine treated U937 cells.
By contrast to U937 TK ' cells, treatment of U937 cells with 1 x 10-%! colchicine was 
associated with enhanced membrane fluidity and reduced receptor expression. If 
replication of H IV -Irp in U937 cells blocked in G2/M by treatment with 1 x 10*8M  
colchicine was enhanced, it would confirm that increased receptor availability and 
decreased membrane fluidity did not contribute to this.
13.7.3 Mechanism of cell cycle related enhancement of HIV-1 replication 
The results indicated that accumulation of cells in the G2/M phase of the cell cycle 
following treatment with either 1 x 10'8M  colchicine or 75 \xM GR39457A could 
enhance infection of U937 TK" cells with HIV-Irf. It would be interesting to elucidate 
the mechanism of this enhanced viral proliferation. The results described above indicate 
that the enhanced infection of cells blocked in G2/M could relate to membrane fluidity 
and receptor availability. However, other factors may also contribute to the initial 
interaction of H IV -1 with susceptible host cells. The viral surface glycoproteins 
(gpl60, gpl20 and gp41) are heavily glycosylated (Mizouchi et al., 1988). Studies 
have indicated that these carbohydrate moieties can moderate interactions between CD4 
and gpl20 and affect the specificity and protection associated with antiviral antibodies. 
Neutralization of HIV infection of permissive CD4+ cells could only be mediated by 
antibodies raised against the native molecules (Benjouad et al., 1992). Further studies 
have indicated that the carbohydrate chains on gpl20 are not required for the interaction 
between gpl20 and CD4, but that AMinked glycosylation is essential for generation of 
the correct conformation of gpl20 to bind CD4 (Li et al., 1993). It is possible that 
minor modifications to the conformation of receptor molecules expressed on the surface 
of U937 TK" cells could occur during the cell cycle. This could enhance the affinity of 
binding between host cell receptors and glycosylated viral surface proteins. It would 
therefore be interesting to compare the affinity with which glycosylated and non­
glycosylated forms of gpl20 can bind to U397 TK" cells that have been treated with 
reversible cell cycle inhibitors.
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15.0 APPENDIX^; COMPOSITION _QF MEDIA AND BUFFERS
15.1 High Growth Enhancement Medium
This medium is a modification of Dulbecco's Minimal Essential Medium (DMEM) in 
which 3.6 g/L fructose is substituted for glucose, resulting in better pH control and 
higher cell yields. The composition is as follows:-
Z-Arginine.HCl 84.0 mg/L
Z-Cystine disodium salt.H20 60.38 mg/L
Z-Glutamine 584.0 mg/L
Glycine 30.00 mg/L
Z-Histidine.HCl.H20 250.00 mg/L
Z-Isoleucine 104.8 mg/L
Z-Leucine 104.8 mg/L
Z-Lysine.HCl 14.62 mg/L
Z-Methionine 30.00 mg/L
Z-Phenylalanine 66.00 mg/L
Z-Serine 42.00 mg/L
Z-Threonine 95.20 mg/L
Z-Tryptophan 16.00 mg/L
Z-Tyrosine disodium salt.214^0 103.20 mg/L
Z-Valine 93.60 mg/L
Z>-Ca pantothenate 4.00 mg/L
Choline chloride 4.00 mg/L
Folic acid 4.00 mg/L
i-Inositol 7.00 mg/L
Nicotinamide 4.00 mg/L
Pyridoxal.HCl 4.00 mg/L
Riboflavin 0.40 mg/L
Thiamine.HCl 4.00 mg/L
Calcium chloride (CaCl2.2H20 ) 264.9 mg/L
Ferrous nitrate (Fe(N0 3)3.9.H20 ) 0.10 mg/L
Potassium chloride (KC1) 400.0 mg/L
Magnesium sulphate (MgS04.7H20 ) 200.00 mg/L
Sodium chloride (NaCl) 6400.0 mg/L
Sodium dihydrogen orthophosphate (NaH2P04) 141.3 mg/L
Sodium hydrogen carbonate (NaHC03) 3600.0 mg/L
D-Fructose 3600.0 mg/L
Phenol red sodium salt ~ ~ * - - - - -15:00 mg/L*
Sodium pyruvate 110.00 mg/L
15.2 Leibovitz L-15 Medium (Modified)
In this medium glucose is replace by galactose. In addition, buffering is provided by the 
free bases of amino acids in place of sodium bicarbonate. The composition is as 
follows:-
Z-Alanine 225.0 mg/L
Z-Arginine 500.0 mg/L
Z-Asparagine.H2Q 250.0 mg/L
Z-Cysteine 120.0 mg/L
Z-Glutamine 300.0 mg/L
Glycine 200.00 mg/L
Z-Histidine 250.00 mg/L
Z-Isoleucine 125.00 mg/L
Z-Leucine 125.00 mg/L
Z-Lysine.HCl 93.70 mg/L
Z-Methionine 75.00 mg/L
Z-Phenylalanine 125.00 mg/L
Z-Serine 200.00 mg/L
Z-Threonine 300.00 mg/L
Z-Tryptophan 20.00 mg/L
Z-Tyrosine disodium salt.2H20 430.0 mg/L
Z-Valine 100.00 mg/L
Z>-Ca pantothenate 1.00 mg/L
Choline chloride 1.00 mg/L
Folic acid 1.00 mg/L
i-Inositol 2.00 mg/L
Nicotinamide 1.00 mg/L
Pyridoxine.HCl 1.00 mg/L
Riboflavin phosphate sodium salt.2H20 0.107 mg/L
Thiamine phosphate chloride 1.00 mg/L
Calcium chloride (CaCl2.2H20 ) 185.5 mg/L
Potassium chloride (KC1) 400.0 mg/L
Potassium dihydrogen orthophosphate (KH2P04) 60.00 mg/L
Magnesium sulphate (MgSCfyTItyQ) 400.00 mg/L
Sodium chloride (NaCl) 8000.0 mg/L
Disodium hydrogen orthophosphate (NajHPO^ 190.0 mg/L
Z)-Galactose 900.00 mg/L
Phenol red sodium salt 10.00 mg/L
Sodium pyruvate 550.00 mg/L
15.3 Roswell Park Memorial Institute 1640 (RPMI 1640) medium
This medium was originally designed for the cultivation of leukaemic cells (Moore et al,
1967). The composition is as follows:
L- Arginine. HC1 200.0 mg/L
Z-Asparagine.H20 56.82 mg/L
Z-Aspartic acid 20.00 mg/L
Z-Cystine disodium salt.ItyO 62.92 mg/L
Z-Glutamic acid 20.00 mg/L
Glutathione 1.00 mg/L
Glycine 10.00 mg/L
Z-Histidine 15.00 mg/L
Z-Hydroxyproline 20.00 mg/L
Z-isoleucine 50.00 mg/L
Z-Leucine 50.00 mg/L
Z-Lysine.HCl 40.00 mg/L
Z-Methionine 15.00 mg/L
Z-Phenylalanine 15.00 mg/L
Z-Proline 20.00 mg/L
Z-Serine 30.00 mg/L
Z-Threonine 20.00 mg/L
Z-Tryptophan 5.00 mg/L
Z-Tyrosine disodium salt.21^0 28.64 mg/L
Z-Valine 20.00 mg/L
Biotin 0.20 mg/L
D -Ca pantothenate 0.25 mg/L
Choline chloride 3.00 mg/L
Folic acid 1.00 mg/L
i-Inositol 35.00 mg/L
Nicotinamide 1.00 mg/L
p-Aminobenzoic acid 1.00 mg/L
Pyridoxine.HCl 1.00 mg/L
Riboflavin 0.20 mg/L
Thiamine.HCl 1.00 mg/L
Vitamin B 12 0.005 mg/L
Calcium nitrate (Ca(N03)2) 69.48 mg/L
Potassium chloride (KC1) 400.0 mg/L
Magnesium sulphate (MgS04.7H20 ) 100.00 mg/L
Sodium chloride (NaCl) 6000.0 mg/L
Sodium hydrogen carbonate (NaHC03) 2000.0 mg/L
Disodium hydrogen orthophosphate (Na2HP0 4) 800.7 mg/L
D-Glucose 2000.00 mg/L
(Phenol red sodium salt 5.00 mg/L)
Sodium pyruvate 550.00 mg/L
15.4 Phosphate buffered saline (PBS) (Dulhecco's formula) 
Calcium chloride (CaC^ttyO )
Magnesium sulphate (MgSC^.TEfyO)
Potassium chloride (KC1)
Potassium dihydrogen orthophosphate (KFfyPC^)
Sodium chloride (NaCL)
Disodium hydrogen orthophosphate (NajHPO^
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